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Abstract 
To investigate the role of the two component systems AdeRS and PmrAB in adaptation to 
the presence of antimicrobials, adeRS and pmrAB were deleted in multi-drug resistant 
Acinetobacter baumannii strain AYE. The effect of deleting these genes on antimicrobial 
susceptibility, growth, accumulation, virulence and ability to form a biofilm was investigated. 
The deletion of adeRS and pmrAB had no effect on bacterial growth or the accumulation of 
Hoechst 33342 (bis-benzimide). AYEΔpmrAB, but not AYEΔadeRS, accumulated significantly 
more norfloxacin than AYE. All strains accumulated more norfloxacin in the presence of the 
efflux inhibitor carbonyl cyanide m-chlorophenylhydrazone. AYE∆adeRS and AYE∆pmrAB, 
but not AYE, accumulated more norfloxacin in the presence of verapamil. AYEΔadeRS was 
more susceptible than AYE to antibiotics and biocides and both strains in biofilm were more 
tolerant of biocides than their planktonic counterparts. Deletion of pmrAB had no effect on 
antibiotic susceptibility. AYE was more virulent than both AYE∆adeRS and AYE∆pmrAB. The 
results of this study suggest that in strain AYE, adeRS are not essential for efflux of 
norfloxacin or Hoechst 33342 and that pmrAB are involved in the accumulation of some 
compounds. Both AdeRS and PmrAB are important for virulence and AdeRS has a role in 
antimicrobial susceptibility. 
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1. Introduction 
1.1 Acinetobacter 
Acinetobacter, first described by Beijerinck in 1911, is a ubiquitous Gram negative 
coccobacillus of the family Moraxellaceae (Rossau et al., 1991). Since identification, this 
organism has had many names such as Bacterium anitratum (Schaub and Hauber, 1948) and 
Moraxella lwoffii (Audureau, 1940). Acinetobacter has been classified into at least 15 
different genera because it did not have enough unique phenotypic characteristics to allow it 
to be differentiated from phenotypically similar organisms (Juni, 1978). This bacterium 
became known as Acinetobacter in the 1950s (Brisou and Prévot, 1954).  
A. baumannii, one of the most important nosocomial species, is generally considered to be 
a low-grade, opportunistic pathogen, as it typically only causes infection in individuals who 
are immunocompromised or have an underlying disease (Joly-Guillou, 2005). A. baumannii 
was not formally recognised or designated until 1986, prior to which Acinetobacter spp. 
were often ignored when identified in clinical samples as they remained susceptible to 
antibiotics such as gentamicin, ampicillin, nalidixic acid and minocycline (Joly-Guillou, 
2005). However, Acinetobacter has since become an important nosocomial pathogen due 
to an increase in the number of genuine A. baumannii infections and in the number of 
multidrug-resistant strains, making treatment of these infections difficult (McConnell et al., 
2012). In addition, A. baumannii is able to survive in a range of environmental conditions, 
allowing it to persist in the hospital environment for years (Wendt et al., 1997; Bergogne-
Berezin and Towner, 1996). A. baumannii is phylogenetically related to Pseudomonas 
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aeruginosa, with 65% of its core genes having orthologues in P. aeruginosa PAO1 (Adams et 
al., 2008). 
1.1.1 Different Species of Acinetobacter 
Most species of Acinetobacter are environmental and are not associated with human 
disease and only a few species are clinically important (Gordon and Wareham, 2010; 
Garnacho-Montero and Amaya-Villar, 2010; Towner, 2009). At the time of writing this 
thesis, 27 species have been formally identified (Table 1.1) and based on DNA-DNA 
hybridisation there are nine provisional species (McConnell et al., 2012). Nemec et al. 
(2011) proposed species names for Acinetobacter genomic species (gen. sp.) 3 and 
Acinetobacter gen. sp. 13TU: A. pittii sp. nov., and A. nosocomialis sp. nov. respectively. A. 
pittii, A. nosocomialis, A. baumannii and A. calcoaceticus cannot be distinguished 
phenotypically, since they are very closely related (Manchanda et al., 2010). These four 
species are often grouped and referred to as the A. calcoaceticus-A. baumannii complex. 
When reporting incidents of Acinetobacter infection this is not a suitable grouping because 
A. calcoaceticus is an environmental strain, whereas the other three species are the most 
common causes of Acinetobacter infection (Peleg et al., 2008). It is of interest to determine 
which species of the A. calcoaceticus-A. baumannii complex is responsible for infection as 
the different species may have different clinical outcomes and different treatment regimes 
may be required (Chuang et al., 2011). For example, patients with A. baumannii 
bacteraemia are more likely to develop pneumonia than those with A. nosocomialis 
bacteraemia. A. baumannii is also associated with decreased antibiotic susceptibility and 
increased mortality than A. nosocomialis (Chuang et al., 2011). However, the majority of 
laboratories that report data for this genus use phenotypic typing systems, which are less 
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Table 1.1 Species of the Genus Acinetobacter. 
Species Habitat Clinical importance Antimicrobial 
susceptibility 
References  
A. baumannii No known natural habitat 
outside of hospital. 
Isolated rarely from 
environment. 
Not ubiquitous. 
Most frequently isolated species 
from human clinical samples e.g. 
blood, respiratory tract 
 
Often MDR Towner, 2009; Adams et al., 
2008; Adams et al., 2009; 
Bouvet and Grimont, 1986 
A. baylyi Activated sludge and soil Has been identified as a 
pathogen for opportunistic 
infection 
 Dijkshoorn et al., 2007; Chen 
et al., 2008; Carr et al., 2003 
A. beijerinckii Soil, water, humans  Has been isolated from clinical 
specimens e.g. faeces, sputum, 
throat swab 
 Nemec et al., 2009 
A. bereziniae     Nemec et al., 2010 
A. bouvetii Activated sludge   Towner, 2009; Dijkshoorn et 
al., 2007 
A. brisouii Wetland   Anandham et al., 2010 
A. calcoaceticus Soil and water  
 
Rarely isolated from human 
specimens 
Sensitive Nemec et al., 2011; Towner, 
2009 
A. gerneri Activated sludge   Towner, 2009; Dijkshoorn et 
al., 2007 
A. guillouiae    Nemec et al., 2010 
A. gyllenbergii Human  Isolated from clinical specimens 
e.g. blood, urine, vaginal swab 
 Nemec et al., 2009 
A. haemolyticus  Humans Isolated from clinical specimens  Bouvet and Grimont, 1986 
A. indicus    Malhotra et al., 2012 
A. junii a Humans, animals Frequently isolated from human 
skin. Infection is rare and usually 
 de Breij et al., 2010; Nemec et 
al., 2009; Dijkshoorn et al., 
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benign. 2007; Towner, 2009; Bouvet 
and Grimont, 1986 
A. johnsonii Normal commensal skin 
flora of humans. 
Environment, soil, 
wastewater. 
Infection is rare and usually 
benign.  
Sensitive Towner, 2009; Dijkshoorn et 
al., 2007; Bouvet and Grimont, 
1986 
A. lwoffii Normal commensal skin 
flora of humans. 
Has been isolated from 
catheter-related bloodstream 
infections. Infections are usually 
not severe. 
Usually sensitive. 
MDR isolates 
have been 
identified. 
Tega et al., 2007; de Breij et 
al., 2010 
A. 
nosocomialisb 
Humans One of the species most 
commonly associated with 
infection 
 Nemec et al., 2011 
 
A. parvus Humans and animals Has been isolated from human 
and animal non-sterile body 
sites, such as skin, eyes and ears 
and from human catheter-
related bloodstream infections. 
 Nemec et al., 2003 
A. pitiib Humans, soil, vegetables One of the species most 
commonly associated with 
infection 
 Nemec et al., 2011 
 
A. 
radioresistens 
Normal commensal skin 
flora of humans and animals 
Spoilage flora of food 
Not associated with infection Sensitive Towner, 2009 
A. rudis Milk and wastewater   Vaz-Moreira et al., 2011 
A. schinleri Humans Has been isolated from 
outpatients. Clinical specimens 
include blood, vaginal swab, skin 
 Nemec et al., 2001 
A. soli Soil Implicated in bloodstream 
infection 
MDR Kim et al., 2008; Pellegrino et 
al., 2011 
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a A. grimontii is a synonym of A. junii; MDR, multi-drug resistant
A. towneri Activated sludge   Carr et al., 2003 
A. tandoii Activated sludge   Carr et al., 2003 
A. tjernbergiae Activated sludge   Carr et al., 2003 
A. ursingii Humans Has been isolated from seriously 
ill patients (e.g. blood, urine) 
and has potential to spread 
amongst patients  
 Nemec et al., 2001 
A. venetianus    Di Cello et al., 1997 
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reliable than molecular methods and meaning that the specific species of the A. 
calcoaceticus-A. baumannii complex cannot be reported (HPA, 2010). 
1.1.1.1 AYE  
A. baumannii AYE is a multi-drug resistant (MDR) clinical isolate which was cultured from a 
patient with pneumonia and a urinary tract infection in France in 2001 (Poirel et al., 2003). 
AYE was epidemic in France in 2003-2006 and was associated with mortality in 26% of 
infected patients (Fournier et al., 2006). However, it is important to note that it is difficult to 
determine whether mortality associated with A. baumannii is attributable to infection or 
another factor, such as an underlying disease.  
AYE has an estimated genome size of 3.9 Mb and three plasmids of 5, 9, and 94 kb. No genes 
associated with antibiotic resistance or virulence have been identified on any of the plasmids 
(Vallenet et al., 2008; Fournier et al., 2006). Multidrug resistance in this strain is associated 
with AbaR1, a large antibiotic resistance island of 86 kb, which has a G+C content of 52.8% 
(the rest of its genome has a G+C content of 38.8%) and contains a cluster of antibiotic 
resistance genes and mobile genetic elements (Fournier et al., 2006). AbaR1 is absent from 
drug susceptible isolates SDF, AB307-0294 and ATCC 17978 (Adams et al., 2008). According 
to amino acid similarity, 99% of the AbaR1 genes are likely to have originated from other 
bacterial species such as Pseudomonas, Salmonella, and Escherichia coli. (Fournier et al., 
2006). 
1.1.2 Physiology 
Acinetobacter cells in logarithmic phase of growth are typically 1-1.5 µm x 1.5-2.5 µm in 
size. (Bergogne-Berezin and Towner, 1996). All species are obligate aerobes and non-
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fermentive (Gordon and Wareham, 2010; Bergogne-Berezin and Towner, 1996). 
Acinetobacter have few nutritional requirements, and most strains are able to grow in a 
medium containing only ammonium or nitrate as a source of nitrogen and a single carbon 
source such as acetate, pyruvate or alcohol (Baumann et al., 1968). However, most strains 
are unable to utilize glucose as a carbon source (Baumann et al., 1968).  
Although the name Acinetobacter means “non-motile rod” (Mussi et al., 2010), motility has 
been observed in this genus. Mussi et al. (2010) identified motility in A. baumannii strain 
ATCC 17978, which was inhibited in response to blue light in a temperature-dependent 
manner. Acinetobacter have fimbriae, which are important for initial adhesion to biotic and 
abiotic surfaces, allowing subsequent formation of biofilms on these surfaces (Gordon and 
Wareham, 2010). Thirty per cent of Acinetobacter strains produce exopolysaccharide, a 
component of an extracellular capsule, and mature biofilms (Joly-Guillou, 2005). The 
capsule enables A. baumannii to resist human serum (Russo et al., 2010).  
1.1.3 Habitat 
Acinetobacter as a genus are widely found in soil and water and can also be isolated from 
the skin of healthy individuals, food and animals (Table 1.1) (Turton et al., 2006; Manchanda 
et al., 2010; Gordon and Wareham, 2010; Munoz-Price and Weinstein, 2008). Although A. 
baumannii has been isolated from the environment, it is not a ubiquitous environmental 
organism (Towner, 2009) and does not appear to be carried by people in the community 
(Peleg et al., 2008). This non-ubiquitous nature is also true for the other members of the A. 
baumannii complex: A. pittii and A. nosocomialis. These three species are generally isolated 
only from the hospital or patients who are infected or colonised with the organism (Towner, 
2009). 
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1.1.4 Disease 
1.1.4.1 Pathogenicity 
As this organism is an opportunistic pathogen, patients who develop an Acinetobacter 
infection usually have an underlying condition such as renal dysfunction or trauma (burn or 
wound injuries) (Towner, 2009; Esterly et al., 2011). Acinetobacter infections usually occur 
in patients in intensive care units with most cases in children younger than 1 year or older 
than 64 years of age, possibly due to the increased likelihood that these cohorts will require 
ICU treatment (HPA, 2010). Other risk factors are the use of invasive procedures such as 
mechanical ventilation and treatment with broad spectrum antibiotics (HPA, 2010). 
The species most frequently isolated from human infections are A. baumannii, A. pittii and 
A. nosocomialis (Dijkshoorn et al., 2007; de Breij et al., 2010). A. baumannii is responsible 
for up to 10% of nosocomial infections (Adams et al., 2008) and is most often associated 
with hospital-acquired pneumonia, since the airways are often the first and main site to be 
colonised (Knapp et al., 2006; Lee et al., 2006). Community-acquired A. baumannii 
infections are rare, although cases of community-acquired pneumonia caused by this 
organism have been reported, mainly among young alcoholics in tropical climates (Chen et 
al., 2001). Other infections caused by A. baumannii include meningitis, bacteraemia, 
urinary tract infection and wound infection (Manchanda et al., 2010). Wound infections are 
a problem in soldiers returning from war in Afghanistan and Iraq (Hujer et al., 2006). Other 
species of Acinetobacter are only pathogenic in rare cases and, like A. baumannii, are 
usually isolated from patients who already have an underlying disease (Joly-Guillou, 2005; 
HPA, 2010). For example, A. lwoffii, a commensal organism carried by 20-25% of healthy 
individuals, was reported as a cause of bacteraemia in England, Wales and Northern Ireland 
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from 2005 to 2009. However, it is possible that some of these reported cases were actually 
due to blood culture contamination, as this species would not be expected to be a cause of 
infection (HPA, 2010).  
A. baumannii easily survives in the hospital environment; it can survive periods of 
desiccation and nutrient starvation, and can grow at many temperatures and pH conditions 
(Bergogne-Berezin and Towner, 1996). A. baumannii is usually MDR, (McConnell et al., 
2012) and is able to form biofilms on both biotic and abiotic surfaces (de Breij et al., 2010). 
All of these characteristics aid its survival (Tomaras et al., 2008). However, the 
environmental signals and regulation of factors aiding survival and pathogenesis of this 
organism are largely unknown (Mussi et al., 2010) and the reservoirs of infection within 
hospitals are poorly understood (Towner, 2009). 
de Breij et al. (2010) reported that A. baumannii induced the production of less 
inflammatory cytokines from human macrophages than A. junii. They hypothesised that A. 
baumannii may be such a successful opportunistic pathogen as the weak immune response 
enables the organism to evade eradication from the host. However, the ability to adhere to, 
and form biofilms on, human airway epithelial cells did not vary between clinically relevant 
and less clinically relevant strains and species of A. baumannii.  
1.1.4.2 Virulence 
In order to cause infection, Acinetobacter must survive the iron-limiting conditions inside 
the host, where the free iron concentration (10-8M) is less than that required for bacterial 
survival (Goel and Kapil, 2001). A. baumannii secrete a catechol-type siderophore, 
acinetobactin, and express outer membrane iron-regulated iron receptors (BauA for 
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acinetobactin) to take up the siderophore-iron complex (Goel and Kapil, 2001; Zimbler et 
al., 2009). A. baumannii species, such as AYE, also express a hemin utilisation system, 
enabling these bacteria to obtain iron from multiple sources during infection (Zimbler et al., 
2009). Gaddy et al. (2012) investigated the role of acinetobactin in infection and virulence 
of A. baumannii. A functional acinetobactin-mediated iron acquisition sytem was required 
for bacterial survival and full virulence in Galleria mellonella and murine sepsis models of 
infection. Acinetobactin was not required for initial interaction of A. baumannii with human 
epithelial cells, but it was required for infection and intracellular persistence. 
Outer membrane protein A (OmpA (previously known as Omp38)), the most abundant 
surface protein of A. baumannii, is likely to be an importance virulence factor of the 
organism (Choi et al., 2008). OmpA has been implicated in cytotoxicity and apoptosis of host 
cells; it has been shown to induce macrophage and dendritic cell death in vitro and frog 
embryonic death in vivo (Choi et al., 2008; Lee et al., 2010; Choi et al., 2005). The protein 
directly binds to the surface of eukaryotic cells, suggesting that it may be involved in the 
interaction of A. baumannii with host cells. It translocates to the nucleus via a novel nuclear 
localisation signal (NLS) and induces apoptosis by targeting mitochondria (Choi et al., 2005; 
Choi et al., 2008). Interestingly, the specific NLS known to target the nucleus is only 
conserved among species of the A. baumannii complex. The NLS in environmental strains 
such as A. baylii and A. radioresistens differ from that of A. baumannii by one amino acid 
(Choi et al., 2008). OmpA inhibits complement-mediated cell lysis and death of dendritic 
cells may lead to defective T- cell responses against the organism. Therefore, OmpA may 
have a detrimental effect on adaptive immunity in the host (Lee et al., 2010).  
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Phospholipase D has also been identified as a virulence factor in A. baumannii. Insertion of a 
transposon in the phospholipase D gene (pld) in a clinical isolate resulted in decreased 
epithelial cell invasion (in vitro) and decreased bacteraemia and infection of visceral organs 
in a mouse model of infection (Jacobs et al., 2010). 
Epidemiology 
Different clones are epidemic in different regions of the world and even different parts of a 
country. European clones I, II and III are 3 major lineages of A. baumannii, which are 
frequently implicated in outbreaks throughout Europe and other parts of the world, such as 
the USA and South Africa (de Breij et al., 2010; van Dessel et al., 2004; Diancourt et al., 
2010). Three widespread clones of A. baumannii have been responsible for infections in UK 
hospitals: OXA-23 Clones 1 and 2 and the “South East” (SE) clone (Turton et al., 2006).  
A. baumannii infections in war repatriates have been attributed to contaminated soil at the 
time of injury. However, this is now debated since this organism is now thought to be rare in 
the environment (Dijkshoorn et al., 2007). Scott et al. (2007) isolated A. baumannii from the 
skin of 1 out of 160 (0.6%) patients, 1 out of 49 (2%) soil samples, but all (7) of the treatment 
areas tested, suggesting that infection is acquired in the hospital after injury.  
Potential sources of A. baumannii infection within the hospital include ventilators, bed linen, 
floor mops and computer keyboards. Once a patient is infected with the organism, they then 
become a reservoir of infection. Spread of infection is often thought to occur via direct 
contact, in which case the hands of hospital staff can sometimes be an important 
transmission vector (Joly-Guillou, 2005; Dijkshoorn et al., 2007). Air transmission has also 
been implicated (Garnacho-Montero and Amaya-Villar, 2010).  
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The ability of Acinetobacter spp. to survive in desiccated conditions plus their resistance to 
antibiotics are thought to be of importance in their ability to persist in the hospital and cause 
outbreaks (Jawad 1998). Jawad et al. (1998) reported that there was no significant 
difference between the survival of outbreak and sporadic cells under desiccated conditions 
and that any strain may cause infection when the conditions are favourable. The outbreak 
strains investigated were more resistant than sporadic strains to aminoglycosides, 
fluoroquinolones and β-lactams, suggesting that antimicrobial resistance affects the 
likelihood of a strain to cause infection and also to become epidemic (Jawad et al., 1998). In 
support of this, Higgins et al. (2004) reported that fluoroquinolone resistant isolates of A. 
baumannii were isolated from multiple patients during a hospital outbreak, whereas isolates 
with lower fluoroquinolone minimum inhibitory concentrations (MICs) were not isolated 
from more than one patient. A. baumannii is more resistant to desiccation than other 
species of Acinetobacter and this may contribute to its higher ability to cause infection than 
species that are more sensitive to desiccation (Jawad et al., 1996). 
Biofilm-forming A. baumannii strains have been found to survive longer than non-biofilm-
forming strains. In a study by Espinal et al. (2012), biofilm-forming strains survived up to 36 
days, whereas non-biofilm-forming strains survived a maximum of 15 days. In dry conditions, 
the non-biofilm-forming strains appeared to be dehydrated in contrast to the biofilm-
forming strains. Therefore, the ability of A. baumannii to form biofilms may increase the 
ability of this bacterium to persist in the hospital. 
Incomplete disinfection of hospital contaminated dry surfaces may also contribute to 
repeated outbreaks of A. baumannii (Jawad et al., 1996). A. baumannii is able to survive in 
the presence of disinfectants when the concentration or exposure time of the agent fall 
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below the manufacturer’s instructions (Wisplinghoff et al., 2007). However, several studies 
have indicated that the development of disinfectant-resistance in A. baumannii does not 
usually occur after exposure to the agent and that the MICs of biocides for this bacterium 
are usually below the in-use concentrations (Martró et al., 2003; Wisplinghoff et al., 2007; 
Kawamura-Sato et al., 2008; Kawamura-Sato et al., 2010). Therefore, biocide resistance in A. 
baumannii is not considered to be involved in epidemic spread of A. baumannii infection, 
but incorrect disinfectant use does increase the chance of an outbreak (Wisplinghoff et al., 
2007). 
It has been proposed that once an Acinetobacter infection is detected within a hospital, the 
number of colonised patients is already high, and that it is too late to prevent an outbreak 
(Joly-Guillou, 2005). However, outbreaks have been prevented by implementing patient 
isolation or ward closures for up to four weeks and in one report, A. baumannii was 
eradicated from a London teaching hospital without closure of the ward or isolation of 
patients (Towner, 2009). Instead, control measures included improved hand 
decontamination by implementing the use of alcohol gels, the use of closed tracheal suction 
for patients on mechanical ventilation and the administration of nebulised colistin to 
patients who were suspected to have ventilator-associated pneumonia caused by 
Acinetobacter (Wilks et al., 2006).  
1.1.5 Treatment 
The scientific evidence used to treat A. baumannii infections is based on in vitro data, 
experimental models and case studies, since there have been very few randomised trials to 
identify the safest and most efficacious drug for treatment (Garnacho-Montero and Amaya-
Villar, 2010). In vitro antimicrobial susceptibility assays are mainly used to guide the 
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treatment of infections caused by Acinetobacter spp., but it is suggested that these assays 
are less reliable than for other bacteria (Kulah et al., 2009). This is because there is limited 
clinical evidence for the efficacy of different antibiotics against A. baumannii infection, 
rendering the antibiotic resistance recommended breakpoint conentrations unreliable 
(Perez et al., 2007).  
Treatment of Acinetobacter infections is difficult since clinically significant species belonging 
to the genus are frequently resistant to most commonly used agents, including 
aminoglycosides, broad-spectrum β-lactams and the quinolones (Towner, 2009; Van 
Looveren and Goossens, 2004). Until the 1970s, gentamicin, minocycline, ampicillin, 
carbenicillin and nalidixic acid could be used alone or in combination to treat nosocomial 
Acinetobacter infections. Unfortunately, resistance to these agents began to arise between 
1971 and 1974 (Bergogne-Berezin and Towner, 1996). 
Carbapenems 
Carbapenems are the drugs of choice for susceptible strains (MIC ≤ 2) (Gordon and 
Wareham, 2010; Bergogne-Berezin and Towner, 1996; Neonakis et al., 2011). Until the early 
1990s, 100% of isolates remained susceptible to imipenem (Bergogne-Berezin and Towner, 
1996). However, resistance to carbapenems (MIC of imipenem and meropenem, 8 µg/ml; 
MIC of doripenem, 4 µg/ml), as well as other agents is now widespread, leaving few 
treatment options (Lopez-Rojas et al., 2011) When deciding upon appropriate treatment for 
Acinetobacter infections, it is recommended that the MIC of imipenem for Acinetobacter is 
determined (Garnacho-Montero and Amaya-Villar, 2010) since this drug has high success 
rates against A. baumannii with low levels of resistance to imipenem (MIC, 8 µg/ml), but is 
inactive in vivo when the organism has a high level of resistance (MIC >512 µg/ml) (Montero 
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et al., 2004). Another carbapenem, doripenem, is less efficacious than imipenem (when 
strains have only a low level resistance to imipenem (MIC, 8µg/ml), but is more effective in 
strains carrying the OXA-58 gene, which encodes a β-lactamase (Section 1.2.2.1). Doripenem 
is not a commonly used drug in the treatment of A. baumannii infections and more clinical 
experience is required before it will become routinely used (Garnacho-Montero and Amaya-
Villar, 2010).  
A new broad spectrum carbapenem, ertapenem, was licensed for use in Europe in 2002. 
However, despite the past efficacy of carbapenems, this newer drug is unfortunately 
ineffective in the treatment of Acinetobacter spp. infections (Burkhardt et al., 2007). 
Fluoroquinolones 
Although fluoroquinolones were once effective against A. baumannii infections, resistance 
has rapidly emerged against these agents since 1990 (Towner, 2009). Higgins et al. (2004) 
reported a case of A. baumannii with mutations in gyrA and parC, which encode the A sub-
units of the targets of fluoroquinolones (a subunit of DNA gyrase and topoisomerase IV, 
respectively) and upregulated adeB expression, conferring increased efflux, which were 
thought to have occurred after ciprofloxacin exposure. Newer fluoroquinolones such as 
moxifloxacin retain greater activity than ciprofloxacin for Acinetobacter, but growth has 
been reported to occur in the presence of moxifloxacin (Towner, 2009), suggesting that 
resistant mutants are rapidly selected. For these reasons, fluoroquinolones are not the 
agents of choice for the treatment of A. baumannii infections. 
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Polymyxins 
Polymyxin E (colistin), an agent used only as a last resort due to its high toxicity, is the last 
remaining drug with high activity against A. baumannii (Fernandez-Reyes et al., 2009). 
Colistin and other polymyxins were abandoned in the 1960s and 1970s due to the 
nephrotoxicity and neurotoxicity associated with treatment (Munoz-Price and Weinstein, 
2008). However, cases of nephrotoxicity are now less frequently reported and neurotoxicity 
is uncommon (Garnacho-Montero and Amaya-Villar, 2010). This could be due to 
inappropriate dosing in the past (Li et al., 2006) or the retrospective nature of more recent 
studies, which rely upon appropriate documentation of toxicity when it occurs (Paksu et al., 
2012).  
Colistin does not penetrate into respiratory secretions efficiently, so is not suitable for 
treatment of pneumonia, although nebulised colistin overcomes this problem (Livermore, 
2005; Peleg et al., 2007b). A side effect of using nebulised colistin is bronchoconstriction, 
although this can be decreased by using intravenous colistin at the same time (Garnacho-
Montero and Amaya-Villar, 2010). 
Polymyxins show promising activity against MDR A. baumannii when used in combination 
with other agents such as meropenem or rifampicin. It is advised that colistin is not used 
alone since heteroresisistance (presence of a resistant sub-population in an otherwise 
susceptible population (Cai et al., 2012)) is higher amongst isolates previously exposed to 
colistin than those never exposed to the agent (Hawley et al., 2008). Nonetheless, colistin is 
currently considered a safe and suitable agent for the treatment of A. baumannii infections 
(Lopez-Rojas et al., 2011). Colistin-resistant outbreaks of Acinetobacter are rare, possibly due 
to the decreased fitness associated with resistance to the antibiotic (Section 1.2.2.3) (Lopez-
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Rojas et al., 2011). Furthermore, mutations that compensate the fitness burden in the 
mutants do not seem to be easily acquired (it has been postulated that colistin may have 
multiple targets), meaning that the fitness cost is generally not overcome (Fernandez-Reyes 
et al., 2009). Colistin also does not promote cross resistance to other agents (Garnacho-
Montero and Amaya-Villar, 2010).  
Tigecycline 
Tigecycline can be used to treat infections caused by colistin-resistant strains of A. 
baumannii (Garnacho-Montero and Amaya-Villar, 2010). Tigecycline is a broad spectrum 
derivative of minocycline (glycylcycline), and activity is not affected by tetracycline-specific 
efflux pumps or tetracycline resistance determinants that protect the ribosome (Peleg et al., 
2007b; Livermore, 2005).  
There have been few clinical reports of tigecycline resistance (Peleg et al., 2007b), but in 
2005, there was a report of resistance which emerged during phase III trials (unpublished) 
(Livermore, 2005). Tigecycline non-susceptible (MIC > 0.5) A. baumannii have also been 
isolated from hospitals in London (MIC, 4-6 µg/ml) (Livermore, 2005). Peleg et al. (2007b) 
also reported two cases of bloodstream infection caused by tigecycline non-susceptible 
isolates of A. baumannii in the USA. The bacteraemia developed following treatment with 
tigecycline, and led to a cautionary report about the use of tigecycline for A. baumannii 
bloodstream infection.  
The sub-inhibitory serum concentrations (mean maximum steady state concentration, 0.63 
µg/ml) can allow the development of Acinetobacter bloodstream infection, exemplified by 
the above cases (Peleg et al., 2007b). Fishbain and Peleg, (2010) recommended that 
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tigecycline should not be used for A. baumannii for which the MIC exceeds 1 µg/ml. 
Tigecycline is also not suitable for urinary tract infections as little active drug is excreted in 
urine; excretion is mostly biliary (Livermore, 2005). However, tigecycline is efficacious in the 
treatment of tissue infections as the level of transfer of tigecycline from the blood to the 
tissues is very high (Livermore, 2005; Peleg et al., 2007b). 
Sulbactam  
Sulbactam (β-lactamase inhibitor) in combination with ampicillin, has been reported to be 
successful in the treatment of Acinetobacter infections (Levin et al., 2003). Early studies 
showed high in vitro activity against Acinetobacter, including against multidrug resistant 
strains (Karageorgopoulos and Falagas, 2008). The activity of sulbactam in combination with 
a β-lactam has shown comparable activity to that of imipenem in ventilator-associated 
pneumonia and bacteraemia caused by MDR strains of A. baumannii (Wood et al., 2002; 
Cisneros et al., 1996). Furthermore, it has been suggested that this agent may be more 
effective in treating pneumonia than colistin, and is considered to be a safe choice for 
therapy (Levin et al., 2003). However, the efficacy of this compound has declined, possibly 
due to its increased use (Karageorgopoulos and Falagas, 2008).  
1.2. Antimicrobial resistance 
1.2.1. Antibiotic and biocide resistance in Gram Negative Bacteria 
1.2.1.1. Chromosomal vs. Transmissible Resistance 
Resistance determinants can be found on the bacterial chromosome, or on mobile genetic 
elements such as plasmids, transposons and integrons. Mobile genetic elements allow 
horizontal transfer of resistance genes between strains and species of bacteria (Biliouris et 
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al., 2011). Resistance genes transferred on mobile elements can also become incorporated 
into the chromosome (Burrus and Waldor, 2004). Likewise, although chromosomally 
encoded resistance is acquired via vertical gene transfer, it can become transmissible. For 
example, some chromosomally encoded β-lactamases have migrated onto plasmids and 
integrons, facilitating their dissemination (Gootz, 2006). Topoisomerase genes are located 
on the chromosome, and have not been found on mobile genetic elements. However, 
transmissible resistance to fluoroquinolones has been described. For instance, the qnr gene, 
whose product protects DNA gyrase against fluoroquinolones, has been identified on 
plasmids predominantly in K. pneumoniae (Martinez-Martinez et al., 1998). Other resistance 
determinants, such as tetracycline resistance genes, are often associated with transmissible 
elements (Biswas et al., 2008). 
1.2.1.2. Brief Overview of Mechanisms of Resistance 
Antibiotic resistance can be acquired either due to the uptake of DNA containing resistance 
genes or due to evolutionary mutations in the organism’s genome (Martinez et al., 2009). 
Bacteria can develop resistance against one agent, or against a broad spectrum of agents. A 
bacterium is said to be MDR if it is resistant to drugs belonging to at least three different 
classes of antibiotic (Piddock, 2006). MDR is often due to the action of a combination of 
mechanisms, each conferring resistance to a different agent (Gootz, 2006), although one 
mechanism alone, such as overexpression of a multi-drug efflux pump, can be responsible 
(Piddock, 2006). Some bacteria can express all mechanisms of resistance described to date, 
such as enzymatic inactivation of the antibiotic, mutation(s) in the structural or regulatory 
genes of the target protein, decreased permeability of the outer membrane and transport of 
the agent out of the cell by efflux (Strateva and Yordanov, 2009; Gootz, 2006). 
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Resistance to β-lactams is often due to the presence of β-lactamase enzymes, which 
hydrolyse the β-lactam ring, the active constituent of the enzyme (Walsh, 2000). 
Aminoglycoside resistance can occur due to enzymatic modification of the agent, which 
reduces the affinity of the agent for its target (Walsh, 2000). Aminoglycoside 
phosphotransferases, acetyltransferases, and nucleotidyltransferases inactivate 
aminoglycosides by catalysing the transfer of a phosphate group, acetyl group or adenosine 
monophosphate (AMP), respectively to the antibiotic (Ramirez and Tolmasky, 2010).  
Fluoroquinolone resistance can be a result of mutations in chromosomal genes which lead to 
an alteration of their target (Marcusson et al., 2009). Mutations can occur in gyrA or gyrB 
which result in alteration of DNA gyrase, or in parC or parE, which encode subunits of 
topoisomerase IV (Hooper, 2001). Clinically relevant resistance to fluoroquinolones in Gram 
negative bacteria is usually the result of a stepwise accumulation of mutations including 
those resulting in alteration of the target and up-regulation of efflux (Komp Lindgren et al., 
2003). Fluoroquinolone-resistance can also arise due to enzymatic inactivation of the 
antibiotic, by a variant of an aminoglycoside acetyltransferase, which recognises some 
fluoroquinolones (Robicsek et al., 2006). 
Innate resistance in Gram negative bacteria is often due to the synergistic effect of the low 
permeability of the outer membrane and active efflux, which results in a decreased 
intracellular drug concentration, allowing survival in the presence of these compounds 
(Nikaido, 1994; Piddock, 2006). All Gram negative bacteria studied to date have porins in 
their outer membrane, which can be non-specific or specific for the solutes they allow 
through (Nikaido, 2003). The intrinsic resistance of P. aeruginosa is at least in part due to the 
low permeability of its outer membrane (Strateva and Yordanov, 2009). However, it has 
21 
 
been reported that the low permeability alone would not prevent the accumulation of toxic 
concentrations of antibiotic; efflux is also important (Livermore and Davy, 1991; Nikaido, 
1994). 
Both antimicrobial resistant and antimicrobial susceptible bacteria express efflux pumps 
(Piddock, 2006). Resistance can arise in a susceptible organism due to the up-regulation of 
an efflux pump, which can be induced by environmental signals or a mutation(s) in a 
regulatory gene (Levy, 2002; Piddock, 2006). For example, transcription of tetA, which 
encodes a tetracycline-specific efflux pump, is dependent on the presence of tetracycline for 
activation (Levy and McMurry, 1978). Alternatively, resistance can be due to a mutation(s) in 
an efflux pump gene, which makes export more efficient (Blair and Piddock, 2009; Piddock, 
2006). Efflux pumps such as CmlA, which transports chloramphenicol, have a specific 
substrate (Coyne et al., 2010b). Other pumps, such as AcrAB-TolC of the resistance 
nodulation division (RND) family, export a wide range of structurally diverse substrates, and 
are the most important family in conferring multidrug resistance to Gram negative bacteria 
(Piddock, 2006). RND efflux pumps are tripartite pumps, which use the proton motive force 
to transport substrates from the periplasm into the extracellular space (Blair and Piddock, 
2009; Piddock, 2006), (Figure 1.1). There are four other families of efflux pump; the major 
facilitator superfamily (MFS), staphylococcal multiresistance (SMR), multidrug and toxic 
compound extrusion (MATE) and ATP binding cassette (ABC) families. Efflux pumps alone 
often lead to lower levels of resistance than other mechanisms, but nevertheless, they are 
often reported to be important in contributing to MDR. It has been proposed that efflux is 
the first step in MDR, since it lowers the concentration of drug inside the cell, increasing the 
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MIC of the agent. This enables the organism to survive long enough for other, more specific 
modifications or mutations to occur (Piddock, 2006). 
Unlike antibiotics, biocides often have many targets within the bacterial cell (Russell, 2003). 
Therefore, biocide resistance in Gram negative bacteria is often due to intrinsic mechanisms, 
such as low permeability of the outer membrane, the ability to sporulate and biofilm 
formation (McDonnell and Russell, 1999). The most common acquired resistance 
mechanisms are a change in permeability of the cell membrane or increased efflux (Poole, 
2002). Adaptation via the acquisition of mutations or alteration of the biocide target is not 
so common because alterations to multiple targets would usually have to occur (Poole, 
2002). However, resistance to triclosan, which has a specific target (FabI, involved in fatty 
acid synthesis), can arise due to mutations in the fabI gene (Webber et al., 2008).  
1.2.2 Antibiotic Resistance and Mechanisms in Acinetobacter baumannii 
A. baumannii is the most resistant species of Acinetobacter and is typically resistant to many 
antibiotics, disinfectants and antiseptics (Garnacho-Montero and Amaya-Villar, 2010). The 
main reason for resistance in this species is the acquisition of genes encoding drug-
inactivating enzymes located on mobile genetic elements, such as plasmids, integrons or 
transposons (Adams et al., 2008; Fournier et al., 2006). Other determinants of resistance are 
mutations in chromosomal genes and overexpression of chromosomal genes encoding efflux 
systems (Coyne et al., 2010a; Coyne et al., 2010b) . Little is known about the permeability of 
the outer membrane in A. baumannii or its outer membrane porins (Vila et al., 2007). Only a 
few porins have been reported in this bacterium, such as OmpW, HMP-MB, CarO and OprD 
(Mussi et al., 2005; Vila et al., 2007).  
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Figure 1.1 Structure of the AcrAB-TolC RND Efflux Pump (Blair and Piddock, 2009).
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1.2.2.1 β-lactams 
The most common mechanism of β-lactam resistance is inactivation of the drug by β-
lactamase enzymes, which can be either chromosomally- or plasmid-encoded (Roca et al., 
2012).  
Two intrinsic β-lactamases are present in most strains of A. baumannii. These are the 
chromosomally-encoded AmpC and OXA-51-like β-lactamases, which must be up-regulated 
to provide resistance (Roca et al., 2012). As observed in several other bacterial species, 
inducible expression of AmpC does not occur in Acinetobacter (Peleg et al., 2008). Increased 
expression is due to the upstream presence of an insertion sequence, ISAba1, which 
provides a promoter for gene expression (Livermore, 2009; Turton et al., 2006). This element 
has also been found upstream of carbapenemase genes such as blaOXA-51, blaOXA-23 and blaOXA-
27 and detected in all representatives of most of the outbreak strains and clones, including 
OXA-23 clones 1 and 2, T-strain (associated with infection in the Midlands, UK) and SE clone. 
It is not present in European clone 1 (Turton et al., 2006).  
Turton et al. (2006) found that isolates that had ISAba1 upstream of their blaOXA-51-like 
gene were resistant to imipenem (MIC 4-8 µg/ml) and/or meropenem (MIC 16- >32 µg/ml). 
By contrast, the bla gene in susceptible isolates (MIC <4 µg/ml) did not have the IS upstream. 
Carbapenem-resistant isolates have been identified, which possess blaOXA-51-like but have 
the IS associated with other carbapenemase genes. However, in isolates whose only 
cabapenemase gene is blaOXA-51-like, ISAba1 must be present for imipenem and/or 
meropenem resistance, suggesting that this IS is acting as a promoter for the gene, and is 
essential for expression.  
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β-lactam resistance is not attributable to the action of efflux pumps alone (Coyne et al., 
2010b). However, overexpression of the RND efflux pump AdeABC in conjunction with the 
action of carbapenemases has been reported to confer high levels of resistance to β-lactams 
(Giamarellou et al., 2008). AdeIJK has also been implicated in intrinsic β-lactam resistance 
(Damier-Piolle et al., 2008), whilst AdeFGH does not transport this class of antibiotic, and 
therefore does not contribute to resistance (Coyne et al., 2010c). A decrease in outer 
membrane permeability (due to loss of or decreased expression of outer membrane 
proteins), resulting in reduced uptake of the agent (Mussi et al., 2005) or changes in the 
structure or expression of penicillin-binding proteins have also been associated with 
resistance to β-lactams (Vashist et al., 2011).  
Secretion of outer membrane vesicles, which harbour the β-lactamase gene, blaOXA-24 have 
been identified in A. baumannii and could result in dissemination of β-lactam resistance 
between A. baumannii and also to other bacteria (Rumbo et al., 2011).  
1.2.2.2 Fluoroquinolones  
Acinetobacter isolates in France were susceptible to fluoroquinolones when these agents 
were first introduced as a treatment strategy. However, within five years of their 
introduction, 75-80% of isolates in this country became insusceptible to pefloxacin and other 
drugs of this class (Bergogne-Berezin and Towner, 1996).  
As for other Gram negative bacteria, mutations in gyrA (Vila et al., 1995) and parC (Vila et 
al., 1997) have been implicated in fluoroquinolone resistance in A. baumannii. Vila et al., 
(1995) identified a Ser83 to Leu mutation in gyrA of 15 A. baumannii clinical isolates. 
However, the MIC of ciprofloxacin for these isolates ranged from 4 to 128 µg/ml. Vila et al., 
(1997) investigated the reason for the varying fluoroquinolone susceptibility in these 
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isolates. They identified that the isolates with higher resistance (MIC≥ 32 µg/ml) also had a 
Ser80 to Leu mutation in parC, suggesting that an accumulation of mutations in both gyrA 
and parC is required to achieve high fluoroquinolone resistance. Mutations in parC, in the 
absence of gyrA mutations have not been identified, suggesting that DNA gyrase is the 
primary target of fluoroquinolones in A. baumannii (Vila et al., 1997). 
Fluoroquinolone resistance can also be conferred by increased activity of the RND efflux 
pumps, AdeABC, AdeIJK and AdeFGH and the MATE efflux pump, AbeM (Magnet et al., 2001; 
Damier-Piolle et al., 2008; Coyne et al., 2010c; Su et al., 2005). In particular, AdeFGH confers 
high-level resistance to fluoroquinolones (Coyne et al., 2010c). The MICs of norfloxacin, 
ciprofloxacin and moxifloxacin for two mutants (BM4454∆adeABC∆adeIJK), which 
overexpressed AdeFGH were >256 µg/ml, >32 µg/ml and 12 µg/ml, respectively and 
increased by at least 16-fold, compared with their parent (Coyne et al., 2010c). 
1.2.2.3 Polymyxins 
Colistin resistance in A. baumannii has only been associated with sporadic outbreaks, which 
is thought to be due to the decreased growth and virulence associated with colistin 
resistance (Lopez-Rojas et al., 2011). In a study by Lopez-Rojas et al. (2011), a colistin-
resistant derivative of A. baumannii ATCC 19606 had a longer generation time than its 
parent and mice infected with the resistant derivative survived twice as long as those 
infected with ATCC 19606.  
Resistance to colistin is usually due to remodelling of lipopolysaccharide (LPS) in the outer 
membrane by PmrC, which decreases the interaction and translocation of the agent across 
the membrane (Section 1.3.2.1.2) (Fernandez-Reyes et al., 2009; Beceiro et al., 2011). This 
resistance mechanism can be attributed to mutations in one or both of the two-component 
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system genes, pmrAB, which regulate pmrC expression (Section 1.3.2.1.2) (Adams et al., 
2009).  
A loss of LPS, resulting from a mutation or deletion in one of the lipid A biosynthesis genes, 
lpxA, lpxC or lpxD has been implicated in colistin resistance in colistin-resistant (MIC > 128 
µg/ml) derivatives of A. baumannii ATCC 19606 (Moffatt et al., 2010). Disruption of lpxA or 
lpxC by the insertion sequence ISAba11 in can also result in loss of LPS and colistin resistance 
(Moffatt et al., 2011). 
Decreased expression of OmpW, an outer membrane protein has also been reported in a 
colistin resistant A. baumannii isolate (Vila et al., 2007; Fernandez-Reyes et al., 2009).  
1.2.2.4 Aminoglycosides  
Acinetobacter spp. exhibit a higher level of aminoglycoside resistance than most other Gram 
negative bacteria, and strains with high levels of resistance have existed since the late 1970s 
(Towner, 2009; Van Looveren and Goossens, 2004). This genus possesses all three classes of 
aminoglycoside enzymes with multiple aminoglycoside-resistance genes present in some 
strains (Bergogne-Berezin and Towner, 1996; Towner, 2009). In addition to modification of 
the drug, efflux pumps such as AdeABC and AdeT have also been reported to mediate 
resistance to aminoglycosides (Giamarellou et al., 2008; Adams et al., 2010; Marchand et al., 
2004). 
1.2.2.5. Tetracycline, Chloramphenicol and Tigecycline 
The main mechanisms of tetracycline resistance are the expression of an efflux pump (TetA-
E and TetK) or a ribosomal protection system (TetO and TetM) (Vila et al., 2007; Peleg et al., 
2007b).  
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cat genes, which encode chloramphenicol acetyltransferases have been identified on an 
integron and resistance island in A. baumannii and confer chloramphenicol resistance by 
enzymatic modification (Fournier et al., 2006; Turton et al., 2005). Chloramphenicol 
resistance can also be a result of efflux by CraA, a MFS family efflux pump (Roca et al., 2009). 
Tigecycline resistance has been associated with increased efflux by AdeABC. Peleg et al. 
(2007a), showed that exposure of resistant clinical isolates B46 and C75 (MIC of tigecycline 4 
and 6 µg/ml, respectively) to PAβN (efflux pump inhibitor) increased their susceptibility to 
tigeycline (MIC reduced to 1 and 4 µg/ml, respectively). Furthermore, adeB expression in 
B46 and C75 was 54- and 40-fold higher than that in a tigecycline-susceptible laboratory 
strain, suggesting that AdeABC was at least partly responsible for tigecycline resistance. 
However, the contribution of other efflux pumps cannot be ruled out, particularly since the 
AdeABC efflux system was not disrupted in this study.  
1.2.2.6. Biocides 
Efflux has been associated with biocide resistance in A. baumannii. Transporters reported to 
be involved are AdeABC, AdeIJK and the SMR efflux pump QacE (Rajamohan et al., 2010). An 
MFS family efflux pump, AmvA has also been described, which conferred significant increase 
in resistance to disinfectants, detergents and dyes in A. baumannii AC0037, an MDR clinical 
isolate (Rajamohan et al., 2010a). AmvA expressed in E. coli conferred only a subtle decrease 
in susceptibility to antibiotics, and appears to be more specific for biocides. AbeS is an MFS 
pump, which transports biocides (Srinivasan et al., 2011). An A. baumannii AC0037 mutant, 
in which abeS had been deleted, exhibited four-fold increased susceptibility to benzalkonium 
chloride compared with its parent and more than 16-fold increased susceptibility to the 
detergents, deoxycholate and sodium dodecyl sulphate. 
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A. baumannii strains, which form strong biofilms, have been reported to be more tolerant of 
biocides than strains that form a weaker biofilm (Rajamohan et al., 2009). Biofilm formation 
can be induced by the presence of biocides at sub-MIC concentration or by the presence of 
aminoglycosides (Hoffman et al., 2005; Rajamohan et al., 2009). Integrons commonly carry 
aminoglycoside-modifying enzymes and the presence of class one integrons correlates with 
the ability of A. baumannii strains to form strong biofilms and with biocide resistance. 
It is hypothesized that bacterial resistance to biocides could arise due to exposure to sub-
inhibitory concentrations of these compounds (Wendt et al., 1997). Fuangthong et al., 
(2011) reported that exposure of A. baylyi to sublethal concentrations (0.000001%) of 
chlorhexidine for 30 minutes induced adaptive resistance to lethal concentrations 
(0.00007%) of the biocide. Efflux was implicated in this adaptation, since the MIC of 
chlorhexidine for this bacterium decreased in the presence of PAβN (50 µg/ml). Kawamura-
Sato (2008) reported that repeated exposure of Acinetobacter spp. to sub-inhibitory levels of 
chlorhexidine gluconate resulted in increased resistance (an increase in MIC of up to 10-
fold). However, It has been reported that clinical isolates of A. baumannii do not become 
resistant to working concentrations of biocides over time (Martró et al., 2003; Wisplinghoff 
et al., 2007) and that whilst MICs may increase after exposure, they usually remain below 
the in-use concentrations (Kawamura-Sato et al., 2008). 
1.2.2.7. Multidrug Resistance 
In the healthcare environment, more than two-thirds of A. baumannii infections are MDR 
(Adams et al., 2010) and some strains are resistant to almost all antibacterial agents 
(Fournier et al., 2006). Not all strains of A. baumannii are MDR; SDF, isolated from a body 
louse, is antibiotic susceptible and ATCC 17978 is susceptible to many antibiotics (Adams et 
al., 2008). Efflux systems are an important determinant of MDR and are involved in both 
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antibiotic and biocide resistance (Coyne et al., 2010b; Rajamohan et al., 2010). Resistance 
islands, such as AbaR1, have been found in all sequenced A. baumannii genomes known to 
contain multiple resistance determinants (Fournier et al., 2006). These genomic regions also 
contribute to MDR (Adams et al., 2008). 
1.2.2.7.1. Efflux 
Efflux pumps transport toxic compounds, such as antibiotics, biocides and heavy metals out 
of the cell and can lead to resistance to these compounds (Mitscher, 2005; Rajamohan et al., 
2010; Levy, 2002). They are also implicated in virulence, cell homeostasis and quorum 
sensing (Piddock, 2006). Efflux pump-mediated resistance in A. baumannii is generally 
associated with the RND and MFS families of efflux pump (Vila et al., 2007). 
AdeABC, an RND Efflux Pump 
The adeABC operon present on the chromosome, encodes components of an efflux pump of 
the RND family (Magnet et al., 2001). adeA encodes the inner membrane fusion protein, 
adeB encodes the trans-membrane pump and adeC encodes the outer membrane 
component (Magnet et al., 2001). AdeA and AdeB share 55% similiarity and 68% similiarity 
to AcrA and AcrB of E. coli, respectively (Piddock, 2006). adeABC are not present in all strains 
and appear to be associated with clinical isolates, rather than environmental strains (Huys et 
al., 2005). Of 116 strains investigated by Nemec et al. (2007b), 68 lacked at least one of the 
genes in the adeABC operon, with 15 of these lacking adeB.  
AdeABC plays a major role in MDR in cells which overexpress it (Coyne et al., 2010a). It has 
broad specificity and was responsible for decreased susceptibility to β-lactams, 
fluoroquinolones, tetracycline, chloramphenicol, erythromycin and aminoglycosides in a 
clinical isolate, BM4454 (Magnet et al., 2001). MDR in BM4454 was lost when adeB was 
 31 
disrupted, suggesting that AdeB is essential for the function of this efflux pump (Magnet et 
al., 2001).  
Other RND Efflux Pumps 
Although AdeABC is often implicated in MDR, other RND efflux pumps also contribute, such 
as AdeIJK and AdeFGH (Damier-Piolle et al., 2008; Coyne et al., 2010c). adeIJK genes have 
been found in all strains examined so far (Coyne et al., 2010b). It has been suggested that 
AdeIJK has a larger role in intrinsic low-level antibiotic resistance (base-line resistance in the 
absence of regulation) than AdeABC in A. baumannii (Damier-Piolle et al., 2008). However, 
AdeIJK is not thought to be involved in increased resistance as a result of enhanced efflux 
since the pump was toxic when overexpressed in A. baumannii strains BM4454 and CIP 70-
10 (growth was impaired) (Damier-Piolle et al., 2008). AdeIJK and AdeABC have overlapping 
substrate profiles and appear to have a synergistic contribution to tetracycline, minocycline 
and tigecycline resistance. It is thought that if one efflux system were impaired, the other 
could transport at least some of the toxic compounds. An exception is ethidium bromide, 
which is not a substrate for AdeIJK (Damier-Piolle et al., 2008). Rajamohan, Srinivasan et al. 
(2010b) described decreased biocide (SDS, benzalkonium chloride and 
tetraphenylphosphonium chloride) susceptibility in four A. baumannii clinical isolates due to 
overexpression of AdeABC and AdeIJK. Inactivation of adeB or adeJ in one of these resistant 
isolates (AC0037) resulted in increased susceptibility to disinfectants, but not a complete 
loss of resistance, suggesting that other efflux pumps contributed to the resistant 
phenotype. AdeFGH is cryptic and therefore does not contribute to intrinsic resistance in A. 
baumannii (Coyne et al., 2010c). However, it can give rise to MDR, when overexpressed 
(Coyne et al., 2010c). 
 
 32 
Non-RND efflux pumps  
AmvA, a MFS family efflux pump, has been reported to confer resistance to antibiotics, dyes, 
antiseptics and disinfectants in A. baumannii isolate AC0037 (Rajamohan et al., 2010a). 
CmlA, a MFS efflux pump, confers chloramphenicol resistance and has been identified in the 
resistance island of A. baumannii AYE (Fournier et al., 2006). SMR efflux pumps encoded by 
qac genes remove quaternary ammonium compounds from the cell, and are involved in 
biocide resistance (Coyne et al., 2010b; Rajamohan et al., 2010). AbeS a member of the SMR 
family, confers low level resistance to antibiotics, dyes and detergents (Srinivasan et al., 
2009). The MATE family pump AbeM, confers resistance to fluoroquinolones although the 
increase in resistance attributable to this pump is thought to be small (Giamarellou et al., 
2008; Coyne et al., 2010b).  
1.3. Two Component Systems 
When there is a change to the extracellular environment of a cell or in the cellular 
homeostasis, it is important that the change is detected so that any necessary modifications 
to the intracellular environment can be made (Mitrophanov and Groisman, 2008; Mascher et 
al., 2006). Extracellular information is tranduced to intracellular proteins by cellular 
signalling. A widespread type of signalling, found in prokaryotes and eukaryotes, is protein 
phosphorylation. Two component systems (TCSs) are the predominant type of such 
signalling in prokaryotes (West and Stock, 2001; Mitrophanov and Groisman, 2008). These 
systems are also found in plants and fungi, but are absent from animals and humans (Zhang 
and Hendrickson, 2010; West and Stock, 2001). Some bacteria such as Myxococcus xanthus, 
a soil bacterium have at least 150 two-component pathways (Vos and Velicer, 2006), which 
has 146 histidine kinases (Bell et al., 2010; Mascher et al., 2006). Other bacteria have far 
fewer TCSs; P. aeruginosa has around 70 TCSs (Goodman et al., 2009) whilst Mycoplasma 
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pneumoniae, the smallest organism known to be capable of self replication (Pitcher and 
Nicholas, 2005), has no TCS genes (Musatovova et al., 2006). However, it is rare that bacteria 
have no TCSs as these pathways play a large role in adaptation to changing conditions 
(Wolanin et al., 2002; Mascher et al., 2006). The larger the number of environments that a 
bacterium is able to inhabit, the larger the genome generally is, and the larger the number of 
TCSs the organism usually has. For example, soil bacteria tend to have more TCSs than 
enteric bacteria (Krell et al., 2009; Goodman et al., 2009).  
TCSs are involved in basic housekeeping functions such as transition to stationary phase, 
competence, metabolism, adaptation to a lack of nutrients, sporulation and osmoregulation. 
They are also involved in other adaptive responses such as expression of toxins and 
antimicrobial resistance (Mitrophanov and Groisman, 2008; West and Stock, 2001). For 
example, mutations in pmrAB have been implicated in colistin resistance in P. aeruginosa, A. 
baumannii and Salmonella (Lopez-Rojas et al., 2011). It is the involvement of TCSs in 
antimicrobial resistance that is of relevance to this project. 
1.3.1. Signal Transduction 
Signalling via TCSs requires a sensor protein to detect a signal and a regulatory protein to 
mediate an intracellular response to adapt to the changed environment (Figure 1.2) 
(Mitrophanov and Groisman, 2008). The sensor protein is a histidine kinase which detects an 
extracellular stimulus and activates or inactivates a response regulator (Figure 1.2) 
(Wieczorek et al., 2008). Histidine kinases are most often homodimeric transmembrane 
proteins which, in Gram negative bacteria, comprise a periplasmic sensor domain and a 
cytoplasmic kinase domain, but they can alternatively be cytosolic proteins (West and Stock, 
2001; Khorchid and Ikura, 2006; Zhang and Hendrickson, 2010). The cytoplasmic domain 
contains a conserved histidine residue which accepts a phosphoryl group from ATP during
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Figure 1.2. Transcription Modification in Response to an Extracellular Stimulus (An 
example of signal transduction through a two component system). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A stimulus is detected by the sensor 
domain of the histidine kinase. The 
signal is transduced to the kinase 
domain which binds ATP and catalyses 
the transfer of a phosphate group to the 
conserved histidine residue. 
 
 
 
 
 
The kinase domain catalyses the 
transfer of the phosphate to the 
conserved aspartate residue in the 
receiver domain of the response 
regulator. The signal is tranduced to the 
effector domain. 
 
 
 
 
The effector domain undergoes a 
conformational change which enables 
the protein to act as a transcription 
factor and bind a specific promoter 
sequence to alter gene transcription. 
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signal tranduction (Khorchid and Ikura, 2006; Wolanin et al., 2002). Once the sensor domain 
has detected a stimulus, usually a chemical ligand (Zhang and Hendrickson, 2010), the 
histidine kinase autophosphorylates at a conserved histidine residue and then catalyses the 
transfer of the phosphate to the receiver domain of the response regulator (Marchand et al., 
2004). It is thought that the binding of a ligand induces a conformational change in the 
histidine kinase. This conformational change is proposed to propagate the signal from its 
sensor domain to the kinase domain (Khorchid and Ikura, 2006; Zhang and Hendrickson, 
2010). Histidine kinases, particularly cytosolic histidine kinases, often have duplicated 
domains which allow responses to be made to multiple signals. For example, KinA, a soluble 
histidine kinase involved in DNA replication, has three sensor domains (Krell et al., 2009; 
Mascher et al., 2006). 
The response regulator is responsible for bringing about the changes inside the cell, often by 
binding directly to DNA and modifying gene expression, since the majority of these proteins 
are transcription factors (Figure 1.2) (Wieczorek et al., 2008; West and Stock, 2001; Zhang 
and Hendrickson, 2010). Alternatively, the response regulator can catalyse reactions, bind 
RNA or interact with other proteins (Mitrophanov and Groisman, 2008). The response 
regulator has two or more domains. All response regulators have a receiver domain which is 
connected to an effector domain by a flexible linker (Marchand et al., 2004). The receiver 
domain accepts a phosphoryl group from the kinase domain of the histidine kinase and 
transduces the signal to the effector domain, which mediates an intracellular response. 
Many response regulators are dependent on phosphorylation for activation, since 
phosphorylation of a conserved Asp residue in the receiver domain brings about a 
conformational change which is necessary for DNA binding (Marchand et al., 2004; 
Mitrophanov and Groisman, 2008; Zhang and Hendrickson, 2010; Mascher et al., 2006). In 
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the PhoB response regulator from E. coli, an α-5 helix in the receiver domain inhibits DNA 
binding of the effector domain, which is otherwise constitutively active (Allen et al., 2001). 
Phosphorylation of the receiver domain relieves this inhibition (Allen et al., 2001).The 
receiver domain also has autophosphatase activity, further controlling the activity of the 
effector domain and determining the half life of the response regulator, which can range 
from seconds to hours and correlates with the protein’s physiological activity (West and 
Stock, 2001). The strength of the response following the detection of an extracellular 
stimulus is determined by the concentration of phosphorylated response regulator (Zhang 
and Hendrickson, 2010). The level of conservation of the various domains in TCS proteins 
reflects the function of these systems. The histidine kinase sensor and response regulator 
effector domains are highly variable due to the wide range of signals detected and responses 
brought about by TCSs. By contrast, the kinase domains of histidine kinases and the receiver 
domains of response regulators are highly conserved in both sequence and tertiary structure 
suggesting a conserved mechanism of signal transduction between the proteins (West and 
Stock, 2001; Zhang and Hendrickson, 2010). 
TCSs often comprise more than two proteins 
Many TCSs do not comprise only one histidine kinase and one response regulator. One 
histidine kinase may transduce a signal to multiple response regulators or one response 
regulator may be able to receive a signal from multiple histidine kinases (West and Stock, 
2001). This allows a larger number of signals and/or responses to be incorporated into the 
signal transduction and more regulation to be obtained (West and Stock, 2001). In addition 
to histidine kinases and response regulators, most TCSs comprise auxiliary proteins, (West 
and Stock, 2001) which post-translationally modify the activity of their cognate histidine 
kinase or response regulator, (Mitrophanov and Groisman, 2008). Auxiliary proteins enable 
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more complex signalling to be obtained as they can connect TCSs which would otherwise 
function independently, as well as enabling more complexity within a single TCS 
(Mitrophanov and Groisman, 2008). Auxiliary proteins are usually synthesised following a 
different stimulus to that detected by the histidine kinase. These proteins can therefore 
bring about changes in gene expression in response to a wider variety of signals than those 
specific for the TCS (Mitrophanov and Groisman, 2008). Components of a TCS can also 
transduce or receive signals if their usual partner is unavailable. In an E. coli phoR mutant, 
the histidine kinase CreC was found to replace PhoR in the activation of its response 
regulator, PhoB (Zhou et al. 2003). Such crosstalk enables the continuation of response and 
may be evidence of integrated cellular processes. 
There is some evidence of crosstalk between components of different TCSs in vitro. It is rare 
in vivo as specificity within a TCS is usually tightly regulated to ensure that a histidine kinase 
only activates its cognate response regulator. (Bell et al., 2010; Mitrophanov and Groisman, 
2008; West and Stock, 2001). However, crosstalk does exist, such as between the YycFG and 
PhoPR TCSs in B. subtilis (Tomaras et al., 2008). A histidine kinase has a strong kinetic 
preference for its cognate response regulator, with molecular recognition being the primary 
mechanism for specificity (Bell et al., 2010). Small molecule donors more readily transfer 
their phosphate group to a response regulator than a non-cognate histidine kinase (West 
and Stock, 2001), but nonetheless, this questions the exact specificity of TCSs. 
1.3.2. Two Component Systems in Acinetobacter 
Nineteen TCSs have been identified in Acinetobacter baumannii strain AB0057 (Adams et al., 
2008), the best characterised of which is AdeRS. AdeS is the histidine kinase and AdeR is the 
response regulator, a transcriptional activator which controls the expression of the adeABC 
operon (Peleg et al., 2007a; Wieczorek et al., 2008). Other TCSs include PmrAB, associated 
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with colistin resistance (Adams et al., 2009) and BfmRS involved in biofilm formation and 
cellular morphology (Tomaras et al., 2008). Two TCSs involved in heavy metal resistance 
have been identified, one of which is CusSR (Adams et al., 2008).  
1.3.2.1 TCSs in Antibiotic and Biocide Resistance 
1.3.2.1.1 AdeRS 
Expression of adeABC is regulated by AdeRS (Figure 1.3) (Marchand et al., 2004). It is unusual 
for efflux pump genes to be controlled by a TCS; they are usually regulated by specific 
regulatory proteins whose genes are adjacent to the pump genes (Magnet et al., 2001). 
However, regulation of efflux by a TCS has been reported in other bacteria such as S. aureus 
(NorA pump) (Fournier et al., 2000).  
Magnet et al. (2001) identified and characterised the adeRS and adeABC operons (Figure 
1.3). The gene products shared sequence homology to sensor kinases (AdeS) and response 
regulators (specifically transcriptional activators) (AdeR), and it was hypothesised that the 
AdeABC efflux pump was regulated by a TCS comprising these proteins (Magnet et al., 2001; 
Marchand et al., 2004).  
To investigate the hypothesis that alterations in AdeRS were responsible for AdeABC 
expression in a MDR clinical isolate BM4454, Marchand et al. (2004) investigated the 
sequences of adeR and adeS in MDR derivatives of CIP 70-10, a susceptible reference strain 
of A. baumannii. Point mutations were identified in both genes and these were hypothesised 
to be responsible for the overexpression of AdeABC and resistance to aminoglycosides in the 
mutants. The amino acid substitution identified in adeS (T153M; Table 1.2) was located four 
amino acids downstream of the conserved histidine residue (H149, the site of 
autophosphorylation) in the kinase domain and led to constitutive resistance. Amino acid  
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Figure 1.3 adeRS Control Expression of adeABC. Adapted from (Marchand et al., 2004). 
 
 
 
The adeRS open reading frames are upstream of the adeABC operon and divergently transcribed.
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Table 1.2 Mutations in adeS Associated with Multi-Drug Resistance. 
Amino acid 
substitution 
Phenotype Strain(s) Source of Strain Reference 
G30D MDR, overexpression of AdeABC (10- to 
30- fold higher in BMK4665 than in 
BM4587) 
Reduced susceptibility to aminoglycosides 
(12- fold increase in MIC than BM4587) 
BM4665 
Spontaneous 
resistant 
mutant 
Mutant of susceptible 
clinical isolate BM4587, 
obtained on gentamicin 
Coyne et al., 2010a 
G103D MDR 
Decreased tigecycline susceptibility (MIC = 
64 µg/ml; MIC for AB210 = 0.5 µg/ml) 
Increased ceftazidime susceptibility (MIC = 
16 µg/ml; MIC for AB210 = 64 µg/ml) 
Increased carbapenem susceptibility (at 
least 4-fold increased susceptibility to 
imipenem and meropenem compared 
with AB210) 
Increase (407-fold) in AdeABC expression 
compared with AB210 
AB210-6  Laboratory mutant 
AB210 (parent) serially 
exposed to tigecycline 
Hornsey et al., 2010 
Amino acid 94: 
Alanine in AB210,  
Valine in AB211. 
AB211: increase in tigecycline resistance, 
overexpression of AdeABC (compared 
with AB210) 
AB211 and 
AB210 (OXA-
23 clone 1)  
Isolated from a patient 
before (AB210) and after 
(AB211) treatment with 
tigecycline 
Hornsey et al., 2010; 
Hornsey et al., 2011 
 
T153M 
 
Indistinguishable resistance phenotype 
from BM4454 (MDR clinical isolate). 
Constitutive adeABC transcription. 
BM4546 Spontaneous one step 
mutant of CIP 70-10 
(susceptible reference 
strain), obtained on 
gentamicin 
Marchand et al., 2004 
MDR, multidrug resistant
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substitutions at this position in other histidine kinases, such as VanSD in Enterococcus 
faecium have been implicated in constitutive expression of their downstream genes 
(Depardieu et al., 2009). The H box, which contains the conserved histidine is also 
responsible for kinase and phosphatase activities of the histidine kinase (Depardieu et al., 
2009). The constitutive resistance in the mutants was suggested to be the result of a defect 
in phosphatase activity, but not kinase activity of AdeS, as has been reported for other 
bacteria (Aiba et al., 1989; Marchand et al., 2004). If so, AdeR would not be inactivated by 
AdeS and this would lead to a higher expression of AdeABC (Marchand et al., 2004). The 
amino acid substitution identified in AdeR (P116L; Table 1.3) was located in the α-helix 
(Section 1.3.1) of its receiver domain. The alteration in AdeR resulted in constitutive 
transcription of adeABC, which Marchand et al., (2004) hypothesised was due to lack of 
inhibition by the α-helix. Coyne et al. (2010) identified a glycine to aspartate substitution in 
the sensor domain of AdeS (Table 1.2), which was hypothesised to be responsible for the 
overexpression of AdeABC since mutations in the sensor domain of other histidine kinases 
have been implicated in constitutive expression of their target genes (Depardieu et al., 
2009).  
Mutations in AdeS or AdeR are not the only reason for AdeABC overexpression; the presence 
of the insertion sequence, ISAba1, upstream of the AdeABC operon has also been implicated 
(Coyne et al., 2010a; Ruzin et al., 2007). Ruzin et al. (2007) investigated the role of AdeABC 
in reduced tigecycline susceptibility in A. baumannii. They identified that adeS was disrupted 
by ISAba1 in two isolates with increased tigecycline resistance (MIC = 4 g/ml), which had 27- 
and 37- fold increased expression of AdeABC compared with less resistant isolates (MIC = 1.5 
µg/ml). However, in the less resistant strains, adeS was not disrupted. There have also been  
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Table 1.3 Mutations in adeR Associated with Multi-Drug Resistance. 
Amino acid 
substitution 
Phenotype/genotype Strain Source of Strain Reference 
P116L 
 
 
MDR, Constitutive adeABC transcription BM4547 Spontaneous one step 
mutant of CIP 70-10 
(on gentamicin) 
Marchand et al., 
2004 
A91V  
(immediately 
upstream of 
putative -10 
promoter seq of 
adeABC) 
MDR 
Decreased tigecycline susceptibility (MIC = 64 µg/ml; 
MIC for AB210 = 0.5 µg/ml) 
Increased ceftazidime susceptibility (MIC = 16 µg/ml; 
MIC for AB210 = 64 µg/ml) 
Increased carbapenem susceptibility (at least 4-fold 
increased susceptibility to imipenem and 
meropenem compared with AB210) 
Increase (407-fold) in AdeABC expression compared 
with AB210 
AB210-6 Laboratory mutant 
AB210 (parent) 
serially exposed to 
tigecycline  
Hornsey et al., 
2010 
Single missense 
mutation at 
nucleotide 58 
(GA) in isolates G 
and J compared 
with isolates A and F 
Led to D20N 
replacement in the 
acidic triad (active 
site for 
phosphorylation) 
Overexpression (>7-fold ) of adeB in isolates G and J 
compared with isolates A and F  
No difference in expression of adeRS 
No ISs identified in vicinity of adeABC 
Decreased susceptibility (according to Etest) to co-
trimozazole (MIC unreported), tigecycline (MIC for 
isolates G and J, 16; MIC for isolates A and F, 4 
µg/ml), meropenem (MIC for isolates G and J, ≥64; 
MIC for isolates A and F, ≤ 32 µg/ml) and 
levofloxacin (MIC for isolates G and J, ≥64; MIC for 
isolates A and F, 8 µg/ml). 
A missense mutation in the β-lactamase blaOXA-164 
(present in isolates A and F) was identified, which 
converted it to blaOXA-58 (present in isolates G and J). 
A. baumannii 
post-therapy 
isolates 
(Strain not 
reported). 
Isolates A and F 
were obtained on 
days 18 and 26 of 
infection; isolates 
G and J were 
obtained on days 
32 and 64. 
Hospitalised patient. Higgins et al., 
2010b 
MDR, multidrug resistant
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reports of MDR associated with increased adeABC expression, where mutations in adeRS 
were not identified (Table 1.4).  
Environmental stimuli detected by AdeRS 
The signals detected by AdeRS are unknown (Marchand et al., 2004), although upregulation 
of AdeABC following antibiotic exposure has been reported (Hornsey et al., 2010). Hornsey 
et al., (2010) showed that exposure of a tigecycline-susceptible clinical isolate (AB210, MIC, 
0.5 µg/ml) to tigecycline (0.5 x MIC, then doubling the concentration every 24 hr until no 
growth was observed) resulted in overexpression of AdeABC and resistance (MIC, 64 µg/ml) 
to the antibiotic. It was not investigated whether the resistance was inducible or stable 
(Michael Hornsey, personal correspondence). A mutant (AB210-6), selected by exposing 
AB210 to tigecycline, had a Gly103 to Asp substitution in AdeS, and an Ala91 to Val 
substitution in AdeR (Table 1.2; Table 2.1), which were not present in the parental strain, 
and so were hypothesised to be responsible for increased AdeABC expression and decreased 
tigecycline susceptibility in the mutant. In the same study, compared with the pre-therapy 
isolate (AB210), a post tigecycline therapy clinical isolate (AB211) was also resistant to 
tigecycline and overexpressed AdeABC. AB211 had an Ala94 to Val substitution, conferred by 
a single single nucleotide polymorphism (SNP), compared with AB210 (Table 1.2) (Hornsey et 
al., 2011; Hornsey et al., 2010). It was postulated that AdeABC overexpression in the post-
therapy isolate was due to the single nucleotide difference in adeS.  
1.3.2.1.2 Other TCSs in Antibiotic and Biocide Resistance 
PmrAB is Implicated in Colistin Resistance 
PmrB is the histidine kinase and PmrA is the response regulator in a TCS associated with 
polymyxin E (colistin) and polymyxin B resistance (MIC of colistin > 2 µg/ml) in A. baumannii.
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Table 1.4 Increased Expression of adeABC with Lack of Mutations in adeRS. 
Strain/isolate Phenotype/ genotype adeRS Source of strain Reference 
AYE MDR 
The expression of adeABC 
was more than 2-fold 
higher than that in Cip 70-
10, a susceptible reference 
strain  
The mutations identified in 
adeRS by Marchand et al. 
were not identified in AYE. 
Clinical isolate Fournier et al., 2006; 
Coyne et al., 2010a 
W7282 Tigecycline resistant (MIC = 
8 µg/ml) 
Nine-fold higher expression 
of adeABC than a pre-
therapy isolate (MIC = 0.5 
µg/ml)  
No difference in adeRS 
nucleotide sequence 
compared with a pre-
therapy isolate 
Clinical isolate. 
Post-therapy with 
tigecycline. 
 
Hornsey et al., 2010 
Nine tigecycline-
resistant isolates 
MDR 
Expessed adeB to levels 
57.6-fold higher than a 
tigecycline-susceptible 
control strain ATCC 15151 
 
No mutations compared 
with ATCC 15151 
No insertion of ISAba1  
Clinical isolates, Taiwan Sun et al., 2010 
A24D Tigecycline-reistant (MIC = 
24 µg/ml) 
Twenty five-fold increase in 
adeB expression compared 
with A24 
Lack of mutations 
compared with A24 
A24, tigecycline susceptible 
clinical isolate (MIC = 1 
µg/ml) exposed to 
tigecycline for four days 
Peleg et al., 2007a 
Various A. 
baumannii (2005-
2007) 
MDR, resistance to biocides 
55% of isolates studied 
possessed adeRSB (most of 
those with adeB were in 
highest resistance group) 
Point mutations in adeRS 
previously described were 
absent from isolates with 
adeB 
Clinical isolates Rajamohan et al., 2010 
MDR, multidrug resistant
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pmrAB are in an operon with pmrC, which encodes a phosphoethanolamine transferase. 
PmrC adds phosphoethanolamine to lipid A, a constituent of LPS. LPS is the target of 
polymyxins and the modified LPS results in a weaker interaction between the antibiotic and 
the outer membrane and gives reduced susceptibility to the agent (Beceiro et al., 2011). 
Beceiro et al. (2011) reported that ∆pmrB mutants had a decreased expression of pmrC, lack 
of addition of phosphoethanolamine to their LPS and were 100 times more susceptible to 
colistin compared with the parental strain. These data highlight the importance of PmrB and 
its regulation of pmrC in colistin resistance. Mutations in pmrAB have also been identified in 
colistin-resistant bacteria (Table 1.5). Adams, Nickel et al. (2009) reported that one colistin 
resistant derivative of A. baumannii AB0057 had a mutation in both pmrA and pmrB, and a 
colistin-resistant derivative of ATCC 17978 had two mutations in pmrB. Beceiro et al. (2011) 
reported amino acid substitutions in PmrB, but not PmrA or PmrC. However, Park et al. 
(2011) did not identify any amino acid substitutions in PmrAB in colistin resistant isolates, 
although mutants derived from susceptible isolates were found to have mutations in pmrB.  
pmrA and pmrB expression is often elevated in polymyxin-resistant clinical isolates and 
polymyxin-resistant mutants (selected in vitro) compared with polymyxin-susceptible clinical 
isolates (Park et al., 2011; Arroyo et al., 2011; Beceiro et al., 2011). Adams et al. (2009) 
reported that pmrA expression was 5-40 times higher in resistant strains compared with 
susceptible strains. However, an increased expression of pmrAB alone was not sufficient to 
result in polymyxin resistance. Arroyo et al. (2011) complemented ∆pmrB mutants with 
pmrAB DNA and reported that elevated expression of pmrAB in the absence of an increased 
expression of pmrC did not result in polymyxin resistance.  
These reports all suggest that increased expression of pmrA and/ or pmrB and a resultant 
increased expression of pmrC are important in polymyxin resistance, but the role of amino 
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Table 1.5 Polymyxin Resistance Associated with Mutations in pmrAB. 
Strain Amino acid substitution Phenotype/genotype Source of Strain Reference 
RC64 (colistin resistant) R134C and A227V (PmrB) Colistin resistant 
Gain-of-function of PmrAB  
Derived from ATCC 
19606 (Colistin 
sensitive) 
Lopez-Rojas et al., 2011 
MAC101  P102H (PmrA) 
A262P (PmrB) 
 
 
Colistin resistant 
Elevated expression of PmrA 
(>40-fold) compared with AB0057 
Selected from 
AB0057 (Colistin 
sensitive clinical 
isolate) 
Adams et al., 2009 
MAC102 A227V (PmrB) Colistin resistant 
Elevated expression of PmrA (5-
fold) compared with AB0057 
Selected from 
AB0057 (Colistin 
sensitive clinical 
isolate) 
Adams et al., 2009 
MAC201 T13N and P233S (PmrB) 
 
Colistin resistant 
Elevated expression of PmrA 
(>40-fold) compared with ATCC 
17978 
Selected from 
ATCC 17978 
(Colistin sensitive 
clinical isolate) 
Adams et al., 2009 
ACCA152 P233S (PmrB) Colistin resistant Clinical isolate Adams et al., 2009 
In vitro selected mutants   In PmrB: T192I (most 
frequently found), I121F, 
A183T, A184V, P190S, 
Q228P 
Colistin resistant 
Elevated expression of pmrA (12 
to 63-fold) and pmrB (9 to 42-
fold) 
No mutations in pmrA or pmrC 
Selected from 
colistin-susceptible 
clinical isolates 
Park et al., 2011 
Clinical isolates S14L, M145K, P233S, L87F 
(Single substitutions in 
PmrB) 
F387Y and S403F (Double 
Colistin-resistant 
Mutations identified compared 
with ATCC 17978 reference 
sequence. 
UK, Spain, Saudi 
Arabia 2000-2009 
Beceiro et al., 2011 
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substitution in PmrB) Increased expression of pmrA 
(mean increase 12.4-fold) and 
pmrB (mean increase 6.8-fold) 
compared with susceptible 
clinical isolates. pmrC expression 
not significantly changed. 
In vitro selected mutants A227V (ATCC 19606) 
N353Y (ABRIM) 
Colistin-resistant 
Increased expression of pmrA and 
pmrB compared with parental 
strains 
Selected from 
ATCC 19606 
(colistin-
susceptible type-
strain) or ABRIM 
(colistin-
susceptible clinical 
isolate)  
Beceiro et al., 2011 
Ten clinical isolates  All isolates had different 
variations of PmrB; four 
had a substitution in the 
kinase domain of PmrB 
Polymyxin B resistant 
Increased expression (26- to 292- 
fold) of pmrC compared with 
laboratory wild-type strain ATCC 
17978 
A. baumannii 
infections from five 
different countries 
2001-2008 
Arroyo et al., 2011 
Spontaneous resistant 
mutants 
Five mutants had 
mutations in pmrB, most 
often in the predicted 
kinase domain 
One mutant had a 
mutation in the predicted 
receiver domain of pmrA. 
Polymyxin B resistant (stable 
resistance; MIC 2-8 µg/ml) 
No mutation in pmrC in any 
mutant 
Increased expression (26- to 292- 
fold) of pmrC compared with 
laboratory wild-type strain ATCC 
17978 
Modified lipid A profile 
Selected from 
ATCC 17978 
(polymyxin B- 
sensitive; MIC 0.5 
µg/ml) on 
polymyxin B 
Arroyo et al., 2011 
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acid changes in PmrAB are yet to be determined. In support of the involvement of amino 
acid changes in polymyxin resistance, Arroyo et al. (2011) reported that ∆pmrB mutants only 
reverted to the polymyxin-resistant phenotype when they were complemented with pmrAB 
from the resistant parental strain. Wild-type DNA, which did not contain mutations in 
pmrAB, did not lead to an increase in pmrC expression or resistance to polymyxin B. This 
study suggested that mutations have a dominant effect on the activity of pmrCAB, leading to 
constitutive expression of genes controlled by this operon. The exact regulatory mechanism 
of PmrAB in A. baumannii is unknown. One ∆pmrB clinical isolate has been reported to 
retain some pmrB expression and some polymyxin B resistance, suggesting that there may 
be multiple copies of pmrB in the isolate, a more complex regulatory mechanism involving 
PmrAB, or mechanisms of PmrAB-independent resistance (Arroyo et al., 2011). In Salmonella 
enterica serovar Typhimurium, PmrA, PhoP and the TCS PreAB are known activators of 
pmrCAB (Merighi et al., 2006). It is yet to be determined whether there are any TCSs in A. 
baumannii, which are involved in crosstalk and regulation of PmrAB. It is known that there 
are other genes, in addition to pmrC, which are annotated as phosphoethanolamine 
transferases in this species; these genes may play a role in polymyxin resistance (Arroyo et 
al., 2011). 
Environmental Stimuli 
Adams and colleagues identified that environmental conditions such as acidity (pH 5.5) 
induced colistin resistance (MIC > 2 µg/ml) in wild-type, antibiotic susceptible strains and 
MICs increased from 1 to ≥64 µg/ml in such conditions. However, for a pmrB deletion 
mutant, the MIC was significantly reduced to 4 µg/ml, suggesting that PmrB is essential for 
colistin resistance. PmrA does not appear to be required for acid-induced resistance since 
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expression of this protein did not increase when pH was decreased from 7.7 to 5.5. 
Resistance occurred rapidly, suggesting that induced regulatory changes were responsible, 
rather than spontaneous resistance. Environmental Fe3+and Mg2+ levels are also sensed by 
PmrAB in bacteria such as Salmonella and P. aeruginosa (Wosten et al., 2000; McPhee et al., 
2003). Beceiro et al. (2011) reported that low Mg2+ levels resulted in a modest increase in 
pmrC expression and the addition of phosphoethanolamine to lipid A in A. baumannii ATCC 
19606. This observation suggests that PmrAB may induce pmrC expression in response to 
Mg2+ in A. baumannii (Beceiro et al., 2011). 
1.3.2.2 TCSs in Acinetobacter Not Involved in Antibiotic or Biocide Resistance 
BfmRS 
BfmRS is important in morphology and biofilm formation in A. baumannii 19606 (Tomaras et 
al., 2008). Inactivation of the histidine kinase (BfmS) resulted in a modest decrease in biofilm 
production and cell attachment, whilst inactivation of the response regulator (BfmR) 
resulted in biofilm deficiency, lack of cellular attachment and morphology changes. BfmR 
controls the expression of a chaperone-usher assembly system (csu operon) responsible for 
production of pili on the cell surface. The lack of expression of this system was responsible 
for the morphology changes. The less drastic effect when BfmS was inactivated suggests that 
a non-cognate histidine kinase may also activate BfmR or that the response regulator is 
active in its non-phosphorylated state. It is unknown whether the csu operon is regulated 
directly by BfmR and whether there are other target genes. Biofilm formation in bacteria is a 
complex process, and is often a result of many signalling pathways; the signals responsible 
for the activation of BfmR remain to be elucidated. Although BfmRS has a role in biofilm 
formation, it is important to note that the composition of the growth medium can affect the 
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ability of A. baumannii to form biofilms, independent of BfmRS. BfmRS has not been 
reported to be involved in antimicrobial resistance. However, biofilm formation is known to 
increase a bacterium’s tolerance to antibiotics (Lewis, 2001). Thus, it is possible that this TCS 
may be linked to the MDR of A. baumannii. Clemmer et al. (2011) used transposon 
mutagenesis to identify genes required for motility in this species. One mutant with an 80% 
reduction in motility compared with the parent was found to have a transposon inserted in 
bfmS. To investigate whether the csu operon is essential for motility, csuD was disrupted. 
CsuD is an outer membrane usher protein, which is required for production of fimbriae. The 
csuD mutant did not exhibit altered motility, but was defective in biofilm formation. These 
results suggest that the reduced motility of the bfmS mutant was not due to altered 
regulation of the csu operon and that BfmRS has other downstream target genes which are 
important for motility. However, the csu operon appears to be important for biofilm 
formation and BfmR may be an important regulator in this process. 
1.4 Methods to Study Acinetobacter 
1.4.1 Genetic Manipulation in A. baumannii  
The activity of bacterial genes can be inhibited by inserting an antibiotic resistance cassette 
(Datsenko and Wanner, 2000) or vector (Magnet et al., 2001; Hornsey et al., 2010) into the 
gene. Alternatively, the gene of interest can deleted, whereby the whole gene, or part of the 
gene, is removed from the chromosome by double recombination (Aranda et al., 2010), 
using a vector that contains sequences flanking the target region. All of these methods have 
been used to genetically manipulate A. baumannii (Marchand et al., 2004; Choi et al., 2009; 
Roca et al., 2009) 
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Gene Disruption: Gene disruption is used in this project to mean that a plasmid is inserted 
into the target gene, thereby inactivating the gene. The gene disruption method was used to 
inactivate adeB, adeC, adeR and adeS in the MDR A. baumannii clinical isolate, BM4454 
(Marchand et al., 2004; Magnet et al., 2001). A DNA fragment internal to the target gene 
was amplified by polymerase chain reaction (PCR) and cloned into pUC18, a vector which 
confers ticarcillin resistance and is a suicide vector in A. baumannii. The vector was 
electrotransformed into BM4454 and mutants were selected on ticarcillin. This method 
involved a single recombination step between the homologous sequences in the gene and 
PCR fragment in the vector, which led to insertion of the vector into the target gene. Since 
only one recombination step is required, it is the least reliable of the discussed methods. 
Aranda et al., (2010) investigated the stability of mutants created by this method. The 
mutants were unstable and could be reverted to wild-type by a second recombination step, 
although maintenance of selection pressure prevented this (Aranda et al., 2010). Another 
disadvantage is that the same vector could not be used to create multiple deletions in the 
same strain since recombination between the vector inserted in the chromosome and the 
newly introduced vector would be very likely (Aranda et al., 2010).  
Gene Replacement: This method involves the introduction of a suicide vector containing a 
deleted or modified gene into the host (Aranda et al., 2010). The vectors, pSSK10, pEX100T 
and pJQ200 have been used for this purpose in A. baumannii (Camarena et al., 2010; Choi et 
al., 2009; Roca et al., 2009). Choi et al., (2009) created an in-frame deletion of the pga locus. 
Sequences flanking the target region were amplified by PCR. The primers contained 
restriction sites, which were also present in the vector pSSK10. The fragments were digested 
and ligated sequentially into pSSK10, which had been digested with the same enzymes. The 
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plasmid was electroporated into A. baumannii and became incorporated into the 
chromosome. Double recombination steps were selected to identify mutants. sacB, which 
prevents growth of bacteria on sucrose was present on the vector and used to counter-
select single recombinants. Aranda et al.(2010) used this method to produce stable mutants 
with a kanamycin cassette inserted in oxyR, omp33 and soxR; no gene reversions were 
identified after 10 passages of these mutants in Luria Bertani (LB) broth. However, there was 
a lower efficiency of mutant selection (10-7) than for the gene disruption method (10-5) due 
to the second recombination step. This method is time consuming since it requires several 
subcloning and verification steps to introduce the inserts into the suicide vector and several 
phenotypic screenings to select single and double recombinants (Kim-Lee Chua, 
Unpublished). The phenotypic screenings alone take at least 4 days (Choi et al., 2009). 
Combination of gene disruption and gene replacement: Aranda et al.(2010) developed a 
quick method of inactivating chromosomal genes that does not require cloning steps, and 
can be confirmed by PCR. A linear PCR fragment carrying an antibiotic resistance cassette 
flanked by DNA homologous to the target gene was transformed into Acinetobacter and the 
target gene was replaced with the resistance cassette by double recombination. Advantages 
of this method are that no cloning steps are required, mutants are stable in the absence of 
antibiotic selective pressure and it could possibly be used to create multiple gene 
inactivations or deletions.  
A major limitation of all the reported methods is that they have relied upon an antibiotic 
resistance cassette for selection of mutants. Since A. baumannii are resistant to most 
antibiotics available, there are few choices when choosing a suitable antibiotic to select 
mutants (Towner, 2009). The method developed by collaborator Kim Lee Chua. 
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(unpublished) to inactivate genes in this study is based on the gene replacement method 
(Hamad et al., 2009), but relies upon tellurite resistance genes on the suicide vector, 
pMo130-TelR (Section 0; Figure 2.1; Figure 2.2). The MIC of tellurite for many A. baumannii 
strains is between 2 and 16 µg/ml (G. Richmond, unpublished data).  
1.4.2 Virulence Models  
Galleria mellonella, the larva of the greater wax moth, can be used to model A. baumannii 
infection and also to assess the effect of antimicrobial treatment upon infection (Peleg et al., 
2009). G. mellonella are a suitable organism for the study of human infection since they can 
be maintained at 37°C, a known inoculum of bacteria can be precisely administered and 
insects have a similar innate immune system to that found in mammals (Kavanagh and 
Reeves, 2004; Peleg et al., 2009). The virulence of bacteria P. aeruginosa in G. mellonella has 
also been shown to correlate with their virulence in mammalian models (Jander et al., 2000). 
A common end point of experiments using G. mellonella is the measurement of percentage 
survival at increasing time-points post-infection. The immune response can also be 
monitored, by measuring the level of haemocytes (phagocytes) present in the larva or by 
measuring the expression of antimicrobial peptides (Kavanagh and Reeves, 2004). Insect 
models of infection are suitable to identify any differences in virulence between mutant 
strains of bacteria. These models are less expensive than mammalian models and are more 
ethically acceptable. However, mammalian-specific disease processes will not be identified, 
thus mammalian models are required to study disease processes in the host (Kavanagh and 
Reeves, 2004).  
Caenorhabditis elegans and mice have also been used to study virulence of A. baumannii 
(Smith et al., 2007; Gaddy et al., 2012). The C. elegans model has limitations compared with 
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the G. mellonella model; exposure of C. elegans to a temperature of 37°C for extended 
periods of time is lethal and the exact bacterial inoculum cannot be quantified, as in this 
model an unknown number of bacterial cells are ingested by the worm (Marsh and May, 
2012).  
In the mouse sepsis model, A. baumannii rapidly disseminates to different organ systems 
(McConnell et al., 2011). This model may not be the best for simulating sepsis in humans, as 
sepsis in human infection is more progressive (McConnell et al., 2012). Other mammalian 
models, such as a rat model of burn infection (Uygur et al., 2009) and murine model of 
pneumonia (Montero et al., 2004) result in dissemination of A. baumannii to other body 
sites, and may be more suitable for modelling human disseminated infection (McConnell et 
al., 2012).  
1.5 Background to the Project 
1.5.1 Overview 
The overall aim of the programme of work in which this project is part, is to investigate the 
role of TCSs in MDR and biocide resistance in A. baumannii.  
The specific questions to be answered are:  
a) how does A. baumannii respond to commonly used biocides (disinfectants)? 
b) can these responses regulate pathways that lead to resistance to multiple antibiotics? 
1.5.2. Hypotheses to be Tested 
The main hypothesis is that the exposure of A. baumannii to biocides in the hospital 
environment predisposes the bacterium to develop resistance to multiple antibiotics. It is 
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hypothesised that two component regulatory systems are involved in the regulation of 
adaptive responses that allow survival of A. baumannii in the presence of these 
antimicrobials. 
The hypotheses to be investigated are: 
1. The deletion of adeS will result in down-regulation of AdeABC, decreased MICs of pump 
substrates and therefore a loss of MDR. Published results by two research teams have 
suggested that a ΔadeS mutant is more susceptible to agents such as aminoglycosides 
and fluoroquinolones than the wild type strain (Wong et al., 2009; Marchand et al., 
2004). 
2. The deletion of pmrB will result in increased susceptibility to polymyxin antibiotics 
(Beceiro et al., 2011; Arroyo et al., 2011). 
3. Deletion of adeS and/or pmrB will affect the level of accumulation of antimicrobials. 
4. Deletion of adeS will affect biocide susceptibility. This will affect growth of planktonic 
cells and formation of a biofilm in the presence of biocides.  
5. Planktonic cells will be more susceptible to biocides than cells in a biofilm. 
6. Deletion of adeS will affect biofilm formation. 
1.5.3. Aims and Objectives  
1. To interrogate the available genome sequences for TCSs. 
2. To use the available genome sequences to identify a representative strain of A. 
baumannii for initial genetic manipulation experiments. (For this study, a representative 
strain was one which was MDR and had the largest number of core genes for its species, 
compared with other candidate strains (Section 3.2.2). 
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3. To use a gene deletion technique established for Acinetobacter (Kim Lee Chua, 
unpublished) to delete adeS and pmrB in a representative strain of A. baumannii. 
4. To confirm and add to published data by determining the phenotype of AYEΔadeS and 
AYE pmrB. 
5. To use the A. baumanii mutants in which adeS and pmrB have been deleted to 
investigate if AdeRS and PmrAB are involved in both antibiotic and biocide susceptibility.  
6. To determine whether deletion of adeS or pmrB influence growth and biofilm formation 
in the presence and absence of biocides.  
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2. Materials and Methods  
2.1. Bioinformatics 
2.1.1. Comparison of A. baumannii Genomes 
Sequence data were obtained from xBASE where possible (Chaudhuri et al., 2008). BM4454 
sequence data (Accession AF370885.1; (Marchand et al., 2004)) and adeR sequence data 
for AB307-0294 were obtained from Genbank (Accession CP001172.1), since these data 
were not in the xBASE database.  
Nucleotide and protein sequences of adeR and adeS were aligned using ClustalW2 (Larkin et 
al., 2007). X-base (http://www.xbase.ac.uk) (Chaudhuri et al., 2008) was used to align adeS 
and the adeRS and adeABC operons from six different strains (Table 2.1) of A. baumannii in 
order to determine the level of conservation of sequence. 
2.1.2. Identification of TCS genes in AYE 
At the start of this project, November 2010, AciBASE (an online database containing 
Acinetobacter genome sequence data, which aims to support research into the 
epidemiology and molecular evolution and biology of Acinetobacter) was used to 
interrogate the genome sequences of the six available genome sequenced A. baumannii 
strains to identify TCSs in this species. Any TCSs reported in the literature, but not found in 
AciBASE were added to these results.  
xBASE (Chaudhuri et al., 2008) was used to search for pmrB and bfmS in AYE. Where the 
gene was unannotated, the literature was searched to find a homologue in an alternative 
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Table 2.1 Strains Compared in Bioinformatic Analyses. 
 
 
  
Strain of A. baumannii Description Reference 
AYE MDR clinical isolate (Poirel et al., 2003) 
AB0057 MDR clinical isolate (Hujer et al., 2006) 
AB307-024 Drug susceptible clinical 
isolate 
(Adams et al., 2008) 
ATCC 17978 Drug susceptible clinical 
isolate 
(Smith et al., 2007) 
ACICU MDR clinical isolate (Iacono et al., 2008) 
BM4454 MDR clinical isolate (Magnet et al., 2001) 
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strain and this nucleotide sequence was compared against the AYE genome in xBASE using 
the Basic Local Alignment Search Tool (BLAST; Altschul et al., 1990) algorithm. The ClustalW 
facility in Genious Pro 4.6.5 (Biomatters_Ltd., 2005-2009) was used for alignments. To check 
for multiple copies of the gene(s) of interest, the known AYE gene sequence was compared 
against the AYE genome sequence using BLAST. (Altschul et al., 1990). The number of DNA 
sequences within the genome that the gene sequence aligned to was taken to be the 
number of copies of that gene present. 
2.2. Bacterial Strains, Growth, Storage and Identification 
The fifteen strains of E. coli and three A. baumannii (Table 2.2) were stored on Protect™ 
beads (Technical Service Consultants Ltd, UK) at -80ᵒC until required. E. coli and A. baumannii 
were grown on LB agar or in LB broth (Sigma-Aldrich, UK, L3022) supplemented with the 
appropriate antibiotic (Table 2.3). For biocide susceptibility assays (Section 2.5.4) Tryptic Soy 
Agar (TSA; Sigma-Aldrich, UK, 22091) and Tryptic Soy Broth (TSB; Sigma-Aldrich, UK, 22092) 
were used to maintain consistency with methods used by collaborators at the Health 
Protection Agency (HPA). To identify bacteria as E. coli, colonies were grown on MacConkey 
medium (Oxoid, UK, CM0007); E. coli grew as translucent colonies and produced red 
pigment. Colonies were Gram stained and observed microscopically to confirm they were 
Gram negative bacilli. The API20E identification system (BioMérieux UK Ltd., 20100) was 
used as a final check. All new strains were verified by the above methods.  
To confirm isolates as A. baumannii, a multiplex PCR which amplifies gyrB was used (Table 
2.4). This PCR can be used to distinguish between members of the A. calcoaceticus-A. 
baumannii complex. To confirm purity of cultures, A. baumannii were Gram stained and 
grown on MacConkey medium. A. baumannii from a plate were observed microscopically as   
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Table 2.2 Strains used in this Study. 
Description Phenotype Reference 
A. baumannii AYE, clinical isolate MDR (Fournier et al., 2006) 
A. baumannii AYEΔadeRS MDR This study 
A. baumannii AYEΔpmrAB MDR This study 
E. coli DH5α + pMo130-TelR KanR; TelR; not viable on 
sucrose 
Kim Lee Chua 
(Unpublished) 
E. coli DH5α + pMo130-
TelR/adeRSUP 
KanR; TelR; not viable on 
sucrose 
This study 
E. coli DH5α + pMo130-
TelR/adeRSUPDOWN 
KanR; TelR; not viable on 
sucrose 
This study 
E. coli DH5α + pMo130-
TelR/pmrABUP 
KanR; TelR; not viable on 
sucrose 
This study 
E. coli DH5α + pMo130-
TelR/pmrABUPDOWN 
KanR; TelR; not viable on 
sucrose 
This study 
E. coli DH5α + pMo130-
TelR/bfmRSUP 
KanR; TelR; not viable on 
sucrose 
This study 
E. coli DH5α + pMo130-
TelR/bfmRSUPDOWN 
KanR; TelR; not viable on 
sucrose 
This study 
E. coli DH5α + pMo130-TelR/UP-
adeRS-DOWN 
KanR; TelR; not viable on 
sucrose 
This study 
E. coli DH5α + pMo130-TelR/UP-
pmrAB-DOWN 
KanR; TelR; not viable on 
sucrose 
This study 
E. coli S17-1 AmpS, TelS (Simon et al., 1983) 
E. coli S17-1 + pMo130-
TelR/adeRSUPDOWN 
KanR; TelR; not viable on 
sucrose 
This study 
E. coli S17-1 + pMo130-
TelR/pmrABUPDOWN 
KanR; TelR; not viable on 
sucrose 
This study 
E. coli S17-1 + pMo130-
TelR/bfmRSUPDOWN 
KanR; TelR; not viable on 
sucrose 
This study 
E. coli S17-1 + pMo130-TelR/UP-
adeRS-DOWN 
KanR; TelR; not viable on 
sucrose 
This study 
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MDR, Multidrug resistant 
E. coli S17-1 + pMo130-TelR/UP-
pmrAB-DOWN 
KanR; TelR; not viable on 
sucrose 
This study 
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Table 2.3 Antibiotics used in this Study. 
Agent Solvent Supplier 
Amikacin disulphate 
salta 
SDW Sigma-Aldrich, UK (A1774) 
Ampicillina,b Sodium bicarbonate and 
SDW 
Merck Chemicals, UK (171254) 
Cefotaximea SDW Sigma-Aldrich, UK (C7912) 
Ceftazidimea SDW Sigma-Aldrich, UK (C3809) 
Chloramphenicola 70% V/V methanol Sigma-Aldrich, UK (C0378) 
Ciprofloxacina,c Drop of 100% V/V acetic 
acid to dissolve and SDW 
Fluka Biochemika, Sigma-Aldrich, UK 
(17850) 
Colistin sulphate 
salta 
SDW Sigma-Aldrich, UK (C4461) 
Erythromycina SDW + drop of acetic acid 
(100% V/V) 
Sigma-Aldrich, UK (E5389) 
Ethidium bromidea SDW Sigma-Aldrich, UK (E8751) 
Gentamicina SDW Sigma-Aldrich, UK (G1264) 
Imipenema N/A Biomeriéux, UK (513608) 
Kanamycinb SDW Sigma-Aldrich, UK (60615) 
Meropenema N/A Biomeriéux, UK (513818) 
Norfloxacinc SDW + drop of acetic acid 
(100% V/V) 
Sigma-Aldrich, UK (N9890) 
Polymyxin Ba SDW Sigma-Aldrich, UK (P1004) 
Potassium tellurite 
hydrateb 
SDW Sigma-Aldrich, UK (P0677) 
Tetracycline SDW Sigma-Aldrich, UK (T3383) 
Tigecyclinea SDW Pfizer, (PF-05208753) 
Tobramycin SDW Sigma-Aldrich, UK (T4014) 
Sulbactama SDW Pfizer, (CP-045899) 
SDW, sterile distilled water; aMinimum inhibitory concentration determined for AYE, 
AYE∆adeRS and AYEΔpmrAB; bUsed during gene deletion; c Used in fluoroquinolone 
accumulation assays.  
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Table 2.4 gyrB Multiplex PCR to Distinguish Between Acinetobacter Species (Higgins et 
al., 2010a; Higgins et al., 2007). 
Primer A. baumannii A. nosocomialis A. calcoaceticus A. pittii 
sp4F 294bp amplimer 
490bp amplimer 
294bp amplimer   
sp4R 
sp2F  
D14  428bp amplimer 
D19 
D16  194bp amplimer 
D8 
In this study, all seven primers were used in a PCR to identify the species of Acinetobacter. 
The primers (Higgins et al. 2010) are specific for the different species.  
The PCR reagents were: 1.1 x Reddymix PCR master mix (22 µl; Thermo Fisher Scientific, PCR-
300-610D), gyrB primer mixa (2 µl) and template DNA (lysate) or Ultrapure water (1 µl). The 
PCR parameters (30 cycles for stages 2-4) were: 94ᵒC, 2 min; 94ᵒC, 1 min; 59ᵒC, 1 min; 72ᵒC, 
1 min; 72ᵒC, 10 min. 
a A gyrB primer mix was prepared for the PCR reaction (all seven primers were added to one 
eppendorf at a final concentration of 25 µM).  
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Gram negative coccobacilli, A. baumannii from a liquid culture were observed 
microscopically as a pleiomorphic population, comprising short coccobacilli and more 
elongated cells, resembling bacilli. On MacConkey agar, A. baumannii grew as opaque pink 
colonies and the medium turned orange.  
To confirm that cells had reached the required stage of growth for experiments, culture (1 
ml) was added to a cuvette and absorbance was measured in a spectrophotometer.  
2.3. DNA Extraction, Purification, Quantification and Sequencing 
Genomic DNA was extracted from A. baumannii AYE using the Wizard® Genomic DNA 
Purification Kit (Promega Corporation, UK, A1120). Plasmids (Table 2.5) were extracted using 
the GeneJET™ Plasmid Miniprep kit (Fermentas Life Sciences, UK, K0503). PCR amplimers 
and pMo130-TelR were purified using the QIAquick® PCR Purification Kit (QIAGEN, UK, 
28104). All kits were used according to the manufacturer’s instructions. Elution of purified 
PCR amplimers was in 30 µl sterile distilled water (SDW) to obtain a high DNA concentration 
for cloning. Elution of plasmids was in 50 µl SDW, since this was found to provide sufficient 
plasmid DNA for downstream manipulation. Where lysates were used as the template for 
PCRs, these were prepared by suspending a colony in SDW (100 µl) and heating the 
suspension (100ᵒC, 10 min).  
Electrophoresis of UP and DOWN fragments was in 1% agarose (100 V, 1 hr). To determine a 
size difference of 1 kb between plasmids, electrophoresis was in 0.7% agarose (80 V, 2 hr). 
Electrophoresed DNA was visualised using GeneSnap (Syngene, Synoptics Ltd, UK, product 
version 6.07) and if required, DNA concentrations were then determined using GeneTools 
(Syngene, Synoptics Ltd, UK, product version 3.07). 
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Table 2.5 Plasmids used in this Study. 
Plasmid Description Antibiotic 
determinants 
Reference 
pMo130-TelR  Contains multiple 
cloning site 
TelR; AmpR Kim-Lee Chua 
(Unpublished) 
pMo130-
TelR/adeRSUPDOWN 
Constructed to 
delete adeRS in AYE 
TelR; AmpR This study 
pMo130-
TelR/pmrABUPDOWN 
Constructed to 
delete pmrAB 
deletion in AYE 
TelR; AmpR This study 
pMo130-
TelR/bfmRSUPDOWN 
Constructed to 
delete bfmRS in AYE 
TelR; AmpR This study 
pMo130-TelR/UP-
adeRS-DOWN 
Constructed to 
complement 
AYEΔadeRS 
TelR; AmpR This study 
pMo130-TelR/UP-
pmrAB-DOWN 
Constructed to 
complement 
AYEΔpmrAB 
TelR; AmpR This study 
A diagram of pMo130-TelR is shown in Figure 2.2.
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All DNA sequencing was carried out by the Functional Genomics, Proteomics and 
Metabolomics Facility, University of Birmingham. 
2.4. Inactivation of Histidine Kinase Genes in A. baumannii AYE 
The method used to inactivate histidine kinase genes in A. baumannii involved a double 
recombination step between chromosomal regions of DNA flanking the gene of interest and 
those same fragments present on a vector (Figure 2.1). The flanking fragments were 
amplified by PCR and cloned into the vector pMo130-TelR. All cloning steps were carried out 
in E. coli DH5α. E. coli S17-1 was used to conjugate pMo130-TelR into A. baumannii AYE. S17-
1 was used as the donor since it is a mobilizing strain with chromosomally integrated 
transfer genes from a broad host range Inc-P-type plasmid, enabling the transfer of pMo130-
TelR to A. baumanii AYE (Simon et al., 1983). DH5α cannot be used for conjugation, as it does 
not have genes for vector mobilisation. Single recombinants were those which produced a 
yellow pigment when sprayed with pyrocatechol. These colonies were passaged in LB broth 
containing sucrose to induce loss of the vector. Deletion mutants were those passaged cells 
which remained white after spraying with pyrocatechol. These colonies had undergone a 
second recombination step and the gene of interest had been incorporated into the vector 
and removed from A. baumanii AYE when the vector was removed. 
2.4.1. Construction of pMo130-TelR/UPDOWN 
2.4.1.1. Primer design 
Primers (Table 2.6) to amplify fragments (approximately 1kb in length) flanking the target 
gene were designed in Geneious Pro 4.6.5 (Biomatters_Ltd., 2005-2009) against DNA 
sequences (2000bp) immediately upstream and downstream of the target gene. All primers  
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Figure 2.1 Gene Deletion Method. 
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Table 2.6 Primers used in this Study 
Description Sequence 
pMo130-TelRFW  
Check primer upstream of multiple 
cloning site in pMo130-TelR 
CCA TCT ACT TCT TCG ACC C 
 
pMo130-TelRRV  
Check primer downstream of multiple 
cloning site in pMo130-TelR 
TCA CAG CTT GTC TGT AAG CG 
 
adeSgeneFW 
adeS internal primer 
GTAAGTTAGGAATTAGTAAGC 
adeSgeneRV 
adeS internal primer 
GCATGTACAACAGCAAGACC 
pmrBgeneFW 
pmrB internal primer 
TTCGCTTGGGAGCTTGCGGG 
pmrBgeneRV 
pmrB internal primer 
TCAGGGTCTATTCCTGCACCGC 
UPFWadeS  
(Contains NotI recognition site) 
GGG GCG GCC GCC CTC CGA CTT 
GCG GAC GGA T 
UPRVadeS 
(Contains BamHI recognition site) 
GGG GGA TCC GGT TCG CTC TAG 
TGC ATC GC 
DOWNFWadeS  
(Contains BamHI recognition site) 
GGG GGA TCC AAG CTG TAA CCG 
CAG CGC CA 
DOWNRVadeS  
(Contains SphI recognition site) 
GGG GCA TGC AGG TGA GCA AGT 
CGG CCC TT 
adeSRVcomp 
(Contains BamHI recognition site) 
GGG GGA TCC AGG TGA GCA AGT 
CGG CCC TT  
UPFWpmrB 
(Contains NotI recognition site) 
GGG GCG GCC GCC TTA TGC AAT 
CGC ACC GAG C 
UPRVpmrB 
(Contains BamHI recognition site) 
GGG GGA TCC CAA ACG GTA GCC 
CAG TCC TC 
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DOWNFWpmrB 
(Contains BamHI recognition site) 
GGG GGA TCC CCT GCA CTT GCA 
TGA CCG CC 
DOWNRVpmrB  
(Contains SphI recognition site) 
GGG GCA TGC GTG ATT GGT GGT 
GCA GCG GG 
UPFWbfmS 
(Contains NotI recognition site) 
GGG GCG GCC GCG AGA TAG CAT 
ACC AAA GCT G 
UPRVbfmS 
(Contains BamHI recognition site) 
GGG GGA TCC ACG TCA ATT GAA 
CGG TCT TG 
DOWNFWbfmS 
(Contains BamHI recognition site) 
GGG GGA TCC AGG TTT GCC GCT 
TCT CAG GC 
DOWNRVbfmS  
(Contains SphI recognition site) 
GGG GCA TGC CGA CTC GGG TCC 
AGG TTC CC 
UP_flankadeS 
(Used for colony PCR during 
complementation; Figure 2.3) 
CCC TGC TCT AAC TTC ACT ACC 
DN_flankadeS 
(Used for colony PCR during 
complementation; Figure 2.3) 
GAT GTT TAT CCT GCC ACT GTA CG 
UPFW_colonyadeS 
(Used for colony PCR during 
complementation; Figure 2.3) 
CGA CTT GCG GAC GGA TTT C 
DNRV_colonyadeS 
(Used for colony PCR during 
complementation; Figure 2.3) 
GAT ACA AAA GGT GAG CAA GTC G  
Recognition sites are highlighted 
The position of primers pMo130-TelRFW and pMo130-TelRRV on pMo130-TelR is shown in 
(Figure 2.2). 
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were ordered from Invitrogen (Invitrogen Ltd., UK). On arrival, the primers were re-hydrated 
with Ultrapure water (Invitrogen Ltd., UK, 10977035) to a concentration of 100 µM and 
these stocks used to prepare working stock solutions (25 µM). All primers were stored at -
20ᵒC. 
2.4.1.2. Cloning 
The upstream fragment (UP fragment) of adeRS, pmrAB and bfmRS was amplified from A. 
baumannii genomic DNA using primers UPFWadeS and UPRVadeS (adeRS), UPFWpmrB and 
UPRVpmrB (pmrAB) and UPFWbfmS and UPRVbfmS (bfmRS) (Table 2.7, Reactions 4, 6 and 
7). The downstream fragment (DOWN fragment) was amplified using primers DOWNFWadeS 
and DOWNRVadeS (adeRS), DOWNFWpmrB and DOWNRVpmrB (pmrAB) and DOWNFWbfmS 
and DOWNRVbfmS (bfmRS) (Table 2.7, Reactions 5, 8 and 9). These primers contain 
restriction sites for cloning the amplimers into pMo130-TelR (Table 2.6).  
The identity of pMo130-TelR was confirmed by restriction digestion with BamHI (Table 2.8, 
Digestion 1) and PCR (Table 2.7, Reaction 1) which amplified across the multiple cloning site 
(Figure 2.2). Digested vector was treated with calf intestinal alkaline phosphatase (CIAP) 
(Promega Corporation, UK, M1821). CIAP 10x reaction buffer (5μl) and CIAP (1μl; 1μg/μl) 
were added directly to the double-digested vector (20μl) and the reaction volume made up 
to 50 μl with Ultrapure water (Invitrogen). Ligation of the digested insert and CIAP-treated 
vector was carried out using Quick-Stick (QS) ligase (Bioline Ltd., UK, BIO-27027). QS Ligase 
(1μl) and QS buffer (5μl) were added to vector and insert DNA (vector: insert volume ratios, 
1:1, 1:2, 1:3, 1:4 and 1:5) and the reaction volume made up to 20μl with Ultrapure water 
(Invitrogen). Incubation was at room temperature (30 min).
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Table 2.7 PCR Parameters used in this Study. 
PCR Primer Forward Primer Reverse 
PCR Parameters (30 cycles) 
Initial 
Denaturation 
Denaturation Annealing Extension Final Extension 
1b pMo130-TelRFW pMo130-TelRRV 95ᵒC (5 min) 95ᵒC (30 sec) 53ᵒC (30 sec) 72ᵒC (3 min) 72ᵒC (10 min) 
2b adeSgeneFW adeSgeneRV 
95ᵒC (5 min) 95ᵒC (30 sec) 53ᵒC (30 sec) 72ᵒC (1 min) 72ᵒC (10 min) 
3b pmrBgeneFW pmrBgeneRV 
4a UPFWadeS  UPRVadeS 
95 °C (5 min) 95 °C (30 sec) 58ᵒC (30 sec) 72ᵒC (1 min) 72ᵒC (10 min) 
5a DOWNFWadeS DOWNRVadeS  
6a UPFWpmrB UPRVpmrB 
95 °C (5 min) 95 °C (30 sec) 58ᵒC (30 sec) 72 °C (75 sec) 72ᵒC (10 min) 
7a UPFWbfmS UPRVbfmS 
8a DOWNFWpmrB DOWNRVpmrB 
9a DOWNFWbfmS DOWNRVbfmS 
10b pMo130-TelRFW UPRVadeS 
95ᵒC (5 min) 95ᵒC (30 sec) 53ᵒC (30 sec) 72ᵒC (3 min) 72ᵒC (10 min) 
11b pMo130-TelRFW UPRVpmrB 
12b pMo130-TelRFW UPRVbfmS 
13b pMo130-TelRFW DOWNRVadeS 
14be pMo130-TelRFW DOWNRVpmrB 
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15b pMo130-TelRFW DOWNRVbfmS 95ᵒC (5 min) 95ᵒC (30 sec) 53ᵒC (30 sec) 72ᵒC (3 min) 72ᵒC (10 min) 
16c pMo130-TelRFW adeSRVcomp 
94 °C (2min) 94 °C (10 min) 58 °C (30 sec) 68 °C (2 ½ min) 68 °C (7 min) 
17ce pMo130-TelRFW DOWNRVpmrB 
18c UPFWadeS  DOWNRVadeS 
94 °C (2min) 94 °C (10 min) 58 °C (30 sec) 68 °C (2 ½ min) 68 °C (7 min) 19c UPFWadeS adeSRVcomp 
20c UPFWpmrB DOWNRVpmrB 
21c UPFWbfmS DOWNRVbfmS      
22d UP_flankadeS DNRV_colonyadeS 
95ᵒC (5 min) 95ᵒC (30 sec) 55ᵒC (30 sec) 72ᵒC (3 ½ min) 72ᵒC (10 min) 
23d UPFW_colonyadeS DN_flankadeS 
 
The primers are listed in Table 2.6 
a 1.1 x Reddymix PCR master mix (90 µl; Thermo Fisher Scientific, PCR-300-610D), forward primer (3 µl), reverse primer (3 µl) and template DNA 
or Ultrapure water (4 µl).  
b 1.1 x Reddymix PCR master mix (22µl), forward primer (1µl), reverse primer (1µl), template DNA or Ultrapure water (1µl). 
c 2.1 x Extensor Hi-Fidelity PCR master mix (11µl; Thermo Fisher Scientific, PCR-110-005G), Ultrapure water (11µl; Invitrogen), forward primer 
(1µl), reverse primer (1µl) and template DNA or Ultrapure water (1µl).  
d GoTaq master mix (12.5 µl; Promega, M5122), Ultrapure water (8.5 µl), forward primer (10 µM, 1 µl), reverse primer (10 µM, 1 µl) and 
template DNA (lysate, 2 µl). 
e The same primers were used for reactions 14 and 17. Reaction 14 was used to verify the deletion construct; reaction 17 was used to verify the 
complementation construct. Extensor was used for reaction 17 because a larger amplimer was expected, which could not be amplified with 
Reddymix PCR master mix.
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Figure 2.2 Vector used in the Construction of pMo130-TelR/UPDOWN 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The multiple cloning site, used for cloning of the UP and DOWN fragments, is highlighted 
with a red box.  
XylE breaks down pyrocatechol to produce a yellow product and so is used to select single 
and double recombinants (Section 2.4.3). SacB confers sucrose toxicity and is a counter 
selectable marker used to select double recombinants (Section 2.4.3). kilAtelAtelB confers 
tellurite resistance; aph confers kanamycin resistance. 
Primers pMo130-TelRFW (FW) and pMo130-TelRRV (RV) were used to verify the identity of 
pMo130-TelR (Table 2.6; Table 2.7). 
The sequence of pMo130-TelR and the locations of primers pMo130-TelRFW (FW) and 
pMo130-TelRRV (RV) are shown in Appendix 2.
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Table 2.8 Restriction Digestions used in this Study. 
Digestion Enzymes Buffer and activity Reaction Incubation Enzyme inactivation 
1 BamHI-HF (R3136)  NEBuffer4 
100% activity 
DNA                   5µl 
BamHI-HF         1µl 
NEBuffer4         2µl 
SDW                  2µl 
1hr Purification [QIAquick® 
PCR Purification Kit 
(QIAGEN, UK, 28104)]. 
2 NotI-HF (R3189)  NEBuffer4 
100% activity 
DNA                   5µl 
NotI-HF             1µl 
NEBuffer4         2µl 
BSA                0.2 µl 
SDW              1.8 µl 
1hr Purification [QIAquick® 
PCR Purification Kit 
(QIAGEN, UK, 28104)]. 
3
 
 
BamHI-HF (R3136) 
NotI-HF (R3189) 
NEBuffer4 
Both enzymes 100% 
active 
DNA                  5µl 
BamHI-HF        1µl 
NotI-HF            1µl 
NEBuffer4        4µl 
BSA                0.4µl 
SDW              8.6µl 
1hr Purification [QIAquick® 
PCR Purification Kit 
(QIAGEN, UK, 28104)]. 
4 BamHI-HF 
SphI-HF (R3182) 
NEBuffer4 
Both enzymes 100% 
active 
DNA                  5µl 
BamHI-HF        1µl 
SphI-HF             1µl 
NEBuffer4        4µl 
BSA                0.4µl 
SDW              8.6µl 
50 min Incubation (65ᵒC, 20min) 
then  
purification  
[QIAquick® PCR 
Purification Kit (QIAGEN, 
UK, 28104)]. 
5 NotI-HF 
SphI-HF 
NEBuffer4 
Both enzymes 100% 
active 
DNA                   5µl 
BamHI-HF        1µl 
NotI-HF            1µl 
NEBuffer4        4µl 
BSA                0.4µl 
SDW              8.6µl 
50 min Incubation (65ᵒC, 20min). 
All enzymes were ordered from New England Biolabs Ltd., UK (product codes in brackets).
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2.4.1.3. Verification of Construct 
Before verification, the constructs were transformed into electrocompetent E. coli DH5α 
(Bioline Ltd., UK, BIO-85028). DH5α were added to construct (3 μl and 5 μlof each ligation 
mixture) in a chilled 0.2 cm electroporation cuvette to a total volume of 50 μl. A negative 
control (no vector) and a positive control (3 μl pMo130-TelR) were also included. 
Electrotransformation was carried out at 1.5 kV (200 Ω, 25 μF; Gene Pulser II, Bio-Rad, UK) 
and cells were immediately recovered with pre-warmed (37ᵒC) LB broth and transferred to a 
universal tube for incubation (2 hr, 37ᵒC, 180 rpm; Multitron Infors, UK). Positive control cells 
(100 µl) were plated directly onto LB agar containing kanamycin (50 µg/ml). All other 
recovered cells were harvested, resuspended in LB broth (100 µl) and plated on LB agar 
containing kanamycin (50 µg/ml) to increase the selection frequency of transformants. The 
plates were incubated for up to 2 days (37ᵒC) and candidate pMo130-TelR transformants 
were subcultured onto LB agar containing kanamycin (50 µg/ml). Construct was extracted 
(Section 2.3) from the candidates and the presence of UP and DOWN fragments was checked 
by PCR using a forward primer specific for pMo130-TelR (pMo130-TelRFW) and a reverse 
primer specific for the insert (Table 2.7, Reactions 10-15). 
A second check for the presence of insert DNA was carried out by digesting the construct 
and unmanipulated pMo130-TelR with BamHI-HF (Table 2.8, digestion 1) and comparing 
their sizes after agarose gel electrophoresis. 
The chosen candidate construct (pMo130-TelR/UPDOWN) was verified by DNA sequencing. A 
PCR amplimer obtained using primer pMo130-TelRFW and the reverse primer specific for the 
DOWN fragment (DOWNRV) was purified and sequenced forwards (primer pMo130-TelRFW) 
and backwards (primer DOWNRV). The following were mixed for sequencing: template (50 
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ng), primer (3.2 pmol), ddH2O to a final volume of 10 µl. The sequence data were aligned 
with the source sequences. 
2.4.2. Transfer of pMo130-TelR/UPDOWN into S17-1 by Transformation 
LB broth (10 ml) was inoculated with a single colony of S17-1 and incubated overnight (37ᵒC, 
200 rpm; Multitron Infors, UK). The following day, fresh LB broth (100 ml) was inoculated 
with overnight culture (4 ml, 4% inoculum) and incubated (37ᵒC, 200 rpm) until mid-
logarithmic phase of growth (OD600nm
 ≈ 0.6). The pellet was sequentially washed to make the 
cells electrocompetent. This was done by resuspending in decreasing volumes of 15% ice 
cold sterile glycerol (50, 25, 10, 5 ml), harvesting the cells (15 min, 3000 x g, 4ᵒC; Heraeus 
Megafuge 40R, Thermo Fisher Scientific, UK) before each resuspension. The competent cells 
were resuspended in ice cold glycerol (1 ml) and kept on ice. Transformation of S17-1 and 
selection and verification of transformants were carried out exactly as described in section 0.  
2.4.3. Transfer of pMo130-TelR/UPDOWN into AYE by Conjugation and Selection of 
Deletion Mutants 
LB broth (2 ml) containing kanamycin (50 µg/ml) and LB broth containing no antibiotic (2 ml) 
were inoculated with a colony of S17-1/pMo130-TelR/UPDOWN and AYE respectively and 
incubated overnight (37ᵒC, 180 rpm; Multitron Infors, UK). Donor (0.2 ml) and recipient (0.2 
ml) were added to LB broth (0.6 ml) in a micro capped centrifuge tube. The mixture was 
centrifuged (2 min, 12,066 x g, room temperature; MiniSpin® microcentrifuge, Scientific 
Laboratory Supplies, UK) and the supernatant discarded. The cells were washed twice in 
fresh LB broth (1 ml). The pellet was resuspended in fresh LB broth (30 µl) and placed onto 
the centre of a 0.45 µm sterile filter disc (Merck Millipore, HNWP02500) on an LB agar plate. 
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The plate was incubated for 6 hr (37ᵒC). The filter disc was placed in a universal tube and 
sterile 0.9% NaCl (400 µl) was added. The NaCl solution was prepared by dissolving 3.6 g 
NaCl (Sigma-Aldrich, UK, S7653) in 500 ml water and passing the solution through a stericup 
(Millipore Corporation; Pro2439). The universal tube was vortexed to resuspend the 
bacterial cells and 100 µl aliquots were spread onto LB plates containing tellurite (10 µg/ml) 
and ampicillin (50 µg/ml). Donor and recipient cultures (100 µl) were also spread onto these 
selective plates to confirm that growth of each was inhibited by the concentrations of agent 
used. The plates were incubated (37ᵒC, overnight) and transconjugants selected for 
subculture the next day. 
pMo130-TelR contains xylE, which encodes catechol 2,3-dioxygenase. This enzyme breaks 
down pyrocatechol (catechol) to produce a yellow product, 2-hydroxymuconic semialdehyde 
(Zukowski et al., 1983). Yellow colonies are single recombinants, which have pMo130-
TelR/UPDOWN incorporated into their chromosome, and are therefore able to break down 
pyrocatechol. Any organisms which have not undergone recombination, or have undergone 
double recombination, would not be viable on these selective plates as pMo130-TelR is a 
suicide vector in A. baumannii (it is lost if not present on the chromosome). To select single 
recombinants, colonies were sprayed (100 ml aerosol bottle, Cole Parmer, UK, EW-06081-
00) with pyrocatechol (0.45 M; prepared by dissolving 0.99 g in 20 ml SDW) (Sigma-Aldrich, 
UK, C9510) and the colour of the colonies observed after one minute. Two yellow colonies 
were cultured overnight (37ᵒC, 180 rpm) in LB broth (2 ml) without NaCl, containing 10% 
sucrose. The gene product of sacB is levansucrase, which breaks down sucrose to produce 
levan, a toxic product (Pelicic et al., 1996). Therefore, the presence of sucrose selects double 
recombinants. Serial dilutions (1/100) were prepared and 100 µl of the 1/1016 and 1/1018 
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dilutions spread onto LB plates (-NaCl) containing 10% sucrose. Each time the culture was 
plated out, a 1/100 dilution of most recent undiluted culture was prepared in fresh LB broth 
(-NaCl +10% sucrose) and incubated (4 hr, 37ᵒC, 180 rpm). Serial dilutions were prepared, 
and the cells plated as above (1/1016 and 1/1018 dilutions were chosen as they gave rise to 
many well isolated colonies after four hours of growth). Cells plated after each passage were 
sprayed with pyrocatechol and screened for white colonies. As the xylE gene is on the 
vector, white colonies comprised cells which had lost the vector, were unable to break down 
the pyrocatechol and so did not produce the yellow product. These cells were derived from 
the single recombinants and previously had the vector incorporated into their chromosome. 
They had therefore lost the vector through a second recombination event and were 
candidate deletion mutants. 
2.4.4. Other methods used to transfer pMo130-TelR Constructs into AYE  
2.4.4.1.  Transformation 
AYE competent cells were prepared exactly as described in section 2.4.2.  
Electrocompetent cells were added to construct (3 μl and 5 μl) in a chilled 0.2 cm 
electroporation cuvette to a total volume of 50 μl. A negative control (50 µl cells, no vector) 
and two positive controls (3 μl and 5 µl unmanipulated pMo130-TelR) were also included. 
Electrotransformation was carried out at 1.6, 1.8 and 2.0 kV (200 Ω, 25 μF; Gene Pulser II, 
Bio-Rad, UK) and cells were incubated, recovered and resuspended as described in Section 
2.4.1.3. The cells were plated on LB agar containing tellurite (30 µg/ml) and incubated for up 
to two days (37ᵒC). Candidate pMo130-TelR transformants were subcultured onto LB agar 
containing tellurite (30 µg/ml). TelR colonies were subcultured onto LB agar and sprayed with 
pyrocatechol to verify presence of the construct. 
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2.4.4.2.  Patch Conjugation 
A single colony of donor and recipient were streaked onto LB agar until growth was just 
visible (early logarithmic phase, approximately 2 hr). At this time, donor and recipient were 
mixed on LB agar on approximately 1/10 of an LB plate and incubated overnight (37ᵒC). The 
aim of the mixing was to obtain a range of ratios of donor and recipient and increase 
conjugation frequency. The next day, all of the cells were resuspended in LB broth (10 ml), 
harvested (2200x g, 10 min, Heraeus Megafuge 40R, Thermo Fisher Scientific, UK) and 
resuspended in a smaller volume (500 µl) of LB broth. Aliquots (100 µl) were spread onto LB 
plates containing tellurite (30 µg/ml) and ampicillin (50 µg/ml) and incubated overnight 
(37ᵒC). 
2.4.5 Verification of Gene Deletion 
The expected sucroseR TelS phenotype of candidate mutants was verified by subculturing the 
mutants on LB agar (-NaCl) containing 10% sucrose and on LB agar containing tellurite (30 
µg/ml). Deletion of the target gene was verified by PCR (Table 2.7, Reactions 18, 20 and 21) 
and one verified mutant was selected for DNA sequencing. The amplimer obtained from this 
mutant was purified and sequenced forwards (forward primer used in the PCR) and 
backwards (reverse primer used in the PCR). The following were mixed for sequencing: 
template (50ng), primer (3.2 pmol) and ddH2O to a final volume of 10 µl. The sequence data 
were aligned with the source sequences. 
2.4. Complementation of deletion mutants 
The aim of this method was to introduce the whole of the deleted region back onto the 
chromosome by double recombination. 
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A region of the wild-type AYE chromosome comprising the region to be complemented and 
the UP and DOWN fragments (Section 2.4.1.2; Figure 3.15; Figure 3.31) was amplified by PCR 
using primers UPFWadeS and adeSRVcomp (Table 2.6; Table 2.7, Reaction 19) to 
complement AYEΔadeRS and primers UPFWpmrB and DOWNRVpmrB to complement 
AYEΔpmrAB (Table 2.6; Table 2.7, Reaction 20).  
The amplified fragment was cloned into pMo130-TelR and the complementation construct 
was verified as described in sections 2.4.1.2 and 2.4.1.3. Introduction of the construct into 
S17-1 and AYE were carried out exactly as described in section 2.4.2 and 2.4.3. Presence of 
the construct in AYE was investigated by colony PCR (Table 2.6; Table 2.7, Reactions 22 and 
23; Figure 2.3). Lysate was prepared from candidate single recombinants and this was used 
as the template DNA in the PCRs. 
2.5. Determination of Phenotype 
2.5.1. Growth Kinetics in the Absence of Antimicrobials 
Overnight cultures of the strain of interest and control strain (approximately 109 colony 
forming units/ml (CFU/ml)) were diluted to approximately 104 CFU/ml. This was done by 
adding 10 µl of the overnight culture to fresh sterile broth (1 ml), and adding 10 µl of this 
dilution to fresh sterile broth (1 ml). This final suspension (10 µl) was added to fresh broth 
(90 µl) in a microtitre tray. Fresh broth (100 µl) was added to three of the wells as 
contamination controls. Growth at 37ᵒC was determined by measuring absorbance at 600 
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Figure 2.3 Colony PCR to Investigate Complementation of AYEΔadeRS. 
 
The AYE chromosome is shown in blue; the pMo130-TelR complementation construct containing the UP-adeRS-DOWN fragment is shown in 
red. UPflank, UP_flankadeS; DNRV, DNRV_colonyadeS; UPFW, UPFW_colonyadeS; DNflank, DN_flankadeS (Table 2.6; Table 2.7). 
a) and b) are two possible orientations of pMo130-TelR/UP-adeRS-DOWN in the AYE chromosome. AYEΔadeRS/pMo130-TelR/UP-adeRS-DOWN 
single recombinants are expected to give rise to a 2.1 kb and 3.4 kb amplimer (one for each PCR, depending on the orientation of the 
construct). Wild-type AYE is expected to give rise to two amplimers of 3.4 kb (one for PCR 1 and one for PCR 2). AYEΔadeRS is expected to give 
rise to two amplimers of 2.1 kb (one for PCR 1 and one for PCR 2). This colony PCR could therefore be used to investigate whether the 
complementation construct was present or absent in AYEΔadeRS, and whether complementation (double recombination) had occurred.  
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nm every 10 min for 16 ½ hr. Growth kinetics were determined for three independent 
cultures, each tested in triplicate. Student’s t test was used to compare the generation times 
and final optical density (600nm) of AYE with AYEΔadeRS and AYEΔpmrAB. 
2.5.2 Growth Kinetics in the Presence of Biocides. 
An MIC plate was set up (Section 2.5.4.1) and growth at room temperature (surface biocides, 
Table 2.9) or 37°C (antiseptics, Table 2.9) was determined by measuring absorbance at 
600nm every 20 min for 24 hr in a plate reader (FLUOstar Omega, BMG Labtech, UK). 
Growth kinetics were determined for at least one culture and each culture was tested in 
duplicate. 
2.5.3. Antibiotic Susceptibility 
The agar doubling dilution method (BSAC, 2011) was used to determine the MIC of all 
antibiotics except imipenem and meropenem (Table 2.3). The agents were prepared on the 
day of use and the appropriate concentration and volume aliquoted into a universal tube to 
which molten iso-sensitest agar (42ᵒC, 20 ml) (Oxoid, UK) was added using a peristaltic pump 
dispenser (Jencons Scientific Ltd., UK). The agar and antibiotic were poured into labelled tri-
vented petri dishes, mixed gently and allowed to set. LB broth (10 ml) was inoculated with 
overnight culture (100 µl) to obtain a culture of approximately 107 CFU/ml. A 21 pin 
multipoint inoculator (AQS manufacturing, UK) was used to deliver 1 µl of this culture to the 
surface of the agar. Two antibiotic-free plates were included as positive growth controls; one 
was inoculated before all antibiotic plates and the other inoculated after all antibiotic plates. 
The MICs were determined after incubation for 18 hours. The MIC of an antibiotic was the  
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Table 2.9 Biocides used in this Study. 
Biocide Agent Concentration/solvent Supplier 
Surface Ethanol 100% Hayman, UK (F200238) 
 H2O2 3%  Sigma-Aldrich, UK (88597) 
 H2O2 50% Sigma-Aldrich, UK (516813) 
 Peracetic acid 36-40% (W/V) in acetic 
acid 
Sigma-Aldrich, UK (433241) 
 Spor-Klenz 100% W.C. Steris, UK (6525) 
 T.B.Q 129 x W.C. Steris, UK (634505) 
Antiseptic Chlorhexidine 
digluconate 
20% (V/V) in H2O Sigma-Aldrich, UK (C9394) 
 Benzalkonium 
chloride 
50% (V/V) in H2O Sigma-Aldrich, UK (63249) 
 Cetylpyridinium 
chloride 
Solvent: SDW  Sigma-Aldrich, UK (C9002) 
H2O2, Hydrogen peroxide (3% used unless a higher concentration was required); 
Cetylpyridinium chloride, Hexadecylpyridinium chloride monohydrate (synonym); W.C., 
working concentration. 
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concentration at which there was no growth compared to the controls (a haze of growth or 
one or two colonies were ignored). MICs were determined in triplicate on at least three 
separate occasions. The MICs of imipenem and meropenem were determined by E-test, 
according to the manufacturer’s instructions. This was carried out with three independent 
biological cultures.  
2.5.4. Biocide Susceptibility 
2.5.4.1. Determination of MICs and MBCs of Biocides for Planktonic Cells 
Biocide was diluted in TSB to obtain double the desired starting concentration. 
Cetylpyridinium chloride (powder) was first dissolved in SDW to obtain a stock solution 
(10,000 µg/ml) before dilution. An overnight culture of each strain was corrected to OD600 ≈ 
0.02 and 100 µl was added to 100 µl of increasing concentrations of biocide in a 96 well 
plate. Fresh TSB was used as a blank control for each concentration of biocide. 
To replicate the conditions in which each biocide is used, the plates containing the surface 
biocides (Table 2.9) were incubated at room temperature (24 hr, static) and those containing 
the antiseptics (Table 2.9) were incubated at 37°C (24 hr, static). After incubation, the OD600 
was determined in a plate reader (FLUOstar Omega, BMG Labtech, UK) and compared with 
the OD600 value for the corresponding blank well. The MIC was the lowest concentration for 
which there was no growth of bacteria.  
To determine the minimum bactericidal concentration (MBC), a loopful (≈100 µl) of the 
culture at the MIC level and the three next highest concentrations was streaked onto a TSA 
plate and incubated overnight (37°C). The MBC was determined as the lowest concentration 
for which there was no visible growth. 
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2.5.4.2. Determination of the Effect of Biocides on Biofilm Growth 
This method is as essentially described in Wand et al. (2012). The biocide concentrations of 
interest, containing each test strain, were prepared as described previously (Section 2.5.4.1), 
except that a microtitre plate (Thermo Fisher Scientific, UK, DIS-976-220U), whose lid 
(Thermo Fisher Scientific, UK, DIS-972-050U) had pegs for biofilm formation was used. TSB 
was used as a blank control for biofilm staining. After incubation (24 hr, static, room 
temperature), the medium was removed and the wells washed twice with phosphate 
buffered saline (PBS). The plate (including the lid) was dried (1 hr, 80°C, static) in a heating 
block (ThermoStat plus, Eppendorf, UK). To stain the biofilm, crystal violet (0.2% V/V, 200 µl; 
Sigma Aldrich, UK, 94448) was added to each well and the plate (including the lid) was left 
for 30 min (room temperature, static). The biofilm was washed by immersing the plate and 
lid separately in a container of cold water until the water ran clear. The biofilm was dried 
and then destained by adding ethanol (100%) to the wells and replacing the lid (incubation 
for 45 min, static, room temperature). Biofilm formation was quantified by measuring the 
absorbance of the crystal violet staining at OD570 in a plate reader (FLUOstar Omega, BMG 
Labtech, UK). The MIC was the lowest concentration at which there was no growth of 
biofilm. The MIC was determined for three independent cultures, each tested four times. 
2.5.4.3. Determination of MBCs of Biocides for Cells in Biofilm (Biofilm Protection Assay). 
A biofilm protection assay was used to measure the ability of established biofilms to tolerate 
biocides. 
The susceptibility of biofilms to biocides was determined as described previously (minimum 
biofilm eradication concentration in Olson et al., 2002). An overnight culture of each test 
 86 
 
organism was corrected to OD600 ≈ 0.01 and 200 µl added directly to four wells of a 
microtitre plate with a pegged lid. TSB was added to four wells as a blank control. The plate 
was incubated (24 hr, static, room temperature) and the lid transferred to a fresh 96 well 
plate containing appropriate concentrations of biocides. The plate was incubated (24 hr 
static, room temperature) and the pegs were placed in a fresh plate containing TSB with no 
biocide. The biofilms were disrupted from the pegs using a Titramax plate shaker (Heidolph, 
UK, 544-12200-00) for 10 min (1,000 rpm, room temperature) and the plate was then 
incubated (24 hr, static, room temperature). Viability of the biofilm in the presence of 
biocide was quantified by measuring the absorbance of each well at OD600. The minimum 
biofim eradication concentration (MBEC) was the lowest concentration at which there was 
no growth (equivalent to the MBC, Section 2.5.4.1). The MBEC was determined for two 
independent cultures, each tested four times. 
2.5.5. Bis-benzimide (Hoechst 33342) assay 
Fresh pre-warmed LB broth (3 ml, 37ᵒC) was inoculated with overnight culture (120 µl; 4% 
inoculm) in a universal tube and incubated (180 rpm, 37ᵒC) until mid-logarithmic phase of 
growth (OD600 ~ 0.6; approximately 1 ½ hr). The cells were harvested by centrifugation (2200 
x g, 10 min, room temperature; Heraeus Megafuge 40R, Thermo Fisher Scientific, UK) and 
the supernatant discarded. The cell pellet was resuspended in ice-cold PBS (3 ml, 0.1 M, pH 
7.2, room temperature; Sigma-Aldrich, UK, P5119) and the absorbance measured at 600nm. 
The OD600 was adjusted to 0.4-0.5 using PBS. As a control and to measure the accumulation 
of bis-benzimide (Hoechst H33342) in the absence of efflux, wild-type AYE cells (overnight 
culture) were boiled (10 min) to kill the cells and 200 µl samples added to a black, flat 
bottomed, 96 well microtitre plate (Greiner, UK, 655076). PBS alone (200 µl) was also 
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included as a blank control for the wells containing cells suspended in PBS. Hoechst (20 µl, 
25 µM) was added to wells containing the test and control strains (180 µl) to a final 
concentration of 2.5 µl. The test and control strains (200 µl) without Hoechst added were 
included as negative fluorescence controls. The fluorescence (excitation 350 nm, emission 
460 nm) was measured in a fluorescent plate reader (FLUOstar Optima, BMG LabTech, 
Germany) for 110 min (37ᵒC). The assay was carried out in triplicate on three separate 
occasions. Steady state fluorescence values were compared by Student’s t test (two-tailed). 
2.5.6. Determination of Cell Dry Weight 
To investigate the amount of fluoroquinolone taken up per milligram of bacterial cells, the 
mass of AYE cells per millilitre of culture was determined for a range of optical densities. 
Sterilin universal tubes were placed in a desiccator and weighed daily until a stable mass was 
recorded. Isosensitest broth (15 ml) was inoculated with a single colony of A. baumannii AYE 
and incubated (overnight, 37°C, 180 rpm). Fresh pre-warmed isosensitest broth (300 ml, 
37°C) was inoculated with overnight culture (12 ml) and incubated (37°C, 180 rpm; Multitron 
Infors, UK). Absorbance of the culture at 660 nm was monitored and samples (20 ml) were 
extracted at an OD660 of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.65, 0.7, 0.75, 0.8, 0.9 and 1.0. Each 
sample was placed in a labelled, pre-weighed universal tube and the cells were harvested 
immediately (2200 x g, 10 min; Heraeus Megafuge 40R). The supernatant was removed and 
the pellet was dried (60°C, overnight). The universal tubes were weighed and placed in a 
desiccator until a stable mass was recorded. The cell weight (mg/ml) was calculated and 
plotted against OD660. 
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2.5.7. Fluoroquinolone Accumulation 
Fluoroquinolone accumulation assays were carried out as described in Mortimer and 
Piddock (1991). Isosensitest broth (12 ml) was inoculated with a single colony of A. 
baumannii and incubated overnight (37°C, 180 rpm; Multitron Infors, UK). Fresh, pre-
warmed isosensitest broth (250 ml, 37°C) was inoculated with overnight culture (10 ml) and 
incubated (37°C, 180 rpm; Multitron Infors, UK) until mid-logarithmic phase of growth (OD660 
~ 0.55). The exact OD660 was recorded and the cells were harvested immediately (4500 x g, 
20 min, 4°C; Heraeus Megafuge 40R). To wash the cells, the cell pellets were resuspended in 
ice-cold sodium phosphate buffer (10 ml, 50 mM, pH 7.0; Appendix 1). The cells were 
harvested (4500 x g, 20 min, 4°C; Heraeus Megafuge 40R) and resuspended in ice-cold 
sodium phosphate buffer (50 mM, pH 7.0) to a final OD660 of 20 units. The cell suspensions 
were divided into two sterile McCartney tubes, each containing a magnetic flea. The cells 
were left to equilibriate to 37°C in a water bath on a magnetic stirrer (10 min). At time 0 min, 
a sample (500 µl) was taken from each McCartney tube and added to a micro capped 
centrifuge tube (on ice) containing ice-cold sterile sodium phosphate buffer (1 ml). 
Ciprofloxacin (Table 2.3; final concentration 10 µg/ml) was added to the remaining cells in 
McCartney tube 1 and ciprofloxacin plus efflux inhibitor (CCCP or PAβN; Table 2.10) were 
added to McCartney tube 2. Five minutes after addition of antibiotic ± inhibitor, duplicate 
samples (500 µl) were removed to micro capped centrifuge tubes (on ice) containing ice-cold 
sterile sodium phosphate buffer (1 ml). Immediately after removal of the final sample, the 
samples were centrifuged (8915 x g, 5 min, 4°C; MiniSpin® microcentrifuge) and returned to 
ice. The supernatants were discarded and the cells resuspended in sterile sodium phosphate 
buffer (1 ml). The cells were centrifuged (8915 x g, 5 min, 4°C; MiniSpin® microcentrifuge) to 
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remove any extracellular ciprofloxacin and lysed by adding 0.1 M glycine hydrochloride (pH 
7.0; Appendix 1) and incubation overnight at room temperature, in the absence of light. The 
samples were centrifuged (8915 x g, 5 min, room temperature; MiniSpin® microcentrifuge) 
to remove cell debris and the supernatants transferred to fresh micro capped centrifuge 
tubes and centrifuged as before. The samples were diluted (1/100) with 0.1 M glycine 
hydrochloride (the level of ciprofloxacin in the undiluted supernatant exceeded the 
measurable range) and fluorescence (excitation 279 nm, emission 447 nm) was measured in 
a calibrated fluorescence spectrophotometer (LS 45 Fluorescence Spectrometer (230 V), 
Perkin Elmer, UK, L2250106). The concentration of ciprofloxacin (ng/mg dry cells) 
accumulated by the cell was calculated (Appendix 3).  
Accumulation of norfloxacin (Table 2.3; final concentration 10 µg/ml) in the presence and 
absence of PAβN, CCCP and verapamil (Table 2.10) was determined exactly as for 
ciprofloxacin, except that fluorescence was measured at excitation wavelength 281 nm and 
emission wavelength 440 nm.  
Experiments were carried out in duplicate for three independent biological cultures. A 
Student’s t test was used to compare the level of accumulation of each fluoroquinolone at 
five minutes for each strain in the presence of efflux inhibitor with that same strain in the 
absence of the efflux inhibitor. The accumulation of norfloxacin at five minutes for the 
mutants in the absence of inhibitor was also compared with the accumulation for AYE in the 
absence of inhibitor. 
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Table 2.10 Efflux Inhibitors used in Fluoroquinolone Uptake Assays. 
Efflux 
inhibitor 
Supplier Solvent Final concentration 
in assay 
Target  
PAβN  
 
Sigma-Aldrich, 
UK (P4157) 
Sterile distilled 
water 
50 µg/ml RND efflux 
pumps (Yu et 
al., 2005) 
 
CCCP 
  
Sigma-Aldrich, 
UK (C2759) 
70% DMSO 50 µM All efflux pumps 
except ABC 
efflux pumps 
(Piddock, 2006) 
 
Verapamil Sigma-Aldrich, 
UK  
(V-4629) 
Sterile distilled 
water 
50 µg/ml ABC efflux 
pumps (Zechini, 
2009) 
 
PAβN, phenylalanine-arginine beta-naphthylamide; CCCP, carbonyl cyanide m-
chlorophenylhydrazone; DMSO, dimethyl sulphoxide; RND, resistance nodulation division; 
ABC, ATP-binding cassette.
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2.5.8. Growth of A. baumannii in the Presence of Efflux Inhibitors 
To ensure that the concentration of efflux inhibitor used in the accumulation assay did not 
have an effect on bacterial growth, viable counts of each strain were determined under the 
conditions of the accumulation assay. During a norfloxacin accumulation assay, additional 
samples (500 µl) were taken from the cultures at time 0 min, and time 5 min both in the 
presence and absence of efflux inhibitor. The samples were harvested and washed exactly as 
discussed in section 2.5.7. At the final step of the protocol, instead of resuspending in glycine 
hydrochloride, which lyses the cells, the cells were resuspended in sodium phosphate buffer. 
Each of the samples (20 µl) was added to isosensitest broth (180 µl) in a 96-well microtitre 
tray and serially diluted ten-fold each time to obtain a final dilution of 1/108. Samples (20 µl) 
of the final three dilutions (1/106 to 1/108) were inoculated in triplicate onto the surface of 
LB plates and the number of colonies counted after incubation (37ᵒC) for 16 hr. The number 
of colonies obtained after dilution were converted to CFU/ml, assuming that each colony 
was derived from a single bacterial cell. The experiment was carried out on three separate 
occasions. Student’s t test was used to compare the growth of the cells in the absence of 
norfloxacin and efflux inhibitor with the growth of each of samples taken at time 5 min. 
2.5.9. Virulence Experiments 
As part of the collaborative research programme, virulence of all A. baumannii strains was 
investigated in Galleria mellonella by Matthew Wand, (HPA, Porton Down). G. mellonella 
were infected with 106 bacterial cells and the percentage survival of Galleria was recorded 
every 12 hours for five days. Experiments were carried out on three separate occasions, 
using ten larvae each time. At Birmingham, Graphpad Prism 5 (GraphPad_Prism) was used to 
generate a survival curve and perform a Log-rank test on the data. 
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3. Construction of Histidine Kinase Deletion Mutants 
3.1. Background 
adeS, adeR (Marchand et al., 2004; Wong et al., 2009), pmrB (Arroyo et al., 2011; Beceiro et al., 
2011) and pmrA (Arroyo et al., 2011) have previously been inactivated in A. baumannii by 
inserting an antibiotic resistance cassette into the gene. bfmS has been inactivated by 
transposon mutagenesis (Clemmer et al., 2011; Tomaras et al., 2008), but there are no reports 
of inactivation or deletion of this histidine kinase. To date, genes have never been deleted 
without relying on susceptibility to an antibiotic. This is not desirable because the A. baumannii 
isolates, which cause infections in hospitals are often resistant to all antibiotics used for genetic 
manipulation. Therefore, representative strains of A. baumannii can often not be investigated, 
using the previously reported methods. 
3.2. Aims and Hypotheses 
It was hypothesised that the role of TCSs in MDR could be investigated in a MDR strain of A. 
baumannii using a method, which used tellurite to overcome the problem of antibiotic 
resistance. The initial aims were to identify and delete histidine kinase genes in a representative 
(MDR) strain of A. baumannii. 
3.2.1. TCSs in Acinetobacter 
Acibase was used to compile a list of TCSs in A. baumannii. The whole gene database was 
searched (search term, two-component) and an initial list made. The gene database was then 
filtered by “Acinetobacter core genome” and the list was manually searched to identify 
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additional TCS genes. These results were compared with those published by Adams et al. (2008; 
2009) and all results were combined (Table 3.1). PubMed was searched to identify the predicted 
functions of the gene products and any potential role in MDR. Where information specific to 
Acinetobacter was not available, these predictions were based on reports in other bacteria. 
AdeRS, PmrAB and BfmRS were predicted to be important for antimicrobial resistance in A. 
baumannii and were selected for investigation (Table 3.1).  
3.2.2. Choice of Strain 
One consideration when choosing the strain in which to delete adeS was that genome data 
were available. The strains selected from xBASE for alignment of adeS and its flanking 
sequences were: AYE, AB0057, AB307-0294, ATCC 17978 and ACICU, since genome sequencing 
of these strains was complete. Strains whose genomes were not fully sequenced such as ATCC 
19606 were ignored. Although the A. baumannii SDF genome has been fully sequenced, it was 
not included in the comparison with other strains. This is because the status of SDF as a human 
pathogen is undetermined and its genome is smaller than that of other A. baumannii (Adams et 
al., 2008). This suggests that SDF is not representative of the A. baumannii species. 
When choosing a representative strain of A. baumannii, the level of conservation of adeS and its 
surrounding genes between five different strains of A. baumannii were aligned in xBASE (Figure 
3.1). BM4454 was included in any sequence analysis where possible, since adeS has already 
been insertionally inactivated in this strain. The sequences of adeS and AdeS in all six strains 
(including BM4454) were aligned to compare the level of identity and similarity between the 
gene and protein, respectively in different strains (Figure 3.2; Figure 3.3). 
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Table 3.1 Putative Two Component System Proteins in Acinetobacter. 
Protein Component Predicted function Predicted involvement in antibiotic or 
biocide resistance 
QseB RR In E. coli, affects motility and virulence in response 
to quorum sensing and hormonal signals (Merighi et 
al., 2009). Transcriptional regulation of flhDC 
(master regulator operon for flagella and motility 
genes) in E. coli 
qseDC E. coli mutants were hypersensitive 
to toxic cations-caesium, cobalt, copper, 
nickel, ruthenium. This TCS may be 
involved in metal metabolism (Zhou et al., 
2003) 
QseC HK 
NtrB (NR(II)) HK Nitrogen regulation (Li and Lu, 2007) ntrBC E. coli mutants were hypersensitive 
to several aminoglycosides (Zhou et al., 
2003) NtrC (NR(I)) RR 
RstB HK RstA promotes RpoS degradation and involved in 
biofilm formation in Salmonella. RstB acts on PhoQ 
to control expression of PhoP-regulated genes (Nam 
et al., 2010; Cabeza et al., 2007) 
rstAB E. coli mutants were hypersensitive 
to ketoprofen, prinidol, troleandomycin. 
((Zhou et al., 2003)) 
RstA  
BfmS HK Controls biofilm formation and cellular morphology 
(Tomaras et al. 2008) 
None found, but biofilms known to 
increase resistance to antibiotics and 
biocides (Lewis, 2001; Rajamohan et al., 
2009) 
BfmR RR 
PhoB RR PhoBR responds to environmental phosphate levels None found for PhoBR but PhoPR is a TCS 
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PhoR HK (Baek et al., 2007). Identified in A. calcoaceticus 
strain ADP1 (Elbahloul and Steinbuchel, 2006) 
 
in Mycobacterium tuberculosis. A 
phoP mutant was more sensitive than the 
wild-type parent to cumene hydrogen 
peroxide (an organic peroxide), CdCl2 (a 
superoxide generator and toxic heavy 
metal), and to the antibiotics vancomycin, 
and cloxacillin (Walters et al., 2006) 
EnvZ HK OmpR-EnvZ controls expression of genes such as 
ompF and ompC in E. coli in response to osmolarity 
(Zhou et al., 2003) 
ompR-envZ E. coli mutants showed greater 
resistance to several antibiotics (including 
cephalosporins and β-lactams), which may 
have been due to defects in porin 
synthesis. The mutants were 
hypersensitive to sodium dichromate and 
cobalt chloride (Zhou et al., 2003) 
OmpR RR 
AgmR RR Alcohol metabolism. 
Glycerol metabolism activator in P. putida (Vrionis et 
al., 2002) 
None found 
spoIIE family RR Sporulation protein. Activates σF in Bacillus subtilis 
sporulation. Promotes polar division of cells (Carniol 
et al., 2005). Acinetobacter do not form spores. 
None found 
 
BvgS precursor HK Virulence sensor protein. Implicated in biofilm 
formation in Bordetella (Mishra et al., 2005). 
Bordetella in biofilm were more resistant 
to antibiotics than planktonic cells (Mishra 
et al., 2005) 
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KdpD HK Osmotic sensor kdpDE E. coli mutants were more resistant 
to novobiocin (targets topoisomerase), but 
more sensitive to hygromycinB 
(aminoglycoside) (Zhou et al., 2003) 
KdpE RR Transcriptional regulatory protein. (Kdp expressed in 
response to osmotic upshift) (Ballal et al., 2007) 
WspR RR In Pseudomonas spp. involved in generation of c-di-
GMP which stimulates biofilm formation and 
suppresses motility (Guvener and Harwood, 2007) 
Biofilm formation is generally associated 
with increased antibiotic resistance (Fux et 
al., 2005) 
AdeR RR Transcription factor of adeABC operon AdeABC has broad specificity (β-lactams, 
fluoroquinolones, tetracyclines, 
chloramphenicol and aminoglycosides 
etc). Best substrates: netilimicin and 
gentamicin (Magnet et al., 2001; Nemec et 
al., 2007a) 
AdeS HK Stimulus unknown. Activates AdeR (Marchand et al., 
2004) 
PmrB HK E. coli: responds to polymyxins, pH, Fe3+ and Mg2+ 
concentrations (Moffatt et al., 2010) 
Colistin resistance (Adams et al., 2009) 
PmrA RR 
CusS HK In E. coli, CusSR stimulates gene transcription in 
response to copper ions (Munson et al., 2000) 
Heavy metal resistance-target genes likely 
to be involved in copper resistance 
(Adams et al. 2008) CusR RR 
IrlR RR Unknown None found 
PetR RR Unknown None found 
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RsbU RR Serine phosphatase, responds to environmental 
stress in B. subtilis (Holtmann et al., 2004) 
Restoring rsbU in rsbU defective S. aureus 
enhanced teicoplanin resistance 
(Galbusera et al., 2011) 
BaeS HK In E. coli, involved in envelope stress response. 
Detected signals of envelope stress include indole, 
spheroblast formation and misfolded PapG (Raffa 
and Raivio, 2002) 
BaeSR activates transcription of a MDR 
efflux pump gene cluster (mdtABCD) in E. 
coli. baeR overexpression has been 
implicated in resistance to novobiocin and 
deoxycholate (Baranova and Nikaido, 
2002) 
GGDEF domain-
containing 
protein 
RR Synthesis of Bis-(3′-5′)-cyclic di-GMP (c-di-GMP), a 
second messenger in bacteria. Involved in processes 
such as commitment to biofilm formation and 
surface attachment (from a motile state) (Zahringer 
et al., 2011) 
Unknown 
Osmolarity RR RR Responds to changes in osmolarity Unknown 
Heavy metal 
sensor 
HK Responds to presence of heavy metals Unknown 
NarL family RR Responds to nitrate or nitrite levels in E. coli 
(Partridge et al., 2008) 
Unknown 
LuxR family RR Involved in survival, replication, virulence and 
biofilm formation in Gram negative bacteria (Chen 
Unknown 
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and Xie, 2011) 
Fis family RR Unknown (But Fis regulates DNA transcription) 
(Browning et al., 2010) 
Unknown 
ColR-like RR ColRS is involved in phenol tolerance in 
Pseudomonas putida (Putrins et al., 2010) 
ColR deficient mutant is sensitive to 
phenol (Putrins et al., 2010) 
ColS-like HK 
PilL Hybrid 
HK/RR 
Encodes an outer membrane lipoprotein involved in 
thin pilus synthesis (Sakai and Komano, 2002) 
 
None found 
PilH RR Part of putative chemosensory system (Chp system 
encoded bypilGHIJK-chpABC gene cluster) PilG is 
involved in pilus extension and PilH is involved in 
pilus retraction (Bertrand et al., 2010) 
None found 
PilG RR None found 
PilR RR In P. aeruginosa, PilR induces the transcription of 
type IV pilus synthesis genes, involved in adhesion 
to host cells and twitching motility (Bertrand et al., 
2010). Postulated to respond to levels of pilin 
(Jelsbak and Kaiser, 2005) 
None found 
Initially found in Acibase; Search by core genome in Acibase; (Adams et al., 2008); (Adams et al., 2009) 
c-di-GMP, cyclic diguanylate; MDR, Multi-drug Resistance 
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Figure 3.1 Alignment of adeRS and its surrounding genes in xBASE. 
 
 
a) Alignment of adeS and its surrounding genes; b) Alignment of adeS. 
Red regions (outlined by black lines) are those, which are conserved between immediately adjacent strains. White regions are those, which do 
not align and are therefore not present in two immediately adjacent strains. 
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Figure 3.2 Alignment of adeS. 
AYE             ATGAAAAGTAAGTTAGGAATTAGTAAGCAACTTTTTATTGCCTTAACTATTGTGAATTTA 60 
AB0057          ATGAAAAGTAAGTTAGGAATTAGTAAGCAACTTTTTATTGCCTTAACTATTGTGAATTTA 60 
AB307-0294      ATGAAAAGTAAGTTAGGAATTAGTAAGCAACTTTTTATTGCCTTAACTATTGTGAATTTA 60 
ATCC            ------------------------------------------------------------ 
ACICU           ATGAAAAGTAAGTTAGGAATTAGTAAGCAACTTTTTATTGCCTTAACTATTGTAAATTTA 60 
BM4454          ATGAAAAGTAAGTTAGGAATTAGTAAGCAACTTTTTATTGCCTTAACTATTGTAAATTTA 60 
                                                                             
 
AYE             AGCGTTACGCTATTTTCTATAGTATTGGGTTATATCATTTATAACTATGCGATTGAAAAA 120 
AB0057          AGCGTTACGCTATTTTCTATAGTATTGGGTTATATCATTTATAACTATGCGATTGAAAAA 120 
AB307-0294      AGCGTTACGCTATTTTCTATAGTATTGGGTTATATCATTTATAACTATGCGATTGAAAAA 120 
ATCC            ------------------------------------------------------------ 
ACICU           AGCGTTACGCTATTTTCTGTAGTACTGGGTTATGTCATTTATAACTATGCGATTGAAAAA 120 
BM4454          AGCGTTACGCTATTTTCTGTAGTACTGGGTTATGTCATTTATAACTATGCGATTGAAAAA 120 
                                                                             
 
AYE             GGCTGGATTAGCTTAAGCTCATTTCAACAAGAAGATTGGACCAGTTTTCATTTTGTAGAC 180 
AB0057          GGCTGGATTAGCTTAAGCTCATTTCAACAAGAAGATTGGACCAGTTTTCATTTTGTAGAC 180 
AB307-0294      GGCTGGATTAGCTTAAGCTCATTTCAACAAGAAGATTGGACCAGTTTTCATTTTGTAGAC 180 
ATCC            ------------------------------------------------------------ 
ACICU           GGCTGGATTAGTTTAAGCTCATTTCAACAAGAAGATTGGACCAGTTTTCATTTTGTAGAC 180 
BM4454          GGCTGGATTAGTTTAAGCTCATTTCAACAAGAAGATTGGACCAGTTTTCATTTTGTAGAC 180 
                                                                             
 
AYE             TGGATCTGGTTAGCCACTGTTATCTTCTGTGGCTGTATTATTTCATTAGTGATTGGCATG 240 
AB0057          TGGATCTGGTTAGCCACTGTTATCTTCTGTGGCTGTATTATTTCATTAGTGATTGGCATG 240 
AB307-0294      TGGATCTGGTTAGCCACTGTTATCTTCTGTGGCTGTATTATTTCATTAGTGATTGGCATG 240 
ATCC            ---------------------------------------------------------ATG 3 
ACICU           TGGATTTGGTTAGCCACTGTTATCTTTTGCGGCTGTATTATTTCATTAGTGATTGGCATG 240 
BM4454          TGGATTTGGTTAGCCACTGTTATCTTTTGCGGCTGTATTATTTCATTAGTGATTGGCATG 240 
                                                                         *** 
 
AYE             CGCCTCGCAAAGCGTTTTATTGTGCCAATTAACTTCTTAGTCGAAGCAGCAAAAAAAATT 300 
AB0057          CGCCTCGCAAAGCGTTTTATTGTGCCAATTAACTTCTTAGTCGAAGCAGCAAAAAAAATT 300 
AB307-0294      CGCCTCGCAAAGCGTTTTATTGTGCCAATTAACTTCTTAGCCGAAGCAGCAAAAAAAATT 300 
ATCC            CGCCTCGCAAAGCGTTTTATTGTGCCAATTAACTTCTTAGCCGAAGCAGCAAAAAAAATT 63 
ACICU           CGCCTCGCAAAGCGTTTTATTGTGCCAATTAACTTCTTAGCCGAAGCAGCAAAAAAAATT 300 
BM4454          CGCCTCGCAAAGCGTTTTATTGTGCCAATTAACTTCTTAGCCGAAGCAGCAAAAAAAATT 300 
                **************************************** ******************* 
 
AYE             AGTCACGGCGACCTCTCTGCTAGAGCTTACGATAATAGAATTCACTCCGCCGAAATGTCG 360 
AB0057          AGTCACGGCGACCTCTCTGCTAGAGCTTACGATAATAGAATTCACTCCGCCGAAATGTCG 360 
AB307-0294      AGTCACGGCGACCTCTCTGCTAGAGCTTACGATAATAGAATTCACTCCGCCGAAATGTCG 360 
ATCC            AGTCACGGCGACCTCTCTGCTAGAGCTTACGATAACCGAATTCACTCCGCCGAAATGTCG 123 
ACICU           AGTCACGGCGACCTCTCTGCTAGAGCTTACGATAATAGAATTCACTCCGCCGAAATGTCG 360 
BM4454          AGTCACGGCGACCTCTCTGCTAGAGCTTACGATAATAGAATTCACTCCGCCGAAATGTCG 360 
                ***********************************  *********************** 
 
AYE             GAGCTTTTATATAATTTTAATGATATGGCTCAAAAGCTAGAGGTTTCCGTCAAAAATGCG 420 
AB0057          GAGCTTTTATATAATTTTAATGATATGGCTCAAAAGCTAGAGGTTTCCGTCAAAAATGCG 420 
AB307-0294      GAGCTTTTATATAATTTTAATGATATGGCTCAAAAGCTAGAGGTTTCCGTCAAAAATGCG 420 
ATCC            GAGCTTTTATATAATTTTAATGATATGGCTCAAAAGCTAGAGGTTTCCGTTAAAAATGCG 183 
ACICU           GAGCTTTTATATAATTTTAATGATATGGCTCAAAAGCTAGAGGTTTCTGTTAAAAATGCG 420 
BM4454          GAGCTTTTATATAATTTTAATGATATGGCTCAAAAGCTAGAGGTTTCTGTTAAAAATGCG 420 
                *********************************************** ** ********* 
 
AYE             CAGGTTTGGAATGCAGCTATCGCACATGAGTTAAGAACGCCTATAACGATATTACAAGGT 480 
AB0057          CAGGTTTGGAATGCAGCTATCGCACATGAGTTAAGAACGCCTATAACGATATTACAAGGT 480 
AB307-0294      CAGGTTTGGAATGCAGCTATCGCACATGAGTTAAGAACGCCTATAACGATATTACAAGGT 480 
ATCC            CAGGTTTGGAATGCAGCCATCGCACATGAGTTAAGAACGCCTATAACGATATTACAAGGT 243 
ACICU           CAGGTTTGGAATGCAGCCATCGCACATGAGTTAAGAACGCCTATAACGATATTACAAGGT 480 
BM4454          CAGGTTTGGAATGCAGCCATCGCACATGAGTTAAGAACGCCTATAACGATATTACAAGGT 480 
                ***************** ****************************************** 
 
AYE             CGTTTACAGGGAATTATTGATGGCGTTTTTAAACCTGATGAAGTCCTATTTAAAAGCCTT 540 
AB0057          CGTTTACAGGGAATTATTGATGGCGTTTTTAAACCTGATGAAGTCCTATTTAAAAGCCTT 540 
AB307-0294      CGTTTACAGGGAATTATTGATGGCGTTTTTAAACCTGATGAAGTCCTATTTAAAAGCCTT 540 
ATCC            CGTTTACAGGGAATTATTGATGGCGTTTTTAAACTTGATGAAGTTCTATTTAAAAGTCTT 303 
ACICU           CGTTTACAAGGCATCATCGACGGTGTTTTTAAACCTGATGAAGTCCTATTTAAAAGCCTT 540 
BM4454          CGTTTACAAGGCATCATCGACGGTGTTTTTAAACCTGATGAAGTCCTATTTAAAAGCCTT 540 
                ******** ** ** ** ** ** ********** ********* *********** *** 
 
AYE             TTAAATCAAGTTGAAGGTTTATCTCACTTAGTCGAAGACTTACGGACTTTAAGCTTAGTA 600 
AB0057          TTAAATCAAGTTGAAGGTTTATCTCACTTAGTCGAAGACTTACGGACTTTAAGCTTAGTA 600 
AB307-0294      TTAAATCAAGTTGAAGGTTTATCTCACTTAGTCGAAGACTTACGGACTTTAAGCTTAGTA 600 
ATCC            TTAAATCAAGTTGAAGGTTTATCTCACTTAGTCGAAGACTTACGGACTTTAAGCTTAGTA 363 
ACICU           TTAAATCAAGTTGAAGTTTTATCTCACTTAGTCGAAGACTTACGGACTTTAAGCTTAGTA 600 
BM4454          TTAAATCAAGTTGAAGTTTTATCTCACTTAGTCGAAGACTTACGGACTTTAAGCTTAGTA 600 
                **************** ******************************************* 
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AYE             GAGAACCAGCAACTCCGGTTAAATTATGAATTGTTTGACTTGAAGGCGGTAGTTGAAAAA 660 
AB0057          GAGAACCAGCAACTCCGGTTAAATTATGAATTGTTTGACTTGAAGGCGGTAGTTGAAAAA 660 
AB307-0294      GAGAACCAGCAACTCCGGTTAAATTATGAATTGTTTGACTTGAAGGCGGTAGTTGAAAAA 660 
ATCC            GAGAACCAGCAACTCCGGTTAAATTATGAATTGTTTGACTTTAAGGCGGTAGTTGAAAAA 423 
ACICU           GAGAACCAGCAACTCCGGTTAAATTATGAATTGTTTGACTTTAAGGCGGTAGTTGAAAAA 660 
BM4454          GAGAACCAGCAACTCCGGTTAAATTATGAATTGTTTGACTTTAAGGCGGTAGTTGAAAAA 660 
                ***************************************** ****************** 
 
AYE             GTTCTTAAAGCATTTGAAGATCGTTTGGATCAAGCTAAGCTAGTACCAGAACTTGACCTA 720 
AB0057          GTTCTTAAAGCATTTGAAGATCGTTTGGATCAAGCTAAGCTAGTACCAGAACTTGACCTA 720 
AB307-0294      GTTCTTAAAGCATTTGAAGATCGTTTGGATCAAGCTAAGCTAGTACCAGAACTTGACCTA 720 
ATCC            GTTCTTAAAGCATTTGAAGATCGTTTGGATCAAGCTAAGCTAGTACCAGAACTTGACCTA 483 
ACICU           GTTCTTAAAGCATTTGAAGATCGTTTGGATCAAGCTAAGCTAGTACCAGAACTTGACCTA 720 
BM4454          GTTCTTAAAGCATTTGAAGATCGTTTGGATCAAGCTAAGCTAGTACCAGAACTTGACCTA 720 
                ************************************************************ 
 
AYE             ACGTCCACTCCTGTATATTGCGACCGCCGTCGTATTGAGCAAGTTTTAATTGCTTTAATT 780 
AB0057          ACGTCCACTCCTGTATATTGCGACCGCCGTCGTATTGAGCAAGTTTTAATTGCTTTAATT 780 
AB307-0294      ACGTCCACTCCTGTATATTGCGACCGCCGTCGTATTGAGCAAGTTTTAATTGCTTTAATT 780 
ATCC            ACGTCCACTCCTGTATATTGCGACCGCCGTCGTATTGAGCAAGTTTTAATTGCTTTAATT 543 
ACICU           ACTTCCACTCCTGTATATTGCGACCGCCGTCGTATTGAGCAAGTTTTAATTGCTTTAATT 780 
BM4454          ACTTCCACTCCTGTATATTGCGACCGCCGTCGTATTGAGCAAGTTTTAATTGCTTTAATT 780 
                ** ********************************************************* 
 
AYE             GATAATGCGATTCGCTATTCAAATGCAGGCAAACTTAAAATCTCTTCAGAAGTGGTTGCA 840 
AB0057          GATAATGCGATTCGCTATTCAAATGCAGGCAAACTTAAAATCTCTTCAGAAGTGGTTGCA 840 
AB307-0294      GATAATGCGATTCGCTATTCAAATGCAGGCAAACTTAAAATCTCTTCAGAAGTGGTTGCA 840 
ATCC            GATAATGCGATTCGCTATTCAAATGCAGGCAAACTTAAAATTTCCTCGGAAGTGGTATCA 603 
ACICU           GATAATGCTATACGCTATTCACATGCAGGCAAACTTAAAATTTCCTCGGAAGTGGTATCA 840 
BM4454          GATAATGCTATACGCTATTCACATGCAGGCAAACTTAAAATTTCCTCGGAAGTGGTATCA 840 
                ******** ** ********* ******************* ** ** ********  ** 
 
AYE             GACAACTGGATATTAAAAATTGAGGATGAAGGCCCCGGCATTGCAACCGAGTTTCGGGAC 900 
AB0057          GACAACTGGATATTAAAAATTGAGGATGAAGGCCCCGGCATTGCAACCGAGTTTCGGGAC 900 
AB307-0294      GACAACTGGATATTAAAAATTGAGGATGAAGGCCCCGGCATTGCAACCGAGTTTCGGGAC 900 
ATCC            CAAAACTGGATATTAAAAATTGAGGATGAAGGCCCTGGCATTGCAACCGAGTTCCAAGAC 663 
ACICU           CAAAACTGGATATTAAAAATTGAGGATGAAGGCCCCGGCATTGCAACCGAGTTCCAAGAC 900 
BM4454          CAAAACTGGATATTAAAAATTGAGGATGAAGGCCCCGGCATTGCAACCGAGTTCCAAGAC 900 
                 * ******************************** ***************** *  *** 
 
AYE             GATTTATTTAAGCCTTTCTTTAGATTAGAAGAATCAAGGAATAAAGAATTTGGCGGCACA 960 
AB0057          GATTTATTTAAGCCTTTCTTTAGATTAGAAGAATCAAGGAATAAAGAATTTGGCGGCACA 960 
AB307-0294      GATTTATTTAAGCCTTTCTTTAGATTAGAAGAATCAAGGAATAAAGAATTTGGCGGCACA 960 
ATCC            GATTTATATAAGCCTTTCTTTAGATTAGAAGAATCAAGGAATAAAGAATTTGGCGGCACA 723 
ACICU           GATTTATTTAAGCCTTTCTTTAGATTAGAAGAATCAAGGAATAAAGAATTTGGCGGCACA 960 
BM4454          GATTTATTTAAGCCTTTCTTTAGATTAGAAGAATCAAGGAATAAAGAATTTGGCGGCACA 960 
                ******* **************************************************** 
 
AYE             GGTTTAGGTCTTGCTGTTGTACATGCAATTATTGTGGCACTGAAAGGCACTATTCAATAT 1020 
AB0057          GGTTTAGGTCTTGCTGTTGTACATGCAATTATTGTGGCACTGAAAGGCACTATTCAATAT 1020 
AB307-0294      GGTTTAGGTCTTGCTGTTGTACATGCAATTATTGTGGCACTGAAAGGCACTATTCAATAT 1020 
ATCC            GGTTTAGGTCTTGCTGTTGTACATGCAATTATTGTGGCACTGAAAGGTACTATTCAATAT 783 
ACICU           GGTTTAGGTCTTGCTGTTGTACATGCAATTATTGTGGCACTGAAAGGCACTATTCAATAT 1020 
BM4454          GGTTTAGGTCTTGCTGTTGTACATGCAATTATTGTGGCACTGAAAGGCACTATTCAATAT 1020 
                *********************************************** ************ 
 
AYE             AGCAATCAAGGCTCGAAAAGTGTTTTCACCATAAAAATTTCTATGGGTCATGAAGAGATG 1080 
AB0057          AGCAATCAAGGCTCGAAAAGTGTTTTCACCATAAAAATTTCTATGGGTCATGAAGAGATG 1080 
AB307-0294      AGCAATCAAGGCTCGAAAAGTGTTTTCACCATAAAAATTTCTATGGGTCATGAAGAGATG 1080 
ATCC            AGCAACCAAGGCTCGAAAAGTGTTTTCACCATAAAAATTTCTATGGGTCATGAAGAAATA 843 
ACICU           AGCAATCAAGGCTCGAAAAGTATTTTCACCATAAAAATTTCTATGAATAACTAA------ 1074 
BM4454          AGCAATCAAGGCTCGAAAAGTATTTTCACCATAAAAATTTCTATGAATAACTAA------ 1074 
                ***** *************** ***********************  * *  **       
 
AYE             GGGTAA 1086 
AB0057          GGGTAA 1086 
AB307-0294      GGGTAA 1086 
ATCC            GGGTAA 849 
ACICU           ------ 
BM4454          ------ 
 
The identity between adeS in all strains was calculated for the aligned regions of the gene 
(extra bases (-) were not included). 
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adeS and its surrounding regions were most highly conserved between AYE, AB0057 and 
AB307-0294 (Figure 3.1). There was 95% identity between the aligned region of adeS in all 
strains investigated (Figure 3.2) although it is important to note that ATCC 17978 had a 
shorter adeS than the other strains, which gave rise to a shorter AdeS protein. There was 
99% similarity between the aligned region of AdeS (Figure 3.3) in all strains. Another 
difference identified for ATCC 17978 is that none of the analysed region of the genome 
aligned with adeC of other strains (Figure 3.1). 
The sequences of adeR and AdeR in the six strains were also compared (Figure 3.4; Figure 
3.5) to investigate the level of identity and similarity between the second component of 
AdeRS. The aligned regions of adeR shared 97% identity and the AdeR proteins were 97% 
similar in all strains. However, ATCC 17978 and BM4454 both produced a smaller AdeR 
protein than AYE, AB0057, ACICU and AB307-0294 due to a shorter gene.  
It was decided that research into the role of TCSs in adaptive responses in A. baumannii 
would be carried out in strain AYE. This was because AYE had the highest number of BLAST 
hits with other sequenced A. baumannii genomes (personal correspondence, Jacqueline 
Chan, University of Birmingham) and AYE is a multidrug-resistant clinical strain (Poirel et al., 
2003). Therefore, the involvement of TCSs and their downstream targets in MDR can be 
investigated in a strain which has been implicated in nosocomial infection. Moreover, the 
genome of AYE has been sequenced and thoroughly analysed. Several publications have 
compared the genome of this strain with those of other isolates (antibiotic resistant, 
susceptible and environmental isolates) to identify virulence and antibiotic resistance 
determinants (Adams et al., 2010; Adams et al., 2008; Coyne et al., 2010a; Fournier et al., 
2006; Vallenet et al., 2008). AB307-0294 and ATCC 17978 were not investigated, since these 
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Figure 3.3 Alignment of AdeS. 
 
AYE             MKSKLGISKQLFIALTIVNLSVTLFSIVLGYIIYNYAIEKGWISLSSFQQEDWTSFHFVD 60 
AB0057          MKSKLGISKQLFIALTIVNLSVTLFSIVLGYIIYNYAIEKGWISLSSFQQEDWTSFHFVD 60 
AB307-0294      MKSKLGISKQLFIALTIVNLSVTLFSIVLGYIIYNYAIEKGWISLSSFQQEDWTSFHFVD 60 
ATCC            ------------------------------------------------------------ 
ACICU           MKSKLGISKQLFIALTIVNLSVTLFSVVLGYVIYNYAIEKGWISLSSFQQEDWTSFHFVD 60 
BM4454          MKSKLGISKQLFIALTIVNLSVTLFSVVLGYVIYNYAIEKGWISLSSFQQEDWTSFHFVD 60 
                                                                             
 
AYE             WIWLATVIFCGCIISLVIGMRLAKRFIVPINFLVEAAKKISHGDLSARAYDNRIHSAEMS 120 
AB0057          WIWLATVIFCGCIISLVIGMRLAKRFIVPINFLVEAAKKISHGDLSARAYDNRIHSAEMS 120 
AB307-0294      WIWLATVIFCGCIISLVIGMRLAKRFIVPINFLAEAAKKISHGDLSARAYDNRIHSAEMS 120 
ATCC            -------------------MRLAKRFIVPINFLAEAAKKISHGDLSARAYDNRIHSAEMS 41 
ACICU           WIWLATVIFCGCIISLVIGMRLAKRFIVPINFLAEAAKKISHGDLSARAYDNRIHSAEMS 120 
BM4454          WIWLATVIFCGCIISLVIGMRLAKRFIVPINFLAEAAKKISHGDLSARAYDNRIHSAEMS 120 
                                   **************.************************** 
 
AYE             ELLYNFNDMAQKLEVSVKNAQVWNAAIAHELRTPITILQGRLQGIIDGVFKPDEVLFKSL 180 
AB0057          ELLYNFNDMAQKLEVSVKNAQVWNAAIAHELRTPITILQGRLQGIIDGVFKPDEVLFKSL 180 
AB307-0294      ELLYNFNDMAQKLEVSVKNAQVWNAAIAHELRTPITILQGRLQGIIDGVFKPDEVLFKSL 180 
ATCC            ELLYNFNDMAQKLEVSVKNAQVWNAAIAHELRTPITILQGRLQGIIDGVFKLDEVLFKSL 101 
ACICU           ELLYNFNDMAQKLEVSVKNAQVWNAAIAHELRTPITILQGRLQGIIDGVFKPDEVLFKSL 180 
BM4454          ELLYNFNDMAQKLEVSVKNAQVWNAAIAHELRTPITILQGRLQGIIDGVFKPDEVLFKSL 180 
                *************************************************** ******** 
 
AYE             LNQVEGLSHLVEDLRTLSLVENQQLRLNYELFDLKAVVEKVLKAFEDRLDQAKLVPELDL 240 
AB0057          LNQVEGLSHLVEDLRTLSLVENQQLRLNYELFDLKAVVEKVLKAFEDRLDQAKLVPELDL 240 
AB307-0294      LNQVEGLSHLVEDLRTLSLVENQQLRLNYELFDLKAVVEKVLKAFEDRLDQAKLVPELDL 240 
ATCC            LNQVEGLSHLVEDLRTLSLVENQQLRLNYELFDFKAVVEKVLKAFEDRLDQAKLVPELDL 161 
ACICU           LNQVEVLSHLVEDLRTLSLVENQQLRLNYELFDFKAVVEKVLKAFEDRLDQAKLVPELDL 240 
BM4454          LNQVEVLSHLVEDLRTLSLVENQQLRLNYELFDFKAVVEKVLKAFEDRLDQAKLVPELDL 240 
                ***** ***************************:************************** 
 
AYE             TSTPVYCDRRRIEQVLIALIDNAIRYSNAGKLKISSEVVADNWILKIEDEGPGIATEFRD 300 
AB0057          TSTPVYCDRRRIEQVLIALIDNAIRYSNAGKLKISSEVVADNWILKIEDEGPGIATEFRD 300 
AB307-0294      TSTPVYCDRRRIEQVLIALIDNAIRYSNAGKLKISSEVVADNWILKIEDEGPGIATEFRD 300 
ATCC            TSTPVYCDRRRIEQVLIALIDNAIRYSNAGKLKISSEVVSQNWILKIEDEGPGIATEFQD 221 
ACICU           TSTPVYCDRRRIEQVLIALIDNAIRYSHAGKLKISSEVVSQNWILKIEDEGPGIATEFQD 300 
BM4454          TSTPVYCDRRRIEQVLIALIDNAIRYSHAGKLKISSEVVSQNWILKIEDEGPGIATEFQD 300 
                ***************************:***********::*****************:* 
 
AYE             DLFKPFFRLEESRNKEFGGTGLGLAVVHAIIVALKGTIQYSNQGSKSVFTIKISMGHEEM 360 
AB0057          DLFKPFFRLEESRNKEFGGTGLGLAVVHAIIVALKGTIQYSNQGSKSVFTIKISMGHEEM 360 
AB307-0294      DLFKPFFRLEESRNKEFGGTGLGLAVVHAIIVALKGTIQYSNQGSKSVFTIKISMGHEEM 360 
ATCC            DLYKPFFRLEESRNKEFGGTGLGLAVVHAIIVALKGTIQYSNQGSKSVFTIKISMGHEEI 281 
ACICU           DLFKPFFRLEESRNKEFGGTGLGLAVVHAIIVALKGTIQYSNQGSKSIFTIKISMNN--- 357 
BM4454          DLFKPFFRLEESRNKEFGGTGLGLAVVHAIIVALKGTIQYSNQGSKSIFTIKISMNN--- 357 
                **:********************************************:*******.:    
 
AYE             G 361 
AB0057          G 361 
AB307-0294      G 361 
ATCC            G 282 
ACICU           - 
BM4454          - 
 
Similarity was calculated for the aligned regions of AdeS (extra residues (-) were not 
included). The following residues were considered to be similar: 
* identical residue 
: strongly similar residue (scoring >0.5 in the Gonnet PAM matrix) 
. weakly similar residue (scoring <0.5 in the Gonnet PAM matrix) 
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Figure 3.4 Aligment of adeR. 
 
AB307-0294      ATGTTTGATCATTCTTTTTCTTTTGATTGCCAAGATAAAGTTATTCTTGTGGTAGAAGAT 60 
ATCC            ------------------------------------------------------------ 
AB0057          ATGTTTGATCATTCTTTTTCTTTTGATTGCCAAGATAAAGTTATTCTTGTGGTAGAAGAT 60 
AYE             ATGTTTGATCATTCTTTTTCTTTTGATTGCCAAGATAAAGTTATTCTTGTGGTAGAAGAT 60 
ACICU           ATGTTTGATCATTCTTTTTCTTTTGATTGCCAAGATAAAGTTATTCTTGTGGTAGAAGAT 60 
BM4454          ATGTTTGATCATTCTTTTTCTTTTGATTGCCAAGATAAAGTTATTCTTGTGGTAGAAGAT 60 
                                                                             
 
AB307-0294      GACTACGATATTGGCAACATTATTGAAAATTATTTAAAACGTGAAGGCATGAGTGTTATT 120 
ATCC            ------------------------------------------------ATGAGTGTTATT 12 
AB0057          GACTACGATATTGGCGACATTATTGAAAATTATTTAAAACGTGAAGGCATGAGTGTTATT 120 
AYE             GACTACGATATTGGCGACATTATTGAAAATTATTTAAAACGTGAAGGCATGAGTGTTATT 120 
ACICU           GACTACGATATTGGCGACATTATTGAAAATTATTTAAAACGTGAAGGCATGAGTGTTATT 120 
BM4454          GACTACGATATTGGCGACATTATTGAAAATTATTTAAAACGTGAAGGCATGAGTGTTATT 120 
                                                                ************ 
 
AB307-0294      CGGGCCATGAATGGAAAGCAAGCGATTGAATTGCACGCTAGCCAACCCATCGATTTAATC 180 
ATCC            CGGGCCATGAATGGAAAGCAAGCAATTGAATTGCATGCGAGCCAACCCATCGATTTAATC 72 
AB0057          CGGGCCATGAATGGAAAGCAAGCGATTGAATTGCACGCTAGCCAACCCATCGATTTAATC 180 
AYE             CGGGCCATGAATGGAAAGCAAGCGATTGAATTGCACGCTAGCCAACCCATCGATTTAATC 180 
ACICU           CGGGCTATGAATGGAAAACAAGCGATTGAATTGCATGCGAGCCAACCCATCGATTTAATT 180 
BM4454          CGGGCTATGAATGGAAAACAAGCGATTGAATTGCATGCGAGCCAACCCATCGATTTAATT 180 
                ***** *********** ***** *********** ** ********************  
 
AB307-0294      TTACTTGATATTAAATTACCCGAATTAAACGGTTGGGAAGTATTAAATAAAATACGCCAA 240 
ATCC            TTACTTGATATTAAATTACCCGAATTAAACGGTTGGGAAGTGTTAAATAAAATACGCCAA 132 
AB0057          TTACTTGATATTAAATTACCCGAATTAAACGGTTGGGAAGTATTAAATAAAATACGCCAA 240 
AYE             TTACTTGATATTAAATTACCCGAATTAAACGGTTGGGAAGTATTAAATAAAATACGCCAA 240 
ACICU           TTACTTGATATTAAATTACCCGAATTAAACGGTTGGGAAGTATTAAATAAAATACGCCAA 240 
BM4454          TTACTTGATATTAAATTACCCGAATTAAACGGTTGGGAAGTATTAAATAAAATACGCCAA 240 
                ***************************************** ****************** 
 
AB307-0294      AAAGCTCAGACTCCCGTGATCATGTTGACGGCGCTAGATCAAGATATTGATAAAGTTATG 300 
ATCC            AAAGCTCAGACTCCCGTGATCATGTTGACGGCGTTAGATCAAGATATTGATAAAGTTATG 192 
AB0057          AAAGCTCAGACTCCCGTGATCATGTTGACGGCGCTAGATCAAGATATTGATAAAGTTATG 300 
AYE             AAAGCTCAGACTCCCGTGATCATGTTGACGGCGCTAGATCAAGATATTGATAAAGTTATG 300 
ACICU           AAAGCTCAGACTCCCGTGATCATGTTGACGGCGCTAGATCAAGATATTGATAAAGTTATG 300 
BM4454          AAAGCTCAGACTCCCGTGATCATGTTGACGGCGCTAGATCAAGATATTGATAAAGTTATG 300 
                ********************************* ************************** 
 
AB307-0294      GCATTACGCATAGGTGCAGATGACTTTGTGGTGAAGCCTTTTAACCCAAATGAAGTCGTC 360 
ATCC            GCATTACGCATAGGTGCAGATGACTTTGTGGTGAAGCCTTTTAACCCAAATGAAGTCGTC 252 
AB0057          GCATTACGCATAGGTGCAGATGACTTTGTGGTGAAGCCTTTTAACCCAAATGAAGTCGTC 360 
AYE             GCATTACGCATAGGTGCAGATGACTTTGTGGTGAAGCCTTTTAACCCAAATGAAGTCGTC 360 
ACICU           GCATTACGCATAGGTGCAGATGACTTTGTGGTGAAGCCTTTTAACCCAAATGAAGTCATC 360 
BM4454          GCATTACGCATAGGTGCAGATGACTTTGTGGTGAAGCCTTTTAACCCAAATGAAGTCATC 360 
                ********************************************************* ** 
 
AB307-0294      GCTAGAGTTCAGGCAGTCCTAAGACGTACTCAGTTTGCAAACAAAGCAACTAATAAAAAT 420 
ATCC            GCTAGAGTTCAGGCAGTCTTAAGACGTACTCAGTTTGCAAACAAAGCAACTAATAAAAAT 312 
AB0057          GCTAGAGTTCAGGCAGTCCTAAGACGTACTCAGTTTGCAAACAAAGCAACTAATAAAAAT 420 
AYE             GCTAGAGTTCAGGCAGTCCTAAGACGTACTCAGTTTGCAAACAAAGCAACTAATAAAAAT 420 
ACICU           GCTAGAGTTCAGGCAGTCTTAAGACGTACTCAGTTTGCAAACAAAGTAACTAATAAAAAT 420 
BM4454          GCTAGAGTTCAGGCAGTCTTAAGACGTACTCAGTTTGCAAACAAAGTAACTAATAAAAAT 420 
                ****************** *************************** ************* 
 
AB307-0294      AAACTCTATAAAAATATTGAAATTGATACCGACACTCATAGCGTTTATATACACTCTGAG 480 
ATCC            AAACTCTATAAAAATATTGAAATTGATACCGACACTCATAGCGTTTATATACACTCTGAG 372 
AB0057          AAACTCTATAAAAATATTGAAATTGATACCGACACTCATAGCGTTTATATACACTCTGAG 480 
AYE             AAACTCTATAAAAATATTGAAATTGATACCGACACTCATAGCGTTTATATACACTCTGAG 480 
ACICU           AAACTCTATAAAAATATTGAAATTGATACCGACACTCATAGCGTTTATATACACTCTGAG 480 
BM4454          AAACTCTATAAAAATATTGAAATTGATACCGACACTCATAGCGTTTATATACACTCTGAG 480 
                ************************************************************ 
 
AB307-0294      AATAAGAAGATCTTGCTTAATCTGACGCTGACTGAATATAAAATTATTTCATTCATGATT 540 
ATCC            AATAAGAAGATCTTGCTTAATCTGACGCTGACTGAATATAAAATTATTTCATTCATGATT 432 
AB0057          AATAAGAAGATCTTGCTTAATCTGACGCTGACTGAATATAAAATTATTTCATTCATGATT 540 
AYE             AATAAGAAGATCTTGCTTAATCTGACGCTGACTGAATATAAAATTATTTCATTCATGATT 540 
ACICU           AATAAGAAGATCTTGCTTAATCTGACGCTGACTGAATATAAAATTATTTCATTCATGATT 540 
BM4454          AATAAGAAGATCTTGCTTAATCTGACGCTGACTGAATATAAAATTATTTCATTCATGATT 540 
                ************************************************************ 
 
AB307-0294      GATCAGCCTCATAAAGTTTTTACGCGCGGAGAGCTTATGAATCACTGCATGAATGATAGC 600 
ATCC            GATCAGCCTCATAAAGTTTTTACGCGCGGAGAGCTTATGAATCACTGCATGAATGATAGC 492 
AB0057          GATCAGCCTCATAAAGTTTTTACGCGCGGAGAGCTTATGAATCACTGCATGAATGATAGC 600 
AYE             GATCAGCCTCATAAAGTTTTTACGCGCGGAGAGCTTATGAATCACTGCATGAATGATAGC 600 
ACICU           GACCAACCTCATAAAGTTTTTACGCGCGGAGAACTTATGAATCACTGCATGAATGATAGC 600 
BM4454          GACCAACCTCATAAAGTTTTTACGCGCGGAGAACTTATGAATCACTGCATGAATGATAGC 600 
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                ** ** ************************** *************************** 
 
AB307-0294      GATGCACTAGAGCGAACCGTAGATAGCCATGTGAGTAAGCTGAGAAAAAAACTAGAAGAA 660 
ATCC            GATGCACTAGAGCGAACCGTAGATAGCCATGTAAGTAAGCTGAGAAAAAAACTAGAAGAA 552 
AB0057          GATGCACTAGAGCGAACCGTAGATAGCCATGTGAGTAAGCTGAGAAAAAAACTAGAAGAA 660 
AYE             GATGCACTAGAGCGAACCGTAGATAGCCATGTGAGTAAGCTGAGAAAAAAACTAGAAGAA 660 
ACICU           GATGCACTAGAGCGAACCGTAGATAGCCATGTAAGTAAGCTGAGAAAAAAACTAGAAGAA 660 
BM4454          GATGCACTAGAGCGAACCGTAGATAGCCATGTAAGTAAGCTGAGAAAAAAACTAAAAGAA 660 
                ******************************** ********************* ***** 
 
AB307-0294      -CAAGGCATATTTCAAATGTTAATTAATGTGCGTGGCGTGGGATATAGACTAGATAATCC 719 
ATCC            -CAAGGCATATTTCAAATGTTAATTAATGTGCGTGGCGTGGGATATAGGCTAGATAATCC 611 
AB0057          -CAAGGCATATTTCAAATGTTAATTAATGTGCGTGGCGTGGGATATAGACTAGATAATCC 719 
AYE             -CAAGGCATATTTCAAATGTTAATTAATGTGCGTGGCGTGGGATATAGACTAGATAATCC 719 
ACICU           -CAAGGCATATTTCAAATGTTAATTAATGTGCGTGGCGTGGGATATAGGCTAGATAATCC 719 
BM4454          ACAAGGCATATTTCAAATGTTAATTAA--------------------------------- 687 
                 **************************                                  
 
AB307-0294      CCTAGCTGTAAAAGATGATGCCTAA 744 
ATCC            CCTAGCTGTAAAAGATGACGCCTAA 636 
AB0057          CCTAGCTGTAAAAGATGATGCCTAA 744 
AYE             CCTAGCTGTAAAAGATGATGCCTAA 744 
ACICU           CCTAGCTGTAAAAGATGACGCCTAA 744 
BM4454          ------------------------- 
 
The identity between adeR in all strains was calculated for the aligned regions of the gene 
(extra bases (-) were not included). 
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Figure 3.5 Alignment of AdeR. 
AB307-0294      MFDHSFSFDCQDKVILVVEDDYDIGNIIENYLKREGMSVIRAMNGKQAIELHASQPIDLI 60 
ATCC            ------------------------------------MSVIRAMNGKQAIELHASQPIDLI 24 
AB0057          MFDHSFSFDCQDKVILVVEDDYDIGDIIENYLKREGMSVIRAMNGKQAIELHASQPIDLI 60 
AYE             MFDHSFSFDCQDKVILVVEDDYDIGDIIENYLKREGMSVIRAMNGKQAIELHASQPIDLI 60 
ACICU           MFDHSFSFDCQDKVILVVEDDYDIGDIIENYLKREGMSVIRAMNGKQAIELHASQPIDLI 60 
BM4454          MFDHSFSFDCQDKVILVVEDDYDIGDIIENYLKREGMSVIRAMNGKQAIELHASQPIDLI 60 
                                                    ************************ 
 
AB307-0294      LLDIKLPELNGWEVLNKIRQKAQTPVIMLTALDQDIDKVMALRIGADDFVVKPFNPNEVV 120 
ATCC            LLDIKLPELNGWEVLNKIRQKAQTPVIMLTALDQDIDKVMALRIGADDFVVKPFNPNEVV 84 
AB0057          LLDIKLPELNGWEVLNKIRQKAQTPVIMLTALDQDIDKVMALRIGADDFVVKPFNPNEVV 120 
AYE             LLDIKLPELNGWEVLNKIRQKAQTPVIMLTALDQDIDKVMALRIGADDFVVKPFNPNEVV 120 
ACICU           LLDIKLPELNGWEVLNKIRQKAQTPVIMLTALDQDIDKVMALRIGADDFVVKPFNPNEVI 120 
BM4454          LLDIKLPELNGWEVLNKIRQKAQTPVIMLTALDQDIDKVMALRIGADDFVVKPFNPNEVI 120 
                ***********************************************************: 
 
AB307-0294      ARVQAVLRRTQFANKATNKNKLYKNIEIDTDTHSVYIHSENKKILLNLTLTEYKIISFMI 180 
ATCC            ARVQAVLRRTQFANKATNKNKLYKNIEIDTDTHSVYIHSENKKILLNLTLTEYKIISFMI 144 
AB0057          ARVQAVLRRTQFANKATNKNKLYKNIEIDTDTHSVYIHSENKKILLNLTLTEYKIISFMI 180 
AYE             ARVQAVLRRTQFANKATNKNKLYKNIEIDTDTHSVYIHSENKKILLNLTLTEYKIISFMI 180 
ACICU           ARVQAVLRRTQFANKVTNKNKLYKNIEIDTDTHSVYIHSENKKILLNLTLTEYKIISFMI 180 
BM4454          ARVQAVLRRTQFANKVTNKNKLYKNIEIDTDTHSVYIHSENKKILLNLTLTEYKIISFMI 180 
                ***************.******************************************** 
 
AB307-0294      DQPHKVFTRGELMNHCMNDSDALERTVDSHVSKLRKKLEEQGIFQMLINVRGVGYRLDNP 240 
ATCC            DQPHKVFTRGELMNHCMNDSDALERTVDSHVSKLRKKLEEQGIFQMLINVRGVGYRLDNP 204 
AB0057          DQPHKVFTRGELMNHCMNDSDALERTVDSHVSKLRKKLEEQGIFQMLINVRGVGYRLDNP 240 
AYE             DQPHKVFTRGELMNHCMNDSDALERTVDSHVSKLRKKLEEQGIFQMLINVRGVGYRLDNP 240 
ACICU           DQPHKVFTRGELMNHCMNDSDALERTVDSHVSKLRKKLEEQGIFQMLINVRGVGYRLDNP 240 
BM4454          DQPHKVFTRGELMNHCMNDSDALERTVDSHVSKLRKKLKET---RHISNVN--------- 228 
                **************************************:*    : : **.          
 
AB307-0294      LAVKDDA 247 
ATCC            LAVKDDA 211 
AB0057          LAVKDDA 247 
AYE             LAVKDDA 247 
ACICU           LAVKDDA 247 
BM4454          ------- 
 
Similarity was calculated for the aligned regions of AdeR (extra residues (-) were not 
included). The following residues were considered to be similar: 
* identical residue 
: strongly similar residue (scoring >0.5 in the Gonnet PAM matrix) 
. weakly similar residue (scoring <0.5 in the Gonnet PAM matrix) 
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are antibiotic-susceptible strains (Adams et al., 2008). Moreover, the genomic region around 
adeS was most different for ATCC 17978 than for the other five strains. However, a 
disadvantage of AYE is that despite numerous descriptions of AYE in the literature, there are no 
reports of gene manipulation in this strain.  The literature was reviewed to compile a list of 
researchers who have deleted or inactivated a gene in A. baumannii and the strains they chose; 
commonly used type strains were ATCC 19606 and ATCC 17978. To gather information for 
choosing an alternative strain if AYE proved difficult to manipulate, seven of the main authors 
were contacted and asked for their views and opinions on the strains used for genetic 
manipulation in A. baumannii (Table 3.2).  
3.3. Gene Deletion and Complementation 
To confirm the identity of pMo130-TelR, the vector was digested with BamHI and a region across 
the multiple cloning site was amplified (Section 2.4.1.2). The linearised plasmid was of the 
correct size (Figure 3.6a) and an amplimer of the expected size was obtained (Figure 3.6b), 
confirming that the correct plasmid had been extracted.  
Unmanipulated pMo130-TelR was transformed into DH5α (Section 2.4.1.3) to determine 
whether this vector could be used as a positive control for transformation of the ligated 
constructs into DH5α. After approximately 20 hr incubation, a bacterial lawn was present on 
each plate containing DH5α transformed with unmanipulated pMo130-TelR. To confirm that the 
correct vector had been introduced, a cell lysate was prepared from one isolated transformant 
and used in a PCR to confirm the vector identity (Section 2.4.1.2, Table 2.7, Reaction 1).  An  
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Table 3.2 Investigation into an Alternative Strain to AYE for Genetic Manipulation. 
 
Question Consensus response 
1. Why has AYE never been used for 
genetic manipulation despite many 
descriptions of this strain in the 
literature? 
 
AYE is MDR and is therefore difficult to manipulate using common techniques. It is 
not possible to use common resistance cassettes to select mutants. 
2. Why did they choose their particular 
strains for gene inactivation or deletion? 
 
ATCC 19606 and ATCC 17978 were commonly used because there were previous 
reports of using these strains in the literature and they are susceptible to many 
antibiotics. Where a type strain was not used, the organism was a clinical isolate 
and was used because its phenotype was important to the study. The clinical 
isolates investigated by Hornsey et al. (2010) and Heritier et al. (2005) were 
susceptible to kanamycin. Therefore, this antibiotic could be used to select 
inactivation mutants to investigate resistance to other classes of antibiotic. 
Likewise, Wong et al. (2009) were able to use ticarcillin and rifampicin. 
3. Did they have any recommendations or 
advice as to which standard strain of 
Acinetobacter would be best for making 
gene deletions? 
 
All of those asked suggested either that ATCC 19606 or ATCC 17978 was most 
suitable since reported gene manipulation has been carried out in these strains 
and genome data are available (although sequencing of ATCC 19606 is incomplete 
(Chaudhuri et al., 2008)). Common resistance markers such as kanamycin and 
rifampicin can also be used to inactivate the genes, since ATCC 19606 and ATCC 
17978 are susceptible to these antibiotics. The consensus was that the most 
important consideration when choosing a strain is that it is susceptible to 
commonly used resistance markers; all of the methods relied upon an antibiotic to 
select mutants. 
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amplimer of the correct size (253bp) was obtained for both the vector pMo130-TelR and the 
transformant confirming that pMo130-TelR could be transformed into DH5α with high efficiency 
and it was included as the positive control for transformation of all constructs created in this 
study.  
To confirm that DH5α and S17-1 did not already contain a vector, plasmid extraction was carried 
out for DH5α and S17-1 before transformation. Plasmid was not obtained from either strain, 
confirming that any plasmids identified in the candidate transformants were likely to be 
pMo130-TelR.   
3.3.1. adeRS 
3.3.1.1. Deletion of adeRS 
3.3.1.1.1. Construction of pMo130-TelR/adeRSUPDOWN 
The adeRSUP and adeRSDOWN fragments were amplified by PCR from AYE genomic DNA and 
verified by electrophoresis (Figure 3.7). 
pMo130-TelR and the adeRSUP fragment were each digested with BamHI and NotI in double 
digests (Section 2.4.1.2; Table 2.8, Digestion 3) and the vector was treated with alkaline 
phosphatase to prevent re-ligation. The insert and vector were then purified and 
electrophoresed to confirm that the DNA had not been lost at any stage (Figure 3.7). Fifteen bp 
DNA was removed from pMo130-TelR in the double digest, and 13 bp DNA was removed from 
the UP fragment. Therefore, the double digestion could not be confirmed by electrophoresis.  
Digestion 1, Table 2.8 
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Figure 3.6 Verification of pMo130-TelR identity.  
 
 
 
 
 
 
Lane DNA Expected size Actual size  
1 pMo130-Tel
R
 undigested --- --- 
2 pMo130-Tel
R
 + BamHI 9392bp 
 
~9392bp 
 
3 Hyperladder™ I (Bioline) --- --- 
    
Digestion 1, Table 2.8 
Lane DNA Expected size Actual size  
1 Contamination control No product No product 
2 pMo130-Tel
R
 253bp 
 
~253bp 
 
3 Hyperladder™ I (Bioline) --- --- 
    
Reaction 1, Table 2.7 
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However, the digestion was assumed to have worked, since the vector had been linearised 
(Figure 3.8). The vector and insert were ligated and transformed into DH5α.   
Approximately 100 colonies were obtained for DH5α transformed with pMo130-TelR/UP and 
three of these were selected for verification. Plasmid extraction and verification by PCR 
confirmed that the correct vector had been introduced and that the UP fragment had been 
ligated into each (Figure 3.9). The construct extracted from candidate 1 was selected for further 
verification. It was digested with BamHI and compared with BamHI-digested pMo130-TelR. 
pMo130-TelR/UP was approximately 1kb larger than pMo130-TelR, confirming that ligation of 
the UP fragment  into S17-1 was successful (Figure 3.10). This construct was used for cloning of 
the DOWN fragment. 
The DOWN fragment and pMo130-TelR/adeRSUP were digested with BamHI and SphI and 
electrophoresed to confirm that DNA was still present (Figure 3.11). The digested vector and 
insert were ligated and transformed into DH5α. Approximately 100 candidate transformants 
were obtained and three large colonies were selected for verification. Plasmid was extracted 
from each candidate and verified by PCR (Figure 3.12) and DNA sequencing (Figure 3.13).  
3.3.1.1.2. Introduction of pMo130-TelR/adeRSUPDOWN into AYE and Verification of Deletion 
pMo130-TelR was transformed into S17-1 and plasmid was extracted from one candidate 
transformant. The identity of the plasmid was verified by PCR (Table 2.7, PCR 13). An amplimer 
of the correct size (2186 bp) was obtained confirming that S17-1 contained pMo130-
TelR/adeRSUPDOWN. pMo130-TelR/adeRSUPDOWN was then transferred from S17-1/pMo130-  
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Figure 3.7 Verification of adeRS UP and DOWN fragments. 
 
 
a Table 2.7 
 
 
 
 
 
Lane PCRa DNA Expected size Actual size  
1 --- Hyperladder™ I (Bioline) --- --- 
2 2 Purified UP fragment 989bp ~989bp 
3 3 Purified DOWN fragment 1040bp ~1040bp 
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Figure 3.8 Digestion of pMo130-TelR and adeRSUP fragment. 
 
 
 
 
 
 
 
 
 
Digestion 3, Table 2.8
Lane DNA 
Expected 
size 
Actual size 
1 pMo130-TelR Undigested --- --- 
2 pMo130-TelR + BamHI + NotI 9377bp ~ 9377bp  
3 UP fragment + BamHI + NotI 976bp ~ 976bp 
4 Hyperladder™ I (Bioline) --- --- 
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Figure 3.9 Verification of pMo130-TelR/adeRSUP by PCR. 
 
 
 
 
 
 
 
 
 
 
 
PCR 10, Table 2.7
Lane DNA Expected size Actual size  
1 Hyperladder™ I (Bioline) --- --- 
2 pMo130-TelR/UP Transformant 1 1158bp 1158bp 
3 pMo130-TelR/UP Transformant 2 1158bp 1158bp 
4 pMo130-TelR/UP Transformant 3 1158bp 1158bp 
5 pMo130-TelR (Negative control) No product 200bp 
6 Contamination control No amplimer No amplimer 
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Figure 3.10 Verification of pMo130-TelR/adeRSUP and pMo130-TelR/adeRSUPDOWN by 
Restriction Digestion.        
 
 
 
 
 
         
 
  
Digestion 1, Table 2.8
Lane DNA Expected size Actual size  
1 pMo130-TelR Undigested --- --- 
2 pMo130-TelR/UP Undigested --- --- 
3 
pMo130-TelR/UPDOWN 
Undigested 
--- --- 
4 pMo130-TelR + BamHI 9392bp ~9392bp 
5 pMo130-TelR/UP + BamHI 10335bp ~10335bp 
6 pMo130-TelR/UPDOWN + BamHI 11367bp ~11367bp 
7 Hyperladder™ I (Bioline) --- --- 
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Figure 3.11 Digestion of pMo130-TelR/adeRSUP and adeRSDOWN fragment.    
 
Digestion 4, Table 2.8
Lane DNA Expected size Actual size  
1 Hyperladder™ I (Bioline) --- --- 
2 pMo130-TelR/UP Undigested --- --- 
3 pMo130-TelR/UP + BamHI + SphI 10335bp 10335bp 
4 Insert + BamHI + SphI 1032bp 1032bp 
5 Hyperladder™ I (Bioline) --- --- 
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Figure 3.12 Verification of pMo130-TelR/adeRSUPDOWN by PCR.  
a PCR number, Table 2.7
Lane PCRa DNA 
Expected 
size 
Actual size  
1 --- Hyperladder™ I (Bioline) --- --- 
2 10 pMo130-TelR/UPDOWN Transformant 1 1158bp 1158bp 
3 10 pMo130-TelR/UPDOWN Transformant 2 1158bp 1158bp 
4 10 pMo130-TelR/UPDOWN Transformant 3 1158bp 1158bp 
5 13 pMo130-TelR/UPDOWN Transformant 1 2186bp 2186bp 
6 13 pMo130-TelR/UPDOWN Transformant 2 2186bp 2186bp 
7 13 pMo130-TelR/UPDOWN Transformant 3 2186bp 2186bp 
8 10 pMo130-TelR/UP (negative control) No amplimer No amplimer 
9 10 ---  No amplimer No amplimer 
10 13 --- No amplimer No amplimer 
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Figure 3.13 Verification of pMo130-TelR/adeSUPDOWN by DNA Sequencing. 
a) Forward sequencing 
 
pMoadeSUPDN Expected      1 CCATCTACTTCTTCGACCCGTCCGGTAACCGCAACGAAGTGTTCTGCGGGGGAGATTACA   60  
                                                          G++++  AGTGTTCTGCGGGGGAGATTACA       
pMoadeSUPDN FW            1 ---------------------------TGGGSMMMMSAGTGTTCTGCGGGGGAGATTACA   33  
 
pMoadeSUPDN Expected     61 ACTACCCGGACCACAAACCGGTGACCTGGACCACCGACCAGCTGGGCAAGGCGATCTTTT  120  
                            ACTACCCGGACCACAAACCGGTGACCTGGACCACCGACCAGCTGGGCAAGGCGATCTTTT       
pMoadeSUPDN FW           34 ACTACCCGGACCACAAACCGGTGACCTGGACCACCGACCAGCTGGGCAAGGCGATCTTTT   93  
 
pMoadeSUPDN Expected    121 ACCACGACCGCATTCTCAACGAACGATTCATGACCGTGCTGACCTGACCTGAGCGGCCGC  180  
                            ACCACGACCGCATTCTCAACGAACGATTCATGACCGTGCTGACCT     GAGCGGCCGC       
pMoadeSUPDN FW           94 ACCACGACCGCATTCTCAACGAACGATTCATGACCGTGCTGACCT-----GAGCGGCCGC  148  
 
pMoadeSUPDN Expected    181 CCTCCGACTTGCGGACGGATTTCCGCCGTACGGAACGCATGTACTCGTGCAGGAAGATTT  240  
                            CCTCCGACTTGCGGACGGATTTCCGCCGTACGGAACGCATGTACTCGTGCAGGAAGATTT       
pMoadeSUPDN FW          149 CCTCCGACTTGCGGACGGATTTCCGCCGTACGGAACGCATGTACTCGTGCAGGAAGATTT  208  
 
pMoadeSUPDN Expected    241 TCACTAAAATTTACCGACTGCGGTTGAATGCTTAATACACTGACTTTAGCCGGTGGTGGC  300  
                            TCACTAAAATTTACCGACTGCGGTTGAATGCTTAATACACTGACTTTAGCCGGTGGTGGC       
pMoadeSUPDN FW          209 TCACTAAAATTTACCGACTGCGGTTGAATGCTTAATACACTGACTTTAGCCGGTGGTGGC  268  
 
pMoadeSUPDN Expected    301 TCAGCTTGAGCGACTTCTTTTGAATCACACCCCTGTAATATCAGCCCAATAGATAAAAAT  360  
                            TCAGCTTGA+CGACTTCTTTTGAATCACACCCCTGTAATATCAGCCCAATA+ATAAAAAT       
pMoadeSUPDN FW          269 TCAGCTTGARCGACTTCTTTTGAATCACACCCCTGTAATATCAGCCCAATAKATAAAAAT  328  
 
pMoadeSUPDN Expected    361 AAAGGAAGTAAAAGATGCTTTTGCATACTGTCCAAACCTAGTGACTTTTTGATGTTCGTA  420  
                            AAAGGAA+TAAAAGATGCTTTTGCATACTGTCCAAACCTA+TGACTTTTTGATGTTCGTA       
pMoadeSUPDN FW          329 AAAGGAARTAAAAGATGCTTTTGCATACTGTCCAAACCTARTGACTTTTTGATGTTCGTA  388  
 
pMoadeSUPDN Expected    421 TTATTTTTGATGAGTGTGTAGGGATAATCACTAAAGTGTGGAGTAAGTGTGGAGAAATAC  480  
                            TTATTTTTGATGA+TGTGTAGGGATAA+C++TA+AGTGTG+AGTAA+TGTGGAGAAATAC       
pMoadeSUPDN FW          389 TTATTTTTGATGASTGTGTAGGGATAAWCWYTAMAGTGTGRAGTAARTGTGGAGAAATAC  448  
 
pMoadeSUPDN Expected    481 GGATAATTTAGCGTATGATGAGTTGAAGCACTTTCTATAGCCAGATTTTCTATGTTTGAT  540  
                            GGATAATTTA+CGTATGATGA+TTGAA+CACTTTC+A+A+CCAGATTTTCTATGTTTGAT       
pMoadeSUPDN FW          449 GGATAATTTARCGTATGATGARTTGAARCACTTTCYAWAKCCAGATTTTCTATGTTTGAT  508  
 
pMoadeSUPDN Expected    541 CATTCTTTTTCTTTTGATTGCCAAGATAAAGTTATTCTTGTGGTAGAAGATGACTACGAT  600  
                            CATTCTTTTTCTTTTGATTGCCAA+ATAA GTTATTCTTGTGGTAGAAGA GACTAC A        
pMoadeSUPDN FW          509 CATTCTTTTTCTTTTGATTGCCAAKATAACGTTATTCTTGTGGTAGAAGAGGACTACCAC  568  
 
pMoadeSUPDN Expected    601 ATTGGCGACATTATTGAAAATTATTTAAAACGTGAAGGCATGAGTGTTATTCGGGCCATG  660  
                             TTGGCGAC TTATTGAAAATTATTT A+ACGTG AGGCATGAGTGTTATTC  GCC T        
pMoadeSUPDN FW          569 CTTGGCGACCTTATTGAAAATTATTTGARACGTGTAGGCATGAGTGTTATTCACGCCTTC  628  
 
pMoadeSUPDN Expected    661 AATGGAAAGCAAGCGATTGAATTGCACGCTAGCCAACCCATCGATTTAATCTTACTTGAT  720  
                              TG A AG AAG GA  G A TG  +GCTA+CCAA+ CATC  TTT ATC  AC TG T       
pMoadeSUPDN FW          629 TCTGYACAGAAAGAGAGAGTAATGTTYGCTAKCCAAMACATCTTTTTCATCACACCTGCT  688  
 
pMoadeSUPDN Expected    721 ATTAAATTACCCGAATTAAACGGTTGGGAAGTATTAAATAAAATACGCCAAAAAGCTCAG  780  
                            AT+AAA    C+ A TT A CG +   GAA  ATT A TAAA TA +    A+  CT          
pMoadeSUPDN FW          689 ATKAAAAACACMAACTTGATCGYYC--GAACGATTTATTAAATTATKWTTTAMT-CTACC  745  
 
pMoadeSUPDN Expected    781 ACTCCCGTGATCATGTTGACGGCGCTAGATCAAGATATTGATAAAGTTATGGCATTACGC  840  
                              TCCC  G  CA G +GA  G G     T  A+ TA TGA+  +        AT  + C       
pMoadeSUPDN FW          746 CTTCCCCCGCCCAAGAKGAGAGTGAGTTGTATAS-TASTGAYSCRCCCCATCWATCCMTC  804  
 
pMoadeSUPDN Expected    841 ATAGGTGCAGATGACTTTGTGGTGAAGCCTTTTAACCCAAATGAAGTCGTCGCTAGAGTT  900  
                            A        G   A++ T +  T A     TT         +G   TC   G TA  +TT       
pMoadeSUPDN FW          805 ACGCCCCGCGCCTASWCTTKTATAATATTATTCTCTGGGGCKGGKCTCTATGGTAATKTT  864  
 
pMoadeSUPDN Expected    901 CAGGCAGTCCTAAGACGTACTCAGTTTGCAAACAAAGCAACTAATAAAAATAAACTCTAT  960  
                              G     CC A  +  T CT   TTT C   C A   A  T      A  + +  C A        
pMoadeSUPDN FW          865 TYGTT--CCCAACTMTTTTCTTTATTTTCCGGCSATATATTTTGSCGSAGGMGRGCCSAA  922  
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pMoadeSUPDN Expected    961 AAAAATATTGAAATTGATACCGACACTCATAGCGTTTATATACACTCTGAGAATAAGAAG 1020  
                             A  A ATT A A+  A    +A AC  ATAG G +      + +TCTG                  
pMoadeSUPDN FW          923 TAGTAAATTAATAWRAACSGWKA-ACCTATAGAGMK------MGMTCTGCTGGCCGCGTC  975  
 
pMoadeSUPDN Expected   1021 ATCTTGCTTAATCTGACGCTGACTGAATATAAAATTATTTCATTCATGATTGATCAGCCT 1080  
                            +   T+++  AT         + T+  T T     ++   C + +  G +       CC+       
pMoadeSUPDN FW          976 RCTATRMWCTATT--------MTTRTGTGTCCYCCYMCCSCYKCMGCGGWGATGAGACCK 1027  
 
pMoadeSUPDN Expected   1081 CATAAAGTTTTTACGCGCGGAGAGCTTATGAATCACTGCATGAATGATAGCGATGC-ACT 1139  
                            C    A++ TTT + ++C +A   +    GA  C+C  C+++A  GATA+ G +G  A+        
pMoadeSUPDN FW         1028 CGAGKARWATTTTMTMKCCSACGAYAC-CGACCCRCCTCMKRAG-GATARAGCYGAGASG 1085  
 
pMoadeSUPDN Expected   1140 AGAGCGAACCGGATCCAAGCTGTAACCGCAGCGCCAATTAAGGCTATACCGGTTTCATAA 1199  
                            A A   AA +  +T CA G                                                
pMoadeSUPDN FW         1086 ACAATCAATSATRTACATG----------------------------------------- 1104  
 
 
b) Reverse sequencing 
 
pMoadeSUPDN Expected    841 ATAGGTGCAGATGACTTTGTGGTGAAGCCTTTTAACCCAAATGAAGTCGTCGCTAGAGTT  900  
                                       T A   +  GGT   + CT TT     A AT  + T GTC+CT  +  T       
pMoadeSUPDN RV            1 ----------CTYAWCCKACGGTCG-STCTGTTGCGATAGATAGM-TGGTCKCTCCRAGT   48  
 
pMoadeSUPDN Expected    901 CAGGCAGTCCTAAGACGTACTCAGTTTGCAAACAAAGCAACTAATAAAAATAAACTCTAT  960  
                            CA G          +CGT CTCAGT T C++      + A TAATA +  T A  +  ++       
pMoadeSUPDN RV           49 CATG---------AMCGT-CTCAGTCTACRM--GGCAYTATTAATAKWCGTGAGTKA-RK   95  
 
pMoadeSUPDN Expected    961 AAAAATATTGAAATTGATACCGACACTCATAGCGTTTATATACACTCTGAGAATAAGAAG 1020  
                             A  A +TTG+A T G  +CC+ C  T++   CGTTTA+   C  TC++  + TA G A+       
pMoadeSUPDN RV           96 TAYGAGWTTGWAGTCGTCMCCRTCYATSMGGCCGTTTAWCCYCTWTCKRGAMGTAGGGAK  155  
 
pMoadeSUPDN Expected   1021 A--TCTTGCTTAATCTGACGCTGACTGAATATAAAATTAT-TTCATTCATGATTGATCAG 1077  
                               +C TGCT++ TC G C + G  TG   A A A TTA+ TTCA+T + + +++++CA        
pMoadeSUPDN RV          156 GRTYCGTGCTKWKTCCG-CTSCGYRTGGTSAAAGAGTTAYATTCAYTGMARSWKKWKCAT  214  
 
pMoadeSUPDN Expected   1078 CCTCATAAAGTTTTTACGCGCGGAGAGCTTATGAATCACTGCATGAATGATAGCGATGCA 1137  
                            C T+A+A  GTT++ A+G+++GGA+  +T + GA TC+C +CA GAAT+ATAG G T+CA       
pMoadeSUPDN RV          215 CATMAYAC-GTTYKGAMGSRYGGASGTSTGWAGACTCWCCKCAMGAATRATAGTG-TKCA  272  
 
pMoadeSUPDN Expected   1138 CTAGAGCGAACCGGATCCAAGCTGTAACCGCAGCGCCAATTAAGGCTATACCGGT-TTCA 1196  
                             TAG GC  ++ GG  C  AGCT+ A CCGC GC  CAATTAAGG TA +C++GT TTC+       
pMoadeSUPDN RV          273 -TAGGGC--RSAGGGGCTCAGCTRCA-CCGCTGCCWCAATTAAGGTTAAMCSKGTCTTCW  328  
 
pMoadeSUPDN Expected   1197 TAAATAATATCTATAACAAATTCGAGCACTCCCTCCGACAAAAAATCTAATGAGCCTGAA 1256  
                            TA+AT ATAT TATAACAAATTCGA+C+CTC+CT+CG+C+AAAA+T TAA++AGCCTGAA       
pMoadeSUPDN RV          329 TAWATTATATWTATAACAAATTCGARCWCTCSCTSCGMCWAAAAMTWTAAKKAGCCTGAA  388  
 
pMoadeSUPDN Expected   1257 AATTTAAGAAATTTAGCTATGGCAACCACTATAACTCCCAATAAAGCGCCAGCCC-ATAA 1315  
                             ATT+AAGAAA+TTAGCTATGGCAACC+CTATAACTCCCA+TAAAGCGCCAGCCC ATA+       
pMoadeSUPDN RV          389 CATTWAAGAAAWTTAGCTATGGCAACCMCTATAACTCCCAMTAAAGCGCCAGCCCCATAM  448  
 
pMoadeSUPDN Expected   1316 GAATATTTTATGAATATTGATAGGTGCCGTGACTTGATCGATTTGATCGGGGTACTTTCG 1375  
                            GAATATTTTATGAATATTGATAGGTGCCGTGAC TGATCGA+TTGATC+GGGTACTTTCG       
pMoadeSUPDN RV          449 GAATATTTTATGAATATTGATAGGTGCCGTGACGTGATCGAWTTGATCKGGGTACTTTCG  508  
 
pMoadeSUPDN Expected   1376 ATAGTACTCAATTTCCTCATCTGTTACTTCAGAGGTAGATTT-----AAATAATAATTTA 1430  
                            ATAGTACTCAA+TTCCTC+ CT+TTACTTCAGAG T GATTT     AAATAATAAT+ A       
pMoadeSUPDN RV          509 ATAGTACTCAAYTTCCTCWCCTSTTACTTCAGAGCTGGATTTGATTTAAATAATAATWAA  568  
 
pMoadeSUPDN Expected   1431 ATAAATAGCTTGTCTTGATCAAGCTTTGTATTTTTCTTCATAGCTGTGATGCGTAATAAG 1490  
                            ATAA+T GCT GTCT GATCAAGCTTT T TTTTTCTTCATAG++GTGATGCGTAATAAG       
pMoadeSUPDN RV          569 ATAARTCGCTCGTCTCGATCAAGCTTTTTTTTTTTCTTCATAGSWGTGATGCGTAATAAG  628  
 
pMoadeSUPDN Expected   1491 TATTCTAATGTTTAATGTTACTCACTTTTTCTTTAGGGAGTAACTGTTTTAAGAGCTTAT 1550  
                            TATT TAATGT+TAATGTTACTCACTTTT CT+TAGGGAGTAACTGT++TAAGAGCT+AT       
pMoadeSUPDN RV          629 TATTATAATGTWTAATGTTACTCACTTTT-CTYTAGGGAGTAACTGTWWTAAGAGCTYAT  687  
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pMoadeSUPDN Expected   1551 CGCTACCTTAACTCATTCATTTCTTCTCTAGCTTGTTGTGGTGTTTTACCCGACCACTCT 1610  
                            CGCTACC+TAACTCATTC+TTTCTTCT+TAGCTTGT+GTGGTGTT++ACCCG+CCACTCT       
pMoadeSUPDN RV          688 CGCTACCWTAACTCATTCWTTTCTTCTSTAGCTTGTWGTGGTGTTYYACCCGMCCACTCT  747  
 
pMoadeSUPDN Expected   1611 TTATAAGCCCGTGTAAATGGACTGTGCTCGGCATAACCTAACAGTAAAGCTATTTCTACA 1670  
                            TTATAAGCCCGTGTAAATGGA+TGTGCTCGGCATAACCTAACAGTAAAGCTATTTCTACA       
pMoadeSUPDN RV          748 TTATAAGCCCGTGTAAATGGAYTGTGCTCGGCATAACCTAACAGTAAAGCTATTTCTACA  807  
 
pMoadeSUPDN Expected   1671 ATTTGTAGCCTTAGATCTTTTAAATACGATTTTGCCAATTCGTAACGGACAGTATTTAAT 1730  
                            ATTTGTAGCCTTAGATCTTTTAAATACGATTTTGCCAATTCGTAACGGACAGTATTTAAT       
pMoadeSUPDN RV          808 ATTTGTAGCCTTAGATCTTTTAAATACGATTTTGCCAATTCGTAACGGACAGTATTTAAT  867  
 
pMoadeSUPDN Expected   1731 TCTTTCCGAAAATTCGTACCTGCCTCGGTTAAACGGCGTTGCAAGGTTCTACGTGAATAA 1790  
                            TCTTTCCGAAAATTCGTACCTGCCTCGGTTAAACGGCGTTGCAAGGTTCTACGTGAATAA       
pMoadeSUPDN RV          868 TCTTTCCGAAAATTCGTACCTGCCTCGGTTAAACGGCGTTGCAAGGTTCTACGTGAATAA  927  
 
pMoadeSUPDN Expected   1791 TTTAATCGCTCTGCAAGCTGTTCAATAGTTGGTTCGCCTTGATGAAGTAAGTAAGCAATC 1850  
                            TTTAATCGCTCTGCAAGCTGTTCAATAGTTGGTTCGCCTTGATGAAGTAAGTAAGCAATC       
pMoadeSUPDN RV          928 TTTAATCGCTCTGCAAGCTGTTCAATAGTTGGTTCGCCTTGATGAAGTAAGTAAGCAATC  987  
 
pMoadeSUPDN Expected   1851 TGTTTACGAACTTGATCTGTAATTTCATCAATATGTGGCAGGCTTGCCAGTAACTTGTCA 1910  
                            TGTTTACGAACTTGATCTGTAATTTCATCAATATGTGGCAGGCTTGCCAGTAACTTGTCA       
pMoadeSUPDN RV          988 TGTTTACGAACTTGATCTGTAATTTCATCAATATGTGGCAGGCTTGCCAGTAACTTGTCA 1047  
 
pMoadeSUPDN Expected   1911 GCATGTTTTTCTAGTATGGCAACTAAGGCGGCGTCGGAGTTTTTAAGCGGTAGACTTAAG 1970  
                            GCATGTTTTTCTAGTATGGCAACTAAGGCGGCGTCGGAGTTTTTAAGCGGTAGACTTAAG       
pMoadeSUPDN RV         1048 GCATGTTTTTCTAGTATGGCAACTAAGGCGGCGTCGGAGTTTTTAAGCGGTAGACTTAAG 1107  
 
pMoadeSUPDN Expected   1971 ATTTCCTTATCAAAACGCATCAGTGCCACAGGCTGTTCAAAAAGCACAGGACAACCAAAA 2030  
                            ATTTCCTTATCAAAACGCATCAGTGCCACAGGCTGTTCAAAAAGCACAGGACAACCAAAA       
pMoadeSUPDN RV         1108 ATTTCCTTATCAAAACGCATCAGTGCCACAGGCTGTTCAAAAAGCACAGGACAACCAAAA 1167  
 
pMoadeSUPDN Expected   2031 TACTCCTCATAAGGCTGAACATTTTCAGGCCGTTCATGAATAAAATGTATTTCTTTGAGT 2090  
                            TACTCCTCATAAGGCTGAACATTTTCAGGCCGTTCATGAATAAAATGTATTTCTTTGAGT       
pMoadeSUPDN RV         1168 TACTCCTCATAAGGCTGAACATTTTCAGGCCGTTCATGAATAAAATGTATTTCTTTGAGT 1227  
 
pMoadeSUPDN Expected   2091 CTTTCTTTTCCTCTAATGAGACTACGGCAAAATTGAACTATAACGGTACGGCCAGTTTCG 2150  
                            CTTTCTTTTCCTCTAATGAGACTACGGCAAAAT GAACTATAACGGTACG CCAGT +C        
pMoadeSUPDN RV         1228 CTTTCTTTTCCTCTAATGAGACTACGGCAAAAT-GAACTATAACGGTACG-CCAGTCKCC 1285  
 
pMoadeSUPDN Expected   2151 TCCGATAAAGGGCCGACTTGCTCACCTGCATGCCCC 2186  
                                                                       
pMoadeSUPDN RV         1286 CWT--------------------------------- 1288  
 
 
The region of pMo130-TelR/adeSUPDOWN comprising the UP and DOWN fragments was 
amplified by PCR (2816bp amplimer) and sequenced. The result was aligned with the expected 
sequence. 
a) pMoUPDN FW was generated using primer pMo130-TelRFW (Table 2.6) , which is specific for 
pMo130-TelR.  
b) pMoUPDN RV was generated using primer DOWNRVadeS (Table 2.6), which is specific for the 
DOWN fragment. This sequence was reverse complemented before alignment. 
The first 1150bp of the sequence corresponds to 174bp of the vector and the entire UP 
fragment (a). The remainder of the sequence corresponds to the DOWN fragment (b). 
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TelR to AYE by conjugation (section 2.4.3). After 24hrs, approximately 60 candidate 
transconjugants were obtained.  
Sixteen candidates were subcultured onto LB plates. The colonies of two of these were light 
yellow in colour and turned the media yellow; the rest exhibited normal A. baumannii 
growth. All candidates were sprayed with pyrocatechol and yellow colonies selected. The 
two yellow subcultures turned a deeper shade of yellow; the white colonies remained white. 
The yellow colonies had undergone single recombination. To select double recombinants, a 
single colony of each yellow subculture was cultured in LB broth (-NaCl) containing 10% 
sucrose. Serial dilutions were plated to obtain single colonies (Section 2.4.3). After five 
passages in LB supplemented with sucrose, white colonies were obtained. Four, well isolated 
white colonies were selected for verification. All candidates were inhibited on LB plates 
containing tellurite (30 g/ml), suggesting that they no longer contained the suicide vector 
pMo130-TelR. The deletion in the four candidates was verified by PCR using AYE wild-type 
genomic DNA as a negative control ( Figure 3.14). The PCR amplimer obtained for candidate 
4 ( Figure 3.14, Lane 6) was sequenced and the results confirmed that adeRS had been 
deleted (Figure 3.15; Figure 3.16). It was initially planned that just adeS would be deleted. 
However, adeS, 126 bp of adeR and 98 bp of a gene encoding a hypothetical protein 
(ABAYE1818) were deleted because the primers, which were designed to delete the whole of 
adeS, also flanked part of adeR and ABAYE1818 (Figure 3.15). 
3.3.1.2. Complementation of adeRS Gene Deletion  
The fragment containing the deleted region (including adeS and 126 bp of adeR) and the UP 
and DOWN fragments used to delete adeRS were amplified by PCR (Figure 3.17; Section 
2.4.5) This amplimer and pMo130-TelR were digested with NotI and BamHI 
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 Figure 3.14 Verification of adeRS Gene Deletion in AYE by PCR. 
 
 
 
 
 
 
 
 
 
 
PCR number 18, Table 2.7 
 
Lane Template Expected size Actual size  
1 Hyperladder™ I (Bioline) --- --- 
2 AYE (wild-type) genomic DNA  3377bp 3377bp 
3 Candidate mutant 1 2011bp 2011bp 
4 Candidate mutant 2 2011bp 2011bp 
5 Candidate mutant 3 2011bp 2011bp 
6 Candidate mutant 4 2011bp 2011bp 
7 --- No amplimer No amplimer 
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Figure 3.15 Region Around adeS in AYE and AYEΔadeRS (expected sequences) and 
Primers used to Delete and Complement adeRS. 
Key for the following DNA sequences: 
 
Deleted region 
 
adeR 
-35: ttcaca 
-10: tatata 
Shine dalgano: agccaga 
 
adeS 
-10: tataa 
-35: ttgctt 
Shine dalgarno: aggga 
 
ABAYE1818 Gene encoding a hypothetical protein (xBASE) 
 
UP primers.  
UPFWadeS (Contains NotI recognition site) 
GGGGCGGCCGCCCTCCGACTTGCGGACGGAT   
UPRVadeS (Contains BamHI recognition site) 
GGGGGATCCGGTTCGCTCTAGTGCATCGC      
DOWN primers 
 
DOWNFWadeS (Contains BamHI recognition site) 
GGGGGATCCAAGCTGTAACCGCAGCGCCA   
DOWNRVadeS (Contains SphI recognition site) 
GGGGCATGCAGGTGAGCAAGTCGGCCCTT   
UPFWadeS was also used to amplify the UP-adeRS-DOWN insert (from wild-type AYE) for the 
complementation construct (Section 2.4). The reverse primer (adeSRVcomp, Table 2.6) 
contained the same chromosome-homologous sequence as DOWNRVadeS, but contained a 
BamHI restriction site, instead of SphI. This was because there was an SphI restriction site 
within adeS.  
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a) Expected Sequence for Wild-type AYE. 
ggccagcaatgctttcatttgagcgacatcggctagagcctgacgatactgagcttgagc 
attacttacttcttgcttactaaccgcattacttggtaatagctgctcataacgttctaa 
ctgaactttgagtcttgccacctcagcttcagctttattgagagaagctctattgctatt 
tacatcggcctcaaaagtctcggaattaattttatataaagcttgccctgctctaacttc 
actaccttgtttaaatagaaccttttcaataatacctccgacttgcggacggatttccgc 
cgtacggaacgcatgtactcgtgcaggaagattttcactaaaatttaccgactgcggttg 
aatgcttaatacactgactttagccggtggtggctcagcttgagcgacttcttttgaatc 
acacccctgtaatatcagcccaatagataaaaataaaggaagtaaaagatgcttttgcat 
actgtccaaacctagtgactttttgatgttcgtattatttttgatgagtgtgtagggata 
atcactaaagtgtggagtaagtgtggagaaatacggataatttagcgtatgatgagttga 
agcactttctatagccagattttctatgtttgatcattctttttcttttgattgccaaga 
TAAAGTTATTCTTGTGGTAGAAGATGACTACGATATTGGCGACATTATTGAAAATTATTT 
AAAACGTGAAGGCATGAGTGTTATTCGGGCCATGAATGGAAAGCAAGCGATTGAATTGCA 
CGCTAGCCAACCCATCGATTTAATCTTACTTGATATTAAATTACCCGAATTAAACGGTTG 
GGAAGTATTAAATAAAATACGCCAAAAAGCTCAGACTCCCGTGATCATGTTGACGGCGCT 
AGATCAAGATATTGATAAAGTTATGGCATTACGCATAGGTGCAGATGACTTTGTGGTGAA 
GCCTTTTAACCCAAATGAAGTCGTCGCTAGAGTTCAGGCAGTCCTAAGACGTACTCAGTT 
TGCAAACAAAGCAACTAATAAAAATAAACTCTATAAAAATATTGAAATTGATACCGACAC 
TCATAGCGTTTATATACACTCTGAGAATAAGAAGATCTTGCTTAATCTGACGCTGACTGA 
ATATAAAATTATTTCATTCATGATTGATCAGCCTCATAAAGTTTTTACGCGCGGAGAGCT 
TATGAATCACTGCATGAATGATAGCGATGCACTAGAGCGAACCGTAGATAGCCATGTGAG 
TAAGCTGAGAAAAAAACTAGAAGAACAAGGCATATTTCAAATGTTAATTAATGTGCGTGG 
CGTGGGATATAGACTAGATAATCCCCTAGCTGTAAAAGATGATGCCTAAataatattaaa 
aaatagctagggaatattttATGAAAAGTAAGTTAGGAATTAGTAAGCAACTTTTTATTG 
CCTTAACTATTGTGAATTTAAGCGTTACGCTATTTTCTATAGTATTGGGTTATATCATTT 
ATAACTATGCGATTGAAAAAGGCTGGATTAGCTTAAGCTCATTTCAACAAGAAGATTGGA 
CCAGTTTTCATTTTGTAGACTGGATCTGGTTAGCCACTGTTATCTTCTGTGGCTGTATTA 
TTTCATTAGTGATTGGCATGCGCCTCGCAAAGCGTTTTATTGTGCCAATTAACTTCTTAG 
TCGAAGCAGCAAAAAAAATTAGTCACGGCGACCTCTCTGCTAGAGCTTACGATAATAGAA 
TTCACTCCGCCGAAATGTCGGAGCTTTTATATAATTTTAATGATATGGCTCAAAAGCTAG 
AGGTTTCCGTCAAAAATGCGCAGGTTTGGAATGCAGCTATCGCACATGAGTTAAGAACGC 
CTATAACGATATTACAAGGTCGTTTACAGGGAATTATTGATGGCGTTTTTAAACCTGATG 
AAGTCCTATTTAAAAGCCTTTTAAATCAAGTTGAAGGTTTATCTCACTTAGTCGAAGACT 
TACGGACTTTAAGCTTAGTAGAGAACCAGCAACTCCGGTTAAATTATGAATTGTTTGACT 
TGAAGGCGGTAGTTGAAAAAGTTCTTAAAGCATTTGAAGATCGTTTGGATCAAGCTAAGC 
TAGTACCAGAACTTGACCTAACGTCCACTCCTGTATATTGCGACCGCCGTCGTATTGAGC 
AAGTTTTAATTGCTTTAATTGATAATGCGATTCGCTATTCAAATGCAGGCAAACTTAAAA 
TCTCTTCAGAAGTGGTTGCAGACAACTGGATATTAAAAATTGAGGATGAAGGCCCCGGCA 
TTGCAACCGAGTTTCGGGACGATTTATTTAAGCCTTTCTTTAGATTAGAAGAATCAAGGA 
ATAAAGAATTTGGCGGCACAGGTTTAGGTCTTGCTGTTGTACATGCAATTATTGTGGCAC 
TGAAAGGCACTATTCAATATAGCAATCAAGGCTCGAAAAGTGTTTTCACCATAAAAATTT 
CTATGGGTCATGAAGAGATGGGGTAAttcgctaaattaaaaaatcttagagttaaagtgc 
cccctcactctcttttattcttctacgaatttcttctcgccattttgtggcattttcctg 
ttgtttgtttaataggacacctaacatataagctgtaaccgcagcgccaattaaggctat 
accggtttcataaataatatctataacaaattcgagcactccctccgacaaaaaatctaa 
tgagcctgaaaatttaagaaatttagctatggcaaccactataactcccaataaagcgcc 
agcccataagaatattttatgaatattgataggtgccgtgacttgatcgatttgatcggg 
gtactttcgatagtactcaatttcctcatctgttacttcagaggtagatttaaataataa 
tttaataaatagcttgtcttgatcaagctttgtatttttcttcatagctgtgatgcgtaa 
taagtattctaatgtttaatgttactcactttttctttagggagtaactgttttaagagc 
ttatcgctaccttaactcattcatttcttctctagcttgttgtggtgttttacccgacca 
ctctttataagcccgtgtaaatggactgtgctcggcataacctaacagtaaagctatttc 
tacaatttgtagccttagatcttttaaatacgattttgccaattcgtaacggacagtatt 
taattctttccgaaaattcgtacctgcctcggttaaacggcgttgcaaggttctacgtga 
ataatttaatcgctctgcaagctgttcaatagttggttcgccttgatgaagtaagtaagc 
aatctgtttacgaacttgatctgtaatttcatcaatatgtggcaggcttgccagtaactt 
gtcagcatgtttttctagtatggcaactaaggcggcgtcggagtttttaagcggtagact 
taagatttccttatcaaaacgcatcagtgccacaggctgttcaaaaagcacaggacaacc 
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aaaatactcctcataaggctgaacattttcaggccgttcatgaataaaatgtatttcttt 
gagtctttcttttcctctaatgagactacggcaaaattgaactataacggtacggccagt 
ttcgtccgataaagggccgacttgctcaccttttgtatcccatgaaagctctacatattc 
agtataaatacgtacagtggcaggataaacatcatagacaagccgctgatatcgctcaaa 
cctttctaaaaccgcccccagattttcacaggcaagaaagactgaccctaaaacacctag 
atgctgagctgtaatggtttgacccacatgtaaaccaatgaaagggtcatttaaataatc 
tttggcaataatgagaagactttcccaatgatcgatatctacgccttctaaatgatttga 
atctgctttaggccacggttcacccaataccttttctgggtcatgtcctagtttttccag
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b) Expected Sequence for AYEΔadeRS. 
cctccgacttgcggacggatttccgc 
cgtacggaacgcatgtactcgtgcaggaagattttcactaaaatttaccgactgcggttg 
aatgcttaatacactgactttagccggtggtggctcagcttgagcgacttcttttgaatc 
acacccctgtaatatcagcccaatagataaaaataaaggaagtaaaagatgcttttgcat 
actgtccaaacctagtgactttttgatgttcgtattatttttgatgagtgtgtagggata 
atcactaaagtgtggagtaagtgtggagaaatacggataatttagcgtatgatgagttga 
agcactttctatagccagattttctatgtttgatcattctttttcttttgattgccaaga 
TAAAGTTATTCTTGTGGTAGAAGATGACTACGATATTGGCGACATTATTGAAAATTATTT 
AAAACGTGAAGGCATGAGTGTTATTCGGGCCATGAATGGAAAGCAAGCGATTGAATTGCA 
CGCTAGCCAACCCATCGATTTAATCTTACTTGATATTAAATTACCCGAATTAAACGGTTG 
GGAAGTATTAAATAAAATACGCCAAAAAGCTCAGACTCCCGTGATCATGTTGACGGCGCT 
AGATCAAGATATTGATAAAGTTATGGCATTACGCATAGGTGCAGATGACTTTGTGGTGAA 
GCCTTTTAACCCAAATGAAGTCGTCGCTAGAGTTCAGGCAGTCCTAAGACGTACTCAGTT 
TGCAAACAAAGCAACTAATAAAAATAAACTCTATAAAAATATTGAAATTGATACCGACAC 
TCATAGCGTTTATATACACTCTGAGAATAAGAAGATCTTGCTTAATCTGACGCTGACTGA 
ATATAAAATTATTTCATTCATGATTGATCAGCCTCATAAAGTTTTTACGCGCGGAGAGCT 
TATGAATCACTGCATGAATGATAGCGATGCACTAGAGCGAACCGGATCC 
aagctgtaaccgcagcgccaattaaggctat 
accggtttcataaataatatctataacaaattcgagcactccctccgacaaaaaatctaa 
tgagcctgaaaatttaagaaatttagctatggcaaccactataactcccaataaagcgcc 
agcccataagaatattttatgaatattgataggtgccgtgacttgatcgatttgatcggg 
gtactttcgatagtactcaatttcctcatctgttacttcagaggtagatttaaataataa 
tttaataaatagcttgtcttgatcaagctttgtatttttcttcatagctgtgatgcgtaa 
taagtattctaatgtttaatgttactcactttttctttagggagtaactgttttaagagc 
ttatcgctaccttaactcattcatttcttctctagcttgttgtggtgttttacccgacca 
ctctttataagcccgtgtaaatggactgtgctcggcataacctaacagtaaagctatttc 
tacaatttgtagccttagatcttttaaatacgattttgccaattcgtaacggacagtatt 
taattctttccgaaaattcgtacctgcctcggttaaacggcgttgcaaggttctacgtga 
ataatttaatcgctctgcaagctgttcaatagttggttcgccttgatgaagtaagtaagc 
aatctgtttacgaacttgatctgtaatttcatcaatatgtggcaggcttgccagtaactt 
gtcagcatgtttttctagtatggcaactaaggcggcgtcggagtttttaagcggtagact 
taagatttccttatcaaaacgcatcagtgccacaggctgttcaaaaagcacaggacaacc 
aaaatactcctcataaggctgaacattttcaggccgttcatgaataaaatgtatttcttt 
gagtctttcttttcctctaatgagactacggcaaaattgaactataacggtacggccagt 
ttcgtccgataaagggccgacttgctcacct 
 
It was expected that a BamHI site (GGATCC) would be introduced in AYEΔadeRS.
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Figure 3.16 Verification of adeRS Gene Deletion in AYE by DNA Sequencing. 
a) Forward Sequencing 
adeS mutant expected      1 GGGGCGGCCGCCCTCCGACTTGCGGACGGATTTCCGCC--GTACGGAACGCATGTACTCG   58  
                                                           TTC GCC  GTACGGAACGCATGTACTCG       
adeS mutant FW            1 -------------------------------TTCGGCCCGGTACGGAACGCATGTACTCG   29  
 
adeS mutant expected     59 TGCAGGAAGATTTTCACTAAAATTTACCGACTGCGGTTGAATGCTTAATACACTGACTTT  118  
                            TGCAGGAAGA+TTTCACTAAAATTTACCGACTG+GGTTGAATG+TTAATACACTGACTTT       
adeS mutant FW           30 TGCAGGAAGAWTTTCACTAAAATTTACCGACTGSGGTTGAATGSTTAATACACTGACTTT   89  
 
adeS mutant expected    119 AGCCGGTGGTGGCTCAGCTTGAGCGACTTCTTTTGAATCACACCCCTGTAATATCAGCCC  178  
                            AGCCGGTGG+GGCTCAGCTTGAGCGACTTCTTTTGAATCACACCCCTG+AATATCAGCCC       
adeS mutant FW           90 AGCCGGTGGKGGCTCAGCTTGAGCGACTTCTTTTGAATCACACCCCTGKAATATCAGCCC  149  
 
adeS mutant expected    179 AATAGATAAAAATAAAGGAAGTAAAAGATGCTTTTGCATACTGTCCAAACCTAGTGACTT  238  
                            AATA+ATAAAAATAAAGGAAGTAAAAGATGCTTTTGCATACTGTCCAAACCTAGTGACTT       
adeS mutant FW          150 AATARATAAAAATAAAGGAAGTAAAAGATGCTTTTGCATACTGTCCAAACCTAGTGACTT  209  
 
adeS mutant expected    239 TTTGATGTTCGTATTATTTTTGATGAGTGTGTAGGGATAATCACTAAAGTGTGGAGTAAG  298  
                            TTTGATGTTCGTATTATTTTTGATGA+TGTGTAGGGATAATCACTAAAGTGTGGA+TAAG       
adeS mutant FW          210 TTTGATGTTCGTATTATTTTTGATGARTGTGTAGGGATAATCACTAAAGTGTGGARTAAG  269  
 
adeS mutant expected    299 TGTGGAGAAATACGGATAATTTAGCGTATGATGAGTTGAAGCACTTTCTATAGCCAGATT  358  
                            TGTGGA+AAATACGGA+AATTTAGCGTATGATGAGTTGAAGCACTTTCTATAGCCAGATT       
adeS mutant FW          270 TGTGGARAAATACGGAWAATTTAGCGTATGATGAGTTGAAGCACTTTCTATAGCCAGATT  329  
 
adeS mutant expected    359 TTCTATGTTTGATCATTCTTTTTCTTTTGATTGCCAAGATAAAGTTATTCTTGTGGTAGA  418  
                            TTCTATGTTTGA+CATTCTTTTTCTTTTGATTGCCAAGA+AAAGTTATTCTTG+GGTA+A       
adeS mutant FW          330 TTCTATGTTTGAWCATTCTTTTTCTTTTGATTGCCAAGAWAAAGTTATTCTTGKGGTARA  389  
 
adeS mutant expected    419 AGATGACTACGATATTGGCGACATTATTGAAAATTATTTAAAACGTGAAGGCATGAGTGT  478  
                            AGA+GACTACGATATTGGCGACATTATTGAAAATTATTTAAAACGTGAAGGCATGAGTGT       
adeS mutant FW          390 AGAWGACTACGATATTGGCGACATTATTGAAAATTATTTAAAACGTGAAGGCATGAGTGT  449  
 
adeS mutant expected    479 TATTCGGGCCATGAATGGAAAGCAAGCGATTGAATTGCACGCTAGCCAACCCATCGATTT  538  
                            TATTCGGGCCATGAATGGAAAGCAAGCGATTGAATTGCACGCTA+CCAACCCATCG+TTT       
adeS mutant FW          450 TATTCGGGCCATGAATGGAAAGCAAGCGATTGAATTGCACGCTARCCAACCCATCGRTTT  509  
 
adeS mutant expected    539 AATCTTACTTGATATTAAATTACCCGAATTAAACGGTTGGGAAGTATTAAATAAAATACG  598  
                            AATCTTACTTGATATTAAATTACCCGAATTAAACGGTTGGGAAGTATTAAATAAAATACG       
adeS mutant FW          510 AATCTTACTTGATATTAAATTACCCGAATTAAACGGTTGGGAAGTATTAAATAAAATACG  569  
 
adeS mutant expected    599 CCAAAAAGCTCAGACTCCCGTGATCATGTTGACGGCGCTAGATCAAGATATTGATAAAGT  658  
                            CCAAAAAGCTCAGA+TCCCGTGATCATGTTGA+GGCGCTAGATCAAGATATTGATAAAGT       
adeS mutant FW          570 CCAAAAAGCTCAGAMTCCCGTGATCATGTTGASGGCGCTAGATCAAGATATTGATAAAGT  629  
 
adeS mutant expected    659 TATGGCATTACGCATAGGTGCAGATGACTTTGTGGTGAAGCCTTTTAACCCAAATGAAGT  718  
                            TATGGCATTACGCATAGGTGCAGA+GACTTTGTGGTGAAGCCTTTTAACCCAAATGAAGT       
adeS mutant FW          630 TATGGCATTACGCATAGGTGCAGAWGACTTTGTGGTGAAGCCTTTTAACCCAAATGAAGT  689  
 
adeS mutant expected    719 CGTCGCTAGAGTTCAGGCAGTCCTAAGACGTACTCAGTTTGCAAACAAAGCAACTAATAA  778  
                            CGTCGCTAGAGTTCAGG+AGTCCTAAGACGTACTCAGTTTG+AAACAAAGCAACTAATAA       
adeS mutant FW          690 CGTCGCTAGAGTTCAGGSAGTCCTAAGACGTACTCAGTTTGYAAACAAAGCAACTAATAA  749  
 
adeS mutant expected    779 AAATAAACTCTATAAAAATATTGAAATTGATACCGACACTCATAGCGTTTATATACACTC  838  
                            AAATAAACTCTATAAAAATATTGAAATTGATACCGACACTCATAGCGTTTATATACACTC       
adeS mutant FW          750 AAATAAACTCTATAAAAATATTGAAATTGATACCGACACTCATAGCGTTTATATACACTC  809  
 
adeS mutant expected    839 TGAGAATAAGAAGATCTTGCTTAATCTGACGCTGACTGAATATAAAATTATTTCATTCAT  898  
                            TGAGAATAAGAAGATCTTGCTTAATCTGACGCTGACTGAA+ATAAAATTATTTCATTCAT       
adeS mutant FW          810 TGAGAATAAGAAGATCTTGCTTAATCTGACGCTGACTGAAKATAAAATTATTTCATTCAT  869  
 
adeS mutant expected    899 GATTGATCAGCCTCATAAAGTTTTTACGCGCGGAGAGCTTATGAATCACTGCATGAATGA  958  
                            GATTGATC++CCTCATAAAGTTTTTACGCGCGGAGAGCTTATGAATCACTGC+TGAATGA       
adeS mutant FW          870 GATTGATCRSCCTCATAAAGTTTTTACGCGCGGAGAGCTTATGAATCACTGCRTGAATGA  929  
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adeS mutant expected    959 TAGCGATGCACTAGAGCGAACCGGATCCAAGCTGTAACCGCAGCGCCAATTAAGGCTATA 1018  
                            TAGCGATGCACTAGA+CGAACCGGATCCAAGCTGTAACCGCAGCGCCAAT AAGGCTA+A       
adeS mutant FW          930 TAGCGATGCACTAGAKCGAACCGGATCCAAGCTGTAACCGCAGCGCCAAT-AAGGCTAWA  988  
 
adeS mutant expected   1019 CCGGTTTCATAAATAATATCTATAACAAATTCGAGCACTCCCTCCGACAAAAAATCTAAT 1078  
                            CCGGTT CATAA+TAA+AT+TATAACAA TTCGAGCACTCCCTCCGAC+AAA+  CTAAT       
adeS mutant FW          989 CCGGTT-CATAARTAAYATSTATAACAA-TTCGAGCACTCCCTCCGACRAAAW--CTAAT 1044  
 
adeS mutant expected   1079 GAGCCTGAAAATTTAAGAAATTTAGCTATGGCAACCACTATAACTCCCAATAAAGCGCCA 1138  
                            GAGC    AAATT+A+ AAATTTAGCTATGGCA+C++ TA+A    CC A +AAGC+C A       
adeS mutant FW         1045 GAGCT--GAAATTYAR-AAATTTAGCTATGGCARCMM-TAYA--CTCCGAAWAAGCKC-A 1097  
 
adeS mutant expected   1139 GCCCATAAGAATATTTTATGAATATTGATAGGTGCCGTGACTTGATCGATTTGATCGGGG 1198  
                            GCCCATA++AA+ TTTTA+GAATAT GATAGG+GC GTGACT G+TCGATT GATCGGG        
adeS mutant FW         1098 GCCCATAMRAAW-TTTTAWGAATAT-GATAGGKGC-GTGACT-GRTCGATT-GATCGGG- 1151  
 
adeS mutant expected   1199 TACTTTCGATAGTACTCAATTTCCTCATCTGTTACTTCAGAGGTAGATTTAAATAATAAT 1258  
                            TAC+T CGA+ GTACTCA T  +++C    G TACT    A GTAGAT    A +A A T       
adeS mutant FW         1152 TACKT-CGAW-GTACTCAGTCCYMWC----GGTACTC--AAAGTAGAT---GACWAGATT 1200  
 
adeS mutant expected   1259 TTAATAAATAGCTTGTCTTGATCAAGCTTTGTATTTTTCTTCATAGCTGTGATGCGTAAT 1318  
                            T AA +A T GC TG    GA   AGCT       TTTCT ++     G+  +GCGTAA        
adeS mutant FW         1201 TCAAARACTGGCCTG----GAC--AGCT----GACTTTCTCMRC----GKTGWGCGTAAA 1246  
 
adeS mutant expected   1319 AAGTATTCTAATGTTTAATGTTACTCACTTTTTCTTTAGGGAGTAACTGTTTTAAGAGCT 1378  
                            A+GTAT C AA G +TAA GTT C+C C                                       
adeS mutant FW         1247 ARGTATCC-AAAGGWTAAGGTTKCWCCCAC------------------------------ 1275  
 
adeS mutant expected   1379 TATCGCTACCTTAACTCATTCATTTCTTCTCTAGCTTGTTGTGGTGTTTTACCCGACCAC 1438  
                                                                                               
adeS mutant FW              ------------------------------------------------------------       
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b) Reverse Sequencing 
adeS mutant expected    661 TGGCATTACGCATAGGTGCAGATGACTTTGTGGTGAAGCCTTTTAACCCAAATGAAGTCG  720  
                                                                                               
adeS RV Sequenced           ------------------------------------------------------------       
 
adeS mutant expected    721 TCGCTAGAGTTCAGGCAGTCCTAAGACGTACTCAGTTTGCAAACAAAGCAACTAATAAAA  780  
                                  GAGTT  GG AG C T A    TA T AG  T CA    A G A   A T   A       
adeS RV Sequenced         1 ---TGCGAGTTGTGGAAGCCTTTACCAATAATGAGAGTTCACCTTACGTA--CAGTTGCA   55  
 
adeS mutant expected    781 ATAAACTCTATAAAAATATTGAAATTGATACCGACACTCATAGCGTTTATATACACTCTG  840  
                                A T TA   A  TAT  AAATTGAT C    ACTCATAGCGT   TAT   CTC         
adeS RV Sequenced        56 CAGCATTATACTTACTTAT-AAAATTGATGCG---ACTCATAGCGT---TAT---CTC--  103  
 
adeS mutant expected    841 AGAATAAGAAGATCTTGCTTAATCTGACGCTGACTGAATATAAAATTATTTCATTCATGA  900  
                              AATAAGA GATCT    TAATCTGACG TGACTGAAT TAAA    TTTCAT CATGA       
adeS RV Sequenced       104 --AATAAGA-GATCTG--CTAATCTGACG-TGACTGAAT-TAAA----TTTCAT-CATGA  151  
 
adeS mutant expected    901 TTGATCAGCCTCATAAAGTTTTTACGCGCGGAGAGCTTATGAATCACTGCATGAATGATA  960  
                            T GATCAGCCTCATAAAGTTTT ACGCGCG AGAGCT ATGAATCACTGCATGAATGATA       
adeS RV Sequenced       152 T-GATCAGCCTCATAAAGTTTT-ACGCGCG-AGAGCT-ATGAATCACTGCATGAATGATA  207  
 
adeS mutant expected    961 GCGATGCACTAGAGCGAACCGGATCCAAGCTGTAACCGCAGCGCCAATTAAGGCTATACC 1020  
                            GCGATGCACTAGAGCGAAC GGATCCAAGCTGTAACCGCAGCGCCAATTAAGGCTATACC       
adeS RV Sequenced       208 GCGATGCACTAGAGCGAAC-GGATCCAAGCTGTAACCGCAGCGCCAATTAAGGCTATACC  266  
 
adeS mutant expected   1021 GGTTTCATAAATAATATCTATAACAAATTCGAGCACTCCCTCCGACAAAAAATCTAATGA 1080  
                            GGTTTCATAAATAATATCTATAACAAATTCGAGCACTCC TCCGACAAAAA TCTAATGA       
adeS RV Sequenced       267 GGTTTCATAAATAATATCTATAACAAATTCGAGCACTCC-TCCGACAAAAA-TCTAATGA  324  
 
adeS mutant expected   1081 GCCTGAAAATTTAAGAAATTTAGCTATGGCAACCACTATAACTCCCAATAAAGCGCCAGC 1140  
                            GCCTGAAAATT AAGAAATT AGCTATGGCAACCACTATAACTCCCAATAAAGCGCCAGC       
adeS RV Sequenced       325 GCCTGAAAATT-AAGAAATT-AGCTATGGCAACCACTATAACTCCCAATAAAGCGCCAGC  382  
 
adeS mutant expected   1141 CCATAAGAATATTTTATGAATATTGATAGGTGCCGTGACTTGATCGATTTGATCGGGGTA 1200  
                            CCATAAGAATATTTTATGAATAT GATAGGTGCCGTGACTTGATCGATTTGATCGGGGTA       
adeS RV Sequenced       383 CCATAAGAATATTTTATGAATAT-GATAGGTGCCGTGACTTGATCGATTTGATCGGGGTA  441  
 
adeS mutant expected   1201 CTTTCGATAGTACTCAATTTCCTCATCTGTTACTTCAGAGGTAGATTTAAATAATAATTT 1260  
                            CTTTCGATAGTACTCAATTTCCTCATCTGTTACTTCAGAGGTAGATTTAAATAATAATTT       
adeS RV Sequenced       442 CTTTCGATAGTACTCAATTTCCTCATCTGTTACTTCAGAGGTAGATTTAAATAATAATTT  501  
 
adeS mutant expected   1261 AATAAATAGCTTGTCTTGATCAAGCTTTGTATTTTTCTTCATAGCTGTGATGCGTAATAA 1320  
                            AATAAATAGCTTGTCTTGATCAAGCTTTGTATTTTTCTTCATAGCTGTGATGCGTAATAA       
adeS RV Sequenced       502 AATAAATAGCTTGTCTTGATCAAGCTTTGTATTTTTCTTCATAGCTGTGATGCGTAATAA  561  
 
adeS mutant expected   1321 GTATTCTAATGTTTAATGTTACTCACTTTTTCTTTAGGGAGTAACTGTTTTAAGAGCTTA 1380  
                            GTATTCTAATGTTTAATGTTACTCACTTTTTCTTTAGGGAGTAACTGTTTTAAGAGCTTA       
adeS RV Sequenced       562 GTATTCTAATGTTTAATGTTACTCACTTTTTCTTTAGGGAGTAACTGTTTTAAGAGCTTA  621  
 
adeS mutant expected   1381 TCGCTACCTTAACTCATTCATTTCTTCTCTAGCTTGTTGTGGTGTTTTACCCGACCACTC 1440  
                            TCGCTACCTTAACTCATTCATTTCTTCTCTAGCTTGTTGTGGTGTTTTACCCGACCACTC       
adeS RV Sequenced       622 TCGCTACCTTAACTCATTCATTTCTTCTCTAGCTTGTTGTGGTGTTTTACCCGACCACTC  681  
 
adeS mutant expected   1441 TTTATAAGCCCGTGTAAATGGACTGTGCTCGGCATAACCTAACAGTAAAGCTATTTCTAC 1500  
                            TTTATAAGCCCGTGTAAATGGACTGTGCTCGGCATAACCTAACAGTAAAGCTATTTCTAC       
adeS RV Sequenced       682 TTTATAAGCCCGTGTAAATGGACTGTGCTCGGCATAACCTAACAGTAAAGCTATTTCTAC  741  
 
adeS mutant expected   1501 AATTTGTAGCCTTAGATCTTTTAAATACGATTTTGCCAATTCGTAACGGACAGTATTTAA 1560  
                            AATTTGTAGCCTTAGATCTTTTAAATACGATTTTGCCAATTCGTAACGGACAGTATTTAA       
adeS RV Sequenced       742 AATTTGTAGCCTTAGATCTTTTAAATACGATTTTGCCAATTCGTAACGGACAGTATTTAA  801  
 
adeS mutant expected   1561 TTCTTTCCGAAAATTCGTACCTGCCTCGGTTAAACGGCGTTGCAAGGTTCTACGTGAATA 1620  
                            TTCTTTCCGAAAATTCGTACCTGCCTCGGTTAAACGGCGTTGCAAGGTTCTACGTGAATA       
adeS RV Sequenced       802 TTCTTTCCGAAAATTCGTACCTGCCTCGGTTAAACGGCGTTGCAAGGTTCTACGTGAATA  861  
 
adeS mutant expected   1621 ATTTAATCGCTCTGCAAGCTGTTCAATAGTTGGTTCGCCTTGATGAAGTAAGTAAGCAAT 1680  
                            ATTTAATCGCTCTGCAAGCTGTTCAATAGTTGGTTCGCCTTGATGAAGTAAGTAAGCAAT       
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adeS RV Sequenced       862 ATTTAATCGCTCTGCAAGCTGTTCAATAGTTGGTTCGCCTTGATGAAGTAAGTAAGCAAT  921  
 
adeS mutant expected   1681 CTGTTTACGAACTTGATCTGTAATTTCATCAATATGTGGCAGGCTTGCCAGTAACTTGTC 1740  
                            CTGTTTACGAACTTGATCTGTAATTTCATCAATATGTGGCAGGCTTGCCAGTAACTTGTC       
adeS RV Sequenced       922 CTGTTTACGAACTTGATCTGTAATTTCATCAATATGTGGCAGGCTTGCCAGTAACTTGTC  981  
 
adeS mutant expected   1741 AGCATGTTTTTCTAGTATGGCAACTAAGGCGGCGTCGGAGTTTTTAAGCGGTAGACTTAA 1800  
                            AGCATGTTTTTCTAGTATGGCAACTAAGGCGGCGTCGGAGTTTTTAAGCGGTAGACTTAA       
adeS RV Sequenced       982 AGCATGTTTTTCTAGTATGGCAACTAAGGCGGCGTCGGAGTTTTTAAGCGGTAGACTTAA 1041  
 
adeS mutant expected   1801 GATTTCCTTATCAAAACGCATCAGTGCCACAGGCTGTTCAAAAAGCACAGGACAACCAAA 1860  
                            GATTTCCTTATCAAAACGCATCAGTGCCACAGGCTGTTCAAAAAGCACAGGACAACCAAA       
adeS RV Sequenced      1042 GATTTCCTTATCAAAACGCATCAGTGCCACAGGCTGTTCAAAAAGCACAGGACAACCAAA 1101  
 
adeS mutant expected   1861 ATACTCCTCATAAGGCTGAACATTTTCAGGCCGTTCATGAATAAAATGTATTTCTTTGAG 1920  
                            ATACTCCTCATAAGGCTGAACATTTTCAGGCCGTTCATGAATAAAATGTATTTCTTTGAG       
adeS RV Sequenced      1102 ATACTCCTCATAAGGCTGAACATTTTCAGGCCGTTCATGAATAAAATGTATTTCTTTGAG 1161  
 
adeS mutant expected   1921 TCTTTCTTTTCCTCTAATGAGACTACGGCAAAATTGAACTATAACGGTACGGCCAGTTTC 1980  
                            TCTT CTTTTCCTCTAATGAGACTACGGCAAAATTGAACTATAACGGTACGGCCAGTT         
adeS RV Sequenced      1162 TCTT-CTTTTCCTCTAATGAGACTACGGCAAAATTGAACTATAACGGTACGGCCAGTT-- 1218  
 
adeS mutant expected   1981 GTCCGATAAAGGGCCGACTTGCTCACCTGCATGCCCC 2017  
                              CCGA                                      
adeS RV Sequenced      1219 -ACCGAA------------------------------ 1224  
 
The region of the AYEΔadeRS genome flanking adeS (UP and DOWN fragments) was amplified 
by a single PCR (2017 bp amplimer) and sequenced. The result was aligned with the expected 
sequence (Figure 3.15b). 
a) adeS FW Sequenced was generated using primer UPFWadeS (Table 2.6); b) adeS RV 
Sequenced was generated using primer DOWNRVadeS (Table 2.6). This sequence was reverse 
complemented before alignment.  
The first 980bp of the sequence corresponds to the UP fragment and 987-2017 bp corresponds 
to the DOWN fragment. A BamHI site has been introduced at 981-986 bp in the mutant 
(highlighted).
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 (Table 2.8, Digestion 3; Figure 3.17) and ligated. The ligation mixture was transformed into 
DH5α and three candidate transformants were obtained, which were all confirmed by PCR to 
harbour the correct construct (Figure 3.18). The construct from candidate 1 was further verified 
by digestion and DNA sequencing. Digestion with NotI (Figure 3.19) confirmed that the 
construct contained an insert. DNA sequencing confirmed that the insert contained the UP and 
DOWN fragments, adeS and the deleted 126 bp of adeR (Figure 3.20). The verified construct was 
transformed into S17-1 and four candidate transformants were obtained. Plasmids were 
extracted from each transformant and their identities were verified by PCR (Figure 3.21). 
Despite 12 attempts at conjugation and modifications to the method (detailed below), no 
AYEΔadeRS/pMo130-TelR/UP-adeRS-DOWN single recombinants were obtained and AYEΔadeRS 
was not complemented. It is important to note that for all of the following experiments, both 
the donor and recipient were inhibited by the selective plates and that AYE/pMo130-
TelR/adeRSUPDOWN (AYE with the adeRS deletion construct in the chromosome) was used as a 
positive control for pyrocatechol exposure.  
Variation in the ratio of donor to recipient: 
Initially, two conjugations between S17-1/pMo130-TelR/UP-adeRS-DOWN and AYEΔadeRS were 
carried out, one according to the original method (Section 2.4.3) and the second using double 
the volume of donor and recipient (same ratio) to increase the chance of obtaining 
transconjugants. A total of 22 colonies were obtained in these two experiments (12 for 
experiment 1 and 10 for experiment 2), which remained white when exposed to pyrocatechol,                                                                                                                                                                                                   
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Figure 3.17 Digestion of pMo130-TelR and UP-adeS-DOWN 
 
Lanes 3 and 5, PCR 19, Table 2.7; Lanes 2 and 4, Digestion 3, Table 2.8.
Lane DNA Expected size Actual size 
1 pMo130-TelR undigested --- --- 
2 pMo130-TelR + NotI + BamHI 9377bp ~ 9377bp 
3 UP-adeRS-DOWN undigested 3377 bp ~ 3377 bp 
4 UP-adeRS-DOWN + NotI + BamHI 3364 bp ~ 3364 bp 
5 --- 
(Contamination control for UP-
adeRS-DOWN amplification) 
No amplimer No amplimer 
6 Hyperladder™ 1 (Bioline) --- --- 
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Figure 3.18 Verification of adeRS Complementation Construct by PCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCR 16, Table 2.7
Lane DNA Expected size Actual size 
1, 6 Hyperladder™ 1 (Bioline) --- --- 
2 Candidate transformant 1 3546 bp ~ 3546 bp 
3 Candidate transformant 3 3546 bp ~3546 bp 
4 Candidate transformant 4 3546 bp ~ 3546 bp 
5 --- No amplimer No amplimer 
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Figure 3.19 Verification of adeRS Complementation Construct by Restriction Digestion. 
 
   Digestion 2, Table 2.8 
 
Lane DNA Expected size Actual size 
1 Hyperladder™ 1 (Bioline) --- --- 
2 pMo130-TelR undigested --- --- 
3 pMo130-TelR + NotI 9392 bp ~ 9392 bp 
4 PMo130-TelR/UP-adeRS-DOWN 
undigested 
--- --- 
5 PMo130-TelR/UP-adeRS-DOWN + 
NotI 
12,741 bp ~ 12,741 bp 
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Figure 3.20 Verification of adeRS Complementation Construct by DNA Sequencing. 
A region of pMo130-TelR containing the UP-adeRS-DOWN complementation fragment was amplified and sequenced (the whole 
amlimer is shown above in four independent sequencing reactions a-d). The result was aligned with the expected sequence. 
a) pMo/UPadeSDN FWUP was generated using primer pMo130-TelR FW, which is specific for pMo130-TelR.  
b) pMo/UPadeSDN FWadeS was generated using primer adeSgeneFW, which binds inside adeS.  
c) pMo/UPadeSDN RVadeS was generated using primer adeSgeneRV, which binds inside adeS. This sequence was reverse 
complemented before alignment. 
d) pMo/UPadeSDN RVDOWN was generated using primer DOWNRVadeS, which is specific for the DOWN fragment. This sequence 
was reverse complemented before alignment.  
The first 1149 bp of the sequence corresponds to 174 bp of the vector and the entire UP fragment (including 126bp of adeR); 1307-
2392 bp corresponds to adeS; 2516-3546 bp corresponds to the DOWN fragment.  
 
The sequences of the above figure (a-d) are shown below.
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a) Forward sequencing of adeRS complementation construct (1). 
pMo/UPadeSDN Expected      1 CCATCTACTTCTTCGACCCGTCCGGTAACCGCAACGAAGTGTTCTGCGGGGGAGATTACA   60  
                                                           GCA+ + AGTGTTCTGCGGGGGAGATTACA       
pMo/UPadeSDN FWUP          1 ----------------------------TTGCAWASGAGTGTTCTGCGGGGGAGATTACA   32  
 
pMo/UPadeSDN Expected     61 ACTACCCGGACCACAAACCGGTGACCTGGACCACCGACCAGCTGGGCAAGGCGATCTTTT  120  
                             ACTACCCGGACCACAAACCGGTGACCTGGACCACCGACCAGCTGGGCAAGG+GATCTTTT       
pMo/UPadeSDN FWUP         33 ACTACCCGGACCACAAACCGGTGACCTGGACCACCGACCAGCTGGGCAAGGSGATCTTTT   92  
 
pMo/UPadeSDN Expected    121 ACCACGACCGCATTCTCAACGAACGATTCATGACCGTGCTGACCTGACCTGAGCGGCCGC  180  
                             ACCACGACCGCATTCTCAACGAACGATTCATGACCGTGCTGACCTGA     GCGGCCGC       
pMo/UPadeSDN FWUP         93 ACCACGACCGCATTCTCAACGAACGATTCATGACCGTGCTGACCTGA-----GCGGCCGC  147  
 
pMo/UPadeSDN Expected    181 CCTCCGACTTGCGGACGGATTTCCGCCGTACGGAACGCATGTACTCGTGCAGGAAGATTT  240  
                             CCTCCGACTTGCGGACGGATTTCCGCCGTACGGAACGCATGTACTCGTGCAGGAAGATTT       
pMo/UPadeSDN FWUP        148 CCTCCGACTTGCGGACGGATTTCCGCCGTACGGAACGCATGTACTCGTGCAGGAAGATTT  207  
 
pMo/UPadeSDN Expected    241 TCACTAAAATTTACCGACTGCGGTTGAATGCTTAATACACTGACTTTAGCCGGTGGTGGC  300  
                             TCACTAAAATTTACCGACTGCGGTTGAATGCTTAATACACTGACTTTAGCCGGTGGTGGC       
pMo/UPadeSDN FWUP        208 TCACTAAAATTTACCGACTGCGGTTGAATGCTTAATACACTGACTTTAGCCGGTGGTGGC  267  
 
pMo/UPadeSDN Expected    301 TCAGCTTGAGCGACTTCTTTTGAATCACACCCCTGTAATATCAGCCCAATAGATAAAAAT  360  
                             TCAGCTTGAGCGACTTCTTTTGAATCACACCCCTGTAATATCAGCCCAATAGATAAAAAT       
pMo/UPadeSDN FWUP        268 TCAGCTTGAGCGACTTCTTTTGAATCACACCCCTGTAATATCAGCCCAATAGATAAAAAT  327  
 
pMo/UPadeSDN Expected    361 AAAGGAAGTAAAAGATGCTTTTGCATACTGTCCAAACCTAGTGACTTTTTGATGTTCGTA  420  
                             AAAGGAAGTAAAAGATGCTTTTGCATACTGTCCAAACCTAGTGACTTTTTGATGTTCGTA       
pMo/UPadeSDN FWUP        328 AAAGGAAGTAAAAGATGCTTTTGCATACTGTCCAAACCTAGTGACTTTTTGATGTTCGTA  387  
 
pMo/UPadeSDN Expected    421 TTATTTTTGATGAGTGTGTAGGGATAATCACTAAAGTGTGGAGTAAGTGTGGAGAAATAC  480  
                             TTATTTTTGATGAGTGTGTAGGGATAATCACTAAAGTGTGGAGTAAGTGTGGAGAAATAC       
pMo/UPadeSDN FWUP        388 TTATTTTTGATGAGTGTGTAGGGATAATCACTAAAGTGTGGAGTAAGTGTGGAGAAATAC  447  
 
pMo/UPadeSDN Expected    481 GGATAATTTAGCGTATGATGAGTTGAAGCACTTTCTATAGCCAGATTTTCTATGTTTGAT  540  
                             GGATAATTTAGCGTATGATGAGTTGAAGCACTTTCTATAGCCAGATTTTCTATGTTTGAT       
pMo/UPadeSDN FWUP        448 GGATAATTTAGCGTATGATGAGTTGAAGCACTTTCTATAGCCAGATTTTCTATGTTTGAT  507  
 
pMo/UPadeSDN Expected    541 CATTCTTTTTCTTTTGATTGCCAAGATAAAGTTATTCTTGTGGTAGAAGATGACTACGAT  600  
                             CATTCTTTTTCTTTTGATTGCCAAGATAAAGTTATTCTTGTGGTAGAAGATGACTACGAT       
pMo/UPadeSDN FWUP        508 CATTCTTTTTCTTTTGATTGCCAAGATAAAGTTATTCTTGTGGTAGAAGATGACTACGAT  567  
 
pMo/UPadeSDN Expected    601 ATTGGCGACATTATTGAAAATTATTTAAAACGTGAAGGCATGAGTGTTATTCGGGCCATG  660  
                             ATTGGCGACATTATTGAAAATTATTTAAAACGTGAAGGCATGAGTGTTATTCGGGCCATG       
pMo/UPadeSDN FWUP        568 ATTGGCGACATTATTGAAAATTATTTAAAACGTGAAGGCATGAGTGTTATTCGGGCCATG  627  
 
pMo/UPadeSDN Expected    661 AATGGAAAGCAAGCGATTGAATTGCACGCTAGCCAACCCATCGATTTAATCTTACTTGAT  720  
                             AATGGAAAGCAAGCGATTGAATTGCACGCTAGCCAACCCATCGATTTAATCTTACTTGAT       
pMo/UPadeSDN FWUP        628 AATGGAAAGCAAGCGATTGAATTGCACGCTAGCCAACCCATCGATTTAATCTTACTTGAT  687  
 
pMo/UPadeSDN Expected    721 ATTAAATTACCCGAATTAAACGGTTGGGAAGTATTAAATAAAATACGCCAAAAAGCTCAG  780  
                             ATTAAATTACCCGAATTAAACGGTTGGGAAGTATTAAATAAAATACGCCAAAAAGCTCAG       
pMo/UPadeSDN FWUP        688 ATTAAATTACCCGAATTAAACGGTTGGGAAGTATTAAATAAAATACGCCAAAAAGCTCAG  747  
 
pMo/UPadeSDN Expected    781 ACTCCCGTGATCATGTTGACGGCGCTAGATCAAGATATTGATAAAGTTATGGCATTACGC  840  
                             ACTCCCGTGATCATGTTGACGGCGCTAGATCAAGATATTGATAAAGTTATGGCATTACGC       
pMo/UPadeSDN FWUP        748 ACTCCCGTGATCATGTTGACGGCGCTAGATCAAGATATTGATAAAGTTATGGCATTACGC  807  
 
pMo/UPadeSDN Expected    841 ATAGGTGCAGATGACTTTGTGGTGAAGCCTTTTAACCCAAATGAAGTCGTCGCTAGAGTT  900  
                             ATAGGTGCAGATGACTTTGTGGTGAAGCCTTTTAACCCAAATGAAGTCGTCGCTAGAGTT       
pMo/UPadeSDN FWUP        808 ATAGGTGCAGATGACTTTGTGGTGAAGCCTTTTAACCCAAATGAAGTCGTCGCTAGAGTT  867  
 
pMo/UPadeSDN Expected    901 CAGGCAGTCCTAAGACGTACTCAGTTTGCAAACAAAGCAACTAATAAAAATAAACTCTAT  960  
                             CAGGCAGTCCTAAGACGTACTCAG TTGCAAACAAAGCAACTAATAAAA TAAACTCTAT       
pMo/UPadeSDN FWUP        868 CAGGCAGTCCTAAGACGTACTCAGCTTGCAAACAAAGCAACTAATAAAA-TAAACTCTAT  926  
 
pMo/UPadeSDN Expected    961 AAAAATATTGAAATTGATACCGACACTCATAGCGTTTATATACACTCTGAGAATAAGAAG 1020  
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                             AAAA TATTGAAATTGATACCGACACTCATAGCGTTTATATACACTCTGAGAATA   AG       
pMo/UPadeSDN FWUP        927 AAAA-TATTGAAATTGATACCGACACTCATAGCGTTTATATACACTCTGAGAATAG--AG  983  
 
pMo/UPadeSDN Expected   1021 ATCTTGCTTAATCTGACGCTGACTGAATATAAAATTATTTCATTCATGATTGATCAGCCT 1080  
                             ATCTTGCTTAATCTGACGCTGACTGAATATAAAATTATTTCATTCATGATTGATCAGCCT       
pMo/UPadeSDN FWUP        984 ATCTTGCTTAATCTGACGCTGACTGAATATAAAATTATTTCATTCATGATTGATCAGCCT 1043  
 
pMo/UPadeSDN Expected   1081 CATAAAGTTTTTACGCGCGGAGAGCTTATGAATCACTGCATGAATGATAGCGATGCACTA 1140  
                             CATAAAGTTTT AC+C+CGGAGAGCTTATGA TCACTGCATGA TGATAGCGATGC+CTA       
pMo/UPadeSDN FWUP       1044 CATAAAGTTTT-ACSCSCGGAGAGCTTATGA-TCACTGCATGA-TGATAGCGATGCMCTA 1100  
 
pMo/UPadeSDN Expected   1141 GAGCGAACCGTAGATAGCCATGTGAGTAAGCTGAGAAAAAAACTAGAAGAACAAGGCATA 1200  
                             +AGCGA CCGTA+A+ GCCATG+GAGTA GCTG   AAAAAACTAGA   A        +       
pMo/UPadeSDN FWUP       1101 RAGCGA-CCGTARAW-GCCATGKGAGTA-GCTG---AAAAAACTAGAGACA------GCW 1148  
 
pMo/UPadeSDN Expected   1201 TTTCAAATGTTAATTAATGTGCGTGGCGTGGGATATAGACTAGATAATCCCCTAGCTGTA 1260  
                              TTCA  T       AAT TG G G+ ++GG         TA++T+A+  CCT++CTGTA       
pMo/UPadeSDN FWUP       1149 ATTCATGT-------AATATGTGCGKGSKGGA--------TARMTRAWATCCTWRCTGTA 1193  
 
pMo/UPadeSDN Expected   1261 AAAGATGATGCCTAAATAATATTAAAAAATAGCTAGGGAATATTTTATGAAAAGTAAGTT 1320  
                             AA    +ATGCCTA        TA AAAAT GCTAG  A TA         AAGTA GTT       
pMo/UPadeSDN FWUP       1194 AAGA--KATGCCTAG-------TATAAAAT-GCTAGAAATTA--------GAAGTA-GTT 1234  
 
pMo/UPadeSDN Expected   1321 AGGAATTAGTAAGCAACTTTTTATTGCCTTAACTATTGTGAATTTAAGCGTTACGCTATT 1380  
                             AGGA T+++  AGC +CTTT                                               
pMo/UPadeSDN FWUP       1235 AGGA-TWWK--AGCCMCTTTG--------------------------------------- 1252  
 
 
 
 
b) Forward sequencing of adeRS complementation construct (2). 
pMo/UPadeSDN Expected   1321 AGGAATTAGTAAGCAACTTTTTATTGCCTTAACTATTGTGAATTTAAGCGTTACGCTATT 1380  
                                             C+ TT A TGCCTT A++ TT TG   TT AGCGTTACGCTATT       
pMo/UPadeSDN FWadeS        1 ---------------CCYATTAAATGCCTTTAMW-TTTTGTGATTTAGCGTTACGCTATT   44  
 
pMo/UPadeSDN Expected   1381 TTCTATAGTATTGGGTTATATCATTTATAACTATGCGATTGAAAAAGGCTGGATTAGCTT 1440  
                             TTCTATAGTATTGGGTTATATCATTTATAACTATG GA  G  AAAGGCTGGATTAGCTT       
pMo/UPadeSDN FWadeS       45 TTCTATAGTATTGGGTTATATCATTTATAACTATG-GAAAGGGAAAGGCTGGATTAGCTT  103  
 
pMo/UPadeSDN Expected   1441 AAGCTCATTTCAACAAGAAGATTGGACCAGTTTTCATTTTGTAGACTGGATCTGGTTAGC 1500  
                             AAGCTCATTTCAACAAGAAGATTG+A+CAGTTTTCATTTTGTAGACTGGATCTGGTTAGC       
pMo/UPadeSDN FWadeS      104 AAGCTCATTTCAACAAGAAGATTGRAMCAGTTTTCATTTTGTAGACTGGATCTGGTTAGC  163  
 
pMo/UPadeSDN Expected   1501 CACTGTTATCTTCTGTGGCTGTATTATTTCATTAGTGATTGGCATGCGCCTCGCAAAGCG 1560  
                             CACTGTTATCTTCTGTGGCTGTATTATTTCATTAGTGATTGGCATGCGCCTCGCAAAGCG       
pMo/UPadeSDN FWadeS      164 CACTGTTATCTTCTGTGGCTGTATTATTTCATTAGTGATTGGCATGCGCCTCGCAAAGCG  223  
 
pMo/UPadeSDN Expected   1561 TTTTATTGTGCCAATTAACTTCTTAGTCGAAGCAGCAAAAAAAATTAGTCACGGCGACCT 1620  
                             TTTTATTGTGCCAATTAACTTCTTAGTCGAAGCAGCAAAAAAAATTAGTCACGGCGACCT       
pMo/UPadeSDN FWadeS      224 TTTTATTGTGCCAATTAACTTCTTAGTCGAAGCAGCAAAAAAAATTAGTCACGGCGACCT  283  
 
pMo/UPadeSDN Expected   1621 CTCTGCTAGAGCTTACGATAATAGAATTCACTCCGCCGAAATGTCGGAGCTTTTATATAA 1680  
                             CTCTGCTAGAGCTTACGATAATAGAATTCACTCCGCCGAAATGTCGGAGCTTTTATATAA       
pMo/UPadeSDN FWadeS      284 CTCTGCTAGAGCTTACGATAATAGAATTCACTCCGCCGAAATGTCGGAGCTTTTATATAA  343  
 
pMo/UPadeSDN Expected   1681 TTTTAATGATATGGCTCAAAAGCTAGAGGTTTCCGTCAAAAATGCGCAGGTTTGGAATGC 1740  
                             TTTTAATGATATGGCTCAAAAGCTAGAGGTTTCCGTCAAAAATGCGCAGGTTTGGAATGC       
pMo/UPadeSDN FWadeS      344 TTTTAATGATATGGCTCAAAAGCTAGAGGTTTCCGTCAAAAATGCGCAGGTTTGGAATGC  403  
 
pMo/UPadeSDN Expected   1741 AGCTATCGCACATGAGTTAAGAACGCCTATAACGATATTACAAGGTCGTTTACAGGGAAT 1800  
                             AGCTATCGCACATGAGTTAAGAACGCCTATAACGAT+TTACAAGGTCGTTTACAGGGAAT       
pMo/UPadeSDN FWadeS      404 AGCTATCGCACATGAGTTAAGAACGCCTATAACGATWTTACAAGGTCGTTTACAGGGAAT  463  
 
pMo/UPadeSDN Expected   1801 TATTGATGGCGTTTTTAAACCTGATGAAGTCCTATTTAAAAGCCTTTTAAATCAAGTTGA 1860  
                             TATTGATGGCGTTTTTAAACCTGATGAAGTCCTATTTAAAAGCCTTTTAAATCAAGTTGA       
pMo/UPadeSDN FWadeS      464 TATTGATGGCGTTTTTAAACCTGATGAAGTCCTATTTAAAAGCCTTTTAAATCAAGTTGA  523  
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pMo/UPadeSDN Expected   1861 AGGTTTATCTCACTTAGTCGAAGACTTACGGACTTTAAGCTTAGTAGAGAACCAGCAACT 1920  
                             AGGTTTATCTCACTTAGTCGAAGACTTACGGACTTTAAGCTTAGTAGAGAACCAGCAACT       
pMo/UPadeSDN FWadeS      524 AGGTTTATCTCACTTAGTCGAAGACTTACGGACTTTAAGCTTAGTAGAGAACCAGCAACT  583  
 
pMo/UPadeSDN Expected   1921 CCGGTTAAATTATGAATTGTTTGACTTGAAGGCGGTAGTTGAAAAAGTTCTTAAAGCATT 1980  
                             CCGGTTAAATTATGAATTGTTTGACTTGAAGGCGGTAGTTGAAAAAGTTCTTAAAGCATT       
pMo/UPadeSDN FWadeS      584 CCGGTTAAATTATGAATTGTTTGACTTGAAGGCGGTAGTTGAAAAAGTTCTTAAAGCATT  643  
 
pMo/UPadeSDN Expected   1981 TGAAGATCGTTTGGATCAAGCTAAGCTAGTACCAGAACTTGACCTAACGTCCACTCCTGT 2040  
                             TGAAGATCGTTTGGATCAAGCTAAGCTAGTACCAGAACTTGACCTAACGTCCACTCCTGT       
pMo/UPadeSDN FWadeS      644 TGAAGATCGTTTGGATCAAGCTAAGCTAGTACCAGAACTTGACCTAACGTCCACTCCTGT  703  
 
pMo/UPadeSDN Expected   2041 ATATTGCGACCGCCGTCGTATTGAGCAAGTTTTAATTGCTTTAATTGATAATGCGATTCG 2100  
                             ATATTGCGACCGCCGTCGTATTGAGCAAGTTTTAATTGCTTTAATTGATAATGCGATTCG       
pMo/UPadeSDN FWadeS      704 ATATTGCGACCGCCGTCGTATTGAGCAAGTTTTAATTGCTTTAATTGATAATGCGATTCG  763  
 
pMo/UPadeSDN Expected   2101 CTATTCAAATGCAGGCAAACTTAAAATCTCTTCAGAAGTGGTTGCAGACAACTGGATATT 2160  
                             CTATTCAAATGCAGGCAAACTTAAAATCTCTTCAGAAGTGGTTGCAGACAACTGGATATT       
pMo/UPadeSDN FWadeS      764 CTATTCAAATGCAGGCAAACTTAAAATCTCTTCAGAAGTGGTTGCAGACAACTGGATATT  823  
 
pMo/UPadeSDN Expected   2161 AAAAATTGAGGATGAAGGCCCCGGCATTGCAACCGAGTTTCGGGACGATTTATTTAA-GC 2219  
                             AAAAATTGAGGATGAAGGCCCCGGCATTGCAACCGAGTTTCGGGACGATTTATTT+A GC       
pMo/UPadeSDN FWadeS      824 AAAAATTGAGGATGAAGGCCCCGGCATTGCAACCGAGTTTCGGGACGATTTATTTWAAGC  883  
 
pMo/UPadeSDN Expected   2220 CTTTCTTTAGATTAGAAGAATCAAGGAATAAAGAATTTGGCGGCACAGGTTTAGGTCTTG 2279  
                             CTTTCTTTAGATTAGAAGAATCAAGGAATAAAGAATTTGGCGG++CA GTTTAGGTCTTG       
pMo/UPadeSDN FWadeS      884 CTTTCTTTAGATTAGAAGAATCAAGGAATAAAGAATTTGGCGGSMCAAGTTTAGGTCTTG  943  
 
pMo/UPadeSDN Expected   2280 CTGTTGTACATGCAATTATTGTGGCACTGAAAGGCACTATTCAA-TATAGCAATCAAGGC 2338  
                             CTGT GTACATGCAATTATTGTG++ CTGAAAGGC+CTATTC+A TA+AGCAATCAAGGC       
pMo/UPadeSDN FWadeS      944 CTGT-GTACATGCAATTATTGTGSM-CTGAAAGGCMCTATTCMAATAWAGCAATCAAGGC 1001  
 
pMo/UPadeSDN Expected   2339 TCGAAAAGTGTTTTCACCATAAAAATTTCTATGGGTC-ATGAAGAGATGGGGTAATTCGC 2397  
                             TCGAAAAGTGTTT +  CATAAAAATTTCTATGGG+C ATGAA AGATGGG TAATTC+C       
pMo/UPadeSDN FWadeS     1002 TCGAAAAGTGTTTCM--CATAAAAATTTCTATGGGKCCATGAAAAGATGGG-TAATTCSC 1058  
 
pMo/UPadeSDN Expected   2398 TAAATTAAAAAATCTTAGAGTTAAAGTGCCCCCTCACTCTCTTTTATTCTTCTACGAATT 2457  
                             T+A T  AAAAAT+ T+GAGTTAAAGTGCCCCCT+ACTC++ TTT+ TCTTCTACGAATT       
pMo/UPadeSDN FWadeS     1059 TMATT--AAAAATYCTWGAGTTAAAGTGCCCCCTYACTCYYCTTTWATCTTCTACGAATT 1116  
 
pMo/UPadeSDN Expected   2458 TCTTCTCGCCATTTTGTGGCATTTTCCTGTTGTTTGTTTAATAGGACACCTAACATATAA 2517  
                              CTTC+++C A TTTG +G+ATT    TGTT  TT    AA+AG AC CCTAACAT+ +        
pMo/UPadeSDN FWadeS     1117 CCTTCYSSC-AGTTTGGKGMATTCCTGTGTTAGTT----AAWAGAAC-CCTAACATWAR- 1169  
 
pMo/UPadeSDN Expected   2518 GCTGTAACCGCAGCGCCAATTAAGGCTATACCGGTTTCATAAATAATATCTATAACAAAT 2577  
                                +TAACCGC+  GCCA  TAAG  TA   CGGTT +A+AA +AAT T TA AACA  +       
pMo/UPadeSDN FWadeS     1170 --CKTAACCGCMA-GCCA--TAAGCATA---CGGTTCYAWAATWAATCTATA-AACAGTY 1220  
 
pMo/UPadeSDN Expected   2578 TCGAGCACTCCCTCCGACAAAAAATCTAATGAGCCTGAAAATTTAAGAAATTTAGCTATG 2637  
                             T++                                                                
pMo/UPadeSDN FWadeS     1221 TMSGAGGA---------------------------------------------------- 1228  
 
 
c) Reverse sequencing of adeRS complementation construct (1).  
pMo/UPadeSDN Expected    901 CAGGCAGTCCTAAGACGTACTCAGTTTGCAAACAAA  936  
                                                                        
pMo/UPadeSDN RVadeS          ------------------------------------       
 
pMo/UPadeSDN Expected    937 GCAACTAATAAAAATAAACTCTATAAAAATATTGAAATTGATACCGACACTCATAGCGTT  996  
                             G+  +T AT+ AAATA   +CT T AAAAT      ATTG TA CG CACTC+  +C          
pMo/UPadeSDN RVadeS     1292 GMGCMTTATWGAAATA---YCTTTCAAAATT----GATTG-TATCG-CACTCWAGSC--- 1245  
 
pMo/UPadeSDN Expected    997 TATATACACTCTGAGAATAAGAAGATCTTGCTTAATCTGACGCTGACTGAATATAAAATT 1056  
                               TATAC  TC   GAATA+GA +   +TGCT  ATC GACG TGACTGAA  TAAAATT       
pMo/UPadeSDN RVadeS     1244 --TATACCTTC---GAATARGAGR--TYTGCT--ATC-GACG-TGACTGAAATTAAAATT 1196  
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pMo/UPadeSDN Expected   1057 ATTTCATTCATGATTGATCAGCCTCATAAAGTTTTTACGCGCGGAGAGCTTATGAATCAC 1116  
                             +TT    TCATGAT GATCAGCCTCATAAAGTTTT ACGCG+ G +    TATGA TCA        
pMo/UPadeSDN RVadeS     1195 WTTCA--TCATGAT-GATCAGCCTCATAAAGTTTT-ACGCGSCGGRGAGCTATGA-TCA- 1142  
 
pMo/UPadeSDN Expected   1117 TGCATGAATGATAGCGATGCACTAGAGCGAACCGTAGATAGCCATGTGAGTAAGCTGAGA 1176  
                             TGCATGAATGATAGCGATGCA TAGAG   ACCGTAGATAGC   ++GAGTAAGCTGAGA       
pMo/UPadeSDN RVadeS     1141 TGCATGAATGATAGCGATGCA-TAGAGGCGACCGTAGATAGC--AKKGAGTAAGCTGAGA 1085  
 
pMo/UPadeSDN Expected   1177 AAAAAACTAGAAGAACAAGGCATATTTCAAATGTTAATTAATGTGCGTGGCGTGGGATAT 1236  
                             AAAAAACTAGA   A    GCATATTTCAAAT++TAATTAATGTGCGTGGCGTGGGAT+T       
pMo/UPadeSDN RVadeS     1084 AAAAAACTAGAGACA----GCATATTTCAAATKKTAATTAATGTGCGTGGCGTGGGATWT 1029  
 
pMo/UPadeSDN Expected   1237 AGACTAGATAATCCCCTAGCTGTAAAAGATGATGCCTAAATAATATTAAAAAATAGCTAG 1296  
                             AGACTAGATA   CCCTAGCTGTAAA GATGATGCCTAAATAATAT AAAAAATAGCTAG       
pMo/UPadeSDN RVadeS     1028 AGACTAGATA--TCCCTAGCTGTAAA-GATGATGCCTAAATAATAT-AAAAAATAGCTAG  973  
 
pMo/UPadeSDN Expected   1297 GGAATATTTTATGAAAAGTAAGTTAGGAATTAGTAAGCAACTTTTTATTGCCTTAACTAT 1356  
                             GGAATATTTTATGAAAAGTAAGTTAGGAATTAGTAAGCAACTTTTTATTGCCTTAACTAT       
pMo/UPadeSDN RVadeS      972 GGAATATTTTATGAAAAGTAAGTTAGGAATTAGTAAGCAACTTTTTATTGCCTTAACTAT  913  
 
pMo/UPadeSDN Expected   1357 TGTGAATTTAAGCGTTACGCTATTTTCTATAGTATTGGGTTATATCATTTATAACTATGC 1416  
                             TGTGAATTTAAGCGTTACGCTATTTTCTATAGTATTGGGTTATATCATTTATAACTATGC       
pMo/UPadeSDN RVadeS      912 TGTGAATTTAAGCGTTACGCTATTTTCTATAGTATTGGGTTATATCATTTATAACTATGC  853  
 
pMo/UPadeSDN Expected   1417 GATTGAAAAAGGCTGGATTAGCTTAAGCTCATTTCAACAAGAAGATTGGACCAGTTTTCA 1476  
                             GATTGAAAAAGGCTGGATTAGCTTAAGCTCATTTCAACAAGAAGATTGGACCAGTTTTCA       
pMo/UPadeSDN RVadeS      852 GATTGAAAAAGGCTGGATTAGCTTAAGCTCATTTCAACAAGAAGATTGGACCAGTTTTCA  793  
 
pMo/UPadeSDN Expected   1477 TTTTGTAGACTGGATCTGGTTAGCCACTGTTATCTTCTGTGGCTGTATTATTTCATTAGT 1536  
                             TTTTGTAGACTGGATCTGGTTAGCCACTGTTATCTTCTGTGGCTGTATTATTTCATTAGT       
pMo/UPadeSDN RVadeS      792 TTTTGTAGACTGGATCTGGTTAGCCACTGTTATCTTCTGTGGCTGTATTATTTCATTAGT  733  
 
pMo/UPadeSDN Expected   1537 GATTGGCATGCGCCTCGCAAAGCGTTTTATTGTGCCAATTAACTTCTTAGTCGAAGCAGC 1596  
                             GATTGGCATGCGCCTCGCAAAGCGTTTTATTGTGCCAATTAACTTCTTAGTCGAAGCAGC       
pMo/UPadeSDN RVadeS      732 GATTGGCATGCGCCTCGCAAAGCGTTTTATTGTGCCAATTAACTTCTTAGTCGAAGCAGC  673  
 
pMo/UPadeSDN Expected   1597 AAAAAAAATTAGTCACGGCGACCTCTCTGCTAGAGCTTACGATAATAGAATTCACTCCGC 1656  
                             AAAAAAAATTAGTCACGGCGACCTCTCTGCTAGAGCTTACGATAATAGAATTCACTCCGC       
pMo/UPadeSDN RVadeS      672 AAAAAAAATTAGTCACGGCGACCTCTCTGCTAGAGCTTACGATAATAGAATTCACTCCGC  613  
 
pMo/UPadeSDN Expected   1657 CGAAATGTCGGAGCTTTTATATAATTTTAATGATATGGCTCAAAAGCTAGAGGTTTCCGT 1716  
                             CGAAATGTCGGAGCTTTTATATAATTTTAATGATATGGCTCAAAAGCTAGAGGTTTCCGT       
pMo/UPadeSDN RVadeS      612 CGAAATGTCGGAGCTTTTATATAATTTTAATGATATGGCTCAAAAGCTAGAGGTTTCCGT  553  
 
pMo/UPadeSDN Expected   1717 CAAAAATGCGCAGGTTTGGAATGCAGCTATCGCACATGAGTTAAGAACGCCTATAACGAT 1776  
                             CAAAAATGCGCAGGTTTGGAATGCAGCTATCGCACATGAGTTAAGAACGCCTATAACGAT       
pMo/UPadeSDN RVadeS      552 CAAAAATGCGCAGGTTTGGAATGCAGCTATCGCACATGAGTTAAGAACGCCTATAACGAT  493  
 
pMo/UPadeSDN Expected   1777 ATTACAAGGTCGTTTACAGGGAATTATTGATGGCGTTTTTAAACCTGATGAAGTCCTATT 1836  
                             ATTACAAGGTCGTTTACAGGGAATTATTGATGGCGTTTTTAAACCTGATGAAGTCCTATT       
pMo/UPadeSDN RVadeS      492 ATTACAAGGTCGTTTACAGGGAATTATTGATGGCGTTTTTAAACCTGATGAAGTCCTATT  433  
 
pMo/UPadeSDN Expected   1837 TAAAAGCCTTTTAAATCAAGTTGAAGGTTTATCTCACTTAGTCGAAGACTTACGGACTTT 1896  
                             TAAAAGCCTTTTAAATCAAGTTGAAGGTTTATCTCACTTAGTCGAAGACTTACGGACTTT       
pMo/UPadeSDN RVadeS      432 TAAAAGCCTTTTAAATCAAGTTGAAGGTTTATCTCACTTAGTCGAAGACTTACGGACTTT  373  
 
pMo/UPadeSDN Expected   1897 AAGCTTAGTAGAGAACCAGCAACTCCGGTTAAATTATGAATTGTTTGACTTGAAGGCGGT 1956  
                             AAGCTTAGTAGAGAACCAGCAACTCCGGTTAAATTATGAATTGTTTGACTTGAAGGCGGT       
pMo/UPadeSDN RVadeS      372 AAGCTTAGTAGAGAACCAGCAACTCCGGTTAAATTATGAATTGTTTGACTTGAAGGCGGT  313  
 
pMo/UPadeSDN Expected   1957 AGTTGAAAAAGTTCTTAAAGCATTTGAAGATCGTTTGGATCAAGCTAAGCTAGTACCAGA 2016  
                             AGTTGAAAAAGTTCTTAAAGCATTTGAAGATCGTTTGGATCAAGCTAAGCTAGTACCAGA       
pMo/UPadeSDN RVadeS      312 AGTTGAAAAAGTTCTTAAAGCATTTGAAGATCGTTTGGATCAAGCTAAGCTAGTACCAGA  253  
 
pMo/UPadeSDN Expected   2017 ACTTGACCTAACGTCCACTCCTGTATATTGCGACCGCCGTCGTATTGAGCAAGTTTTAAT 2076  
                             ACTTGACCTAACGTCCACTCCTGTATATTGCGACCGCCGTCGTATTGAGCAAGTTTTAAT       
pMo/UPadeSDN RVadeS      252 ACTTGACCTAACGTCCACTCCTGTATATTGCGACCGCCGTCGTATTGAGCAAGTTTTAAT  193  
 140 
 
 
pMo/UPadeSDN Expected   2077 TGCTTTAATTGATAATGCGATTCGCTATTCAAATGCAGGCAAACTTAAAATCTCTTCAGA 2136  
                             TGCTTTAATTGATAATGCGATTCGCTATTCAAATGCAGGCAAACTTAAAATCTCTTCAGA       
pMo/UPadeSDN RVadeS      192 TGCTTTAATTGATAATGCGATTCGCTATTCAAATGCAGGCAAACTTAAAATCTCTTCAGA  133  
 
pMo/UPadeSDN Expected   2137 AGTGGTTGCAGACAACTGGATATTAAAAATTGAGGATGAAGGCCCCGGCATTGCAACCGA 2196  
                             AGTGGTTGCAGACAACTGGATATTAAAAATTGAGGATGAAGGCCCCGGCAT+GCAACCGA       
pMo/UPadeSDN RVadeS      132 AGTGGTTGCAGACAACTGGATATTAAAAATTGAGGATGAAGGCCCCGGCATKGCAACCGA   73  
 
pMo/UPadeSDN Expected   2197 GTTTCGGGACGATTTATTTAAGCCTTTCTTTAGATTAGAAGAATCAAGGAATAAAGAATT 2256  
                             GTTTCGGGACGATTTATTTAAGCCTTTCTTTAGATTAGAAGAATCAAGGAATAAAGA TT       
pMo/UPadeSDN RVadeS       72 GTTTCGGGACGATTTATTTAAGCCTTTCTTTAGATTAGAAGAATCAAGGAATAAAGA-TT   14  
 
pMo/UPadeSDN Expected   2257 TGGCGGCACAGGT 2269  
                              G +  C   +G        
pMo/UPadeSDN RVadeS       13 GGCSCACCTTSGC    1  
 
 
d) Reverse sequencing of adeRS complementation construct (2). 
pMo/UPadeSDN Expected   2221 TTTCTTTAGATTAGAAGAATCAA 2243  
                                                           
pMo/UPadeSDN RVDOWN          -----------------------       
 
pMo/UPadeSDN Expected   2244 GGAATAAAGAATTTGGCGGCACAGGTTTAGGTCTTGCTGTTGTACATGCAATTATTGTGG 2303  
                             G   TAAAG   TT   G C        A    TTG+     TA   GC  +TA TG          
pMo/UPadeSDN RVDOWN     1223 GATGTAAAGCCCTTCTAGTCGAGATCAGATAGATTGSGCAGTTAGTCGCTGKTACTGCAT 1164  
 
pMo/UPadeSDN Expected   2304 CACTGAAAGGCACTATTCAATATAGCAATCAAGGCTCGAAAAGTGTTTTCACCATAAAAA 2363  
                                TG  + G  C A+TCAAT  +GCA TCA      G AAAGTGTTT    CA  AAAA       
pMo/UPadeSDN RVDOWN     1163 WTTTGGCMTGAGCAAWTCAAT--WGCA-TCAG---CTGGAAAGTGTTT----CACTAAAA 1114  
 
pMo/UPadeSDN Expected   2364 TTTCTATGGGTCATGAAGAGATGGGGTAATTCGCTAAATTAAAAAATCTTAGAGTTAAAG 2423  
                             TT  T   GGTCA+  AG++ATGGG         TA   TAA AAA   TAGAGTTAA G       
pMo/UPadeSDN RVDOWN     1113 TTCWT---GGTCAK--AGRRATGGG---------TATCGTAATAAAATCTAGAGTTAA-G 1069  
 
pMo/UPadeSDN Expected   2424 TGCCCCCTCACTCTCTTTTATTCTTCTACGAATTTCTTCTCGCCATTTTGTGGCATTTTC 2483  
                             TGCCCC TCACTCT+TTT   T+TTCTACGA T TCT   CGC   TTTGTG CATTT         
pMo/UPadeSDN RVDOWN     1068 TGCCCC-TCACTCTYTTT--ATYTTCTACGAGTCTCT---CGCA--TTTGTG-CATTTCT 1018  
 
pMo/UPadeSDN Expected   2484 CTGTTGTTTGTTTAATAGGACACCTAACATATAAGCTGTAACCGCAGCGCCAATTAAGGC 2543  
                              TGTT +TT T       GACAC   ACATATAAGCTGTA  CGCAGCGCCAATTAAGGC       
pMo/UPadeSDN RVDOWN     1017 GTGTTTKTTAT------AGACACT--ACATATAAGCTGTA--CGCAGCGCCAATTAAGGC  968  
 
pMo/UPadeSDN Expected   2544 TATACCGGTTTCATAAATAATATCTATAACAAATTCGAGCACTCCCTCCGACAAAAAATC 2603  
                             TATACCGGTTTCATAAATAATATCTATA CAAATTCGAGCACTCC TCCGACAAAAAATC       
pMo/UPadeSDN RVDOWN      967 TATACCGGTTTCATAAATAATATCTATA-CAAATTCGAGCACTCC-TCCGACAAAAAATC  910  
 
pMo/UPadeSDN Expected   2604 TAATGAGCCTGAAAATTTAAGAAATTTAGCTATGGCAACCACTATAACTCCCAATAAAGC 2663  
                             TAATGAGC TGAAA  TTAAGAAATTTAGCTATGGCAACCACTATAACTCCCAATAAAGC       
pMo/UPadeSDN RVDOWN      909 TAATGAGC-TGAAA--TTAAGAAATTTAGCTATGGCAACCACTATAACTCCCAATAAAGC  853  
 
pMo/UPadeSDN Expected   2664 GCCAGCCCATAAGAATATTTTATGAATATTGATAGGTGCCGTGACTTGATCGATTTGATC 2723  
                             GCCAGCCCATAAGAATATTTTATGAATATTGATAGGTGCCGTGACTTGATCGATTTGATC       
pMo/UPadeSDN RVDOWN      852 GCCAGCCCATAAGAATATTTTATGAATATTGATAGGTGCCGTGACTTGATCGATTTGATC  793  
 
pMo/UPadeSDN Expected   2724 GGGGTACTTTCGATAGTACTCAATTTCCTCATCTGTTACTTCAGAGGTAGATTTAAATAA 2783  
                             GGGGTACTTTCGATAGTACTCAATTTCCTCATCTGTTACTTCAGAGGTAGATTTAAATAA       
pMo/UPadeSDN RVDOWN      792 GGGGTACTTTCGATAGTACTCAATTTCCTCATCTGTTACTTCAGAGGTAGATTTAAATAA  733  
 
pMo/UPadeSDN Expected   2784 TAATTTAATAAATAGCTTGTCTTGATCAAGCTTTGTATTTTTCTTCATAGCTGTGATGCG 2843  
                             TAATTTAATAAATAGCTTGTCTTGATCAAGCTTTGTATTTTTCTTCATAGCTGTGATGCG       
pMo/UPadeSDN RVDOWN      732 TAATTTAATAAATAGCTTGTCTTGATCAAGCTTTGTATTTTTCTTCATAGCTGTGATGCG  673  
 
pMo/UPadeSDN Expected   2844 TAATAAGTATTCTAATGTTTAATGTTACTCACTTTTTCTTTAGGGAGTAACTGTTTTAAG 2903  
                             TAATAAGTATTCTAATGTTTAATGTTACTCACTTTTTCTTTAGGGAGTAACTGTTTTAAG       
pMo/UPadeSDN RVDOWN      672 TAATAAGTATTCTAATGTTTAATGTTACTCACTTTTTCTTTAGGGAGTAACTGTTTTAAG  613  
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pMo/UPadeSDN Expected   2904 AGCTTATCGCTACCTTAACTCATTCATTTCTTCTCTAGCTTGTTGTGGTGTTTTACCCGA 2963  
                             AGCTTATCGCTACCTTAACTCATTCATTTCTTCTCTAGCTTGTTGTGGTGTTTTACCCGA       
pMo/UPadeSDN RVDOWN      612 AGCTTATCGCTACCTTAACTCATTCATTTCTTCTCTAGCTTGTTGTGGTGTTTTACCCGA  553  
 
pMo/UPadeSDN Expected   2964 CCACTCTTTATAAGCCCGTGTAAATGGACTGTGCTCGGCATAACCTAACAGTAAAGCTAT 3023  
                             CC CTCTTTATAAGCCCGTGTAAATGGACTGTGCTCGGCATAACCTAACAGTAAAGCTAT       
pMo/UPadeSDN RVDOWN      552 CCGCTCTTTATAAGCCCGTGTAAATGGACTGTGCTCGGCATAACCTAACAGTAAAGCTAT  493  
 
pMo/UPadeSDN Expected   3024 TTCTACAATTTGTAGCCTTAGATCTTTTAAATACGATTTTGCCAATTCGTAACGGACAGT 3083  
                             TTCTACAATTTGTAGCCTTAGATCTTTTAAATACGATTTTGCCAATTCGTAACGGACAGT       
pMo/UPadeSDN RVDOWN      492 TTCTACAATTTGTAGCCTTAGATCTTTTAAATACGATTTTGCCAATTCGTAACGGACAGT  433  
 
pMo/UPadeSDN Expected   3084 ATTTAATTCTTTCCGAAAATTCGTACCTGCCTCGGTTAAACGGCGTTGCAAGGTTCTACG 3143  
                             ATTTAATTCTTTCCGAAAATTCGTACCTGCCTCGGTTAAACGGCGTTGCAAGGTTCTACG       
pMo/UPadeSDN RVDOWN      432 ATTTAATTCTTTCCGAAAATTCGTACCTGCCTCGGTTAAACGGCGTTGCAAGGTTCTACG  373  
 
pMo/UPadeSDN Expected   3144 TGAATAATTTAATCGCTCTGCAAGCTGTTCAATAGTTGGTTCGCCTTGATGAAGTAAGTA 3203  
                             TGAATAATTTAATCGCTCTGCAAGCTGTTCAATAGTTGGTTCGCCTTGATGAAGTAAGTA       
pMo/UPadeSDN RVDOWN      372 TGAATAATTTAATCGCTCTGCAAGCTGTTCAATAGTTGGTTCGCCTTGATGAAGTAAGTA  313  
 
pMo/UPadeSDN Expected   3204 AGCAATCTGTTTACGAACTTGATCTGTAATTTCATCAATATGTGGCAGGCTTGCCAGTAA 3263  
                             AGCAATCTGTTTACGAACTTGATCTGTAATTTCATCAATATGTGGCAGGCTTGCCAGTAA       
pMo/UPadeSDN RVDOWN      312 AGCAATCTGTTTACGAACTTGATCTGTAATTTCATCAATATGTGGCAGGCTTGCCAGTAA  253  
 
pMo/UPadeSDN Expected   3264 CTTGTCAGCATGTTTTTCTAGTATGGCAACTAAGGCGGCGTCGGAGTTTTTAAGCGGTAG 3323  
                             CTTGTCA+CATGTTTTTCTAGTATGGCAACTAAGGCGGCGTCGGAGTTTTTAAGCGGTAG       
pMo/UPadeSDN RVDOWN      252 CTTGTCASCATGTTTTTCTAGTATGGCAACTAAGGCGGCGTCGGAGTTTTTAAGCGGTAG  193  
 
pMo/UPadeSDN Expected   3324 ACTTAAGATTTCCTTATCAAAACGCATCAGTGCCACAGGCTGTTCAAAAAGCACAGGACA 3383  
                             ACTTAAGATTTCCTTATCAAAACGCATCAGTGCC+CAGGCTGTTCAAAAAGC+CAGGACA       
pMo/UPadeSDN RVDOWN      192 ACTTAAGATTTCCTTATCAAAACGCATCAGTGCCMCAGGCTGTTCAAAAAGCMCAGGACA  133  
 
pMo/UPadeSDN Expected   3384 ACCAAAATACTCCTCATAAGGCTGAACATTTTCAGGCCGTTCATGAATAAAATGTATTTC 3443  
                             ACCAAAATACTCCTCATAAGGCTGA+CATTTTCAGGCCGTTCATGAATAAAATGTATTTC       
pMo/UPadeSDN RVDOWN      132 ACCAAAATACTCCTCATAAGGCTGAMCATTTTCAGGCCGTTCATGAATAAAATGTATTTC   73  
 
pMo/UPadeSDN Expected   3444 TTTGAGTCTTTCTTTTCCTCTAATGAGACTACGGCAAAATTGAACTATAACGGTACGGCC 3503  
                             TTTGAGTCTTTCTTTTCCTCTAATGAGA+TACGGCAAAAT GAACTATAACGGTACG CC       
pMo/UPadeSDN RVDOWN       72 TTTGAGTCTTTCTTTTCCTCTAATGAGAYTACGGCAAAAT-GAACTATAACGGTACGCCC   14  
 
pMo/UPadeSDN Expected   3504 AGTTTCGTCCGATA 3517  
                             AGT +C  CCG T        
pMo/UPadeSDN RVDOWN       13 AGTCKC-CCCGGTG    1  
 
pMo/UPadeSDN Expected   3518 AAGGGCCGACTTGCTCACCTGGATCCCCC 3546  
                                                                 
pMo/UPadeSDN RVDOWN          -----------------------------      
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Figure 3.21 Verification of adeRS Complementation Construct in S17-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 PCR 16, Table 2.7 
Lane DNA Expected size Actual size 
1 Hyperladder™ 1 (Bioline) --- --- 
2-5 Candidate S17-1 transformants 3546 bp ~ 3546 bp 
6 pMo130-TelR/UP-adeRS-DOWN (positive 
control) 
3546 bp ~ 3546 bp 
7 --- No amplimer No amplimer 
8 Hyperladder™ 1 (Bioline) --- --- 
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suggesting that these did not contain the construct (single recombinants are expected to be 
yellow when exposed to pyrocatechol). A conjugation was next carried out using 2 ml of both 
donor and recipient. This gave rise to one colony after overnight incubation and a further eight 
colonies after the plates had been left at room temperature for two days. All nine colonies 
remained white after pyrocatechol exposure. The original method used the donor and recipient 
in a 1:2 ratio, according to the absorbance of each stationary phase culture at OD600. For the 
third conjugation, the donor and recipient (2 ml of each) were used in a 1:1 ratio since AYE 
grows faster than S17-1 and it was possible that increasing the concentration of donor would 
increase the chance of obtaining single recombinants. The bacteria were incubated on the filter 
for 6 hr (original method) and also 24 hr to allow conjugation to occur for a longer period of 
time.  
A different strategy was to follow the original method, but using donor:recipient ratios of 2:1, 
4:1, 6:1, 8:1 and 10:1, using approximately 0.6 ml donor for each ratio. The cells were incubated 
on the filters overnight and half of the resuspended cells were plated onto LB agar and the 
other half plated onto LB agar containing high magnesium (MgLB, Appendix 1) since high 
magnesium was previously found to increase conjugation efficiency in Photorhabdus (Watson, 
2007). One colony was obtained from the 2:1 ratio on MgLB and one colony was obtained from 
the 10:1 ratio on LB. No more colonies were obtained after incubation for a further 24 hr. Both 
of these colonies were streaked onto LB (both remained white after pyrocatechol exposure) and 
onto LB containing tellurite (30 µg/ml) to confirm that they were definitely tellurite resistant. 
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They both grew on tellurite, suggesting that they were spontaneous tellurite resistant mutants, 
but did not contain the construct.  
Altered strategy for Conjugation: The Patch Method (Section 2.4.4.2) 
This method was followed using donor and recipient cells after approximately 2 hr of growth 
and also after S17-1/pMo130-TelR/UP-adeRS-DOWN had been incubated for an extra 2 hr, since 
AYE grew faster. After incubation for 48 hr, no candidate transconjugants were obtained when 
S17-1 was grown for the extra two hours and three colonies were obtained when the donor and 
recipient were grown for the same length of time. However, these three colonies remained 
white after subculture and pyrocatechol exposure.  
A combination of Different Ratios and Different Growth Phase: 
A conjugation using a range of ratios (donor:recipient; 1:1, 2:1, 5:1, 10:1) of actively growing 
donor and recipient was carried out, to investigate whether an active growth phase would 
increase conjugation frequency. Dilutions of AYEΔadeRS (1/20) and S17-1/pMo130-TelR/UP-
adeRS-DOWN (1/10) overnight culture were incubated for 1 hr (37ᵒC, 180 rpm). The absorbance 
of AYEΔadeRS at OD600 was 0.49 and that of S17-1/pMo130-Tel
R/UP-adeRS-DOWN was 0.25. 
The donor and recipient were both dropped onto opposite sides of the filter disc and mixed on 
the disc to obtain a range of ratios. The filter was incubated for 20 hr before the cells were 
resuspended. One colony (from the 2:1 ratio conjugation) was obtained after 24 hr on selective 
media. This colony was confirmed to be tellurite-resistant but remained white after 
pyrocatechol exposure and was thought to not contain the construct.  
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The remaining conjugations used large volumes of donor and recipient in a range of ratios and 
combined all cells from all filters in the same NaCl before plating aliquots onto selective media.  
Can AYEΔadeRS act as a recipient? 
In addition to the conjugations with complementation construct, two conjugations were carried 
out using S17-1/pMo130-TelR/adeRSUPDOWN or S17-1/pMo130-TelR/pmrABUPDOWN 
(containing the adeRS and pmrAB deletion constructs previously conjugated into AYE) as the 
donor to investigate whether AYEΔadeRS could receive plasmids by conjugation. AYE was used 
as a positive control as both constructs had previously been introduced into this, the parental 
strain. Seventy-eight colonies were obtained when S17-1/pMo130-TelR/adeRSUPDOWN was 
used as the donor. Most of these colonies were obtained after 21 hr incubation (37°C), but the 
plates were left at room temperature overnight before counting and sub-culturing 18 colonies 
onto LB agar. All subcultures were yellow after pyrocatechol exposure, suggesting that it was 
possible to a) introduce a plasmid into AYEΔadeRS by conjugation and b) introduce a construct 
into the adeS UP or DOWN region of the chromosome, which were the target sites for 
recombination of the complementation construct into AYEΔadeRS. One colony, which was 
yellow after pyrocatechol exposure, was also obtained when S17-1/pMo130-
TelR/pmrABUPDOWN was used as the donor. This further confirms that the conjugation 
conditions were not the limiting factor in complementing AYEΔadeRS. It is interesting that only 
two colonies, which remained white upon pyrocatechol exposure, were obtained when a 
conjugation was carried out between S17-1/pMo130-TelR/adeRSUPDOWN and AYE. Therefore, 
the conjugation was unsuccessful on this occasion.  
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To confirm that the white colonies obtained after these conjugations were AYEΔadeRS, which 
did not contain the complementation construct and had not undergone double recombination, 
two colony PCRs were used (Section 2.4; Figure 2.3; Figure 3.22), which were expected to give 
one product for the UP and DOWN fragments remaining on the chromosome and a larger 
product for the UP-adeRS-DOWN insert on the construct, if present in the chromosome. Since 
one primer in each reaction was specific for the chromosome, this could be used to investigate 
whether the plasmid was incorporated into the genome. Ten colonies were screened (Figure 
3.22) they were all confirmed to be AYEΔadeRS, with no construct incorporated into the 
chromosome and were not complements (i.e. they had not undergone double recombination).  
In conclusion, despite using exactly the same method used to delete adeRS (in addition to other 
methods), it was not possible to re-insert adeRS. 
Can the complementation constructs be introduced into AYE? 
To investigate further whether the complementation construct could be introduced into AYE 
and whether it was just the deletion mutants, which would not accept the vector, conjugations 
were carried out to introduce both the adeRS and pmrAB complementation constructs into AYE. 
Conjugations (original method, Section 2.4.3) were carried out on two separate occasions. One 
conjugation was set up on the first occasion and five conjugations were set up in parallel on the 
second occasion. No colonies were obtained after 48 hr in both cases. 
3.3.2. pmrAB 
3.3.2.1. Deletion of pmrAB 
 147 
 
3.3.2.1.1. Identification of pmrB in AYE 
The search terms “pmrB” and “lipid A phosphoethanolamine” were used to search for pmrB in 
the AYE genome. Both search terms did not return pmrB, but “lipid A phosphoethanolamine 
returned eptA. Therefore, pmrB was unannotated in the AYE genome. The gene sequences of 
pmrB, pmrA and pmrC in AB0057 had been submitted to Genbank (accession numbers 
AB57_3172, AB57_3173 and AB57_3174 respectively, (Adams et al., 2009)). pmrB, pmrA and 
pmrC in AB0057 aligned with “qseC”, “qseB” and “eptA” in AYE (Figure 3.23). The sequences of 
qseC, qseB and eptA were blasted against the AYE genome and each returned one result, 
suggesting that there is only one copy of each gene in AYE. The alignment of qseC and 
AB57_3172 confirmed that qseC is the pmrB gene in AYE. (Figure 3.24).  
3.3.2.1.2. Construction of pMo130-TelR/pmrABUPDOWN 
The UP and DOWN fragments for pmrAB were amplified and the purified amplimers were 
verified by electrophoresis (Figure 3.25).  
pMo130-TelR and the pmrABUP fragment were digested with NotI and BamHI (Table 2.8, 
Digestion 3), ligated and then transformed into DH5α. One candidate transformant was 
obtained, which was confirmed to harbour pMo130-TelR/pmrABUP (Figure 3.26). 
Twenty transformants were obtained when pMo130-TelR/pmrABUP was ligated with DOWN 
fragment and transformed into DH5α. Eight of these were verified by PCR (Figure 3.27) and 
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Figure 3.22 Screening of adeRS Candidate Complementation Transconjugants by Colony 
PCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aPCR number, Table 2.7. PCR 22, primer flanking the UP fragment on the chromosome and a 
primer specific for the DOWN fragment; PCR 23, primer flanking the DOWN fragment on the 
chromosome and a primer specific for the UP fragment. b this strain was included to confirm 
that the PCR could indicate presence of a construct.
Lane PCR
a 
DNA Expected size Actual size 
1 --- 2-Log ladder (New England Biolabs) --- --- 
2-11 22 Candidate single recombinants 2048 or 3414 bp ~ 2048 bp 
12 22 AYE (negative control for presence of 
construct) 
3414 bp ~ 3414 bp 
13 22 AYE/pMo130-Tel
R
/adeRSUPDOWN 
(positive control for PCR
b
) 
2048 or 3414 ~ 3414 bp 
14 22 --- 
(Contamination control for PCR 1) 
No amplimer No amplimer 
15, 16 --- 2-Log ladder (New England Biolabs) --- --- 
17-26 23 Candidate single recombinants 2048 or 3414 bp ~ 2048bp 
27 23 AYE (negative control) 3414 bp ~ 3414 bp 
28 23 AYE/pMo130-Tel
R
/adeRSUPDOWN 
(positive control) 
2048 or 3414 ~ 2048 bp 
29 23 --- 
(Contamination control for PCR 2) 
No amplimer No amplimer 
30 --- 2-Log ladder (New England Biolabs) --- --- 
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Figure 3.23 Alignment of the pmrCAB Operon in A. baumannii AB0057 and AYE. 
 
 
 
 
 
AB57_3172 and qseC, pmrB; star and qseB, pmrA; eptA, pmrC.  
 
 
 
 
 
 
 
Figure 3.24 Alignment of pmrB in AB0057 and AYE. 
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Figure 3.25 Amplification of pmrAB UP and DOWN Fragments 
 
 
a PCR number, Table 2.7 
 
 
 
 
Lane PCRa DNA Expected size Actual size 
1, 6 --- Hyperladder™ 1 (Bioline) --- --- 
 
2 6 Purified pmrAB UP 
fragment 
924 bp ~ 924 bp 
 
3 8 Purified pmrAB DOWN 
fragment 
 
982 bp ~ 982 bp 
 
4 6 Contamination control for 
pmrAB UP fragment 
 
No amplimer No amplimer 
5 8 Contamination control for 
pmrAB DOWN fragment 
 
No amplimer No amplimer 
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Figure 3.26 Verification of pMo130-TelR/pmrABUP 
 
PCR11, Table 2.7; Lane 1, undigested vector extracted from a candidate transformant and 
electrophoresed 
Lane DNA Expected size Actual size 
1 pMo130-TelR/pmrABUP 
extracted from transformant 
(No PCR) 
 
--- --- 
2, 6 Hyperladder™ 1 (Bioline) 
 
--- --- 
3 pMo130-TelR undigested 
(negative control) 
 
No amplimer No amplimer 
4 pMo130-TelR/pmrABUP from 
transformant 
 
1093 bp ~ 1093 bp 
5 --- 
 
No amplimer No amplimer 
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Figure 3.27 Verification of pMo130-TelR/pmrABUPDOWN. 
 
PCR 14, Table 2.7 
 
 
Lane DNA Expected 
size 
Actual size 
1-8 Lysate from 
transformants 1-8 
 
2063 bp ~ 2063 bp (transformants 1-6 and 8) 
~ 1kb (transformant 7) 
9 Hyperladder™ 1 (Bioline) 
 
--- --- 
10 --- 
 
No amplimer No amplimer 
 153 
 
candidate 1 was chosen for further verification. The vector from candidate 1 was extracted and 
confirmed to be pMo130-TelR/pmrABUPDOWN by DNA sequencing (Figure 3.28).  
3.3.2.1.3. Introduction of pMo130-TelR/pmrABUPDOWN into AYE and Verification of 
Deletion 
Two candidate S17-1/pMo130-TelR/pmrABUPDOWN transformants were obtained. Plasmid was 
extracted from both candidates and used as the template in a PCR (Figure 3.29). One of these 
vectors (from candidate 2; Figure 3.29) yielded an amplimer of the correct size. Therefore, 
candidate 2 was used as the donor in a conjugation to introduce pMo130-TelR/pmrABUPDOWN 
into AYE. Of six candidate AYE transconjugants obtained after 24hr incubation, three were 
yellow upon pyrocatechol exposure suggesting that these were single recombinants. These 
three colonies were passaged in LB (-NaCl) containing sucrose to cure the plasmid incorporated 
in the chromosome. Colonies from passages four and five that remained white after 
pyrocatechol exposure were streaked onto LB plates containing tellurite (30 µg/ml). Eleven 
colonies were completely sensitive to tellurite or only gave rise to one colony on LB plates 
containing tellurite (30 µg/ml), suggesting that these were deletion mutants. Two of the 
tellurite-sensitive colonies were confirmed to be deletion mutants by PCR (Figure 3.30) and DNA 
sequencing (Figure 3.31; Figure 3.32).  
It was initially planned that just pmrB would be deleted. However, pmrB, 12 bp of pmrA and 244 
bp of a gene encoding a hypothetical protein (ABAYE0734) were deleted because the primers,  
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Figure 3.28 Verification of pMo130-TelR/pmrABUPDOWN Construct by Sequencing 
a) Forward sequencing. 
 
pMo/pmrBUPDN Expected      1 CCATCTACTTCTTCGACCCGTCCGGTAACCGCAACGAAGTGTTCTGCGGGGGAGATTACA   60  
                                                           G AA+  AGTGTT+TGCGGGGGAGATTACA       
pMo/pmrBUPDN FW Seq        1 -----------------------------GGGAAYASAGTGTTMTGCGGGGGAGATTACA   31  
 
pMo/pmrBUPDN Expected     61 ACTACCCGGACCACAAACCGGTGACCTGGACCACCGACCAGCTGGGCAAGGCGATCTTTT  120  
                             ACTACCCGGACCACAAACCGGTGACCTGGACCACCGACCAGCTGGGCAAGGCGATCTTTT       
pMo/pmrBUPDN FW Seq       32 ACTACCCGGACCACAAACCGGTGACCTGGACCACCGACCAGCTGGGCAAGGCGATCTTTT   91  
 
pMo/pmrBUPDN Expected    121 ACCACGACCGCATTCTCAACGAACGATTCATGACCGTGCTGACCTGACCTGAGCGGCCGC  180  
                             ACCACGACCGCATTCTCAACGAACGATTCATGACCGTGCTGAC     CTGAGCGGCCGC       
pMo/pmrBUPDN FW Seq       92 ACCACGACCGCATTCTCAACGAACGATTCATGACCGTGCTGAC-----CTGAGCGGCCGC  146  
 
pMo/pmrBUPDN Expected    181 CTTATGCAATCGCACCGAGCCAACAAACACATGTACCAATGATTATGTGGTTCTCTGAAA  240  
                             CTTATGCAATCGCACCGAGCCAACAAACACATGTACCAATGATTATGTGGTTCTCTGAAA       
pMo/pmrBUPDN FW Seq      147 CTTATGCAATCGCACCGAGCCAACAAACACATGTACCAATGATTATGTGGTTCTCTGAAA  206  
 
pMo/pmrBUPDN Expected    241 GTTGGAAACAACGTAATCTTGCTCAAGTGAATTGTTTAAGCCAACAAACTAAACAAAAGT  300  
                             GTTGGAAACAACGTAATCTTGCTCAAGTGAATTGTTTAAGCCAACAAACTAAACAAAAGT       
pMo/pmrBUPDN FW Seq      207 GTTGGAAACAACGTAATCTTGCTCAAGTGAATTGTTTAAGCCAACAAACTAAACAAAAGT  266  
 
pMo/pmrBUPDN Expected    301 TAAGTCAGGATAATTTATTCCCAAGTTTGTTAAGTTTGCTGGATGTAAAAACTCAGGTCA  360  
                             TAAGTCAGGATAATTTATTCCCAAGTTTGTTAAGTTTGCTGGATGTAAAAACTCAGGTCA       
pMo/pmrBUPDN FW Seq      267 TAAGTCAGGATAATTTATTCCCAAGTTTGTTAAGTTTGCTGGATGTAAAAACTCAGGTCA  326  
 
pMo/pmrBUPDN Expected    361 TCAACCCTCAACTGGACATGTTGCACTCTTGTGCCCATGTAAACTAAAGCGAGCCTAGAA  420  
                             TCAACCCTCAACTGGACATGTTGCACTCTTGTGCCCATGTAAACTAAAGCGAGCCTAGAA       
pMo/pmrBUPDN FW Seq      327 TCAACCCTCAACTGGACATGTTGCACTCTTGTGCCCATGTAAACTAAAGCGAGCCTAGAA  386  
 
pMo/pmrBUPDN Expected    421 CATGACAAAAATCTTGATGATTGAAGATGATTTTATGATTGCAGAATCAACGATCACGTT  480  
                             CATGACAAAAATCTTGATGATTGAAGATGATTTTATGATTGCAGAATCAACGATCACGTT       
pMo/pmrBUPDN FW Seq      387 CATGACAAAAATCTTGATGATTGAAGATGATTTTATGATTGCAGAATCAACGATCACGTT  446  
 
pMo/pmrBUPDN Expected    481 GCTGCAATATCATCAGTTTGAGGTGGAATGGGTCAATAACGGTTTAGATGGTTTGGCTCA  540  
                             GCTGCAATATCATCAGTTTGAGGTGGAATGGGTCAATAACGGTTTAGATGGTTTGGCTCA       
pMo/pmrBUPDN FW Seq      447 GCTGCAATATCATCAGTTTGAGGTGGAATGGGTCAATAACGGTTTAGATGGTTTGGCTCA  506  
 
pMo/pmrBUPDN Expected    541 ATTGGCGAAGACTAAATTTGATCTTATTCTTTTGGATTTAGGATTGCCTATGATGGATGG  600  
                             ATTGGCGAAGACTAAATTTGATCTTATTCTTTTGGATTTAGGATTGCCTATGATGGATGG       
pMo/pmrBUPDN FW Seq      507 ATTGGCGAAGACTAAATTTGATCTTATTCTTTTGGATTTAGGATTGCCTATGATGGATGG  566  
 
pMo/pmrBUPDN Expected    601 TATGCAAGTTTTGAAGCAGATCCGTCAAAGAGCAGCAACACCAGTATTAATTATTTCTGC  660  
                             TATGCAAGTTTTGAAGCAGATCCGTCAAAGAGCAGCAACACCAGTATTAATTATTTCTGC       
pMo/pmrBUPDN FW Seq      567 TATGCAAGTTTTGAAGCAGATCCGTCAAAGAGCAGCAACACCAGTATTAATTATTTCTGC  626  
 
pMo/pmrBUPDN Expected    661 TCGAGATCAATTACAAAACCGTGTCGATGGTTTAAATTTGGGTGCAGATGATTATTTAAT  720  
                             TCGAGATCAATTACAAAACCGTGTCGATGGTTTAAATTTGGGTGCAGATGATTATTTAAT       
pMo/pmrBUPDN FW Seq      627 TCGAGATCAATTACAAAACCGTGTCGATGGTTTAAATTTGGGTGCAGATGATTATTTAAT  686  
 
pMo/pmrBUPDN Expected    721 TAAACCTTATGAGTTTGATGAGTTGCTTGCCCGTATTCATGCATTACTACGCCGTAGTGG  780  
                             TAAACCTTATGAGTTTGATGAGTTGCTTGCCCGTATTCATGCATTACTACGCCGTAGTGG       
pMo/pmrBUPDN FW Seq      687 TAAACCTTATGAGTTTGATGAGTTGCTTGCCCGTATTCATGCATTACTACGCCGTAGTGG  746  
 
pMo/pmrBUPDN Expected    781 AGTAGAAGCTCAACTTGCGAGTCAAGATCAACTATTAGAAAGTGGCGATCTGGTTTTAAA  840  
                             AGTAGAAGCTCAACTTGCGAGTCAAGATCAACTATTAGAAAGTGGCGATCTGGTTTTAAA       
pMo/pmrBUPDN FW Seq      747 AGTAGAAGCTCAACTTGCGAGTCAAGATCAACTATTAGAAAGTGGCGATCTGGTTTTAAA  806  
 
pMo/pmrBUPDN Expected    841 TGTTGAACAGCATATTGCGACGTTTAAAGGTCAACGCATTGATCTATCAAATCGTGAATG  900  
                             TGTTGAACAGCATATTGCGACGTTTAAAGGTCAACGCATTGATCT+TCAA TCGTGAATG       
pMo/pmrBUPDN FW Seq      807 TGTTGAACAGCATATTGCGACGTTTAAAGGTCAACGCATTGATCTMTCAA-TCGTGAATG  865  
 
pMo/pmrBUPDN Expected    901 GGCAATCTTAATTCCACTTATGACTCACCCAAATAAAATCTTTTCTAAAGCCAACTTAGA  960  
                             GGCAATCTTAATTCCACTTATGACTCACCCAA TAAAATCTTTTCTAAAGCCAACTTA+A       
pMo/pmrBUPDN FW Seq      866 GGCAATCTTAATTCCACTTATGACTCACCCAA-TAAAATCTTTTCTAAAGCCAACTTAKA  924  
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pMo/pmrBUPDN Expected    961 AGATAAGTTATATGATTTTGATAGTGATGTGACCAGTAATACTATTGAAGTATATGTTCA 1020  
                              GATAAGTTATATGATTTTGATAGTGATGTGACCAGTAATACTATTG+A+TATATGTTCA       
pMo/pmrBUPDN FW Seq      925 TGATAAGTTATATGATTTTGATAGTGATGTGACCAGTAATACTATTGMASTATATGTTCA  984  
 
pMo/pmrBUPDN Expected   1021 CCATTTAAGAGCGAAGCTGGGTAAAGATTTTATCCGAACCATCCGAGGACTGGGCTACCG 1080  
                             +CATTTAAGA+CGAAGCTGG TAAA+ATTT ATCCGAA CATCCGAG ACTGG CTAC G       
pMo/pmrBUPDN FW Seq      985 SCATTTAAGAKCGAAGCTGG-TAAASATTT-ATCCGAAGCATCCGAGAACTGG-CTAC-G 1040  
 
pMo/pmrBUPDN Expected   1081 TTTGGGATCCCCTGCACTTGCATGACCGCCTGGAAAACAATGGCCATGTTTAGCGCTAAA 1140  
                              TTGGGATCCC TGCACTTGCATGAC   C+ G AAACA TGGC ATGTT   CG+TAA        
pMo/pmrBUPDN FW Seq     1041 GTTGGGATCCC-TGCACTTGCATGACG--CWTGCAAACA-TGGC-ATGTT--ACGMTAA- 1092  
 
pMo/pmrBUPDN Expected   1141 GTCCCAAATATAGCTTCCTAAAGTATTAGGGTGAACCATATTCCAAGGGCAGGCGTGAGC 1200  
                             GTCC A+++  AGCT     A+GTAT  G G   A CAT        GGCAG CGTGAGC       
pMo/pmrBUPDN FW Seq     1093 GTCCTARWW--AGCTCT---ARGTATAGGTGACTATCAT--------GGCAG-CGTGAGC 1138  
 
pMo/pmrBUPDN Expected   1201 AGATTGTGACTTTATTAGGCCAACTATACTGCTACCGAGCATACTGACAAAAAACATATA 1260  
                              +AT G+GACTT ATTAG C  ACTATACTG    CGA CAT CTGACAA        TA       
pMo/pmrBUPDN FW Seq     1139 GRAT-GKGACTT-ATTAGCC--ACTATACTGGCTACGA-CAT-CTGACAAC-----CTTA 1187  
 
pMo/pmrBUPDN Expected   1261 GCCATATTGCCAGCGATAAGGTTTTAATTTTTTTAATTTAAATGACGCAAGCCATAAACC 1320  
                             GC  TATTG CA+CGATA+G TT+TA  TT TT A TT+AA +G                       
pMo/pmrBUPDN FW Seq     1188 GC--TATTGACAKCGATAMGCTTKTASATTSTTCACTTYAA-YG---------------- 1228 
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b) Reverse sequencing 
 
pMo/pmrBUPDN Expected    721 TAAACCTTATGAGTTTGAT  739  
                                                       
pMo/pmrBUPDN RV Seq          -------------------       
 
pMo/pmrBUPDN Expected    740 GAGTTGCTTGCCCGTATTCATGCATTACTACGCCGTAGTGGAGTAGAAGCTC---AACTT  796  
                             G  +   T G  C +A  CA  C T  C   G  +    +  +   AA CT    A+  +       
pMo/pmrBUPDN RV Seq     1314 GGAWACGTAGATCAWAG-CACYCGTAGCAGAGATRCGARRAGSCTYAAACTTTGGAWTAY 1256  
 
pMo/pmrBUPDN Expected    797 GCGAGTCAAGATCAACTATTAGAAAGTGGCGATCTG-GTTTTAAATGTTG---AACAGCA  852  
                               G +TCA + TC   T T A A  + GG+ ++ +G  TTTT A T+T++   A+  GCA       
pMo/pmrBUPDN RV Seq     1255 CAGTKTCACKKTCTTTTGT-AAAGTKCGGMWWYKWGWATTTTGAGTRTKKSAAAMAGGCA 1197  
 
pMo/pmrBUPDN Expected    853 TATTGCGA-CGTTTAAAGGT-CAACGCATTGATCTATC--AAATCGTGAAT--GGGCAAT  906  
                             T++T+C+A C T+  AAG+T CAACGCA T  + T T   A++TC + +AT  GGGCA         
pMo/pmrBUPDN RV Seq     1196 TWWTKCRAACATYACAAGKTTCAACGCAATAGWKTGTTCAAMRTCTKAWATTTGGGCATS 1137  
 
pMo/pmrBUPDN Expected    907 CTTAATTCCACTTATGACTCACCC--AAATAAAATCTTTTCTAAAGCCAA-CTTAGAAGA  963  
                              TTA TTCC+ +   +A T++C C  A+ATAAA+TC+TTT T+AAGCC+A  TTA+A GA       
pMo/pmrBUPDN RV Seq     1136 TTTATTTCCMAWMTMKAATSMCKCCWAMATAAAMTCWTTTTTWAAGCCMAGTTTAKACGA 1077  
 
pMo/pmrBUPDN Expected    964 TAAGTTATA-TGATTTTGATAGTGATGTGACCAGTAATACTATTGAAGTATA--TGTTCA 1020  
                               A+ TAT+ +GAT TT A AG+GA G GACC+GTAA+ C+ TTG AGTA +  + T +A       
pMo/pmrBUPDN RV Seq     1076 AKARCTATRGWGATSTTAA-AGKGAAGCGACCMGTAAK-CKTTTGGAGTAAWATWTTCMA 1019  
 
pMo/pmrBUPDN Expected   1021 CCATTTAAGAGCGAAG-CTGGGTAAAGATTTTATCCGAACCATCCGAGGACTGGGCTACC 1079  
                             C AT+TA GAG+GAAG CTGG TA AGA +TTATCCGAACCATC G+GGA TGGGCTACC       
pMo/pmrBUPDN RV Seq     1018 CAATWTAGGAGSGAAGKCTGGTTATAGAAWTTATCCGAACCATC-GRGGA-TGGGCTACC  961  
 
pMo/pmrBUPDN Expected   1080 G-TTTGGGATCCCCTGCACTTGCATGACCGCCTGGAAAACAATGGCCATGTTTAGCGCTA 1138  
                             G TT++GGATCCCCTGCA  TGC+TGACCGC++GG+AAACAA GG C  GTTTAG G TA       
pMo/pmrBUPDN RV Seq      960 GGTTYSGGATCCCCTGCAACTGCWTGACCGCMWGGRAAACAAAGGTCCAGTTTAGTGTTA  901  
 
pMo/pmrBUPDN Expected   1139 AAGT-CCCAAATATAGCTTCCTAAAGTATTAGGGTGAACCATATTCCAAGGGCAGGCGTG 1197  
                             AA+T CCCAAATATAG T    AA GT +TAG GTGA CCATATTCCAAGGGCAGGCGTG       
pMo/pmrBUPDN RV Seq      900 AARTTCCCAAATATAGATCGTAAAGGTGKTAGCGTGATCCATATTCCAAGGGCAGGCGTG  841  
 
pMo/pmrBUPDN Expected   1198 AGCAGATT-GTGACTTTATTAGGCCAACTATACTGCTACCGAGCATACTGACAAAAAA-C 1255  
                             AGCAGATT GT+ACTTT+TTAG+CCA+CT+T C+GCTAC+GAGCA+AC+GACAAAAAA C       
pMo/pmrBUPDN RV Seq      840 AGCAGATTTGTKACTTTRTTAGKCCAWCTWTTCYGCTACMGAGCAKACWGACAAAAAAWC  781  
 
pMo/pmrBUPDN Expected   1256 ATATAGCCATATTGCCAGCGATAAGGTTTTAATTTTTTTAATTTAAATGACGCAAGCCAT 1315  
                             ATATAG+CAT+T+GCCAGCGATAAGGTTTT+ TTTTTTTAATTT+A+TG+CGC+AGCCAT       
pMo/pmrBUPDN RV Seq      780 ATATAGYCATWTKGCCAGCGATAAGGTTTTW-TTTTTTTAATTTRARTGRCGCRAGCCAT  722  
 
pMo/pmrBUPDN Expected   1316 AAACCAAAAAAGATAACATAAACGGCGGTGATGATTTGTTTT-ACAATTTCATGATTAAG 1374  
                             AAACCAAAAAAGATAACATAA+CGGCGGTGATG+TTT TT+T ACAATTTCATGA+TAAG       
pMo/pmrBUPDN RV Seq      721 AAACCAAAAAAGATAACATAARCGGCGGTGATGWTTTTTTWTTACAATTTCATGAYTAAG  662  
 
pMo/pmrBUPDN Expected   1375 CCTTTCAAGATACCAATTGTCCCGATTGAAAAAATGACCTGTTGAATCAATCCAAGGTTG 1434  
                             CCT++CAAGATACCA+TTGTCCCGATTGAAAAA++GACC+ +TGAATCAATCCA+GGTTG       
pMo/pmrBUPDN RV Seq      661 CCTWWCAAGATACCAWTTGTCCCGATTGAAAAAMKGACCKAWTGAATCAATCCARGGTTG  602  
 
pMo/pmrBUPDN Expected   1435 GATGAGGTACATATCAATTTTCCCACCGACTGGAAATACAAATAGAAGAATAAAAAAACT 1494  
                             GATGAGGTACATATCAATTTTCCCACCG+CTGGAAATACAAAT+GAAGAATAAAAAAACT       
pMo/pmrBUPDN RV Seq      601 GATGAGGTACATATCAATTTTCCCACCGRCTGGAAATACAAATRGAAGAATAAAAAAACT  542  
 
pMo/pmrBUPDN Expected   1495 GAAAAAAAGAAAGAGAATATTAATTTGGAAAAAAAGTTTTTGATTAGTCATTCTGATGCA 1554  
                             GAAAAAAAGAAAGAGAATATTAATT GGAAAAAAAGTTTTTGATTAGTCATT+TGATGCA       
pMo/pmrBUPDN RV Seq      541 GAAAAAAAGAAAGAGAATATTAATT-GGAAAAAAAGTTTTTGATTAGTCATTMTGATGCA  483  
 
pMo/pmrBUPDN Expected   1555 ATATCAATCGACAATAGGTGCGACTAATTACATAAAATTAATCTTAAATTGCTCTTAAAC 1614  
                             ATATCAATCGACAATAGGTGCGACTAATTACATAAAATTAATCTTAAATTGCTCTTAAAC       
pMo/pmrBUPDN RV Seq      482 ATATCAATCGACAATAGGTGCGACTAATTACATAAAATTAATCTTAAATTGCTCTTAAAC  423  
 
pMo/pmrBUPDN Expected   1615 TATACTGGTGAAAGAAGTTCAATTTTCCTTAAAAAATAAAAAAGCGACGAATAGTATCGT 1674  
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                             TATACTGGTGAAAGAAGTTCAATTTTCCTTAAAAAATAAAAAAGCGACGAATAGTATCGT       
pMo/pmrBUPDN RV Seq      422 TATACTGGTGAAAGAAGTTCAATTTTCCTTAAAAAATAAAAAAGCGACGAATAGTATCGT  363  
 
pMo/pmrBUPDN Expected   1675 CGCCTTAAGCACTTTAGAAAGTATTAAAACATACCTTCTTCAGAGTTTGCTGAGATCTTA 1734  
                             CGCCTTAAGCACTTTAGAAAGTATTAAAACATAC+TT+TTCAGAGTTTGC+GAGAT+TTA       
pMo/pmrBUPDN RV Seq      362 CGCCTTAAGCACTTTAGAAAGTATTAAAACATACSTTSTTCAGAGTTTGCWGAGATMTTA  303  
 
pMo/pmrBUPDN Expected   1735 TGAATAGATAAGTCTGCACCACGGAACTCATCTTCTTGAGATAGGCGAATGCCTATGGTC 1794  
                             +GAATAGATAAGT++GCACCACGGAA+TCAT+TT++TGAGATAGG+GAATGCCTATGGTC       
pMo/pmrBUPDN RV Seq      302 WGAATAGATAAGTYKGCACCACGGAAYTCATMTTYWTGAGATAGGYGAATGCCTATGGTC  243  
 
pMo/pmrBUPDN Expected   1795 GCTTTAAGGATGCCATAAACAATGAAACCGCCAGCCAGTGCAATAGCAATCGCGAGTGCT 1854  
                             GCT+TAAGGATGCCATAAACAATGAAACCGCCAGCCAGTGCAATAGCAATCGCGAGT CT       
pMo/pmrBUPDN RV Seq      242 GCTWTAAGGATGCCATAAACAATGAAACCGCCAGCCAGTGCAATAGCAATCGCGAGTACT  183  
 
pMo/pmrBUPDN Expected   1855 GTACCGATGAGCTGAGAGATGAATGATACGCCGCCTAAACCACCTAGCCATTTTTGACCA 1914  
                             GTACCGATGAG+TGAGAGATGAATGATACGCCGC+TAAACCACCTAGCCATTTTTGACCA       
pMo/pmrBUPDN RV Seq      182 GTACCGATGAGSTGAGAGATGAATGATACGCCGCSTAAACCACCTAGCCATTTTTGACCA  123  
 
pMo/pmrBUPDN Expected   1915 AAAATACCTACGGCAATTCCACCAAATGCACCGCATACACCATGTAGCGGCCAGACACCA 1974  
                             AAAATACCTACGGCAATTCCACCAAATGCACCGCATACACCATGTAGCGGCCAGACACCA       
pMo/pmrBUPDN RV Seq      122 AAAATACCTACGGCAATTCCACCAAATGCACCGCATACACCATGTAGCGGCCAGACACCA   63  
 
pMo/pmrBUPDN Expected   1975 AGAACGTCATCAACTTTGAGTTTGTTTTGAGTATAGGTGAATAGATACACGAACATAGCA 2034  
                             AGAACGTCATCAACTTTGAGTTTGTTT GAGTATAGG+ AATAGA    CGA C+TA C        
pMo/pmrBUPDN RV Seq       62 AGAACGTCATCAACTTTGAGTTTGTTT-GAGTATAGGK-AATAGAMCATCGATCWTACCT    5  
 
pMo/pmrBUPDN Expected   2035 CCCG 2038  
                              ++G       
pMo/pmrBUPDN RV Seq        4 ASSG    1  
 
pMo/pmrBUPDN Expected   2064 CTGCACCACCAATCACGCATGCCCC 2088  
                                                             
pMo/pmrBUPDN RV Seq          -------------------------       
A region of pMo130-TelR containing pmrAB UP and DOWN fragments was amplified and 
sequenced.  The result was aligned with the expected sequence. 
a) pMo/pmrBUPDN FW Sequenced was generated using primer pMo130-TelR FW, which is 
specific for pMo130-TelR.  
b) pMo/pmrBUPDNUPDN RV Sequenced was generated using primer DOWNRVpmrB, which is 
specific for the DOWN fragment. This sequence was reverse complemented before alignment. 
The first 1085 bp of the sequence corresponds to 174 bp of the vector and the entire UP 
fragment (a). The remainder of the sequence corresponds to the DOWN fragment (b). 
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Figure 3.29 Verification of pMo130-TelR/pmrABUPDOWN in S17-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCR 14, Table 2.7
Lane DNA Expected size Actual size  
1 pMo130-TelR/pmrABUPDOWN plasmid 
extraction from transformant 1 
--- --- 
2 pMo130-TelR/pmrABUPDOWN plasmid 
extraction from transformant 2 
--- --- 
3, 8 Hyperladder™ 1 (Bioline) --- --- 
4 pMo130-TelR/pmrABUPDOWN (positive 
control) 
2063 bp ~2063 bp 
5 pMo130-TelR /pmrABUPDOWN 
Transformant 1 
2063 bp No amplimer 
6 pMo130-TelR /pmrABUPDOWN 
Transformant 2 
2063 bp ~2063 bp 
7 --- No amplimer No amplimer 
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Figure 3.30 Verification of pmrAB gene Deletion in AYE by PCR. 
 
 
Lane  DNA  Expected size  Actual size  
1, 15  Hyperladder™ 1 (Bioline)  ---  ---  
2  AYE (wild-type) genomic DNA  3506 bp  ~3506 bp  
3 - 13  AYEΔpmrAB candidates 1-11  1890 bp  ~ 1890 bp 
(AYEΔpmrAB) 
~ 3506 bp (AYE wild-
type)  
14  ---  No amplimer  No amplimer  
PCR 20, Table 2.7
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Figure 3.31 Region Around pmrB in AYE and AYEΔpmrAB (Expected Sequences) and 
Primers to Delete and Complement pmrAB. 
 
Key for the following DNA sequences: 
 
pmrC 
 
pmrA 
 
pmrB 
-35: GTGACC 
-10: TATATG 
Shine dalgarno: ggga 
 
ABAYE0734: gene encoding a hypothetical protein (xBASE) 
 
 
UP primers 
 
UPFWpmrB (Contains NotI recognition site) 
GGGGCGGCCGCCTTATGCAATCGCACCGAGC   
UPRVpmrB (Contains BamHI recognition site) 
GGGGGATCCCAAACGGTAGCCCAGTCCTC     
 
 
DOWN primers 
 
DOWNFWpmrB (Contains BamHI recognition site) 
GGGGGATCCCCTGCACTTGCATGACCGCC   
DOWNRVpmrB(Contains SphI recognition site) 
GGGGCATGCGTGATTGGTGGTGCAGCGGG  
 
 
 
UPFWpmrB and DOWNRVpmrB were also used to amplify the UP-pmrAB-DOWN insert for 
the complementation construct (Table 2.6).  
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a) Expected Sequence for Wild-type AYE. 
tggctaaatatagcttctaagaacgatttttagctaaaaatagaaaaggcgaggttaaac 
ttatcctcgtcttttttattttttaaatttaaaaaataataatgaaataaggcctctaaa 
ttagatcattttttatttaagtcatttttaagtttcaatttctacattaaagcatcataa 
aaagattgtagtcactcacgATGCTGAATTTTTTTTCAACATTAAGAAATAAACAGATTT 
CTCTGTTTATGTTTAATCTCATTATAGCCATTTGGCTAGGTGCAATTTTAAATATTGGTT 
TTTATCATCAAGTCCATACTTTAACTCCATATTTTGGAGTAAAGGCTATTTTGTTTTTAG 
CTGCTACTCTCGTAATTCTTGTTGCTACCTATTATGCGGTTTTACAAATCTTAAATTGGA 
AATGGACTGCCAAAATCTTTGCAATTTTATTGATATTTATTGGTGGCTTTAGCTCTTATT 
TTGTAAACACATTGGGTGTCATTATTTCACCTGACCAAATTCAAAACATGGTCCAGACAG 
ATGTTTCAGAAGTTACCGATCTAATCTCTTTACGCTTTGTTTTATGGACAGTTTTTTTTG 
TTATTTTACCCATTTTTTTAATTACTCAAGTTAAATTTAAACAAGAAAAAGTATCACGGT 
TGTTATTGAAGAAAGTATTCTCACTGGTAGCTTCATTTGCAGTGGTCGGTGTTTTACTTT 
TTACCTACTATGTCGATTTCGCTGCAATATTTCGTGAACATCGTGATTTAAAAGGGATGA 
TTTCACCGCAAAATAGTATTTCATCGCTTATGTCTTACTATCATAAGAAGGCTCCGAAGA 
AAAATCTGCCTCTTGTGATATATGGACAAGATGCTCATCAAGTTCAGCGCGTACAAAAGA 
ACCTCCCTAAGTTAATGATACTTGTTGTAGGTGAAACGGCACGTGCCGAAAGTTTCTCTC 
TAAATGGGTATGCAAAAAATACGAATCCGGAGCTTTCTAAACAAGATATTTTCAACTTTT 
CGCAAGTGAGCTCATGCGGTACGGCGACAGCAGTTTCTGTGCCATGTATGTTCTCGGGTA 
TGCCACGTGTAGATTATGATGAGCAATTAGCCAGTCACCGCGAAGGTTTACTAGATATTG 
CAAAACGTGCGGGTTACCAAGTGACTTGGATTGATAATAACTCGGGTTGTAAAGGTGCAT 
GTGATCGTGTTGAACAATACCAGATTCCAGAAAACTTAAAGAAAAAATGGTGTAAAGATG 
GCGAATGTTATGATGACATTCTCATTGACAGCTTAAAGCAGTATTTGGCTACTATTGCCA 
AAGATGATGATCGCCCACGTTTGATTGTTTTGCATCAGGTGGGTAGTCACGGGCCTGCAT 
ATTACAAGCGTGCGCCTGAGGCATATCAACCCTTTAAACCGACTTGTGATACGAATGCGA 
TACAGGGCTGTTCGCAAACCGAATTGCTAAATAGTTATGATAATACAATCGTATATACAG 
ACCATGTATTAAGCCAAATGATTAATACTCTAAAAGAAATATCAAAATATCAGACAGGTT 
TATGGTATTTATCTGATCATGGCGAATCAACCGGAGAACATGGTTTATATTTACATGGTT 
CACCTTATGCAATCGCACCGAGCCAACAAACACATGTACCAATGATTATGTGGTTCTCTG 
AAAGTTGGAAACAACGTAATCTTGCTCAAGTGAATTGTTTAAGCCAACAAACTAAACAAA 
AGTTAAGTCAGGATAATTTATTCCCAAGTTTGTTAAGTTTGCTG 
gatgtaaaaactcaggtcatcaaccctcaactggacatgttgcactcttgtgcccatgta 
aactaaagcgagcctagaacATGACAAAAATCTTGATGATTGAAGATGATTTTATGATTG 
CAGAATCAACGATCACGTTGCTGCAATATCATCAGTTTGAGGTGGAATGGGTCAATAACG 
GTTTAGATGGTTTGGCTCAATTGGCGAAGACTAAATTTGATCTTATTCTTTTGGATTTAG 
GATTGCCTATGATGGATGGTATGCAAGTTTTGAAGCAGATCCGTCAAAGAGCAGCAACAC 
CAGTATTAATTATTTCTGCTCGAGATCAATTACAAAACCGTGTCGATGGTTTAAATTTGG 
GTGCAGATGATTATTTAATTAAACCTTATGAGTTTGATGAGTTGCTTGCCCGTATTCATG 
CATTACTACGCCGTAGTGGAGTAGAAGCTCAACTTGCGAGTCAAGATCAACTATTAGAAA 
GTGGCGATCTGGTTTTAAATGTTGAACAGCATATTGCGACGTTTAAAGGTCAACGCATTG 
ATCTATCAAATCGTGAATGGGCAATCTTAATTCCACTTATGACTCACCCAAATAAAATCT 
TTTCTAAAGCCAACTTAGAAGATAAGTTATATGATTTTGATAGTGATGTGACCAGTAATA 
CTATTGAAGTATATGTTCACCATTTAAGAGCGAAGCTGGGTAAAGATTTTATCCGAACCA 
TCCGAGGACTGGGCTACCGTTTGGGGCAATCATAAtttaaaatttcgggacttcataaaa 
GTGCATTATTCATTAAAAAAACGACTGATTTGGGGCACCTCAATTTTCAGTGTCATCTTA 
GGTTGTATTTTAATTTTTAGTGCTTACAAGGTTGCACTTCAAGAAGTCGATGAAATTCTA 
GATACTCAAATGAAGTATTTAGCGGAAAGAACAGCTGAGCACCCTTTAAAAACTGTAAGC 
AGTAAGTTCGATTTTCATAAAACTTACCACGAAGAAGATCTGTTTATCGATATTTGGGCT 
TATAAGGATCAGGCTCATTTGTCTCATCATTTACATTTGCTGGTTCCACCTGTTGAGCAA 
GCGGGATTTTATTCTCATAAAACCGCTCAAGGTATAGTCAGAACTTATGTTTTACCTTTG 
AAGGATTACCAGATTCAGGTCAGCCAGCAAGAGAGGGTTCGTGAAGCTTTCGCTTGGGAG 
CTTGCGGGCAGTATGTTTATTCCGTATTTAATTATTTTACCTTTTGCAATATTTGCTTTA 
GCAGCCATTATTCGTCGTGGTTTAAAACCAATAGATGATTTTAAAAATGAGTTAAAAGAA 
CGCGATTCCGAAGAACTCACCCCAATTGAAGTACATGATTATCCTCAAGAGCTTTTACCT 
ACTATTGACGAAATGAACCGTCTTTTTGAGCGAATTTCTAAAGCTCAAAATGAACAGAAG 
CAATTTATTGCCGATGCTGCTCATGAACTACGAACACCTGTGACTGCATTGAACTTACAA 
ACCAAGATTTTGCTAAGTCAGTTCCCTGAGCATGAATCATTGCAAAACTTAAGCAAAGGT 
TTGGCACGTATTCAGCATTTGGTGACTCAGCTTTTAGCATTGGCAAAGCAAGATGTAACT 
TTAAGTATGGTCGAGCCTACTGGATATTTTCAACTCAATGATGTGGCATTAAATTGTGTG 
GAGCAGTTGGTTAACTTGGCTATGCAAAAAGAAATCGATTTAGGTTTTGTTAGAAATGAA 
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CCCATCGAAATGCATAGTATTGAACCTACTGTACATTCGATTATTTTTAATTTAATTGAT 
AATGCAATTAAGTACACCCCGCATCAGGGTGTTATTAATATTTCAGTTTATACCGATCAA 
GATCACTACGCATGTATTCAAATTGAAGATAGCGGTGCAGGAATAGACCCTGAAAATTAC 
GATAAAGTCCTTAAGCGTTTTTATCGCGTGCATCACCATCTTGAGGTGGGAAGTGGTCTA 
GGTTTATCTATTGTAGATCGTGCAACTCAAAGGCTTGGTGGGACTTTAACTCTCGATAAG 
AGCTTAGAGCTTGGCGGTCTTTCTGTATTAGTGAAATTACCTAAAGTCTTACATTTACAT 
GAAACAAGAGCGTGAttacgtaagctcttgtttcacttgtttttcgaactcaaaacgatg 
aatacaaatcgcataaaataaaatatttattgcccaaacgacccagcctgtccataagtt 
atggcttaggaaatgtgctcctcgcatcatttgcgcccaacccatcatgaaacctaataa 
aataccggagaataaataaaagtaagcacgtttaggttgttcaagacgataaacaaaata 
acctgtcattaaaataaaacctgcacttgcatgaccgcctggaaaacaatggccatgttt 
agcgctaaagtcccaaatatagcttcctaaagtattagggtgaaccatattccaagggca 
ggcgtgagcagattgtgactttattaggccaactatactgctaccgagcatactgacaaa 
aaacatatagccatattgccagcgataaggttttaatttttttaatttaaatgacgcaag 
ccataaaccaaaaaagataacataaacggcggtgatgatttgttttacaatttcatgatt 
aagcctttcaagataccaattgtcccgattgaaaaaatgacctgttgaatcaatccaagg 
ttggatgaggtacatatcaattttcccaccgactggaaatacaaatagaagaataaaaaa 
actgaaaaaaagaaagagaatattaatttggaaaaaaagtttttgattagtcattctgat 
gcaatatcaatcgacaataggtgcgactaattacataaaattaatcttaaattgctctta 
aactatactggtgaaagaagttcaattttccttaaaaaataaaaaagcgacgaatagtat 
cgtcgccttaagcactttagaaagtattaaaacataccttcttcagagtttgctgagatc 
ttatgaatagataagtctgcaccacggaactcatcttcttgagataggcgaatgcctatg 
gtcgctttaaggatgccataaacaatgaaaccgccagccagtgcaatagcaatcgcgagt 
gctgtaccgatgagctgagagatgaatgatacgccgcctaaaccacctagccatttttga 
ccaaaaatacctacggcaattccaccaaatgcaccgcatacaccatgtagcggccagaca 
ccaagaacgtcatcaactttgagtttgttttgagtataggtgaatagatacacgaacata 
gcacccgctgcaccaccaatcacaagtgcactgactggatgaacaatgtcagaacctgcg 
caaatagcgactaaacccgcaagtggaccgttgtgtaagaaaccagggtcatttttccca 
atcgcatttgctgtaattgtaccgccaaccattgccataagtgagttaatcgcaacgaga 
ccagagattgcatcaacacgctgagcactcatcacattaaagccaaaccagcctacaatc 
aaaatccatgaaccaagcgccaaaaatggaatagaagaaggtgggtgagcacttacacga 
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b) Expected Sequence for AYEΔpmrAB. 
CTTATGCAATCGCACCGAGCCAACAAACACATGTACCAATGATTATGTGGTTCTCTG 
AAAGTTGGAAACAACGTAATCTTGCTCAAGTGAATTGTTTAAGCCAACAAACTAAACAAA 
AGTTAAGTCAGGATAATTTATTCCCAAGTTTGTTAAGTTTGCTG 
gatgtaaaaactcaggtcatcaaccctcaactggacatgttgcactcttgtgcccatgta 
aactaaagcgagcctagaacATGACAAAAATCTTGATGATTGAAGATGATTTTATGATTG 
CAGAATCAACGATCACGTTGCTGCAATATCATCAGTTTGAGGTGGAATGGGTCAATAACG 
GTTTAGATGGTTTGGCTCAATTGGCGAAGACTAAATTTGATCTTATTCTTTTGGATTTAG 
GATTGCCTATGATGGATGGTATGCAAGTTTTGAAGCAGATCCGTCAAAGAGCAGCAACAC 
CAGTATTAATTATTTCTGCTCGAGATCAATTACAAAACCGTGTCGATGGTTTAAATTTGG 
GTGCAGATGATTATTTAATTAAACCTTATGAGTTTGATGAGTTGCTTGCCCGTATTCATG 
CATTACTACGCCGTAGTGGAGTAGAAGCTCAACTTGCGAGTCAAGATCAACTATTAGAAA 
GTGGCGATCTGGTTTTAAATGTTGAACAGCATATTGCGACGTTTAAAGGTCAACGCATTG 
ATCTATCAAATCGTGAATGGGCAATCTTAATTCCACTTATGACTCACCCAAATAAAATCT 
TTTCTAAAGCCAACTTAGAAGATAAGTTATATGATTTTGATAGTGATGTGACCAGTAATA 
CTATTGAAGTATATGTTCACCATTTAAGAGCGAAGCTGGGTAAAGATTTTATCCGAACCA 
TCCGAGGACTGGGCTACCGTTTG GGATCC 
cctgcacttgcatgaccgcctggaaaacaatggccatgttt 
agcgctaaagtcccaaatatagcttcctaaagtattagggtgaaccatattccaagggca 
ggcgtgagcagattgtgactttattaggccaactatactgctaccgagcatactgacaaa 
aaacatatagccatattgccagcgataaggttttaatttttttaatttaaatgacgcaag 
ccataaaccaaaaaagataacataaacggcggtgatgatttgttttacaatttcatgatt 
aagcctttcaagataccaattgtcccgattgaaaaaatgacctgttgaatcaatccaagg 
ttggatgaggtacatatcaattttcccaccgactggaaatacaaatagaagaataaaaaa 
actgaaaaaaagaaagagaatattaatttggaaaaaaagtttttgattagtcattctgat 
gcaatatcaatcgacaataggtgcgactaattacataaaattaatcttaaattgctctta 
aactatactggtgaaagaagttcaattttccttaaaaaataaaaaagcgacgaatagtat 
cgtcgccttaagcactttagaaagtattaaaacataccttcttcagagtttgctgagatctt 
atgaatagataagtctgcaccacggaactcatcttcttgagataggcgaatgcctatggtcgc 
tttaaggatgccataaacaatgaaaccgccagccagtgcaatagcaatcgcgagtgctgtacc 
gatgagctgagagatgaatgatacgccgcctaaaccacctagccatttttgaccaaaaatacc 
tacggcaattccaccaaatgcaccgcatacaccatgtagcggccagacaccaagaacgtcatc 
aactttgagtttgttttgagtataggtgaatagatacacgaacatagcacccgctgcaccacc 
aatca 
 
It was expected that a BamHI site (GGATCC) would be introduced in AYEΔadeRS.
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Figure 3.32 Verification of pmrAB Deletion in AYE by DNA Sequencing. 
a) Forward sequencing 
pmrB candidate7 FW        1 --------------------------------ACCACAAMMATGTACCAATGATTATGTG   28  
                                                            A CA A ++ATGTACCAATGATTATGTG       
pmrB mutant expected      1 GGGGCGGCCGCCTTATGCAATCGCACCGAGCCAACAAACACATGTACCAATGATTATGTG   60  
 
pmrB candidate7 FW       29 GTTCTCTGAA-GTTGGAAACAACGTAATCTTGCTCAAGTGAATTGTTTAAGCCAACAAAC   87  
                            GTTCTCTGAA GTTGGAAACAACGTAATCTTGCTCAAGTGAATTGTTTAAGCCAACAAAC       
pmrB mutant expected     61 GTTCTCTGAAAGTTGGAAACAACGTAATCTTGCTCAAGTGAATTGTTTAAGCCAACAAAC  120  
 
pmrB candidate7 FW       88 TAAACAAAAGTTAAGTCAGGATAATTTATTCCCAAGTTTGTTAAGTTTGCTGGATGTAAA  147  
                            TAAACAAAAGTTAAGTCAGGATAATTTATTCCCAAGTTTGTTAAGTTTGCTGGATGTAAA       
pmrB mutant expected    121 TAAACAAAAGTTAAGTCAGGATAATTTATTCCCAAGTTTGTTAAGTTTGCTGGATGTAAA  180  
 
pmrB candidate7 FW      148 AACTCAGGTCATCAACCCTCAACTGGACATGTTGCACTCTTGTGCCCATGTAAACTAAAG  207  
                            AACTCAGGTCATCAACCCTCAACTGGACATGTTGCACTCTTGTGCCCATGTAAACTAAAG       
pmrB mutant expected    181 AACTCAGGTCATCAACCCTCAACTGGACATGTTGCACTCTTGTGCCCATGTAAACTAAAG  240  
 
pmrB candidate7 FW      208 CGAGCCTAGAACATGACAAAAATCTTGATGATTGAAGATGATTTTATGATTGCAGAATCA  267  
                            CGAGCCTAGAACATGACAAAAATCTTGATGATTGAAGATGATTTTATGATTGCAGAATCA       
pmrB mutant expected    241 CGAGCCTAGAACATGACAAAAATCTTGATGATTGAAGATGATTTTATGATTGCAGAATCA  300  
 
pmrB candidate7 FW      268 ACGATCACGTTGCTGCAATATCATCAGTTTGAGGTGGAATGGGTCAATAACGGTTTAGAT  327  
                            ACGATCACGTTGCTGCAATATCATCAGTTTGAGGTGGAATGGGTCAATAACGGTTTAGAT       
pmrB mutant expected    301 ACGATCACGTTGCTGCAATATCATCAGTTTGAGGTGGAATGGGTCAATAACGGTTTAGAT  360  
 
pmrB candidate7 FW      328 GGTTTGGCTCAATTGGCGAAGACTAAATTTGATCTTATTCTTTTGGATTTAGGATTGCCT  387  
                            GGTTTGGCTCAATTGGCGAAGACTAAATTTGATCTTATTCTTTTGGATTTAGGATTGCCT       
pmrB mutant expected    361 GGTTTGGCTCAATTGGCGAAGACTAAATTTGATCTTATTCTTTTGGATTTAGGATTGCCT  420  
 
pmrB candidate7 FW      388 ATGATGGATGGTATGCAAGTTTTGAAGCAGATCCGTCAAAGAGCAGCAACACCAGTATTA  447  
                            ATGATGGATGGTATGCAAGTTTTGAAGCAGATCCGTCAAAGAGCAGCAACACCAGTATTA       
pmrB mutant expected    421 ATGATGGATGGTATGCAAGTTTTGAAGCAGATCCGTCAAAGAGCAGCAACACCAGTATTA  480  
 
pmrB candidate7 FW      448 ATTATTTCTGCTCGAGATCAATTACAAAACCGTGTCGATGGTTTAAATTTGGGTGCAGAT  507  
                            ATTATTTCTGCTCGAGATCAATTACAAAACCGTGTCGATGGTTTAAATTTGGGTGCAGAT       
pmrB mutant expected    481 ATTATTTCTGCTCGAGATCAATTACAAAACCGTGTCGATGGTTTAAATTTGGGTGCAGAT  540  
 
pmrB candidate7 FW      508 GATTATTTAATTAAACCTTATGAGTTTGATGAGTTGCTTGCCCGTATTCATGCATTACTA  567  
                            GATTATTTAATTAAACCTTATGAGTTTGATGAGTTGCTTGCCCGTATTCATGCATTACTA       
pmrB mutant expected    541 GATTATTTAATTAAACCTTATGAGTTTGATGAGTTGCTTGCCCGTATTCATGCATTACTA  600  
 
pmrB candidate7 FW      568 CGCCGTAGTGGAGTAGAAGCTCAACTTGCGAGTCAAGATCAACTATTAGAAAGTGGCGAT  627  
                            CGCCGTAGTGGAGTAGAAGCTCAACTTGCGAGTCAAGATCAACTATTAGAAAGTGGCGAT       
pmrB mutant expected    601 CGCCGTAGTGGAGTAGAAGCTCAACTTGCGAGTCAAGATCAACTATTAGAAAGTGGCGAT  660  
 
pmrB candidate7 FW      628 CTGGTTTTAAATGTTGAACAGCATATTGCGACGTTTAAAGGTCAACGCATTGATCTATCA  687  
                            CTGGTTTTAAATGTTGAACAGCATATTGCGACGTTTAAAGGTCAACGCATTGATCTATCA       
pmrB mutant expected    661 CTGGTTTTAAATGTTGAACAGCATATTGCGACGTTTAAAGGTCAACGCATTGATCTATCA  720  
 
pmrB candidate7 FW      688 AATCGTGAATGGGCAATCTTAATTCCACTTATGACTCACCCAAATAAAATCTTTTCTAAA  747  
                            AATCGTGAATGGGCAATCTTAATTCCACTTATGACTCACCCAAATAAAATCTTTTCTAAA       
pmrB mutant expected    721 AATCGTGAATGGGCAATCTTAATTCCACTTATGACTCACCCAAATAAAATCTTTTCTAAA  780  
 
pmrB candidate7 FW      748 GCCAACTTAGAAGATAAGTTATATGATTTTGATAGTGATGTGACCAGTAATACTATTGAA  807  
                            GCCAACTTAGAAGATAAGTTATATGATTTTGATAGTGATGTGACCAGTAATACTATTGAA       
pmrB mutant expected    781 GCCAACTTAGAAGATAAGTTATATGATTTTGATAGTGATGTGACCAGTAATACTATTGAA  840  
 
pmrB candidate7 FW      808 GTATATGTTCACCATTTAAGAGCGAAGCTGGGTAAAGATTTTATCCGAACCATCCGAGGA  867  
                            GTATATGTTCACCATTTAAGAGCGAAGCTGGGTAAAGATTTTATCCGAACCATCCGAGGA       
pmrB mutant expected    841 GTATATGTTCACCATTTAAGAGCGAAGCTGGGTAAAGATTTTATCCGAACCATCCGAGGA  900  
 
pmrB candidate7 FW      868 CTGGGCTACCGTTTGGGATCCCCTGCACTTGCATGACCGCCTGGAAAC--ATGGCCATGT  925  
                            CTGGGCTACCGTTTGGGATCCCCTGCACTTGCATGACCGCCTGGAAA   ATGGCCATGT       
pmrB mutant expected    901 CTGGGCTACCGTTTGGGATCCCCTGCACTTGCATGACCGCCTGGAAAACAATGGCCATGT  960  
 
pmrB candidate7 FW      926 TTAGCGCTAAAGTCCCAA-TATAGCTTCCTAA-GTAT--AGGTGAAC-ATATTCCA-GGG  979  
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                            TTAGCGCTAAAGTCCCAA TATAGCTTCCTAA GTAT   GGTGAAC ATATTCCA GGG       
pmrB mutant expected    961 TTAGCGCTAAAGTCCCAAATATAGCTTCCTAAAGTATTAGGGTGAACCATATTCCAAGGG 1020  
 
pmrB candidate7 FW      980 CAG-CGTGAGCAGAT-GTGACTTW--TAGCC--ACTATACTGCTACCGAGCATACTGACA 1033  
                            CAG CGTGAGCAGAT GTGACTT+  TAG C  ACTATACTGCTACCGAGCATACTGACA       
pmrB mutant expected   1021 CAGGCGTGAGCAGATTGTGACTTTATTAGGCCAACTATACTGCTACCGAGCATACTGACA 1080  
 
pmrB candidate7 FW     1034 AAAMW---AWAGC-ATATTGC-AGCGATAAGGTTTAA--TTTTTTAATTTAA-TGACGCA 1085  
                            AAA++   A+AGC ATATTGC AGCGATAAGGTTT A  TTTTTTAATTTAA TGACGCA       
pmrB mutant expected   1081 AAAAACATATAGCCATATTGCCAGCGATAAGGTTTTAATTTTTTTAATTTAAATGACGCA 1140  
 
pmrB candidate7 FW     1086 G--CAWAAC---AAAAAGAWAM--WAAACGGSGGKGATGATTG--TTTACA--TTCATGA 1134  
                               CA+AA    AAAAAGA+A+  +AAACGG+GG+GATGATT   TTTACA  TTCATGA       
pmrB mutant expected   1141 AGCCATAAACCAAAAAAGATAACATAAACGGCGGTGATGATTTGTTTTACAATTTCATGA 1200  
 
pmrB candidate7 FW     1135 TTAG--CTTTCARAW---CMATTGTCC-GAT--GAAAAATGAC-TGTKAWY---AYYCAG 1182  
                            TTA   CTTTCA+ +   C+ATTGTCC GAT   AAAAATGAC TGT+ +    A++CA        
pmrB mutant expected   1201 TTAAGCCTTTCAAGATACCAATTGTCCCGATTGAAAAAATGACCTGTTGAATCAATCCAA 1260  
 
pmrB candidate7 FW     1183 GKT--GAKRARGWMYW-AYWMATTTCCAC---GMSKGAWWCCATAGR------------- 1223  
                            G+T  GA++A+G++++ A+ +ATTT C C   G+++G ++  A A +                    
pmrB mutant expected   1261 GGTTGGATGAGGTACATATCAATTTTCCCACCGACTGGAAATACAAATAGAAGAATAAAA 1320  
 
 
 166 
 
b) Reverse sequencing 
pmrB candidate7 RV          ---------------------------------------------       
                                                                                
pmrB mutant expected    481 ATTATTTCTGCTCGAGATCAATTACAAAACCGTGTCGATGGTTTA  525  
 
pmrB candidate7 RV     1278 CACTCGAGCGCAGAKKCMTATTTATTTA----TCATTRGTTSTRTGTGCTGC-----CGA 1228  
                             A T G G GCAGA++  TATTTA TTA    T AT +GTT  +TG G TGC     CG        
pmrB mutant expected    526 AATTTGGGTGCAGATGATTATTTAATTAAACCTTATGAGTTTGATGAGTTGCTTGCCCGT  585  
 
pmrB candidate7 RV     1227 TTTCATGCATTAC-GCGTACGAGTGGAGTC--------ACTTG--ARTCAG--TCAACT- 1182  
                             TTCATGCATTAC  CG    AGTGGAGT         ACTTG  A+TCA   TCAACT        
pmrB mutant expected    586 ATTCATGCATTACTACGCCGTAGTGGAGTAGAAGCTCAACTTGCGAGTCAAGATCAACTA  645  
 
pmrB candidate7 RV     1181 ---KGRAATGGGCRTTCGTTAKTGACAGCWR----------TGCGASRTK---AAGTCAS 1138  
                               + +A TGG  +T  G T +T A  G ++          TGCGA++T+   A GTCA        
pmrB mutant expected    646 TTAGAAAGTGGCGATCTGGTTTTAAATGTTGAACAGCATATTGCGACGTTTAAAGGTCAA  705  
 
pmrB candidate7 RV     1137 CATGATCATCAATC------KGAATSGGCATCTATCACT------WTGACTCACCCGAAT 1090  
                            C    T ATC ATC      +GAAT+GGCA    T A T      +TGACTCACCC AAT       
pmrB mutant expected    706 CGCATTGATCTATCAAATCGTGAATGGGCAATCTTAATTCCACTTATGACTCACCCAAAT  765  
 
pmrB candidate7 RV     1089 CAAATCWTT-CTAAAGCYAACT-MGWAGMTAAGY-ATATGATT--GATAGTGATGTGACC 1035  
                             AAATC+TT CTAAAGC+AACT +G+AG+TAAG+ ATATGATT  GATAGTGATGTGACC       
pmrB mutant expected    766 AAAATCTTTTCTAAAGCCAACTTAGAAGATAAGTTATATGATTTTGATAGTGATGTGACC  825  
 
pmrB candidate7 RV     1034 AGTAATACTATS--AGTATATGT-CAYCATT-AAGAGCGAWGCTGGGTAAMGATTT-ATC  980  
                            AGTAATACTAT   AGTATATGT CA+CATT AAGAGCGA+GCTGGGTAA+GATTT ATC       
pmrB mutant expected    826 AGTAATACTATTGAAGTATATGTTCACCATTTAAGAGCGAAGCTGGGTAAAGATTTTATC  885  
 
pmrB candidate7 RV      979 CGATCCATCYSAGGACTGGGCTACCGTT-GGGATCCC-TGCACTTGCATGACCGCATGGA  922  
                            CGA CCATC++AGGACTGGGCTACCGTT GGGATCCC TGCACTTGCATGACCGC TGGA       
pmrB mutant expected    886 CGAACCATCCGAGGACTGGGCTACCGTTTGGGATCCCCTGCACTTGCATGACCGCCTGGA  945  
 
pmrB candidate7 RV      921 AAACAATGGCCATGTKW-GCGCTAAAGTCCCAAATATASCTTCCTAAAGTMTTAGGGTGA  863  
                            AAACAATGGCCATGT++ GCGCTAAAGTCCCAAATATA+CTTCCTAAAGT+TTAGGGTGA       
pmrB mutant expected    946 AAACAATGGCCATGTTTAGCGCTAAAGTCCCAAATATAGCTTCCTAAAGTATTAGGGTGA 1005  
 
pmrB candidate7 RV      862 ACCATATTCCAAGGGCAGGCGTGAGCAGATTGTGWCTTTAKTAGGCCAACTATACTGCTA  803  
                            ACCATATTCCAAGGGCAGGCGTGAGCAGATTGTG+CTTTA+TAGGCCAACTATACTGCTA       
pmrB mutant expected   1006 ACCATATTCCAAGGGCAGGCGTGAGCAGATTGTGACTTTATTAGGCCAACTATACTGCTA 1065  
 
pmrB candidate7 RV      802 CCGAGCATACTGACAAAAAACATATAKCCATATTGCCAKCGATAAGGTTTTAATTTTTTT  743  
                            CCGAGCATACTGACAAAAAACATATA+CCATATTGCCA+CGATAAGGTTTTAATTTTTTT       
pmrB mutant expected   1066 CCGAGCATACTGACAAAAAACATATAGCCATATTGCCAGCGATAAGGTTTTAATTTTTTT 1125  
 
pmrB candidate7 RV      742 AATTTAAATGACGCAAGCCATAAACCAAAAAAGATAACATAAACGGCGGTGATGATTTGT  683  
                            AATTTAAATGACGCAAGCCATAAACCAAAAAAGATAACATAAACGGCGGTGATGATTTGT       
pmrB mutant expected   1126 AATTTAAATGACGCAAGCCATAAACCAAAAAAGATAACATAAACGGCGGTGATGATTTGT 1185  
 
pmrB candidate7 RV      682 TTTACAATTTCATGATTAAGCCTYTCAAGATACCAATTSTCCCGATTGAAAAAATGMCCT  623  
                            TTTACAATTTCATGATTAAGCCT+TCAAGATACCAATT+TCCCGATTGAAAAAATG+CCT       
pmrB mutant expected   1186 TTTACAATTTCATGATTAAGCCTTTCAAGATACCAATTGTCCCGATTGAAAAAATGACCT 1245  
 
pmrB candidate7 RV      622 GTTGAATCAATCCAAGGTTGGATGAGGTACATATCAATTTTCCCACCGACTGGAAATACA  563  
                            GTTGAATCAATCCAAGGTTGGATGAGGTACATATCAATTTTCCCACCGACTGGAAATACA       
pmrB mutant expected   1246 GTTGAATCAATCCAAGGTTGGATGAGGTACATATCAATTTTCCCACCGACTGGAAATACA 1305  
 
pmrB candidate7 RV      562 AATAGAAGAATAAAAAAACTGAAAAAAAGAAAGAGAATATTAATTTGGAAAAAAAGTTTT  503  
                            AATAGAAGAATAAAAAAACTGAAAAAAAGAAAGAGAATATTAATTTGGAAAAAAAGTTTT       
pmrB mutant expected   1306 AATAGAAGAATAAAAAAACTGAAAAAAAGAAAGAGAATATTAATTTGGAAAAAAAGTTTT 1365  
 
pmrB candidate7 RV      502 YGATTAGTCATTCTGATSCAATATCAATCGACAATAGGTGCGACTAATTACATAAAATTA  443  
                            +GATTAGTCATTCTGAT+CAATATCAATCGACAATAGGTGCGACTAATTACATAAAATTA       
pmrB mutant expected   1366 TGATTAGTCATTCTGATGCAATATCAATCGACAATAGGTGCGACTAATTACATAAAATTA 1425  
 
pmrB candidate7 RV      442 ATCTTAAATTGCTCTTAAACTATACTGGTGAAAGAAGTTCAATTTTCCTTAAAAAATAAA  383  
                            ATCTTAAATTGCTCTTAAACTATACTGGTGAAAGAAGTTCAATTTTCCTTAAAAAATAAA       
pmrB mutant expected   1426 ATCTTAAATTGCTCTTAAACTATACTGGTGAAAGAAGTTCAATTTTCCTTAAAAAATAAA 1485  
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pmrB candidate7 RV      382 AAAGCGACGAATAGTATCGTCGCCTTAAGCACTTTAGAAAGTATTMAAACATACCTTCTT  323  
                            AAAGCGACGAATAGTATCGTCGCCTTAAGCACTTTAGAAAGTATT+AAACATACCTTCTT       
pmrB mutant expected   1486 AAAGCGACGAATAGTATCGTCGCCTTAAGCACTTTAGAAAGTATTAAAACATACCTTCTT 1545  
 
pmrB candidate7 RV      322 CAGAGTTTGCTGAGATCTTATGAATAGATAAGTCTGCACCACGGAACTCATCTTCTTGAG  263  
                            CAGAGTTTGCTGAGATCTTATGAATAGATAAGTCTGCACCACGGAACTCATCTTCTTGAG       
pmrB mutant expected   1546 CAGAGTTTGCTGAGATCTTATGAATAGATAAGTCTGCACCACGGAACTCATCTTCTTGAG 1605  
 
pmrB candidate7 RV      262 ATAGGCGAATGCCTATGGTCGCYTTAAGGATGCCATAAACAATGAAACCGCCAGCCAGTG  203  
                            ATAGGCGAATGCCTATGGTCGC+TTAAGGATGCCATAAACAATGAAACCGCCAGCCAGTG       
pmrB mutant expected   1606 ATAGGCGAATGCCTATGGTCGCTTTAAGGATGCCATAAACAATGAAACCGCCAGCCAGTG 1665  
 
pmrB candidate7 RV      202 CAATAGCAATCGCGAGTGCTGYACCGAYGAGCTGAGAGATGAATSATACGCCGCCTAAAC  143  
                            CAATAGCAATCGCGAGTGCTG+ACCGA+GAGCTGAGAGATGAAT+ATACGCCGCCTAAAC       
pmrB mutant expected   1666 CAATAGCAATCGCGAGTGCTGTACCGATGAGCTGAGAGATGAATGATACGCCGCCTAAAC 1725  
 
pmrB candidate7 RV      142 CACCTAGCCATTYTTGACCAAAAATACCTACGGCAATTCCACCAAATGCACCGCATACAC   83  
                            CACCTAGCCATT+TTGACCAAAAATACCTACGGCAATTCCACCAAATGCACCGCATACAC       
pmrB mutant expected   1726 CACCTAGCCATTTTTGACCAAAAATACCTACGGCAATTCCACCAAATGCACCGCATACAC 1785  
 
pmrB candidate7 RV       82 CATGTAGCGGCCAGACACCAAGAACGTCATCAACTTTGAGTTTGTTTTGWGTATAGGK-A   24  
                            CATGTAGCGGCCAGACACCAAGAACGTCATCAACTTTGAGTTTGTTTTG+GTATAGG+ A       
pmrB mutant expected   1786 CATGTAGCGGCCAGACACCAAGAACGTCATCAACTTTGAGTTTGTTTTGAGTATAGGTGA 1845  
 
pmrB candidate7 RV       23 ATAGATACACGAA-ACATMACCTG    1  
                            ATAGATACACGAA A A +ACC G       
pmrB mutant expected   1846 ATAGATACACGAACATAGCACCCG 1869  
 
pmrB candidate7 RV          -------------------------       
                                                            
pmrB mutant expected   1870 CTGCACCACCAATCACGCATGCCCC 1894  
 
The region of the AYEΔpmrAB genome flanking pmrB (UP and DOWN fragments) was amplified 
by a single PCR (1894 bp amplimer) and sequenced. The result was aligned with the expected 
sequence. 
a) pmrB candidate7 FW was generated using primer UPFWpmrB (Table 2.6); b) pmrB candidate7 
RV was generated using primer DOWNRVpmrB (Table 2.6). This sequence was reverse 
complemented before alignment. 
The first 915 bp of the sequence corresponds to the UP fragment and 922-1894 bp corresponds 
to the DOWN fragment. A BamHI site has been introduced at 916-921 bp in the mutant 
(highlighted). 
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which were designed to delete the whole of pmrB, also flanked part of pmrA and ABAYE0734 
(Figure 3.31). Candidate 7 was selected for phenotypic characterisation. 
3.3.2.2. Complementation of pmrAB Gene Deletion 
The fragment containing the deleted region (including pmrB and 12 bp of pmrA) and the UP and 
DOWN fragments used to delete pmrAB was amplified and verified by PCR (Figure 3.33; Section 
2.4). This amplimer and pMo130-TelR were digested and ligated (Figure 3.33). The ligation 
mixture was transformed into DH5α and 15 candidate transformants were obtained, and four of 
these were confirmed by PCR to harbour pMo130-TelR/UP-pmrAB-DOWN (Figure 3.34). The 
construct from candidate 3 was further verified by digestion and DNA sequencing. Digestion 
with NotI (Figure 3.35) confirmed that the construct contained an insert. DNA sequencing 
confirmed that the insert contained the UP and DOWN fragments and the region deleted in 
AYEΔpmrAB (Figure 3.36). 
The verified construct was transformed into S17-1 and four candidate transformants were 
obtained. Plasmid was extracted from each transformant and its identity was verified by PCR 
(Figure 3.37). 
Despite 12 attempts at conjugation and several modifications to the method, no 
AYEΔpmrAB/pMo130-TelR/UP-pmrAB-DOWN single recombinants were obtained and 
AYEΔpmrAB was not complemented. The strategies and method modifications used to attempt 
to introduce the complementation construct into AYEΔpmrAB were as described previously 
(Section 3.3.1.2). As for the conjugations carried out to complement AYEΔadeRS, colonies were 
usually not obtained until after 48 hr incubation. All colonies remained white after pyrocatchol   
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Figure 3.33 Digestion of pMo130-TelR and UP-pmrAB-DOWN. 
 
Lanes 4 and 6, PCR 20, Table 2.7; Lanes 3 and 5, Digestion 5, Table 2.8. 
 
Lane DNA Expected size Actual size 
1 pMo130-TelR undigested --- --- 
2 pMo130-TelR + NotI + sphI 9377bp ~ 9377bp 
3 UP-pmrAB-DOWN undigested 3504 bp ~3504bp 
4 UP-pmrAB-DOWN + NotI + 
sphI 
3495 bp ~ 3495 bp 
5 --- 
(Contamination control for UP-
pmrAB-DOWN amplification) 
 
No amplimer 
 
No amplimer 
6 Hyperladder™ 1 (Bioline) --- --- 
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Figure 3.34 Verification of pmrAB Complementation Construct by PCR. 
 
 
 
 
 
 
 
 
 
 
 
 
PCR 14, Table 2.7
Lane DNA Expected size Actual size 
1 Hyperladder™ 1 (Bioline) --- --- 
2 Plasmid from candidate transformant 3 3673 bp ~3673 bp 
3 Plasmid from candidate transformant 4 3673 bp ~3673 bp 
4 Plasmid from candidate transformant 6 3673 bp ~3673 bp 
5 Plasmid from candidate transformant 7 3673 bp ~3673 bp 
6 --- No amplimer No amplimer 
7 Hyperladder™ 1 (Bioline) --- --- 
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Figure 3.35 Verification of pmrAB Complementation Construct by Digestion. 
 
Digestion 2, Table 2.8 
Lane DNA Expected 
size 
Actual size 
1 Hyperladder™ 1 (Bioline) --- --- 
2 pMo130-TelR undigested --- --- 
3 pMo130-TelR + NotI 9392 bp ~ 9392 bp 
4 pMo130-TelR/UP-pmrAB-DOWN undigested --- --- 
5 pMo130-TelR/UP-pmrAB-DOWN + NotI 12, 854 bp ~ 12, 854 bp 
6 Hyperladder™ 1 (Bioline) --- --- 
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Figure 3.36 Verification of pmrAB Complementation Construct by DNA Sequencing. 
 A region of pMo130-TelR containing the UP-pmrAB-DOWN complementation fragment was amplified and sequenced (the whole 
amlimer is shown above in four independent sequencing reactions a-d). The result was aligned with the expected sequence. 
a) pMo/UPpmrBDN FWUP was generated using primer pMo130-TelR FW, which is specific for pMo130-TelR.  
b) pMo/UPpmrBDN FWpmrB was generated using primer pmrBgeneFW, which binds inside pmrB.  
c) pMo/UPpmrBDN RVpmrB was generated using primer pmrBgeneRV, which binds inside pmrB. This sequence was reverse 
complemented before alignment. 
d) pMo/UPpmrBDN RVDOWN was generated using primer DOWNRVpmrB, which is specific for the DOWN fragment. This sequence 
was reverse complemented before alignment. 
The first 1084 bp of the sequence corresponds to 174 bp of the vector and the entire UP fragment; 1122-2456 bp corresponds to 
pmrB ; 2701-3673 bp corresponds to the DOWN fragment. The sequences of the above figure (a-d) are shown below.
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a) Forward sequencing of pmrAB complementation construct (1). 
pMo/UPpmrBDN Expected      1 CCATCTACTTCTTCGACCCGTCCGGTAACCGCAACGAAGTGTTCTGCGGGGGAGATTACA   60  
                                                        A  G ++C+A GTGTTCTGCGGGGGAGATTACA       
pMo/UPpmrBDN FWUP          1 --------------------------TATGGAWWCSA-GTGTTCTGCGGGGGAGATTACA   33  
 
pMo/UPpmrBDN Expected     61 ACTACCCGGACCACAAACCGGTGACCTGGACCACCGACCAGCTGGGCAAGGCGATCTTTT  120  
                             ACTACCCGGACCACAAACCGGTGACCTGGACCACCGACCAGCTGG+CAAGGCGATCTTTT       
pMo/UPpmrBDN FWUP         34 ACTACCCGGACCACAAACCGGTGACCTGGACCACCGACCAGCTGGSCAAGGCGATCTTTT   93  
 
pMo/UPpmrBDN Expected    121 ACCACGACCGCATTCTCAACGAACGATTCATGACCGTGCTGACCTGACCTGAGCGGCCGC  180  
                             ACCACGACCGCATTCTCAACGAACGATTCATGACCGTGCTGACCTG     AGCGGCCGC       
pMo/UPpmrBDN FWUP         94 ACCACGACCGCATTCTCAACGAACGATTCATGACCGTGCTGACCTG-----AGCGGCCGC  148  
 
pMo/UPpmrBDN Expected    181 CTTATGCAATCGCACCGAGCCAACAAACACATGTACCAATGATTATGTGGTTCTCTGAAA  240  
                             CTTATGCAATCGCACCGAGCCAACAAACACATGTACCAATGATTATGTGGTTCTCTGAAA       
pMo/UPpmrBDN FWUP        149 CTTATGCAATCGCACCGAGCCAACAAACACATGTACCAATGATTATGTGGTTCTCTGAAA  208  
 
pMo/UPpmrBDN Expected    241 GTTGGAAACAACGTAATCTTGCTCAAGTGAATTGTTTAAGCCAACAAACTAAACAAAAGT  300  
                             GTTGGAAACAACGTAATCTTGCTCAAGTGAATTGTTTAAGCCAACAAACTAAACAAAAGT       
pMo/UPpmrBDN FWUP        209 GTTGGAAACAACGTAATCTTGCTCAAGTGAATTGTTTAAGCCAACAAACTAAACAAAAGT  268  
 
pMo/UPpmrBDN Expected    301 TAAGTCAGGATAATTTATTCCCAAGTTTGTTAAGTTTGCTGGATGTAAAAACTCAGGTCA  360  
                             TAAGTCAGGATAATTTATTCCCAAGTTTGTTAAGTTTGCTGGATGTAAAAACTCAGGTCA       
pMo/UPpmrBDN FWUP        269 TAAGTCAGGATAATTTATTCCCAAGTTTGTTAAGTTTGCTGGATGTAAAAACTCAGGTCA  328  
 
pMo/UPpmrBDN Expected    361 TCAACCCTCAACTGGACATGTTGCACTCTTGTGCCCATGTAAACTAAAGCGAGCCTAGAA  420  
                             TCAACCCTCAACTGGACATGTTGCACTCTTGTGCCCATGTAAACTAAAGCGAGCCTAGAA       
pMo/UPpmrBDN FWUP        329 TCAACCCTCAACTGGACATGTTGCACTCTTGTGCCCATGTAAACTAAAGCGAGCCTAGAA  388  
 
pMo/UPpmrBDN Expected    421 CATGACAAAAATCTTGATGATTGAAGATGATTTTATGATTGCAGAATCAACGATCACGTT  480  
                             CATGACAAAAATCTTGATGATTGAAGATGATTTTATGATTGCAGAATCAACGATCACGTT       
pMo/UPpmrBDN FWUP        389 CATGACAAAAATCTTGATGATTGAAGATGATTTTATGATTGCAGAATCAACGATCACGTT  448  
 
pMo/UPpmrBDN Expected    481 GCTGCAATATCATCAGTTTGAGGTGGAATGGGTCAATAACGGTTTAGATGGTTTGGCTCA  540  
                             GCTGCAATATCATCAGTTTGAGGTGGAATGGGTCAATAACGGTTTAGATGGTTTGGCTCA       
pMo/UPpmrBDN FWUP        449 GCTGCAATATCATCAGTTTGAGGTGGAATGGGTCAATAACGGTTTAGATGGTTTGGCTCA  508  
 
pMo/UPpmrBDN Expected    541 ATTGGCGAAGACTAAATTTGATCTTATTCTTTTGGATTTAGGATTGCCTATGATGGATGG  600  
                             ATTGGCGAAGACTAAATTTGATCTTATTCTTTTGGATTTAGGATTGCCTATGATGGATGG       
pMo/UPpmrBDN FWUP        509 ATTGGCGAAGACTAAATTTGATCTTATTCTTTTGGATTTAGGATTGCCTATGATGGATGG  568  
 
pMo/UPpmrBDN Expected    601 TATGCAAGTTTTGAAGCAGATCCGTCAAAGAGCAGCAACACCAGTATTAATTATTTCTGC  660  
                             TATGCAAGTTTTGAAGCAGATCCGTCAAAGAGCAGCAACACCAGTATTAATTATTTCTGC       
pMo/UPpmrBDN FWUP        569 TATGCAAGTTTTGAAGCAGATCCGTCAAAGAGCAGCAACACCAGTATTAATTATTTCTGC  628  
 
pMo/UPpmrBDN Expected    661 TCGAGATCAATTACAAAACCGTGTCGATGGTTTAAATTTGGGTGCAGATGATTATTTAAT  720  
                             TCGAGATCAATTACAAAACCGTGTCGATGGTTTAAATTTGGGTGCAGATGATTATTTAAT       
pMo/UPpmrBDN FWUP        629 TCGAGATCAATTACAAAACCGTGTCGATGGTTTAAATTTGGGTGCAGATGATTATTTAAT  688  
 
pMo/UPpmrBDN Expected    721 TAAACCTTATGAGTTTGATGAGTTGCTTGCCCGTATTCATGCATTACTACGCCGTAGTGG  780  
                             TAAACCTTATGAGTTTGATGAGTTGCTTGCCCGTATTCATGCATTACTACGCCGTAGTGG       
pMo/UPpmrBDN FWUP        689 TAAACCTTATGAGTTTGATGAGTTGCTTGCCCGTATTCATGCATTACTACGCCGTAGTGG  748  
 
pMo/UPpmrBDN Expected    781 AGTAGAAGCTCAACTTGCGAGTCAAGATCAACTATTAGAAAGTGGCGATCTGGTTTTAAA  840  
                             AGTAGAAGCTCAACTTGCGAGTCAAGATCAACTATTAGAAAGTGGCGATCTGGTTT AAA       
pMo/UPpmrBDN FWUP        749 AGTAGAAGCTCAACTTGCGAGTCAAGATCAACTATTAGAAAGTGGCGATCTGGTTT-AAA  807  
 
pMo/UPpmrBDN Expected    841 TGTTGAACAGCATATTGCGACGTTTAAAGGTCAACGCATTGATCTATCAAATCGTGAATG  900  
                             TGTTGAACA+CATATTGC+AC+TTTAA+GG CAACGCATTGATCTATCAA TCGTGAA+G       
pMo/UPpmrBDN FWUP        808 TGTTGAACARCATATTGCSACKTTTAARGG-CAACGCATTGATCTATCAA-TCGTGAAWG  865  
 
pMo/UPpmrBDN Expected    901 GGCAATCTTAATTCCACTTATGACTCACCCAAATAAAATCTTTTCTAAAGCCAACTTAGA  960  
                             GGCAA C TAATT+CACTTATGACTC+CCC+AATAAA TCTTTTC AAAGCCA CTTA A       
pMo/UPpmrBDN FWUP        866 GGCAA-CCTAATTYCACTTATGACTCMCCCWAATAAA-TCTTTTC-AAAGCCA-CTTAAA  921  
 
pMo/UPpmrBDN Expected    961 AGATAAGTTATATGATTTTGATAGTGATGTGACCAGTAATACTATTGAAGTATATGTTCA 1020  
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                             A   AA ++A A GAT+TTGA +G    GTGA+ A  AA    ATTG A +ATAT TT         
pMo/UPpmrBDN FWUP        922 A---AAAWKAAAAGATYTTGAARG----GTGASGACAAAATACATTGGAAKATATTTT--  972  
 
pMo/UPpmrBDN Expected   1021 CCATTTAAGAGCGAAGCTGGGTAAAGATTTTATCCGAACCATCCGAGGACTGGGCTACCG 1080  
                                                                                                
pMo/UPpmrBDN FWUP            ------------------------------------------------------------   
 
 
b) Forward sequencing of pmrAB complementation construct (2). 
pMo/UPpmrBDN Expected   1501 TCAGCCAGCAAGAGAGGGTTCGTGAAGCTTTCGCTTGGGAGCTTGCGGGCAGTATGTTTA 1560  
                                                                                  + + +T+       
pMo/UPpmrBDN FWpmrB        1 ---------------------------------------------------CSRRRAYTW    9  
 
pMo/UPpmrBDN Expected   1561 TTCCGTATTTAATTATTTTACCTTTTGCAATATTTGCTTTAGCAGCCATTATTCGTCGTG 1620  
                               CCG+ATT+A TTATTTTACCTTTTG+A TATTTGCTTTAGCAGCCATTATTCGTCGTG       
pMo/UPpmrBDN FWpmrB       10 AACCGWATTWA-TTATTTTACCTTTTGMA-TATTTGCTTTAGCAGCCATTATTCGTCGTG   67  
 
pMo/UPpmrBDN Expected   1621 GTTTAAAACCAATAGATGATTTTAAAAATGAGTTAAAAGAACGCGATTCCGAAGAACTCA 1680  
                             GTTTA AAC AAT++A+GATTTTAAA+ATGAGTTAAAAGAACGCGATTCC AAGAACTCA       
pMo/UPpmrBDN FWpmrB       68 GTTTAGAAC-AATWKAWGATTTTAAAWATGAGTTAAAAGAACGCGATTCCCAAGAACTCA  126  
 
pMo/UPpmrBDN Expected   1681 CCCCAATTGAAGTACATGATTATCCTCAAGAGCTTTTACCTACTATTGACGAAATGAACC 1740  
                             C+CCAA+TGAAGTACATGATTATCC+C+A+AGCTTTTA                             
pMo/UPpmrBDN FWpmrB      127 CMCCAAWTGAAGTACATGATTATCCYCMAKAGCTTTTA----------------------  164  
 
 
 
c) Reverse sequencing of pmrAB complementation construct (1). 
pMo/UPpmrBDN Expected   1501 TCAGCCAGCAAGAGAGGGTTCGTGAAGCTTTCGCTTGGGAGCTTG 1545  
                                                                                 
pMo/UPpmrBDN RVpmrB          ---------------------------------------------       
 
pMo/UPpmrBDN Expected   1546 CGGGCAGTATGTTTATTCCGTATTTAATTATTTTACCTTTTGCAATATTTGCTTTAGCAG 1605  
                             CGGGCAGTATGTTTATTCCGTATTTAATTAT++TACCTTTTGCAATATTTGCTTTAGCAG       
pMo/UPpmrBDN RVpmrB      683 CGGGCAGTATGTTTATTCCGTATTTAATTATWKTACCTTTTGCAATATTTGCTTTAGCAG  624  
 
pMo/UPpmrBDN Expected   1606 CCATTATTCGTCGTGGTTTAAAACCAATAGATGATTTTAAAAATGAGTTAAAAGAACGCG 1665  
                             CCATTATT+GTCGTGGTTTA AACCAATAGATGATTTTAAAAATGAGTTAAAAGAACGCG       
pMo/UPpmrBDN RVpmrB      623 CCATTATTYGTCGTGGTTTAGAACCAATAGATGATTTTAAAAATGAGTTAAAAGAACGCG  564  
 
pMo/UPpmrBDN Expected   1666 ATTCCGAAGAACTCACCCCAATTGAAGTACATGATTATCCTCAAGAGCTTTTACCTACTA 1725  
                             ATTCCGAAGAACTCACCCCAATTGAAGTACATGATTATCCTCAAGAGCTTTTACCTACTA       
pMo/UPpmrBDN RVpmrB      563 ATTCCGAAGAACTCACCCCAATTGAAGTACATGATTATCCTCAAGAGCTTTTACCTACTA  504  
 
pMo/UPpmrBDN Expected   1726 TTGACGAAATGAACCGTCTTTTTGAGCGAATTTCTAAAGCTCAAAATGAACAGAAGCAAT 1785  
                             TTGACGAAATGAACCGTCTTTTTGAGCGAATTTCTAAAGCTCAAAATGAACAGAAGCAAT       
pMo/UPpmrBDN RVpmrB      503 TTGACGAAATGAACCGTCTTTTTGAGCGAATTTCTAAAGCTCAAAATGAACAGAAGCAAT  444  
 
pMo/UPpmrBDN Expected   1786 TTATTGCCGATGCTGCTCATGAACTACGAACACCTGTGACTGCATTGAACTTACAAACCA 1845  
                             TTATTGCCGATGCTGCTCATGAACTACGAACACCTGTGACTGCATTGAACTTACAAACCA       
pMo/UPpmrBDN RVpmrB      443 TTATTGCCGATGCTGCTCATGAACTACGAACACCTGTGACTGCATTGAACTTACAAACCA  384  
 
pMo/UPpmrBDN Expected   1846 AGATTTTGCTAAGTCAGTTCCCTGAGCATGAATCATTGCAAAACTTAAGCAAAGGTTTGG 1905  
                             AGATTTTGCTAAGTCAGTTCCCTGAGCATGAATCATTGCAAAACTTAAGCAAAGGTTTGG       
pMo/UPpmrBDN RVpmrB      383 AGATTTTGCTAAGTCAGTTCCCTGAGCATGAATCATTGCAAAACTTAAGCAAAGGTTTGG  324  
 
pMo/UPpmrBDN Expected   1906 CACGTATTCAGCATTTGGTGACTCAGCTTTTAGCATTGGCAAAGCAAGATGTAACTTTAA 1965  
                             CACGTATTCAGCATTTGGTGACTCAGCTTTTAGCATTGGCAAAGCAAGATGTAACTTTAA       
pMo/UPpmrBDN RVpmrB      323 CACGTATTCAGCATTTGGTGACTCAGCTTTTAGCATTGGCAAAGCAAGATGTAACTTTAA  264  
 
pMo/UPpmrBDN Expected   1966 GTATGGTCGAGCCTACTGGATATTTTCAACTCAATGATGTGGCATTAAATTGTGTGGAGC 2025  
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                             GTATGGTCGAGCCTACTGGATATTTTCAACTCAATGATGTGGCATTAAATTGTGTGGAGC       
pMo/UPpmrBDN RVpmrB      263 GTATGGTCGAGCCTACTGGATATTTTCAACTCAATGATGTGGCATTAAATTGTGTGGAGC  204  
 
pMo/UPpmrBDN Expected   2026 AGTTGGTTAACTTGGCTATGCAAAAAGAAATCGATTTAGGTTTTGTTAGAAATGAACCCA 2085  
                             AGTTGGTTAACTTGGCTATGCAAAAAGAAATCGATTTAGGTTTTGTTAGAAATGAACCCA       
pMo/UPpmrBDN RVpmrB      203 AGTTGGTTAACTTGGCTATGCAAAAAGAAATCGATTTAGGTTTTGTTAGAAATGAACCCA  144  
 
pMo/UPpmrBDN Expected   2086 TCGAAATGCATAGTATTGAACCTACTGTACATTCGATTATTTTTAATTTAATTGATAATG 2145  
                             TCGAAATGCATAGTATTGAACCTACTGTACATTCGATTATTTTTAATTTAATTGATAATG       
pMo/UPpmrBDN RVpmrB      143 TCGAAATGCATAGTATTGAACCTACTGTACATTCGATTATTTTTAATTTAATTGATAATG   84  
 
pMo/UPpmrBDN Expected   2146 CAATTAAGTACACCCCGCATCAGGGTGTTATTAATATTTCAGTTTATACCGATCAAGATC 2205  
                             CAATTAAGTACACCCCGCATCAGGGTGTTATTAATATTTCAGTTTATACCGATCAAGATC       
pMo/UPpmrBDN RVpmrB       83 CAATTAAGTACACCCCGCATCAGGGTGTTATTAATATTTCAGTTTATACCGATCAAGATC   24  
 
pMo/UPpmrBDN Expected   2206 ACTACGCATGTATTCAAATTGAAG 2229  
                             ACTACGCA G +T +AA +++++G       
pMo/UPpmrBDN RVpmrB       23 ACTACGCA-GAWTCMAAKKWRRWG    1  
 
 
 
d) Reverse sequencing of pmrAB complementation construct (2). 
pMo/UPpmrBDN Expected   3001 TTGT 3004  
                                        
pMo/UPpmrBDN RVDOWN          ----       
 
pMo/UPpmrBDN Expected   3005 CCCGATTGAAAAAA-TGACCTGTTGAATCAATCCAAGGTTGGATGAGGTACATATCAATT 3063  
                              +CGATT+AAAAAA TG+CCTGTTGAATCAATCCAAGGT+GGATGAGGTACATATCAATT       
pMo/UPpmrBDN RVDOWN      640 AYCGATTRAAAAAAATGRCCTGTTGAATCAATCCAAGGTWGGATGAGGTACATATCAATT  581  
 
pMo/UPpmrBDN Expected   3064 TTCCCACCGACTGGAAATACAAATAGAAGAATAAAAAAACTGAAAAAAAGAAAGAGAATA 3123  
                             TTCCCACCG CTGGAAATACAAATAGAAGAATAAAAAA CTGAAAAAAAGAAAGAGAATA       
pMo/UPpmrBDN RVDOWN      580 TTCCCACCGTCTGGAAATACAAATAGAAGAATAAAAAA-CTGAAAAAAAGAAAGAGAATA  522  
 
pMo/UPpmrBDN Expected   3124 TTAATTTGGAAAAAAAGTTTTTGATTAGTCATTCTGATGCAATATCAATCGACAATAGGT 3183  
                             TTAATTTGGAAAAAAAGTTTTTGATTAGTCATTCTGATGCAATATCAATCGACAATAGGT       
pMo/UPpmrBDN RVDOWN      521 TTAATTTGGAAAAAAAGTTTTTGATTAGTCATTCTGATGCAATATCAATCGACAATAGGT  462  
 
pMo/UPpmrBDN Expected   3184 GCGACTAATTACATAAAATTAATCTTAAATTGCTCTTAAACTATACTGGTGAAAGAAGTT 3243  
                             GCGACTAATTACATAAAATTAATCTTAAATTGCTCTTAAACTATACTGGTGAAAGAAGTT       
pMo/UPpmrBDN RVDOWN      461 GCGACTAATTACATAAAATTAATCTTAAATTGCTCTTAAACTATACTGGTGAAAGAAGTT  402  
 
pMo/UPpmrBDN Expected   3244 CAATTTTCCTTAAAAAATAAAAAAGCGACGAATAGTATCGTCGCCTTAAGCACTTTAGAA 3303  
                             CAATTTTCCTTAAAAAATAAAAAAGCGACGAATAGTATCGTCGCCTTAAGCACTTTAGAA       
pMo/UPpmrBDN RVDOWN      401 CAATTTTCCTTAAAAAATAAAAAAGCGACGAATAGTATCGTCGCCTTAAGCACTTTAGAA  342  
 
pMo/UPpmrBDN Expected   3304 AGTATTAAAACATACCTTCTTCAGAGTTTGCTGAGATCTTATGAATAGATAAGTCTGCAC 3363  
                             AGTATTAAAACATACCTTCTTCAGAGTTTGCTGAGATCTTATGAATAGATAAGTCTGCAC       
pMo/UPpmrBDN RVDOWN      341 AGTATTAAAACATACCTTCTTCAGAGTTTGCTGAGATCTTATGAATAGATAAGTCTGCAC  282  
 
pMo/UPpmrBDN Expected   3364 CACGGAACTCATCTTCTTGAGATAGGCGAATGCCTATGGTCGCTTTAAGGATGCCATAAA 3423  
                             CACGGAACTCATCTTCTTGAGATAGGCGAATGCCTATGGTCGCTTTAAGGATGCCATAAA       
pMo/UPpmrBDN RVDOWN      281 CACGGAACTCATCTTCTTGAGATAGGCGAATGCCTATGGTCGCTTTAAGGATGCCATAAA  222  
 
pMo/UPpmrBDN Expected   3424 CAATGAAACCGCCAGCCAGTGCAATAGCAATCGCGAGTGCTGTACCGATGAGCTGAGAGA 3483  
                             CAATGAAACCGCCAGCCAGTGCAATAGCAATCGCGAGTGCTGTACCGATGAGCTGAGAGA       
pMo/UPpmrBDN RVDOWN      221 CAATGAAACCGCCAGCCAGTGCAATAGCAATCGCGAGTGCTGTACCGATGAGCTGAGAGA  162  
 
pMo/UPpmrBDN Expected   3484 TGAATGATACGCCGCCTAAACCACCTAGCCATTTTTGACCAAAAATACCTACGGCAATTC 3543  
                             TGAATGATACGCCGCCTAAACCACCTAGCCATTTTTGACCAAAAATACCTACGGCAATTC       
pMo/UPpmrBDN RVDOWN      161 TGAATGATACGCCGCCTAAACCACCTAGCCATTTTTGACCAAAAATACCTACGGCAATTC  102  
 
pMo/UPpmrBDN Expected   3544 CACCAAATGCACCGCATACACCATGTAGCGGCCAGACACCAAGAACGTCATCAACTTTGA 3603  
                             CACCAAATGCACCGCATACACCATGTAGCGGCCAGACACCAAGAACGTCATCAACTTTGA       
pMo/UPpmrBDN RVDOWN      101 CACCAAATGCACCGCATACACCATGTAGCGGCCAGACACCAAGAACGTCATCAACTTTGA   42  
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pMo/UPpmrBDN Expected   3604 GTTTGTTTTGAGTATAGGTGAATAGATACACGAACATAGCACC 3646  
                             GTTTGTTTTGAGTATAGG+ AATAGA ACACGA CA+A  AC        
pMo/UPpmrBDN RVDOWN       41 GTTTGTTTTGAGTATAGGK-AATAGA-ACACGATCAWAARACT    1  
 
pMo/UPpmrBDN Expected   3648 CGCTGCACCACCAATCACGCATGCCCC 3674  
                                                               
pMo/UPpmrBDN RVDOWN          ---------------------------       
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Figure 3.37 Verification of pmrAB Complementation Construct in S17-1. 
PCR 14, Table 2.7 
Lane DNA Expected size Actual size 
1 Hyperladder™ 1 (Bioline) --- --- 
2 Plasmid from candidate transformant 1 3673 bp ~3673 bp 
3 Plasmid from candidate transformant 2 3673 bp ~3673 bp 
4 Plasmid from candidate transformant 3 3673 bp ~3673 bp 
5 Plasmid from candidate transformant 4 3673 bp ~3673 bp 
6 pMo130-TelR/UP-pmrAB-DOWN 
(positive control) 
3673 bp ~3673 bp 
7 --- No amplimer No amplimer 
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exposure. 
3.4. bfmRS 
3.4.1. Deletion of bfmRS 
3.4.1.1. Identification of bfmS in AYE 
bfmS was unannotated in AYE, but a search of bfmS in the whole of xBASE retrieved the bfmS 
gene sequence in A. baumannii ATCC 17978 (A1S_0749), which was used to identify bfmS in AYE 
(Figure 3.38). This gene sequence was BLASTED against the AYE genome and one result was 
obtained, suggesting that there is only one copy of this gene in AYE. An alignment of bfmS in 
ATCC 17978 and that identified in AYE confirmed the identity of the gene in AYE (Figure 3.38; 
Figure 3.39). 
3.4.1.2. Construction of pMo130-TelR/bfmRSUPDOWN 
The UP and DOWN fragments for bfmRS were amplified and the purified amplimers were 
verified by electrophoresis (Figure 3.40). 
3.4.1.2.1. Cloning of the UP Fragment into pMo130-TelR and Verification of Construct 
pMo130-TelR and the bfmRSUP fragment were digested with NotI and BamHI (Table 2.8, 
digestion 3). They were ligated and transformed into DH5α. Three candidate transformants  
were obtained, two of which were confirmed to harbour the correct construct (pMo130-
TelR/bfmRSUP) (Figure 3.41). 
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Figure 3.38 Alignment of bfmS in A. baumannii ATCC 17978 and AYE 
  
 
 
 
A 
 
1S_0749 and ABAYE3063, bfmS  
 
 
Figure 3.39 Alignment of bfmS in A. baumannii ATCC 17978 and AYE. 
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Figure 3.40 Amplification of bfmRS UP and DOWN fragments. 
aPCR number, Table 2.7 
 
Lane PCRa DNA Expected size Actual size  
1, 6 --- Hyperladder™ 1 (Bioline) --- --- 
2 7 Purified bfmRS UP 
fragment 
966 bp ~ 966 bp 
3 9 Purified bfmRS DOWN 
fragment 
1206 bp ~1206 
4 7 Contamination control for 
bfmRS UP fragment 
No amplimer No 
amplimer 
5 9 Contamination control for 
bfmRS DOWN fragment 
No amplimer No 
amplimer 
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Figure 3.41 Verification of pMo130-TelR/bfmRSUP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCR 12, Table 2.
Lane  DNA  Expected size  Actual size  
1  Undigested pMo130-TelR/UPbfmRS 
extracted from candidate 2 (no 
PCR)  
--- --- 
2  Undigested pMo130-TelR/UPbfmRS 
extracted from candidate 3 (no 
PCR)  
---- ---- 
3, 8  Hyperladder™ 1 (Bioline)  --- --- 
4  pMo130-TelR/UPbfmRS from 
candidate 2  
1136 bp  ~1136 bp  
5  pMo130-TelR/UPbfmRS from 
candidate 3  
1136 bp  ~1136 bp  
6  pMo130-TelR unmanipulated 
(negative control) 
No amplimer  ~0.7 bp and ~ 
0.2 bp  
7  ___ No amplimer  No amplimer  
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3.4.1.2.2. Cloning of the DOWN Fragment into pMo130-TelR/bfmRSUP and Verification of 
Construct 
Approximately 100 candidate transformants were obtained when pMo130-TelR/bfmRSUP was 
ligated with the DOWN fragment and transformed into DH5α. Twenty of these were screened 
by PCR (using lysate as the template; Figure 3.42) and eight yielded the correct sized amplimer. 
Plasmid was extracted from candidate 5 (Figure 3.42) and sequencing (Figure 3.43) of the 
plasmid multiple cloning site confirmed that the correct construct had been obtained. 
3.4.1.3. Introduction of pMo130-TelR/bfmRSUPDOWN into AYE 
The construct was transformed into E. coli S17-1 and four candidate S17-1/pMo130-TelR/bfmRS 
transformants were confirmed by PCR to harbour the plasmid. One transformant (transformant 
1) was carried forward to introduce the construct into AYE (Figure 3.44, lanes 1 and 5). Two 
conjugations between S17-1/pMo130-TelR/bfmRS and AYE did not give rise to any single 
recombinants. Transformation of S17-1 with pMo130-TelR/bfmRSUPDOWN was repeated 
(transformation 2) and two more conjugations carried out, using a verified transformant from 
both transformations (Figure 3.44). Colonies were obtained when both donors were used, but 
the candidates remained white after pyrocatechol exposure. To increase the likelihood of 
recombination occurring, conjugation was carried out using larger volumes of donor and 
recipient strains. All colonies remained white after exposure to pyrocatechol and were 
therefore not single recombinants. To investigate whether any of these colonies were in fact  
 183 
 
Figure 3.42 Screening of pMo130-TelR/bfmRSUPDOWN Candidate DH5α Transformants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCR 15, Table 2.7
Lane  DNA  Expected size Actual size  
1  Hyperladder™ 1 (Bioline)  --- ---  
2-11  Lysate from candidates 1-10  2330 bp ~ 2330 bp  
12, 13  Hyperladder™ 1 (Bioline)  --- ---  
14-23  Lysate from candidates 11-20  2330 bp ~ 2330 bp  
24  ---  No amplimer No amplimer  
25  Hyperladder™ 1 (Bioline)  --- ---  
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Figure 3.43 Verification of pMo130-TelR/bfmRSUPDOWN construct by sequencing. 
a) Forward sequencing 
pMo/bfmSUPDN Expected      1 CCATCTACTTCTTCGACCCGTCCGGTAACCGCAACGAAGTGTTCTGCGGGGGAGATTACA   60  
                                                           G+A    AGTGTTCTGCGGGGGAGATTACA       
pMo/bfmSUPDN FW Seq        1 ----------------------------GTGSAYACGAGTGTTCTGCGGGGGAGATTACA   32  
 
pMo/bfmSUPDN Expected     61 ACTACCCGGACCACAAACCGGTGACCTGGACCACCGACCAGC-TGGGCAAGGCGATCTTT  119  
                             ACTACCCGGACCACAAACCGG++ACCTGGACC+++G+C+AGC TG++C+ +GCGATCTTT       
pMo/bfmSUPDN FW Seq       33 ACTACCCGGACCACAAACCGGKRACCTGGACCMSMGWCSAGCMTGRSCMCRGCGATCTTT   92  
 
pMo/bfmSUPDN Expected    120 TACCACGACCGCATTCTCAACGAACGATTCATGACCGTGCTGACCTGACCTGAGCGGCCG  179  
                             TACCACGACCGCATTCTCAACGAACGATTCATGACCGTGCTGACCTGA     GCGGCCG       
pMo/bfmSUPDN FW Seq       93 TACCACGACCGCATTCTCAACGAACGATTCATGACCGTGCTGACCTGA-----GCGGCCG  147  
 
pMo/bfmSUPDN Expected    180 CGAGATAGCATACCAAAGCTGTGAAAAAACACTTATAGATAACTTTGTGGATAACTCAAA  239  
                             CGAGATAGCATACCAAAGCTGTGAAAAAACACTTATAGATAACTTTGTGGATAACTCAAA       
pMo/bfmSUPDN FW Seq      148 CGAGATAGCATACCAAAGCTGTGAAAAAACACTTATAGATAACTTTGTGGATAACTCAAA  207  
 
pMo/bfmSUPDN Expected    240 AAACAAACACTTGAGTGAATTTAAATTTAGTGAAGAAATAATTTGTTTAATATTCATACA  299  
                             AAACAAACACTTGAGTGAATTTAAATTTAGTGAAGAAATAATTTGTTTAATATTCATACA       
pMo/bfmSUPDN FW Seq      208 AAACAAACACTTGAGTGAATTTAAATTTAGTGAAGAAATAATTTGTTTAATATTCATACA  267  
 
pMo/bfmSUPDN Expected    300 TAGGAAATATGAATAGATTATGACATTTAAGAACAATAAACAGATAATAAAAATACCTGA  359  
                             TAGGAAATATGAATAGATTATGACATTTAAGAACAATAAACAGATAATAAAAATACCTGA       
pMo/bfmSUPDN FW Seq      268 TAGGAAATATGAATAGATTATGACATTTAAGAACAATAAACAGATAATAAAAATACCTGA  327  
 
pMo/bfmSUPDN Expected    360 AAATTCAAAGATTAATAAAATGCAACAAAACATGGTTGTCATGTATCAGTTTGGTGAACG  419  
                             AAATTCAAAGATTAATAAAATGCAACAAAACATGGTTGTCATGTATCAGTTTGGTGAACG       
pMo/bfmSUPDN FW Seq      328 AAATTCAAAGATTAATAAAATGCAACAAAACATGGTTGTCATGTATCAGTTTGGTGAACG  387  
 
pMo/bfmSUPDN Expected    420 CCTACTTGTTTACAATGTAAACGTGTGTATATTGCAAATGATAAACGAATGTATCTGCAA  479  
                             CCTACTTGTTTACAATGTAAACGTGTGTATATTGCAAATGATAAACGAATGTATCTGCAA       
pMo/bfmSUPDN FW Seq      388 CCTACTTGTTTACAATGTAAACGTGTGTATATTGCAAATGATAAACGAATGTATCTGCAA  447  
 
pMo/bfmSUPDN Expected    480 GATTTTTAAGATACATGTAATGAGATTTATAGGGGCAATGATATGAGCCAAGAAGAAAAG  539  
                             GATTTTTAAGATACATGTAATGAGATTTATAGGGGCAATGATATGAGCCAAGAAGAAAAG       
pMo/bfmSUPDN FW Seq      448 GATTTTTAAGATACATGTAATGAGATTTATAGGGGCAATGATATGAGCCAAGAAGAAAAG  507  
 
pMo/bfmSUPDN Expected    540 TTACCAAAGATTCTGATCGTTGAAGACGACGAGCGTTTAGCGCGATTAACTCAAGAATAT  599  
                             TTACCAAAGATTCTGATCGTTGAAGACGACG GCGTTTAGCGCGATTAACTCAAGAATAT       
pMo/bfmSUPDN FW Seq      508 TTACCAAAGATTCTGATCGTTGAAGACGACGGGCGTTTAGCGCGATTAACTCAAGAATAT  567  
 
pMo/bfmSUPDN Expected    600 TTAATCCGTAATGGTTTGGAAGTTGGTGTAGAAACCGATGGTAACCGTGCAATTCGTCGT  659  
                             TTAATCCGTAATGGTTTGGAAGTTGGTGTAGAAACCGATGGTAACCGTGCAATTCGTCGT       
pMo/bfmSUPDN FW Seq      568 TTAATCCGTAATGGTTTGGAAGTTGGTGTAGAAACCGATGGTAACCGTGCAATTCGTCGT  627  
 
pMo/bfmSUPDN Expected    660 ATTATTAGTGAGCAACCGGATCTTGTGGTCTTGGATGTCATGTTGCCGGGTGCAGATGGT  719  
                             ATTATTAGTGAGCAACCGGATCTTGTGGTCTTGGATGTCATGTTGCCGGGTGCAGATGGT       
pMo/bfmSUPDN FW Seq      628 ATTATTAGTGAGCAACCGGATCTTGTGGTCTTGGATGTCATGTTGCCGGGTGCAGATGGT  687  
 
pMo/bfmSUPDN Expected    720 TTAACCGTTTGTCGTGAAGTTCGCCCACACTATCATCAACCAATCTTAATGTTGACTGCA  779  
                             TTAACCGTTTGTCGTGAAGTTCGCCCACACTATCATCAACCAATCTTAATGTTGACTG++       
pMo/bfmSUPDN FW Seq      688 TTAACCGTTTGTCGTGAAGTTCGCCCACACTATCATCAACCAATCTTAATGTTGACTGYW  747  
 
pMo/bfmSUPDN Expected    780 CGTACTGAAGATATGGATCAGGTACTTGGTCTGGAAATGGGTGCAGACGATTATGTCGCG  839  
                             CGTACTGAAGATATGGATCAGGTACTTGGTCTGGAAATGGGTGCAGACGATTATGTC+CG       
pMo/bfmSUPDN FW Seq      748 CGTACTGAAGATATGGATCAGGTACTTGGTCTGGAAATGGGTGCAGACGATTATGTCKCG  807  
 
pMo/bfmSUPDN Expected    840 AAACCAGTTCAACCACGTGTATTATTAGCGCGTATTCGTGCTTTGCTACGCCGTACGGAT  899  
                             AAACCAGTTCA CCACGTGTATTATTAGCGCGTATTCGTGCTTTGCTACGCCGTACGGAT       
pMo/bfmSUPDN FW Seq      808 AAACCAGTTCA-CCACGTGTATTATTAGCGCGTATTCGTGCTTTGCTACGCCGTACGGAT  866  
 
pMo/bfmSUPDN Expected    900 AAAACTGTTGAAGATGAAGTTGCTCAACGTATTGAGTTTGACGACCTTGTTATCGACAAT  959  
                             AAAACTGTTGAAGATGAAGTTGCTCAACGTATTGAGT+TGA+GACC+T+TTATCGA+AAT       
pMo/bfmSUPDN FW Seq      867 AAAACTGTTGAAGATGAAGTTGCTCAACGTATTGAGTKTGASGACCWTRTTATCGAYAAT  926  
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pMo/bfmSUPDN Expected    960 GGTGGCCGTTCGGTAACGTTGAACGGTGAGCTTGTTGACTTTACAAGTGCTGAATATGAC 1019  
                             G TGGCCGTTCG TAACGTTGAACGGTGAGCTTGTTGACTTT+CA GTGCTGAATATGAC       
pMo/bfmSUPDN FW Seq      927 GATGGCCGTTCG-TAACGTTGAACGGTGAGCTTGTTGACTTTRCA-GTGCTGAATATGAC  984  
 
pMo/bfmSUPDN Expected   1020 TTGTTATGGTTGCTTGCATCAAACGCTGGCCGTATTTTATCGCGTGAAGATATCTTCGAA 1079  
                             TTGT ATGGTTGCTTGC+TCAA CG++GGCCG +TTT ATCGCGTG+  ++  CTTCGAA       
pMo/bfmSUPDN FW Seq      985 TTGT-ATGGTTGCTTGCMTCAA-CGMYGGCCGARTTT-ATCGCGTGWGAWW--CTTCGAA 1039  
 
pMo/bfmSUPDN Expected   1080 CGTTTACGTGGTATCGAATACGATGGTCAAGACCGTTCAATTGACGTGGATCCAGGTTTG 1139  
                             C+TT AC+T GTATCGA TA+GATGGTC+ +ACCG+TCAAT GACG+GGATC   GTTTG       
pMo/bfmSUPDN FW Seq     1040 CRTT-ACRTWGTATCGA-TASGATGGTCR-SACCGYTCAAT-GACGWGGATC--AGTTTG 1093  
 
pMo/bfmSUPDN Expected   1140 CCGCTTCTCAGGCTATTGAGTGCATCTGTATTAAAGTCAATCAAGAGCGAATTATTTTTA 1199  
                             C G+T CTCAG CTAT    TGCATCTG AT  +AGTCA    A AGCGAAT AT+T          
pMo/bfmSUPDN FW Seq     1094 CAGMT-CTCAG-CTAT--GMTGCATCTGAAT--RAGTCATC--ACAGCGAAT-ATYTACS 1144  
 
pMo/bfmSUPDN Expected   1200 GCATCAATTTGATATTTTTGAATAAGAGGCTGATCCCCATTCAAAGTCTCAACTCTATAT 1259  
                             ++A          ++TTTTGAA++    GCTGATC  CATTC A  TC   AC  T++         
pMo/bfmSUPDN FW Seq     1145 RSACTSG------MWTTTTGAAYRTA--GCTGATC--CATTCCAGCTC---ACCTTMWGA 1191  
 
pMo/bfmSUPDN Expected   1260 GAGTCTG-CAATATGTAAAATGCCTTCTAGATTTGTTGTGGTTGATGCGAAATCTTGCCT 1318  
                             + GTC+  +AAT+   +AA                 TG  G TGA GCGAA  CT GCCT       
pMo/bfmSUPDN FW Seq     1192 RTGTCWATSAATRCTCRAA-----------------TGATGCTGA-GCGAA--CTGGCCT 1231  
 
pMo/bfmSUPDN Expected   1319 AAAAATTTCATAGACATCTCGCAAGTCAAAAATGGCATTATCTGCATCTGGGTGTTTATG 1378  
                             A+AA T   +++     + CGC+AGT+  A A  G                                
pMo/bfmSUPDN FW Seq     1232 ARAA-TCCTRWRACTYAYACGCMAGTMTCAGACTG------------------------- 1265  
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b) Reverse sequencing 
 
pMo/bfmSUPDN Expected    901 AAACTGTTGAAGATGAAGTTGCTCAACGTATTGAGTTTGACGACCTTGTT  950  
                                                                                      
pMo/bfmSUPDN RV Seq          --------------------------------------------------       
 
pMo/bfmSUPDN Expected    951 ATCGACAATGGTGGCCGTTCGGTAACGTTGAACGGTGAGCTTGTTGACTTTACAAGTGCT 1010  
                             A   A+ A+G T++C  T++++ AA  TT +   + G +CT   + AC+  +C +   +T       
pMo/bfmSUPDN RV Seq     1323 ACGTASGAKG-TRSC--TKMKKGAAKMTTTMCAMKGGKKCTCAGYAACKSRRCKMTGWMT 1267  
 
pMo/bfmSUPDN Expected   1011 GAATATGACTTGTTATGGTTGCTTGCATCAAACGCTGGCCGTATTTTATCGCGTGAAGAT 1070  
                              +    +     TT++  ++ CTT+    +  +G T     TATT  A ++ +  A G++       
pMo/bfmSUPDN RV Seq     1266 CMGGGSRGTC--TTMYYYKWTCTTSGSGRRGCSGGTATTTTTATTC-AGSSGKAAACGWY 1210  
 
pMo/bfmSUPDN Expected   1071 ATCTTCGAACGTTTACGTGGTATCGAATACGATGGTCAAGACCGTTCAATTGACGTGGAT 1130  
                              T T+ G+  +TT+ C +G+TAT GA++ C+AT++TCAAGA CG TCAATT+A+ TGG T       
pMo/bfmSUPDN RV Seq     1209 TTATKTGRGAKTTKTCAYGKTATTGAMKTCSATKKTCAAGAGCGRTCAATTRAS-TGGGT 1151  
 
pMo/bfmSUPDN Expected   1131 CCAGGTTTGCCGCTTCTCAGGCTATTGAGTGCATCTGTATTAAAGTCAATCAAGAGCGAA 1190  
                              C+GGTTT+C+  +T ++ GG T +T AG++C TCT   TT+AA+TCAATCA GAG++A+       
pMo/bfmSUPDN RV Seq     1150 TCMGGTTTSCS-TKTTKYYGGGTTKTTAGKKCTTCT---TTRAARTCAATCA-GAGSRAM 1096  
 
pMo/bfmSUPDN Expected   1191 TTATTTTTAGCATCAATTTGATATTTTTGAATAAGAGGCTGATCCCCATTCAAAGTCTCA 1250  
                             T ++TTT+++C +CA  T+GA A T +   A+ AG   CTGATC CCA+T AAA T T+A       
pMo/bfmSUPDN RV Seq     1095 T-MYTTTYWRCTYCA--TWGAAAATGY--GAWTAGGCCCTGATCTCCAWTWAAATTTTSA 1041  
 
pMo/bfmSUPDN Expected   1251 ACTCTATATGAGTCTGCAATATGTAAAATGCCTTCTAGATTTGTTGTGGTTGATGCGAAA 1310  
                             A T T+ A GA+T T +AA +  TAAAAT C TT   G+ TTG TG GG+TGATGC+AAA       
pMo/bfmSUPDN RV Seq     1040 ATTTTWAA-GAKTTTAMAAAWATTAAAATCCTTT---GRGTTGGTGGGGWTGATGCSAAA  985  
 
pMo/bfmSUPDN Expected   1311 TCTTGCCTAAAAATTTCATAGACATCTCGCAAGTCAAAAATGGCATTATCTGCATCTGGG 1370  
                             T+T GC+TAAAAA++TCAT+GAC TCT +CAAGTCAAAA +G C+TT T  GCAT+TGGG       
pMo/bfmSUPDN RV Seq      984 TMT-GCYTAAAAAWKTCATRGACTTCTARCAAGTCAAAATKGCCWTTTTGGGCATSTGGG  926  
 
pMo/bfmSUPDN Expected   1371 TGTTTATGAATATAGCTTTCTATATGTCGCACCAGTAATTGTGCAAACAAGTAATAGTCT 1430  
                              +TT   GA + TAGCTTT+T T+ GTCGCACCAG+AAT G  CAAACAAGTAATAGTCT       
pMo/bfmSUPDN RV Seq      925 ARTTA--GATWKTAGCTTTYT-TMCGTCGCACCAGKAATCG-ACAAACAAGTAATAGTCT  870  
 
pMo/bfmSUPDN Expected   1431 GGTTTATGCGTATATTCTAGATT-CATGCATTTTTCTCCTT-ATTATCTGTTATTAGCAT 1488  
                             GGTTTATG GTATATTCTAGATT CAT+CATTTTT T CTT ATTATC+GTT+TTAGCAT       
pMo/bfmSUPDN RV Seq      869 GGTTTATGGGTATATTCTAGATTTCATKCATTTTTTTTCTTTATTATCKGTTRTTAGCAT  810  
 
pMo/bfmSUPDN Expected   1489 ACATGGCAAAACAGAAGATATTGTATAAAATTCATTACACTAGATGATGACTTGGAAATA 1548  
                             ACATGGC+AAACAGAAGATATTGTAT+AA+TTCATTACACT+GATGATGACTTGGAAATA       
pMo/bfmSUPDN RV Seq      809 ACATGGCRAAACAGAAGATATTGTATMAAWTTCATTACACTWGATGATGACTTGGAAATA  750  
 
pMo/bfmSUPDN Expected   1549 TTACAAAGAAATAAAAACTCTATTACGCCCTTGGCGCTTTGCTTGATAGAGTGCATCGTC 1608  
                             TTACAAAGAAATAAAAACTCTATTACGCCCT+GGCGCTTTGC++GATAGAGTGCATCGTC       
pMo/bfmSUPDN RV Seq      749 TTACAAAGAAATAAAAACTCTATTACGCCCTKGGCGCTTTGCKWGATAGAGTGCATCGTC  690  
 
pMo/bfmSUPDN Expected   1609 TGCTTCTTTAAACAAACTTTCAATAGAACGGTGATAGCTTGGAGAATATAAGCTAATACC 1668  
                             TG+TTCT+TAAACAAACTTTCAATAGA+CGGTGATAGCTTGGAGAATATAAG+TAATACC       
pMo/bfmSUPDN RV Seq      689 TGYTTCTYTAAACAAACTTTCAATAGARCGGTGATAGCTTGGAGAATATAAGYTAATACC  630  
 
pMo/bfmSUPDN Expected   1669 AATACTTACCTGCACAAAGATGGGTAATTTGCCATATACATAAATCGGTTGCTGACTAAT 1728  
                             AATACTTACCTGCACAAAGATGGGTAATTTGCCATATACATAAATCGGTTGCTGACTAAT       
pMo/bfmSUPDN RV Seq      629 AATACTTACCTGCACAAAGATGGGTAATTTGCCATATACATAAATCGGTTGCTGACTAAT  570  
 
pMo/bfmSUPDN Expected   1729 TTGAATGCGTATTCTTTCCGCGAGTTCAAAGGCAGCCTCTCTGGTGGTATCCGGAATAAA 1788  
                             TTGAATG+GTATTCTTTCCGCGAGTTCAAAGGCAGCCTCTCTGGTGGTATCCGGAATAAA       
pMo/bfmSUPDN RV Seq      569 TTGAATGMGTATTCTTTCCGCGAGTTCAAAGGCAGCCTCTCTGGTGGTATCCGGAATAAA  510  
 
pMo/bfmSUPDN Expected   1789 AATTGCGAATTCTTCTCCACCAAAACGTCCTAGTAAGTCATGAGGATGTAAAATATTTTG 1848  
                             AATTGCGAATT+TTCTCCACCAAAACGTCCTAGTAAGTCATGAGGATGTAAAATATTTTG       
pMo/bfmSUPDN RV Seq      509 AATTGCGAATTYTTCTCCACCAAAACGTCCTAGTAAGTCATGAGGATGTAAAATATTTTG  450  
 
pMo/bfmSUPDN Expected   1849 TATGGTCGTTACACAGGTCTGTAAGGCTCTATCCCCAATTAAGTGGCCATAACTATCATT 1908  
                             TATGGTCGTTACACAG+ CTGTAAGGCTCTATCCCCAATTAAGTGGCCATAACTATCATT       
 
 
187 
 
pMo/bfmSUPDN RV Seq      449 TATGGTCGTTACACAGSCCTGTAAGGCTCTATCCCCAATTAAGTGGCCATAACTATCATT  390  
 
pMo/bfmSUPDN Expected   1909 CACTTTTTTAAAATGATCGACGTCCAACATAAAAAATGCAGAGGTCTTATTTTCCTTTTG 1968  
                             CACTTTTTTAAAATGATCGACGTCCAACATAAAAAATGCAGAGGTCTTATTTTCCTTTTG       
pMo/bfmSUPDN RV Seq      389 CACTTTTTTAAAATGATCGACGTCCAACATAAAAAATGCAGAGGTCTTATTTTCCTTTTG  330  
 
pMo/bfmSUPDN Expected   1969 TACTTTTTCTTGGAGTAAGCGGACTGACTGTAAAAATTGGCGTCGAGTTAAACTTGAGGT 2028  
                             TACTTTTTCTTGGAGTAAGCGGACTGACTGTAAAAATTGGCGTCGAGTTAAACTTGAGGT       
pMo/bfmSUPDN RV Seq      329 TACTTTTTCTTGGAGTAAGCGGACTGACTGTAAAAATTGGCGTCGAGTTAAACTTGAGGT  270  
 
pMo/bfmSUPDN Expected   2029 GAGTTCATCATGGGCAATTGCATGTTGTAACTTCTGAATTAATTCAGAATGGAGTGCGCT 2088  
                             GAGTTCATCATGGGCAATTGCATGTTGTAACTTCTGAATTAATTCAGAATGGAGTGCGCT       
pMo/bfmSUPDN RV Seq      269 GAGTTCATCATGGGCAATTGCATGTTGTAACTTCTGAATTAATTCAGAATGGAGTGCGCT  210  
 
pMo/bfmSUPDN Expected   2089 AATACTGGAAACAGTAAGTGGCGCAACCGTCATCATGATCAGCCCTATACGTATAGAAAT 2148  
                             AATACTGGAAACAGTAAGTGGCGCAACCGTCATCATGATCAGCCCTATACGTATAGAAAT       
pMo/bfmSUPDN RV Seq      209 AATACTGGAAACAGTAAGTGGCGCAACCGTCATCATGATCAGCCCTATACGTATAGAAAT  150  
 
pMo/bfmSUPDN Expected   2149 GTTATTGCTTAAATAGTCTTGCGGATACAGTAATAAATAATGCCCTGAGACATGATAAAT 2208  
                             GTTATTGCTTAAATAGTCTTGCGGATACAGTAATAAATAATGCCCTGAGACATGATAAAT       
pMo/bfmSUPDN RV Seq      149 GTTATTGCTTAAATAGTCTTGCGGATACAGTAATAAATAATGCCCTGAGACATGATAAAT   90  
 
pMo/bfmSUPDN Expected   2209 AATATATGCACTGGTAAAGGATGTAATGAGAGCAACAATAATCGGTTTATAGCGGATAGC 2268  
                             AATATATGCACT  T A  G T+T + G   G   C  T A CG  ++  AG++ +T+G        
pMo/bfmSUPDN RV Seq       89 AATATATGCACTCCTTATAGTTSTTMGGCCCGTC-CGGTTACCGCAWYGAAGYKTMTRGG   31  
 
pMo/bfmSUPDN Expected   2269 GCACCAGATTAATGCGGCGATGGGGTAGAGTAG 2301  
                             GC        AAT C  CGAT   G AGA           
pMo/bfmSUPDN RV Seq       30 GCGGAGATACAATACC-CGATC--GCAGATCCA    1  
 
pMo/bfmSUPDN Expected   2304 GGAACCTGGACCCGAGTCGGGATCCCCC 2331  
                                                                
pMo/bfmSUPDN RV Seq          ----------------------------       
 
A region of pMo130-TelR containing bfmRS UP and DOWN fragments was amplified and 
sequenced. The result was aligned with the expected sequence. 
a) pMo/bfmSUPDN FW Sequenced was generated using primer pMo130-TelR FW, which is 
specific for pMo130-TelR.  
b) pMo/bfmSUPDNUPDN RV Sequenced was generated using primer DOWNRVbfmS, which is 
specific for the DOWN fragment. This sequence was reverse complemented before alignment. 
The first 1070bp of the sequence corresponds to 174 bp of the vector and the entire UP 
fragment (a). The remainder of the sequence corresponds to the DOWN fragment (b). 
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Figure 3.44 Verification of pMo130-TelR/bfmRSUPDOWN in S17-1 
 
 
 
 
 
 
 
 
 
 
PCR 15, Table 2.7
Lane  DNA  Expected size  Actual size  
1  pMo130-TelR/bfmRSUPDOWN from 
transformation 1  
---  ---  
2  pMo130-TelR/bfmRSUPDOWN from 
transformation 2  
---  ---  
3  Hyperladder™ 1 (Bioline)  ---  ---  
4  pMo130-TelR/bfmRSUPDOWN 
(positive control)  
2330 bp  ~ 2330 bp  
5  pMo130-TelR/bfmRSUPDOWN from 
transformation 1 into S17-1  
2330 bp  ~ 2330 bp  
6  pMo130-TelR/bfmRSUPDOWN from 
transformation 2 into S17-1  
2330 bp  ~ 2330 bp  
7  --- No amplimer  No 
amplimer  
8  Hyperladder™ 1 (Bioline)  ---  ---  
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double recombinants (which would account for their white phenotype), 12 were screened by 
PCR for gene deletion (Table 2.7, PCR 21). Only one amplimer was obtained and this was of the 
size expected for wild-type AYE. Twenty more colonies were screened, but no double 
recombinants were identified. Since a single recombinant had not been obtained by 
conjugation, transformation was carried out to introduce pMo130-TelR/bfmRSUPDOWN directly 
into AYE (Section 2.4.4.1). All candidate transformants obtained from two transformations 
remained white after pyrocatechol exposure. At this stage, construction of a bfmRS deletion 
mutant was suspended to focus on the phenotypic characterisation and complementation of 
AYE∆adeRS and AYE∆pmrAB. 
It was initially planned that only bfmS would be deleted. However, due to the location of the 
deletion primers, the whole of bfmS, 112 bp of bfmR and 30 bp of ABAYE3062 would have been 
deleted (Figure 3.45). 
3.5. Discussion 
Investigation of the role of TCSs in A. baumannii was carried out in AYE. The conservation of 
adeRS in the strains investigated in this study was high; there was at least 95% identity between 
the aligned regions of the genes from different strains. However, the length of the genes did 
vary between strains, giving rise to different sized proteins, particularly in ATCC 17978 (Section 
3.2.2). Strain ATCC 17978 was not used as it was antibiotic-susceptible, rather than its lack of 
adeC or its smaller adeRS genes. In a study by Nemec et al. (2007a), 41% of 116 strains did not 
have an adeC gene suggesting that this is a common feature in A. baumannii strains. AB0057 
and ACICU were other possible candidate strains in which to delete adeRS, as they are MDR
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Figure 3.45 Region around bfmS in AYE (Expected Sequences) and Primers Designed to 
Delete bfmRS. 
Key for the following DNA sequences: 
 
Expected deleted region 
 
bfmR 
 
bfmS 
 
ABAYE3062 hypothetical protein (xBASE) 
 
 
 
UP primers 
 
UPFWbfmS (Contains NotI recognition site) 
GGGGCGGCCGCGAGATAGCATACCAAAGCTG  
UPRVbfmS (Contains BamHI recognition site) 
GGGGGATCCACGTCAATTGAACGGTCTTG   
 
 
DOWN primers 
 
DOWNFWbfmS (Contains BamHI recognition site) 
GGGGGATCCAGGTTTGCCGCTTCTCAGGC   
DOWNRVbfmS (Contains SphI recognition site) 
GGGGCATGCCGACTCGGGTCCAGGTTCCC 
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a) Wild-type AYE Expected Sequence. 
 
ggtgaaagcaaatcaagctctacaccttttttcaagaatgcttcaagtgcattgttttca 
gctgtatcggccggtaaacctaagaatgctaagccagtgcttaccaactcatcacgaagc 
aaacgtgcagttacgtatgtatagttaggttcttgttcaatacgtgtacgtgttgccatc 
atcatggtggtagcaatatcgctttcttttacgccgttatataagtttttaacggtttca 
tcgataattgcttgaacatcaataccttctaagccttcagcagctcgatttacagttgct 
tgcagtgcacttaaatcaagtggttgaagctgaccgtttgcatcggtaacttgcaaggta 
gggtgatgattagaatttgtgtctttacgggcacttgcgcgttgatcgcgatagataacg 
taagcacgagcgactttgtgctccccagtacgcatcagtgcaagttcaacttgatcttga 
atctcttcaatatgaatggtaccgccagaaggtaaacggcgagtgaaagtgttcagtacc 
atttccgtcagttgggtaatacggtcgtgaatacggctcgaatccgcactttgttgacct 
tccacagcaagaaaagctttaccaatcgcaacagaaattttctctgcatcaaatgcagca 
acatctccggtgcgtttaatcacctgaatttgaccgggagtcgaagtaattacgctcatg 
ccagcatagctccattgtcacttttgttatgttcatagaccgtttgaaccgagcaaaaaa 
catgccacgatatttgagggataaacacaagacttagtagttaaagtttattttcaacac 
aagatacgggattttttacggtagatcaatcttgactttttagtaattttttatctgtat 
gatttgtcgggagatagcataccaaagctgtgaaaaaacacttatagataactttgtgga 
taactcaaaaaacaaacacttgagtgaatttaaatttagtgaagaaataatttgtttaat 
attcatacataggaaatatgaatagattatgacatttaagaacaataaacagataataaa 
aatacctgaaaattcaaagattaataaaatgcaacaaaacatggttgtcatgtatcagtt 
tggtgaacgcctacttgtttacaatgtaaacgtgtgtatattgcaaatgataaacgaatg 
tatctgcaagatttttaagatacatgtaatgagatttataggggcaatgatatgagccaa 
gaagaaaagttaccaaagattctgatcgttgaagacgacgagcgtttagcgcgattaact 
caagaatatttaatccgtaatggtttggaagttggtgtagaaaccgatggtaaccgtgca 
attcgtcgtattattagtgagcaaccggatcttgtggtcttggatgtcatgttgccgggt 
gcagatggtttaaccgtttgtcgtgaagttcgcccacactatcatcaaccaatcttaatg 
ttgactgcacgtactgaagatatggatcaggtacttggtctggaaatgggtgcagacgat 
tatgtcgcgaaaccagttcaaccacgtgtattattagcgcgtattcgtgctttgctacgc 
cgtacggataaaactgttgaagatgaagttgctcaacgtattgagtttgacgaccttgtt 
atcgacaatggtggccgttcggtaacgttgaacggtgagcttgttgactttacaagtgct 
gaatatgacttgttatggttgcttgcatcaaacgctggccgtattttatcgcgtgaagat 
atcttcgaacgtttacgtggtatcgaatacgatggtcaagaccgttcaattgacgtacgt 
atttcacgtattcgtccaaaaattggcgatgatcctgaaaatccaaaacgtattaaaact 
gtacgtagtaaaggttacttgtttgttaaagaaaccaatggattgtaaaatctgattaaa 
cttcctataaggttggtcgaGTGTTTAAACACAGTATATTCCTGCGAATATATGCGGGGC 
TGGTAATTCTTGTTGTTTTGGTGGCTGTTTTTGGGTATTTACTGGTACAAATTATCAACT 
ACCAACGCGCACAAGAATACCGAGAATCTTTAACTGATGGTATTTCTTATGTCATTAGTG 
AAGGAGTCGCTCGACAACCTGGGAAGCAGCAAAAAATAGATTGGATTTCTGACGCATCTG 
ATTTGCTCGAACTTCCAATTTATTATACCGATGCAAGTAAGGTTGAGCTGTCTCGGACCG 
AGAAAAAGCGGATCGAAGCACAAAAATCTGTAGTTCGTTACGATGCAAGCAATAGCATTG 
CATATGTCATTATTGGCTTGCGTGACGACCCACAACATTACCTATCTATAAAAGTCGACA 
AAATCACTGAACGCCAAATGAAGGCTCTTCCTATTTTTGTGCTCGACTATTTAATGTTTT 
ATCCGGGGCAGGAACAAGAATATCTTGCCAAGATTCAAAAGCATTTCTCATATCCGATCA 
ATATTCAAAACATTCAAGATGTAAATCTGGATTCTGAACAGATTGGACGTTTGCGCCAAG 
ACCAAAGTGTCATGTTGTACAAAGATAGCGCAACAGTGCGCGGTACAACCATTTCGATTG 
TGTCTCCAATACCGAATCATCCTGCGCAGGTGTTAGTGCTGGGTCCGGTTCCAATGTTTA 
ACTGGATGCCTTTACAGCTTTCGGCGGGTATTACCTTATTTAGCTTATTCTTATTAAGTC 
TAGGTGTTTACGGTTTGATTTTGCCGTTAGAGCGCAAAATCCGACAGGTGCGTTATGCAT 
TAAACCGTATGAAATCGGGTGATTTGTCACTGCGTGTTCCTATTGAGGGAAGCGACGAAA 
TGGCAAACTTAGCTTCAAGTTATAACAATATGTCTGACCATATTCAGCGTTTGATTGAGG 
CTCAACGTGAGTTAATGAGAGCCGTATCTCATGAGCTGAGAACGCCTGTGGCACGTATTC 
GCTTTGGTACAGAAATGTTAGCCGAAGAAGATGATTATAATCATCGTATGCATCAGGTCG 
ACATGATTGATAAAGATATTGAAGCACTCAATACCTTAATTGATGAAATCATGACTTATG 
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CAAAACTAGAGCAGGGTACACCTTCACTAGATTTTGCAGAAATTGTACTCTTTGAAGTGT 
TGGATCAGGTTGCAGTTGAAACTGAGGCTTTAAAAACACAGAAAGAAATTGAACTTATTC 
CACCGCCTTTATATGTGAAAGTAGATGCAGAGCGTCGTTACCTTCACCGTGTCGTGCAAA 
ATCTGGTAGGTAATGCAGTTCGTTATTGTGATAACAAAGTTCGGATTACGGGCGGTATTC 
ATAGTGATGGCATGGCTTTTGTCTGTGTTGAAGACGACGGACCGGGTATTCCTGAGCAAG 
ACCGCAAACGTGTATTCGAAGCCTTTGCCCGTTTAGATGACAGTCGTACACGCGCATCTG 
GCGGTTATGGTTTGGGTCTCTCTATCGTAAGTCGTATTGCTTACTGGTTTGGTGGGGAAA 
TTAAGGTAGATGAAAGTCCAAGTTTGGGAGGCGCACGCTTTATTATGACTTGGCCAGCAC 
ATCGCTTTAAACAACCGCCATTAAAGAGCAATAAAAAAGCACCTGCATAAggtgcttttt 
tattggttcatttataactgagttgcatcaggttccaaaataggtttgccgcttctcagg 
ctattgagtgcatctgtattaaagtcaatcaagagcgaattatttttagcatcaatttga 
tatttttgaataagaggctgatccccattcaaagtctcaactctatatgagtctgcaata 
tgtaaaatgccttctagatttgttgtggttgatgcgaaatcttgcctaaaaatttcatag 
acatctcgcaagtcaaaaatggcattatctgcatctgggtgtttatgaatatagctttct 
atatgtcgcaccagtaattgtgcaaacaagtaatagtctggtttatgcgtatattctaga 
ttcatgcatttttctccttattatctgttattagcatacatggcaaaacagaagatattg 
tataaaattcattacactagatgatgacttggaaatattacaaagaaataaaaactctat 
tacgcccttggcgctttgcttgatagagtgcatcgtctgcttctttaaacaaactttcaa 
tagaacggtgatagcttggagaatataagctaataccaatacttacctgcacaaagatgg 
gtaatttgccatatacataaatcggttgctgactaatttgaatgcgtattctttccgcga 
gttcaaaggcagcctctctggtggtatccggaataaaaattgcgaattcttctccaccaa 
aacgtcctagtaagtcatgaggatgtaaaatattttgtatggtcgttacacaggtctgta 
aggctctatccccaattaagtggccataactatcattcacttttttaaaatgatcgacgt 
ccaacataaaaaatgcagaggtcttattttccttttgtactttttcttggagtaagcgga 
ctgactgtaaaaattggcgtcgagttaaacttgaggtgagttcatcatgggcaattgcat 
gttgtaacttctgaattaattcagaatggagtgcgctaatactggaaacagtaagtggcg 
caaccgtcatcatgatcagccctatacgtatagaaatgttattgcttaaatagtcttgcg 
gatacagtaataaataatgccctgagacatgataaataatatatgcactggtaaaggatg 
taatgagagcaacaataatcggtttatagcggatagcgcaccagattaatgcggcgatgg 
ggtagagtagggaacctggacccgagtcgtaataacttactcctatcgaaattaaaacag 
cgaataaaggcaaaaaatcaatcgctttgatatatatacgattacccttaaggtgggttt 
ttattttaaggtaaggagggatatttaaaataatgggcagcaacaataaggcattttgaa 
gctctgatgtaacccaataaccaaattcggcccaaaaactaccaatcataaatttggtgt 
taaacataggcacaaaagttgctgcaaaaaaagcaccggttatgctgccaatcccgcata 
gtgcgaataagagtaaataagaatagccttgataagctgcttttatatggcgattaaaca 
atattgcgagtgctaaagtcgttactacatacaggtagttggatatcgttaaaataaggg 
tgagaaaaagaggtgtgccattaactaaatcggcaaccatgtaaccggtaaaagcaccag 
caaaactaactatttggcgtgtttgtggaaatcgaagcaataggcctagaaataccgagt 
tagcaggccagaaaaaagcaagaaaactaagaggacgagatgcaattccaataaagcaac 
ataacgtaataatgatggtaaataagagaaaaaatttcagggaggtagaaaatgaaaatt 
cacgaagtgagtatggcatcagctgcccttaatgataaacactcttatccaagagtaata 
aaatattaatgcatgattaaacattcatcataattcagaggggaagatgaatacaataaa 
aaaccgatta 
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b) AYEΔbfmRS Expected Sequence 
 
gatttgtcgggagatagcataccaaagctgtgaaaaaacacttatagataactttgtgga 
taactcaaaaaacaaacacttgagtgaatttaaatttagtgaagaaataatttgtttaat 
attcatacataggaaatatgaatagattatgacatttaagaacaataaacagataataaa 
aatacctgaaaattcaaagattaataaaatgcaacaaaacatggttgtcatgtatcagtt 
tggtgaacgcctacttgtttacaatgtaaacgtgtgtatattgcaaatgataaacgaatg 
tatctgcaagatttttaagatacatgtaatgagatttataggggcaatgatatgagccaa 
gaagaaaagttaccaaagattctgatcgttgaagacgacgagcgtttagcgcgattaact 
caagaatatttaatccgtaatggtttggaagttggtgtagaaaccgatggtaaccgtgca 
attcgtcgtattattagtgagcaaccggatcttgtggtcttggatgtcatgttgccgggt 
gcagatggtttaaccgtttgtcgtgaagttcgcccacactatcatcaaccaatcttaatg 
ttgactgcacgtactgaagatatggatcaggtacttggtctggaaatgggtgcagacgat 
tatgtcgcgaaaccagttcaaccacgtgtattattagcgcgtattcgtgctttgctacgc 
cgtacggataaaactgttgaagatgaagttgctcaacgtattgagtttgacgaccttgtt 
atcgacaatggtggccgttcggtaacgttgaacggtgagcttgttgactttacaagtgct 
gaatatgacttgttatggttgcttgcatcaaacgctggccgtattttatcgcgtgaagat 
atcttcgaacgtttacgtggtatcgaatacgatggtcaagaccgttcaattgacgt 
aggtttgccgcttctcaggGGATCC 
ctattgagtgcatctgtattaaagtcaatcaagagcgaattatttttagcatcaatttga 
tatttttgaataagaggctgatccccattcaaagtctcaactctatatgagtctgcaata 
tgtaaaatgccttctagatttgttgtggttgatgcgaaatcttgcctaaaaatttcatag 
acatctcgcaagtcaaaaatggcattatctgcatctgggtgtttatgaatatagctttct 
atatgtcgcaccagtaattgtgcaaacaagtaatagtctggtttatgcgtatattctaga 
ttcatgcatttttctccttattatctgttattagcatacatggcaaaacagaagatattg 
tataaaattcattacactagatgatgacttggaaatattacaaagaaataaaaactctat 
tacgcccttggcgctttgcttgatagagtgcatcgtctgcttctttaaacaaactttcaa 
tagaacggtgatagcttggagaatataagctaataccaatacttacctgcacaaagatgg 
gtaatttgccatatacataaatcggttgctgactaatttgaatgcgtattctttccgcga 
gttcaaaggcagcctctctggtggtatccggaataaaaattgcgaattcttctccaccaa 
aacgtcctagtaagtcatgaggatgtaaaatattttgtatggtcgttacacaggtctgta 
aggctctatccccaattaagtggccataactatcattcacttttttaaaatgatcgacgt 
ccaacataaaaaatgcagaggtcttattttccttttgtactttttcttggagtaagcgga 
ctgactgtaaaaattggcgtcgagttaaacttgaggtgagttcatcatgggcaattgcat 
gttgtaacttctgaattaattcagaatggagtgcgctaatactggaaacagtaagtggcg 
caaccgtcatcatgatcagccctatacgtatagaaatgttattgcttaaatagtcttgcg 
gatacagtaataaataatgccctgagacatgataaataatatatgcactggtaaaggatg 
taatgagagcaacaataatcggtttatagcggatagcgcaccagattaatgcggcgatgg 
ggtagagtagggaacctggacccgagtcg 
 
It was expected that a BamHI site (GGATCC) would be introduced in AYEΔbfmRS.
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clinical isolates (Adams et al., 2008). AYE was chosen as it had the most BLAST hits with 
other A. baumannii genomes and was considered to have the core set of genes for the 
species and therefore to be a representative strain.  
The adeRS deletion in AYE was verified by PCR and DNA sequencing. In addition, an adeS 
transcript was detected in AYE, but not in AYEΔadeRS (as shown in RNA sequencing; 
Richmond and Piddock, unpublished). However, despite repeated attempts, it was not 
possible to delete bfmRS in AYE. This gene is not essential in other strains of A. baumannii 
(clinical isolate and type strain, ATCC 19606 and clinical isolate, M2), since it has previously 
been inactivated with a transposon (Clemmer et al., 2011; Tomaras et al., 2008). However, 
there have been no reports of targeted deletion or inactivation of bfmR or bfmS in AYE. It is 
possible that there are some regions of the chromosome into which pMo130-TelR is harder 
to introduce.  
It was also not possible to re-introduce the wild-type adeRS or pmrAB into AYEΔadeRS and 
AYEΔpmrAB, respectively after multiple attempts. It was initially suspected that AYEΔadeRS 
and AYEΔpmrAB had a reduced ability compared with AYE to accept DNA by conjugation. 
However, AYE, AYEΔadeRS and AYEΔpmrAB were all able to accept the adeRS and pmrAB 
deletion constructs by conjugation and incorporate them into their chromosome. Moreover, 
AYE was able to incorporate the deletion constructs, but not the complementation 
constructs. Therefore, the problem is with the complementation constructs, rather than the 
method, or the recipient strains. It is possible that the presence of adeRS or pmrAB in the 
complementation construct is responsible for an inability of the constructs to recombine 
into the chromosome, or maybe the increased construct size had an effect on conjugation. 
The most likely explanation for the white tellurite-resistant colonies is that they were 
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spontaneous tellurite-resistant mutants, since the colonies obtained when attempting to 
complement AYEΔadeRS were confirmed by PCR to be deletion mutants, with no 
complementation vector in their chromosome. 
3.6. Further Work 
3.6.1. Problems with gene deletion - how to resolve 
An alternative strategy to delete bfmRS could be to use different UP and DOWN fragments 
for recombination. For example, the UP and DOWN pairs of primers could be designed closer 
together, to delete an internal gene region, rather that the whole gene. Nonetheless, if 
pMo130-TelR were to be used for further work, it would be important at this stage to verify 
that certain genes on the vector have not been disrupted (genes responsible for conjugation, 
replication and gene expression). This should also be carried out for the bfmRS deletion 
construct and complementation constructs (Section 3.6.2) to check that the genes have not 
been disrupted during construction.  
3.6.2. Problems with complementation - how to resolve 
Although the reasons for using the current complementation strategy are discussed later 
(Chapter 6), an alternative strategy would be to use a plasmid known to replicate in A. 
baumannii to complement the gene deletions. A third and preferable option would be to 
introduce the tellurite-resistance cassette onto a new suicide vector and use the same 
complementation strategy used in this study. This is because replacing the gene directly into 
its original genomic location is more stable than using a plasmid (which could be lost) returns 
the strain to its original state and also removes any problems with increased or decreased 
gene expression due to plasmid copy number. 
 
 
196 
 
There was not enough time to investigate the white tellurite-resistant colonies obtained 
during pmrAB complementation. However, it would be more important at this stage to 
change the complementation strategy or to establish the problems with the current 
constructs.  
3.7. Key Findings 
 Identifying representative strain to make mutants 
 Making AYEΔadeRS and AYEΔpmrAB 
 Making vector to delete bfmRS 
 Making vectors to complement AYEΔadeRS and AYEΔpmrAB 
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4. Role of adeRS in Growth, Antimicrobial and Biocide 
Susceptibility and Accumulation 
4.1. Background 
adeRS are involved in antimicrobial susceptibility due to their regulation of adeABC. Deletion 
of adeS in BM4454 resulted in increased susceptibility to gentamicin and kanamycin 
(Marchand et al., 2004) and deletion of adeS in clinical isolates resulted in increased 
susceptibility to meropenem, cefotaxime, gentamicin, amikacin and ciprofloxacin (Wong et 
al., 2009). Mutations in adeR and/or adeS give increased MICs (MDR) (Table 1.2; Table 1.3). 
Investigation into the role of adeRS in growth, efflux, biocide susceptibility and virulence has 
not been reported to date. Based on MIC data for an A. baumannii clinical isolate, AdeABC 
transports biocides such as benzalkonium chloride, chlorhexidine and 
tetraphenylphosphonium chloride (Rajamohan et al., 2010b). The antibiotic and biocide 
susceptibility profiles for AYE have not been reported. 
4.2. Aims and hypotheses 
AYEΔadeRS was hypothesised to be more susceptible to antimicrobials and to accumulate 
higher levels of these compounds, due to decreased expression of adeABC. Therefore, the 
aims were to investigate whether deletion of adeRS affected growth, antibiotic and biocide 
susceptibility, efflux and virulence in AYE.  
4.3 Effect of adeRS Deletion on Growth of Planktonic Cells and Biofilm in vitro 
There was no significant difference in generation time or final optical density at 600nm 
between planktonic AYE and AYEΔadeRS grown in LB broth (Figure 4.1; Table 4.1). There was  
 198 
 
Figure 4.1 Growth of AYE and AYE∆adeRS in LB broth. 
 
Data are the mean of three separate experiments, each carried out in duplicate.  
 
 
 
 
Table 4.1 Mean Generation time and Optical Density at Stationary Phase (± standard 
deviation). 
Data are the mean of three separate experiments, each carried out in duplicate. The 
generation times were determined from the steepest part of the exponential curve. A two-
tailed, unpaired Student’s t test was used to determine any significant difference (P < 0.05) 
between strains. 
Strain Mean generation time (min) T-test (P) 
Mean OD600 at 
stationary phase 
T-test (P) 
AYE 167.25 ± 22.62 --- 1.31 ± 0.05 --- 
AYEΔadeRS 183.89 ± 23.87 0.43 1.30 ± 0.06 0.89 
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also no significant difference in the ability of AYE and AYEΔadeRS to grow as a biofilm in TSB 
(Figure 4.2). 
4.4. Effect of adeRS Deletion on Antibiotic and Biocide Susceptibility 
MICs of various antibiotics were determined for AYE and AYE∆adeRS (Table 4.2). These 
antibiotics were chosen for three reasons: a) to compare the antibiotic susceptibility of 
AYEΔadeRS in the present study with published data for other strains, b) to ensure that 
many antibiotic classes were investigated, to obtain a wide susceptibility profile and c) to 
ensure that clinically relevant antibiotics (Table 4.2) were investigated. The mutant strain 
was significantly more susceptible to gentamicin, tobramycin and tigecycline. There was 
two-fold difference in susceptibility to kanamycin and amikacin (MIC value for AYE was 
always at least 2-fold higher than for AYEΔadeRS on five separate occasions for both 
antibiotics). There was no difference in susceptibility to any of the other antibiotics tested.  
The MIC and MBC of eight biocides were determined for AYE and AYEΔadeRS. Five of these 
biocides were surface biocides used to clean inanimate objects. Three antiseptics were also 
investigated. These two groups of biocides were of interest because the hospital 
environment and infected patients are two reservoirs of A. baumannii infection (Dijkshoorn 
et al., 2007). There was no difference in the MIC or MBC of any of the surface biocides or for 
cetylpyridinium chloride for planktonic AYE compared with planktonic AYEΔadeRS (Table 4.3; 
Table 4.4). However, there was a significant increase in chlorhexidine and benzalkonium 
chloride susceptibility when adeRS were deleted (Table 4.4). The two-fold increase in the 
MIC and MBC of benzalkonium chloride was recorded on three separate occasions. There 
may be a significant difference in the MBC of chlorhexidine for AYE and AYEΔadeRS, but 
there was too much variation in the results to draw a conclusion, despite the starting OD600 
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Figure 4.2 Effect of adeRS Deletion on the Ability of AYE to Grow as a Biofilm. 
 
 
Data are the mean of eight separate experiments each carried out four times. The OD570 
(indicating biofilm formation) for AYEΔadeRS is presented as fold change compared with the 
OD570 for AYE ± standard deviation. An unpaired, two-tailed Student’s t test on fold change 
values generated a P value of 0.29. 
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Table 4.2 Minimum inhibitory concentrations of antibiotics for AYE and AYEΔadeRS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CIP, ciprofloxacin; AMK, amikacin; GEN, gentamicin; KAN, kanamycin; TOB, tobramycin; TIG, tigecycline; TET, tetracycline ; COL, colistin; PMX, 
polymyxin B; AMP, ampicillin; CAZ, ceftazidime; CTX, cefotaxime; IMP, imipenem; MER, meropenem; CHL, chloramphenicol; ERY, erythromycin; 
AMP/SUL, ampicillin/sulbactam combination; EtBr, ethidium bromide. 
 
The minimum inhibitory concentration (MIC) values are the mode value of at least three agar-dilution experiments, each carried out in 
triplicate. The MIC of IMP and MER, were determined three times by E-test.  
Significant decreases in MIC are indicated in blue text and MICs which correspond to resistance (I intermediate resistance) to that agent are in 
bold (abreakpoint concentration not available). Clinically relevant antibiotics (used to treat Acinetobacter infection) are highlighted in yellow.
  CIP AMK GEN KANa TOB TIG TETa COL PMXa AMPa 
AYE 64 16I 256 512 16 1 128 1 0.5 >1024 
AYEΔadeRS 32 8 8 256 4 0.25 128 1 0.5 >1024 
  CAZa CTXa IMP MER CHLa ERYa AMP/SULa EtBra 
AYE >1024 1024 0.38 1.5 256 128 8 512 
AYEΔadeRS >1024 512 0.38 1.5 256 128 8 512 
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Table 4.3 Minimum Inhibitory and Bactericidal Concentrations of Surface Biocides for AYE and AYEΔadeRS. 
  Peracetic acid % TBQ % Hydrogen peroxide % SporKlenz % Ethanol % 
  MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC 
AYE  planktonic 0.08 0.16 0.375 0.75 0.06 0.06 3.125 3.125b 6.25 25 
 biofilm 0.08 0.16 --- 6.25 0.06 >2 3.125 12.5 --- 25 
AYE∆adeRS  planktonic 0.08 0.08 or 0.16a 0.375 0.75 0.06 0.06 3.125 6.25c 6.25 25 
 biofilm 0.08 0.16 --- 6.25/12.5 0.06 ≥2 3.125 12.5 --- 25 
 
Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) for planktonic cells were each determined in 
duplicate for three independent cultures. MICs for cells in biofilm were determined for three independent cultures, each with four technical 
repeats. MBC concentrations for cells in biofilm were determined for two independent cultures, each with four technical repeats. 
a MBC values of 0.08 and 0.16 µg/ml were each obtained three times; b An MBC of 6.25 µg/ml was obtained twice; c An MBC of 1.5µg/ml was 
obtained once and 3.125 µg/ml was obtained twice. Significant increases in MBC for cells in biofilm compared with planktonic cells are 
indicated in red text. 
 
Table 4.4 Minimum Inhibitory and Bactericidal Concentrations of Antiseptics for AYE and AYEΔadeRS. 
 Chlorhexidine (µg/ml) Benzalkonium chloride (µg/ml) Cetylpyridinium chloride (µg/ml) 
 MIC MBC MIC MBC MIC MBC 
AYE 18.75 18.75 - >150 4 16 2 4 
AYE∆adeRS 4.5 9 - 75 2 2 – 8
a 
2 4 
 
 
Minimum inhibitory concentrations and minimum bactericidal concentrations were each determined in duplicate on at least two separate 
occasions. a MBC values of 2 µg/ml and 8 µg/ml were each obtained twice. Significant decreases in MIC or MBC are indicated in blue text.
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being the same for each experiment. 
Cells naturally survive on inanimate objects as a biofilm (Smith and Hunter, 2008). Therefore, 
the ability of planktonic cells to form a biofilm (Section 2.5.4.2) in the presence of surface 
biocides was investigated to determine whether the presence of biocides induces biofilm 
formation. The ability of an established biofilm to tolerate surface biocides (Section 2.5.4.3) 
was also compared with the biocide susceptibility of planktonic cells. Three surface biocides 
were chosen for more detailed investigation (growth curves and growth of a biofilm). H2O2 
was selected because interest in this biocide for the elimination of hospital pathogens has 
increased recently (Otter et al., 2010; Piskin et al., 2011). Peracetic acid was chosen because 
it is a peroxygen compound, like hydrogen peroxide, but is considered to be a more potent 
biocide and is active in the presence of organic material. SporKlenz was included since it is a 
mixture of hydrogen peroxide and peracetic acid, and to investigate whether the 
combination of these disinfectants is more effective that each used alone. 
There was no difference in the ability of either AYE or AYEΔadeRS cells to grow as a 
planktonic culture or as a biofilm in the presence of H2O2, peracetic acid or Spor-Klenz (MIC 
values, Table 4.3). However, cells in biofilm were more tolerant of TBQ, Spor-Klenz and H2O2 
than planktonic cells (MBC values, Table 4.3).  
Although there was no difference in the MICs of each surface biocide for AYE and 
AYEΔadeRS, growth kinetics were determined in the presence of H2O2,
 peracetic acid and 
Spor-Klenz to establish whether there were any growth differences between the two strains. 
Deletion of adeRS had no effect on the ability of the strains to grow in the presence of each 
surface biocide (Figure 4.3). Growth kinetics of the two strains in the presence of 
chlorhexidine and benzalkonium chloride were also determined to investigate the 
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Figure 4.3 Effect of adeRS Deletion on Growth of AYE in the Presence of Surface 
Biocides. 
 
 
 
Data are the mean of two independent experiments, each carried out in duplicate. H2O2, 
hydrogen peroxide.
AYE∆adeRS AYE 
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susceptibility difference in greater detail (Figure 5.4). Growth of AYE was impaired in the 
presence of sub-inhibitory concentrations of chlorhexidine and benzalkonium chloride and 
growth of AYEΔadeRS was impaired in the presence of a sub-inhibitory concentration of 
chlorhexidine compared with growth in the absence of biocide (Figure 4.4).  
4.5. Effect of adeRS Deletion on Accumulation of Dyes and Fluoroquinolones 
Hoechst 33342 is a membrane-permeable molecule which fluoresces when bound to DNA, 
or in a hydrophobic environment in the cell, such as the cell membrane. Therefore, Hoechst 
33342 can be used to determine relative differences in efflux between strains (Richmond et 
al., 2012). There was no significant difference in the level of accumulation of Hoechst 33342 
between AYE and AYEΔadeRS at steady state (Figure 4.5). There was also no difference in the 
accumulation of Hoechst 33342 in the presence of efflux inhibitors PAβN or CCCP, compared 
with the accumulation in the absence of efflux inhibitors for AYE or AYEΔadeRS. To 
determine whether deletion of adeRS affected fluoroquinolone accumulation, accumulation 
of ciprofloxacin was measured. The values obtained after five min showed great variation 
(Figure 4.6). It was possible that there was a molecule present in the bacterial supernatant, 
which fluoresced at the excitation wavelength used to measure ciprofloxacin and this gave 
rise to the large differences in values for different experiments. To investigate this, the 
emission profile for the AYE and AYEΔadeRS supernatants at excitation wavelength 279 nm 
was compared with that for ciprofloxacin (10 µg/ml). The supernatants did not emit at the 
same wavelength as ciprofloxacin; therefore this was not the reason for the variation 
observed. Since there was a large variation in the accumulation of ciprofloxacin between. 
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Figure 4.4 Effect of adeRS Deletion on Growth of AYE in the Presence of Antiseptics. 
 
 
Data are the result of one experiment carried out in duplicate. CHX, chlorhexidine; BZK, 
benzalkonium chloride.
AYE∆adeRS AYE 
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Figure 4.5 Effect of adeRS Deletion on the Accumulation of Hoechst H33342 (Bis-
benzimide). 
Data are the mean of four separate experiments, each carried out in duplicate. The steady 
state accumulation for AYE∆adeRS is presented as fold change compared with the steady 
state value for AYE ± standard deviation. An unpaired, two-tailed Student’s t test on fold 
change values generated a P value of 0.40. 
 
 
Figure 4.6 Accumulation of Ciprofloxacin in AYE and AYE∆adeRS at Five Minutes in the 
Presence and Absence of Efflux Inhibitors. 
 
PAβN was added to a final concentration of 50 µg/ml; CCCP was added to a final 
concentration of 50 µM. The results are all data obtained from two experiments, each 
carried out in duplicate, except for AYE∆adeRS in the presence of PAβN, which are the data 
from one experiment, carried out in duplicate.  
 208 
 
experiments, norfloxacin was used for further experiments. Norfloxacin accumulates to 
higher levels (Mortimer and Piddock, 1991) and higher fluorescence levels are measured 
More consistent results were obtained when norfloxacin was used. However, there was no 
significant difference in the concentration of norfloxacin accumulated by AYE and 
AYEΔadeRS in the absence of efflux inhibitors after five min (Figure 4.7).  
An increase in accumulation in the presence of an efflux inhibitor indicates that the target 
classes of efflux pump are active in the absence of efflux inhibitor. To investigate whether 
efflux pumps were active in AYE and AYEΔadeRS, CCCP, which targets pumps that use the 
proton motive force (such as RND pumps AdeABC) was used. There was a significant 
increase in the concentration of norfloxacin accumulated in both strains in the presence of 
CCCP (50 mM) (Figure 4.7). Since AdeABC was predicted to be down-regulated in 
AYEΔadeRS, PAβN was used to specifically investigate whether other RND efflux pumps 
could compensate for down-regulation of AdeABC in AYEΔadeRS. There was no significant 
difference in the accumulation of norfloxacin for AYE or AYEΔadeRS in the presence or 
absence of PAβN (50 µg/ml) (Figure 4.7). However, in the presence of verapamil, there was a 
significant increase in the concentration of norfloxacin accumulated for AYEΔadeRS, but no 
difference for AYE (Figure 4.7). 
The concentration of efflux inhibitors and norfloxacin used in the norfloxacin uptake assay 
were confirmed to have no effect on growth of AYE and AYE∆adeRS. Comparison of viable 
count at time 0 min with the same strain after addition of norfloxacin, both in the presence 
and absence of efflux inhibitor, generated a P value of greater than 0.05 (Figure 4.8).   
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Figure 4.7 Accumulation of Norfloxacin in AYE and AYE∆adeRS at Five Minutes in the 
Presence and Absence of Efflux Inhibitors. 
 
 
 PAβN and verapamil were added to a final concentration of 50 µg/ml; CCCP was added to a 
final concentration of 50 µM. 
An unpaired, two-tailed Student’s t test was carried out to compare the accumulation of 
norfloxacin in presence of efflux inhibitor with accumulation in the same strain in the 
absence of efflux inhibitor. A significant difference is one which generated a P value of <0.05.
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Figure 4.8 Viable Count of AYE and AYEΔadeRS in the Presence and Absence of Efflux Inhibitors. 
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4.6. Discussion  
AdeRS was not essential for growth of AYE cells as a planktonic culture or as a biofilm in the 
absence of antimicrobials, or in the presence of surface biocides. However, compared with 
AYE, growth of AYEΔadeRS was impaired in the presence of chlorhexidine and benzalkonium 
chloride.  
So far, the only reported regulatory system of AdeABC expression is the AdeRS two 
component system. If there are no others, the absence of adeRS in AYE∆adeRS should result 
in down-regulation of AdeABC, which would be expected to result in decreased efflux. This 
would have an impact on susceptibility to antimicrobials that are substrates for this pump. 
AYE∆adeRS was more susceptible to five of the sixteen antibiotics tested, compared with 
AYE (Table 4.2). 
AYEΔadeRS was significantly more susceptible than AYE to gentamicin, tobramycin, 
tigecycline, kanamycin and amikacin. Increased resistance to these antibiotics in strains in 
which adeS, adeR or adeB have been disrupted have been reported previously (Table 4.5; 
Magnet et al., 2001; Marchand et al., 2004; Ruzin et al., 2007; Wong et al., 2009). Although 
AYEΔadeRS was more susceptible to gentamicin than AYE, the MIC for AYEΔadeRS did not 
fall below the BSAC breakpoint, so this result is not clinically significant. There is no 
recommended breakpoint concentration for tigecycline for Acinetobacter spp. since there 
are insufficient clinical data. According to the BSAC non-specific recommended breakpoint 
concentrations for tigecycline, AYE was resistant (MIC > 0.5 µg/ml), whilst AYEΔadeRS was 
susceptible (MIC ≤ 0.25 µg/ml). AYE was resistant (MIC > 4 µg/ml) to tobramycin, whilst 
AYEΔadeRS was susceptible (MIC ≤ 4 µg/ml) (EUCAST, 2012). Therefore, adeRS are important 
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Table 4.5 Comparison of MICs of Antibiotics for AYE and other Strains in which adeRS or adeB Genes are Inactivated or 
Overexpressed. 
a)  
Strain/isolate 
Antibiotic 
Reference 
CIP AMK GEN KAN TIG TET COL 
AYE 64 16 256 512 1 128 1 
This study 
AYEΔadeRS 32 8 8 256 0.25 128 1 
BM4454 (MDR clinical 
isolate) 
 8 8 4  64  (Magnet et 
al., 2001) 
BM4454 adeB::pAT794  1 ≤0.25 1  8  
BM4454 (MDR clinical 
isolate) 
  12 4    
(Marchand et 
al., 2004) 
BM4454 adeB::pAT794   0.25 0.25    
BM4454 adeR::pAT799   0.25 0.5    
BM4454 adeS::pAT800   0.5 1    
CIP 70-10 AdeST153M (over-
expresses adeABC) 
  12 4     
CIP70-12 AdeRP116L (over-
expresses adeABC) 
  12 4     
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a) continued 
Strain 
Antibiotic 
Reference 
 
CIP AMK GEN KAN TIG TET COL  
G5140 (one of two 
clinical isolates studied) 
  48  4   
(Ruzin et al., 
2007) 
G5140 adeB::pCLL3469   0.75  0.5    
15 (one of three 
carbapenem-resistant 
clinical isolates studied) 
64 8 128     
(Wong et 
al., 2009) 15 adeB::pAT801-RA 4 0.5 16     
15 adeS::pAT801-RA 2 1 32     
15 adeR:: pAT801-RA 2 1 32     
AB210 (Tig-susceptible 
clinical isolate) 
>8    0.5  ≤0.5 
(Hornsey et 
al., 2010) 
AB210-6 (TigR laboratory 
mutant selected on Tig; 
derived from AB210) 
>8    64  ≤0.5 
AB211 (TigR clinical isolate 
isolated from same site as 
AB210) 
>8    16  ≤0.5 
AB2B211 adeB::pBK-5 >8    0.5  ≤0.5 
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b) 
Strain/isolate 
Antibiotic 
Reference 
AMP CAZ CTX IMP MER CHL ERY 
AYE >1024 >1024 1024 0.38 1.5 256 128 
This study 
AYEΔadeRS >1024 >1024 512 0.38 1.5 256 128 
BM4454 (MDR clinical isolate)   16   512 64 (Magnet et 
al., 2001) BM4454 adeB::pAT794   4   128 8 
15 (one of three carbapenem-
resistant clinical isolates studied) 
>512 > 512 32 32 64   
(Wong et al., 
2009) 
15 adeB::pAT801-RA 256 256 2 32 16   
15 adeS::pAT801-RA 256 256 2 32 16   
15 adeR:: pAT801-RA 256 256 2 32 16   
AB210 (Tig-susceptible clinical 
isolate) 
 64  >32 >32   
(Hornsey et 
al., 2010) 
AB210-6 (TigR laboratory mutant 
selected on Tig; derived from 
AB210) 
 16  8 4   
AB211 (TigR clinical isolate isolated 
from same site as AB210) 
 64  >32 >32   
AB2B211 adeB::pBK-5  128  >32 >32   
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for resistance to these compounds, and thus far, there are no resistance mechanisms against 
these agents that can compensate for loss of adeRS. 
An MIC of 8 µg/ml (susceptible ≤ 8 µg/ml) was obtained five times for AYEΔadeRS, whilst the 
MIC for AYE was always either 16 or 32 µg/ml (above the BSAC resistance breakpoint). 
Therefore, adeRS has a role in amikacin susceptibility in AYE. This is consistent with a 
previous study in which disruption of adeS in three amikacin-susceptible A. baumannii 
clinical isolates resulted in at least a four-fold increase in susceptibility to this antibiotic 
(Table 4.5a ; Wong et al., 2009).  
Likewise, AYEΔadeRS was consistently more susceptible to kanamycin. This is consistent with 
that reported previously for a strain in which adeS had been disrupted (Table 4.5a; 
Marchand et al. 2004).  
Both AYE and AYEΔadeRS were susceptible to colistin (MIC ≤ 2 µg/ml), which remains one of 
the last available antibiotics for treatment of A. baumannii infections.  
There was no difference in the MICs of imipenem or meropenem for both AYE and 
AYEΔadeRS and both strains were susceptible to these carbapenems (MIC < 2 µg/ml). This 
suggests that AdeRS (and AdeABC) does not have any effect on susceptibility to these 
agents. There was also no difference in susceptibility to imipenem in three carbapenem-
resistant isolates in which adeS and adeB had been disrupted, although a four-fold decrease 
in the MIC of meropenem was reported (Table 4.5; Wong et al., 2009). The unchanged 
susceptibility of AYEΔadeRS to meropenem may be because AYE was already susceptible to 
meropenem, in contrast to the isolates studied by Wong et al. (2009) which were resistant.  
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In this study, there was no difference in the MIC of ciprofloxacin for AYEΔadeRS or AYE (MIC 
values of 64 and 32 µg/ml were obtained for both). This is in contrast to a study by Wong et 
al. (2009) in which the MIC of ciprofloxacin decreased at least four-fold in three 
ciprofloxacin-resistant clinical isolates when adeS was insertionally inactivated (Table 4.5). 
In contrast to the results of this study, there was a decrease in the MIC of tetracycline and 
chloramphenicol for BM4454-1 (Table 4.5; Magnet et al., 2001). AYE contains cmlA (MFS 
efflux pump) and a cat gene (encoding a chloramphenicol acetyl transferase) (Fournier et al., 
2006), which could mask any change in susceptibility to chloramphenicol conferred by lack 
of AdeRS. TetA, an MFS family efflux pump, which exports tetracycline (Fournier et al., 2006) 
has also been identified in AYE and this could mask the effect of the adeRS deletion on 
tetracycline susceptibility. In contrast to previously published data (Magnet et al., 2001; 
Marchand et al., 2004), lack of AdeRS had no effect on susceptibility to erythromycin, or 
cefotaxime (Table 4.5b) (MICs of 512 µg/ml and 1024 µg/ml cefotaxime were recorded for 
both AYE and AYEΔadeRS). Many β-lactamases are present in A. baumannii; those present in 
AYE include VEB-1, OXA-10, AmpC and OXA-69, which could mask any effect of the adeRS 
deletion on cefotaxime susceptibility (Fournier et al., 2006).  
The results of this study suggest that adeRS are involved in tolerance to chlorhexidine and 
benzalkonium chloride, since the MIC of these antiseptics decreased at least two-fold when 
adeRS were deleted. Rajamohan et al. (2010b) observed an 8-fold decrease in the MIC of 
chlorhexidine and a 4-fold decrease for benzalkonium chloride when adeB was deleted in a 
MDR clinical isolate. This suggests that the increased susceptibility of AYEΔadeRS is likely to 
be due to down-regulation of adeABC. The susceptibility of AYE to the surface biocides and 
cetylpyridinium chloride did not increase when adeRS were deleted, suggesting that adeRS 
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are not involved in suseptibilty to these agents, or that other mechanisms can compensate 
for loss of adeRS. For example, qac genes have been identified in AYE and could retain 
tolerance against the quaternary ammonium compounds, TBQ and cetylpyridinium chloride 
(Fournier et al., 2006). 
Collaborators at the HPA obtained chlorhexidine MBC values of 64 µg/ml and 512 µg/ml for 
AYE, supporting the results of the present study. These suggest that the MBC of 
chlorhexidine is variable for AYE (the experimental parameters were identical each time) and 
that chlorhexidine may not be reliable for eradication of A. baumannii from the skin of 
infected patients. A. baumannii AYE is not inhibited by the working concentrations of 
chlorhexidine (2-4%) (Borer et al., 2007; Soma et al., 2012). This is of concern because 
chlorhexidine is a widely used antiseptic in hospitals for whole body washing and in hospital 
disinfectants (Fuangthong et al., 2011) and it has been suggested that the tolerance of A. 
baumannii clinical isolates to chlorhexidine can increase after repeated exposure to sub-
inhibitory concentrations (Kawamura-Sato et al., 2008).  
Rajamohan et al. (2009) reported that biofilm formation can increase in the presence of 
biocides (specific agents not reported). None of the surface biocides investigated induced 
biofilm formation. However, when biofilms were formed in the absence of selective 
pressure, these were significantly more tolerant of TBQ, Spor-Klenz and H2O2. Biofilms are 
known to be more tolerant of antimicrobials than planktonic cells (Maillard, 2007). Factors 
accounting for this increased tolerance include the presence of dormant cells within the 
biofilm, which are able to persist in concentrations that eradicate more peripheral cells and 
the presence of organic material around a biofilm, which can reduce the activity of biocides. 
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There have been several reports of H2O2 being used to eradicate Gram negative bacteria in 
the event of an outbreak. It is concerning that in these cases, concentrations less than the 
MBC (>20,000 ppm) for AYE in biofilm have been used. Hardy et al. (2007) reported the use 
of 280 ppm and Chmielarczyk et al. (2012) reported the use of up to 400 ppm of vapourised 
H2O2. A dry mist-generated H2O2 system contained 5% H2O2; this may be expected to kill AYE 
biofilms, although the final concentration on the hospital surfaces was not reported (Piskin 
et al., 2011). Therefore, unless a high enough concentration of H2O2 is used, this agent may 
not be an effective biocide for removal of A. baumannii.  
There was no difference in the concentration of norfloxacin accumulated by AYE and 
AYEΔadeRS, despite the hypothesised down-regulation of AdeABC in the mutant. This could 
be due to up-regulation of other efflux pumps in AYEΔadeRS. The significant increase in 
accumulation of norfloxacin for AYE and AYEΔadeRS in the presence of CCCP indicates that 
efflux pumps that use the proton motive force are active in both strains. PAβN is an inhibitor 
of MexB and AcrB, RND efflux pumps in P. aeruginosa and E. coli, respectively (Lomovskaya 
et al., 2001; Yu et al., 2005) PAβN has been shown to result in increased accumulation of 
Hoechst 33342 in AYE (Richmond et al., 2012). Furthermore, it has been shown to inhibit the 
A. baumannii RND efflux pump AdeFGH (Cortez-Cordova and Kumar, 2011). It is 
hypothesised that PAβN may also inhibit other RNA pumps in A. baumannii such as AdeABC. 
Based on this hypothesis, further investigation with PAβN suggested that AdeABC is not 
solely responsible for norfloxacin efflux because there was no difference in the 
concentration of norfloxacin accumulated by AYE or AYEΔadeRS when PAβN was used. It is 
likely that other families of efflux pump can compensate for loss of RND pumps in AYE. 
Verapamil, which targets ABC efflux pumps, caused a significant increase in the 
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concentration of norfloxacin accumulated by AYEΔadeRS, but not for AYE, suggesting that an 
ABC pump may be over-produced in AYEΔadeRS (Figure 4.7). Therefore, loss of AdeABC in 
AYEΔadeRS may be compensated by an upregulation of ABC efflux pumps.  
Data from collaborators Wand and Sutton showed that virulence was significantly impaired 
in AYEΔadeRS compared with AYE (P = 0.0053) (unpublished data). RND efflux pumps can 
confer innate resistance to host defence molecules such as bile (Piddock, 2006). In 
Salmonella enterica serovar Typhimurium, all components of the AcrAB-TolC efflux pump are 
required for efficient adhesion to and invasion of cells in vitro (Buckley et al., 2006). Also, 
loss of AcrB or TolC of the RND efflux pump AcrAB-TolC in S. enterica serovar Typhimurium 
resulted in decreased expression of genes involved in pathogenesis (Webber et al., 2009). 
Therefore, AdeABC may enable AYE to survive more easily in Galleria mellonella and to 
establish a more effective infection. However, little is known about the pathogenicity of A. 
baumannii, including the role of efflux pumps such as AdeABC in the virulence of this 
bacterium (Wand et al., 2012). AdeRS could regulate other genes, which contribute to 
virulence. 
4.7. Further Work 
RNA from AYE and AYEΔadeRS was sent for sequencing (ARK-Genomics, Roslin Institute, 
Edinburgh) in June 2012 but the data have not yet been received. Analysis of the 
transcriptomes will confirm whether adeABC is down-regulated in AYEΔadeRS. It will also 
indicate whether AdeRS is the only regulator of adeABC expression and confirm whether the 
phenotypic differences are likely to be at least partly due to decreased expression of this 
efflux pump. Analysis of the whole transcriptome is of further interest, to investigate 
whether AdeRS also regulates other genes, which could be involved in the increased 
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susceptibility to antibiotics and biocides. It would also be interesting to carry out RNA 
sequencing (RNAseq) for AYE and AYEΔadeRS in the presence and absence of an 
antimicrobial to which AYEΔadeRS was more susceptible, to investigate whether adeRS 
interact with different genes in the presence and absence of the agent and whether the 
antimicrobial is likely to be a stimulus for AdeRS. 
Coyne et al. (2010a) showed that AdeABC was overexpressed in AYE compared with CIP 70-
10, a non-MDR reference strain (expression of adeA, adeB and adeC in AYE was 2.84-, 2.80- 
and 2.28-fold higher, respectively). Had more time been available, a mutant that does not 
overexpress adeABC would have been constructed. To do this, ΔadeRS should be 
complemented with adeRS (adeRSS) from an antibiotic susceptible strain. To determine 
which strain from which to clone adeRSS, the sequences of the adeS genes in AYE and a 
susceptible A. baumannii clinical isolate, S1 (obtained from Network for Antimicrobial 
Resistance Surveillance, Singapore) were determined and compared. AYE had the same SNP 
responsible for the Ala94to Val substitution identified in A. baumannii isolate AB211, which 
overexpressed AdeABC (Hornsey et al., 2010; Hornsey et al., 2011). This SNP was not present 
in S1. No other reported adeS mutations were present in AYE or S1 (Table 1.2). Therefore, it 
was hypothesised that the Ala94 to Val substitution in adeS confers adeABC overexpression 
in AYE and that introduction of adeS from S1 into AYEΔadeS would result in down-regulation 
of genes in the AdeRS regulon. RNAseq of this mutant would also indicate which genes are 
under control of AdeRS and also whether AdeR is a broad-spectrum or narrow-spectrum 
regulator. Prior to cloning, RT-PCR of adeB, (or analysis of RNAseq data if available) in both 
strains should be carried out to confirm that the expression level of adeB is lower for S1 and 
that adeRS from this strain is suitable for this further work. 
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The biofilm and biocide susceptibility assays could be amended to replicate hospital 
conditions more closely. In a hospital, there would be the presence of organic material, 
which can affect the efficacy of biocides (Kawamura-Sato et al., 2008) and low nutrient 
availability. These conditions could be simulated by using minimal media and including 
bovine serum albumin in the biocide susceptibility assays. The susceptibility of biofilms to 
biocides can depend on the surface to which the biofilm is attached (Smith and Hunter, 
2008). Therefore, growing the biofilm on common hospital surfaces such as stainless steel 
(used for surfaces and equipment) (Smith and Hunter, 2008) and Teflon and silicone (used to 
coat catheters) (Ostadi et al., 2010) would also provide more insight into the susceptibility of 
AYE biofilms to biocides in the hospital environment.   
Although there was no difference in growth of AYE and AYEΔadeRS in vitro, in the absence of 
any stress, it would be interesting to investigate whether there is any difference in growth of 
AYE and AYEΔadeRS in G. mellonella. Deletion of adeRS could reduce the ability of AYE to 
survive and cause infection in the presence of antimicrobial peptides and other stressors. 
This could be investigated by determining viable counts of bacteria extracted from G. 
mellonella after infection, to determine the ability of the two strains to replicate during 
infection.  
4.8. Key Findings 
 AdeRS is not essential for growth of AYE as a planktonic culture or as a biofilm in vitro 
 AdeRS is not essential for efflux in AYE 
 AdeRS is involved in antibiotic and biocide susceptibility 
 AdeRS is required for full virulence in a G. mellonella model of infection
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5. Role of pmrAB in Growth, Antimicrobial and Biocide 
Susceptibility and Accumulation 
5.1. Background 
pmrAB have been disrupted previously in ATCC 19606 (Beceiro et al., 2011), ATCC 17978 
(Arroyo et al., 2011) and polymyxin-resistant clinical isolates (Arroyo et al., 2011; Beceiro et 
al., 2011) by inserting a kanamycin cassette into the gene; this resulted in increased 
susceptibility to polymyxin antibiotics. The involvement of pmrAB in growth, efflux and 
biocide susceptibility has not been reported to date. The role of pmrAB in virulence has not 
been directly investigated, but a colistin-resistant derivative of ATCC 19606 (Lopez-Rojas et 
al., 2011) and a clinical isolate (Rolain et al., 2011) were less virulent than their colistin- 
susceptible counterparts. 
5.2. Aims and hypotheses 
pmrAB are involved in outer membrane modification (Beceiro et al., 2011). It was 
hypothesised that deletion of pmrAB would result in a difference in biocide and antibiotic 
susceptibility for AYEΔpmrAB compared with AYE, since a change in the outer membrane is 
one of the contributing resistance mechanisms against these compounds (Nikaido, 1994; 
McDonnell and Russell, 1999). In particular, AYEΔpmrAB was hypothesised to be more 
susceptible to polymyxin antibiotics than AYE, since PmrAB are involved in resistance to 
these agents (Adams et al., 2009). 
pmrAB have been reported to be involved in virulence in Salmonella enterica serovar 
Typhimurium (Tamayo et al., 2005) and in Pseudomonas aeruginosa, PmrAB is activated by 
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antimicrobial peptides (McPhee et al., 2003). In light of these publications, AYEΔpmrAB was 
hypothesised to be less virulent than AYE in a G. mellonella model of infection. 
The aims were to investigate whether pmrAB have a role in growth, antibiotic and biocide 
susceptibility, accumulation and virulence in AYE. 
5.3. Effect of pmrAB Deletion on Growth and Antibiotic and Biocide Susceptibility in vitro. 
There was no significant difference in generation time or final optical density at 600 nm 
between AYE and AYEΔpmrAB grown in LB broth (Figure 5.1; Table 5.1).  
There was no difference in susceptibility of AYE or AYEΔpmrAB to any of the antibiotics or 
biocides tested including polymyxin B (Table 5.2; Table 5.3).  
5.4. Effect of pmrAB Deletion on Accumulation of Dyes and Fluoroquinolones 
There was no significant difference in accumulation of Hoechst 33342 between AYE and 
AYEΔpmrAB (Figure 5.2). 
As in the experiments in section 4.4, great variation was observed when ciprofloxacin was 
used to compare accumulation in AYE and AYEΔpmrAB (Figure 5.3). The supernatant of 
AYEΔpmrAB was scanned to ensure that there was not a molecule present in the 
supernatant, which could account for this variation (section 4.5). No fluorescence was 
measured for the supernatant of AYEΔpmrAB. 
There was a significant difference in the concentration of norfloxacin accumulated by AYE 
and AYEΔpmrAB in the absence of efflux inhibitors, with a higher concentration accumulated 
in the mutant (53.96 ± 13.60 ng/mg dry cells vs. 73.43 ± 7.14 ng/mg dry cells) (Figure 5.4).
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Figure 5.1 Growth of AYE and AYEΔpmrAB in LB broth. 
 
Data are the mean of three separate experiments, each carried out in duplicate. Data for AYE 
are the same as those presented in Figure 4.1. 
 
Table 5.1 Mean Generation Times and Optical Density (± Standard Deviation). 
 
Data are the mean of three separate experiments, each carried out in duplicate. The generation 
times were determined from the steepest part of the exponential curve. A two-tailed Student’s t 
test was used to determine any significant difference (P < 0.05) between strains. Data for AYE 
are the same as those included in Table 4.1. 
Strain 
Mean generation time 
(min) 
T-test (P) 
Mean OD600 at 
stationary phase 
T-test (P) 
AYE 163.76 --- 1.19 --- 
AYEΔpmrAB 163.50 0.995 1.11 0.45 
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Table 5.2 Minimum inhibitory concentrations of antibiotics for AYE and AYEΔpmrAB. 
 
 
 
 
 
 
 
 
 
CIP, ciprofloxacin; AMK, amikacin; GEN, gentamicin; KAN, kanamycin; TOB, tobramycin; TIG, tigecycline; TET, tetracycline ; COL, colistin; PMX, 
polymyxin B; AMP, ampicillin; CAZ, ceftazidime; CTX, cefotaxime; IMP, imipenem; MER, meropenem; CHL, chloramphenicol; ERY, erythromycin; 
AMP/SUL, ampicillin/sulbactam combination; EtBr, ethidium bromide. 
 
The minimum inhibitory concentration (MIC) values are the mode value of at least three agar-dilution experiments, each carried out in 
triplicate. The MIC of IMP and MER were determined three times by E-test.  
MICs which correspond to resistance (I intermediate resistance) to that agent are in bold (abreakpoint concentration not available). Clinically 
relevant antibiotics (used to treat Acinetobacter infection) are highlighted in yellow. 
Data for AYE are the same as those in Table 4.2 
  CIP AMK GEN KANa TOB TIG TETa COL PMXa AMPa 
AYE 64 16I 256 512 16 1 128 1 0.5 >1024 
AYEΔpmrAB 64 16I 128 1024 16 1 128 1 0.5 >1024 
 CAZa CTXa IMP MER CHLa ERYa AMP/SULa EtBra 
AYE >1024 1024 0.38 1.5 256 128 8 512 
AYEΔpmrAB >1024 512 0.5 1.5 256 128 8 512 
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Table 5.3 Minimum Inhibitory and Bactericidal Concentrations of Biocides for AYE and AYEΔpmrAB. 
  Peracetic acid % TBQ % Hydrogen peroxide % SporKlenz % Ethanol % 
  MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC 
AYE  0.08 0.08/0.16 0.375 0.75 0.03/0.06 0.03/0.06 3.125 3.125/6.25 3.125/6.25 25 
∆pmrAB 0.08 0.08 0.375 0.75 0.03/0.06 0.03/0.06 3.125 3.125 3.125/6.25 25 
 
Minimum inhibitory concentrations and minimum bactericidal concentrations were each determined in duplicate on two separate 
occasions. 
Data for AYE are the same as those in Table 4.3.
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Figure 5.2 Effect of pmrAB Deletion on the Accumulation of Hoechst H33342 (Bis-
benzimide). 
 
Data are the mean of three separate experiments, each carried out in duplicate. The steady state 
accumulation for AYE∆pmrAB is presented as fold change compared with the steady state value for 
AYE ± standard deviation. Student’s t test on fold change values returned a P value of 0.98. Data for 
AYE are the same as those in Figure 4.3. 
Figure 5.3 Accumulation of Ciprofloxacin in AYE and AYE∆pmrAB at Five Minutes in the 
Presence and Absence of Efflux Inhibitors. 
 
PAβN was added to a final concentration of 50 µg/ml; CCCP was added to a final concentration of 50 µM. 
The results are all data from two experiments, each carried out in duplicate. Data for AYE are the same 
as those in Figure 4.4. 
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To investigate whether efflux pumps were active in the two strains, CCCP was used. In the 
presence of CCCP, there was a significant difference in the concentration of norfloxacin 
accumulated by both AYE and AYEΔpmrAB. In the presence of PAβN, there was no difference 
in the concentration of norfloxacin accumulated for either strain. In the presence of 
verapamil, there was a significant increase in norfloxacin accumulation for AYEΔpmrAB, but 
not for AYE (Figure 5.4). 
The concentration of efflux inhibitors and norfloxacin used in the norfloxacin uptake assay 
were confirmed to have no effect on growth of AYE and AYE∆pmrAB. Comparison of viable 
count at time 0 min with the same strain after addition of norfloxacin, both in the presence 
and absence of efflux inhibitor generated a P value of greater than 0.05 (Figure 5.5).  
5.5. Discussion 
There was no difference in growth of AYE and AYEΔpmrAB suggesting that pmrAB are not 
essential for the growth of AYE.  
In AYE, pmrAB were also not involved in susceptibility to any of the antibiotics and biocides 
tested. PmrAB has been implicated in resistance to polymyxin B and colistin and disruption 
of pmrAB in colistin or polymyxin B-resistant strains and clinical isolates has been shown to 
cause loss of resistance to these agents (Arroyo et al., 2011; Beceiro et al., 2011). Therefore, 
it was hypothesised that AYEΔpmrAB would be more susceptible to the polymyxins. Arroyo 
et al. (2011) reported that when pmrAB were disrupted in polymyxin-resistant derivatives of 
ATCC 17978, the MIC of the antibiotic decreased by 8-16-fold. However, there was no 
significant change in MIC of polymyxin B for wild-type ATCC 17978, which is sensitive to 
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Figure 5.4 Accumulation of Norfloxacin in AYE and AYE∆pmrAB at Five Minutes in the 
Presence and Absence of Efflux Inhibitors. 
 
PAβN and verapamil were added to a final concentration of 50 µg/ml; CCCP was added to a 
final concentration of 50 µM. 
A two-tailed Student’s t test was carried out to compare the accumulation of norfloxacin in 
presence of efflux inhibitor with accumulation in the same strain in the absence of efflux 
inhibitor. A significant difference is one which generated a P value of <0.05. 
Data for AYE are the same as those in Figure 4.5.
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Figure 5.5 Viable Count of AYE and AYEΔpmrAB in the Presence and Absence of Efflux Inhibitors.
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polymyxin B. This result suggests that pmrAB can mediate resistance to polymyxins, but that 
it contributes little to the intrinsic level of resistance in ATCC 17978. These data support the 
results obtained for AYE. AYE is susceptible to colistin and polymyxin B, which could account 
for the lack of MIC change when pmrAB were deleted.  
By contrast, Beceiro et al. (2011) did observe increased susceptibility to colistin in both 
resistant (MIC 32 µg/ml compared with 0.19 µg/ml) and susceptible derivatives (MIC 1 µg/ml 
compared with 0.125 µg/ml) of ATCC 19606 when pmrAB were disrupted. The results of this 
study may suggest that pmrAB are not expressed in wild-type AYE, but that they are 
expressed in wild-type ATCC 19606.  
Other factors, which could compensate for loss of pmrAB in AYE are differences in the outer 
membrane of AYE and ATCC 19606. Soon et al. (2012; 2011a; 2011b) investigated the 
surface hydrophobicity, net charge and rigidity of the outer membrane of colistin-resistant 
and -susceptible A. baumannii. Differences in cell membrane, such as a more hydrophobic 
cell surface, a less rigid outer membrane and a more positively charged cell surface were 
identified in resistant bacteria in these studies. Differences in the capsules of the two strains 
could also provide AYE with more protection than ATCC 19606; increased production of 
capsule polysaccharide has been implicated in polymyxin B resistance in K. pneumoniae 
(Campos et al., 2004). The MIC of colistin for both AYE in this study and ATCC 19606 (Beceiro 
et al., 2011) was 1 µg/ml. However, the results of this study suggest that the intrinsic 
protective mechanisms against colistin differ between the strains, with pmrAB being 
important in ATCC 19606, but not in AYE. Complete loss of LPS production has been 
observed in colistin-resistant ATCC 19606 derivatives, but there are no published reports of 
this phenomenon in other strains of A. baumannii to date. The outer membrane of ATCC 
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19606 may have a higher affinity for the polymyxins than other strains, which would account 
for PmrAB having a more important role in this strain than in AYE and ATCC 17978, and 
explain why loss of LPS is a more common resistance mechanism in ATCC 19606 than in 
others.  
The increased concentration of norfloxacin accumulated in AYEΔpmrAB compared with AYE 
suggests that PmrAB is important for the level of accumulation of some antimicrobials in 
AYE. However, there was no difference in the level of Hoechst 33342 accumulation, so this 
conclusion cannot be drawn for all agents. PmrAB could be involved in the regulation of 
efflux pumps, and the deletion of pmrAB may result in fewer active efflux pumps. The 
increased activity of ABC efflux pumps (there was increased norfloxacin accumulation in the 
presence of verapamil) could be a compensatory mechanism.  
Alternatively, the deletion of pmrAB may have resulted in an alteration in the cell outer 
membrane, allowing more norfloxacin into the cell, with no change in the level of efflux. It 
has been reported that PmrAB is involved in maintaining outer membrane integrity in 
Citrobacter rodentium and Salmonella enterica serovar Typhimurium (Viau et al., 2011; 
Murata et al., 2007). There was no difference in accumulation of the membrane-permeable 
molecule, Hoechst 33342, which fluoresces when in the lipid membrane (Richmond et al., 
2012), which could indicate that there was no difference in the hydrophobicity of the outer 
membrane of AYEΔpmrAB. However, there was a difference in the concentration of 
norfloxacin accumulated. Norfloxacin enters the bacterial cell through porins suggesting that 
the porin composition of the outer membrane could have changed (Hirai et al., 1986). 
However, the reason for this result may be that norfloxacin is a better indicator of overall 
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accumulation in AYE. The highly significant (P <0.001) difference in norfloxacin accumulation 
in the presence of CCCP confirms that efflux pumps are active in both strains. 
Data from collaborators Wand and Sutton showed that compared with AYE, the ability of 
AYEΔpmrAB to kill G. mellonella was significantly impaired (P = 0.0007) (unpublished data). 
The Galleria mellonella haemolymph is analogous to the blood in mammals and is important 
in the clearance of microbial infections. Antimicrobial peptides are released into the 
haemolymph and these target bacterial cell walls (Kavanagh and Reeves, 2004). The TCS 
PmrAB has been implicated in mediating antimicrobial peptide resistance and increased 
virulence in Salmonella enterica serovar Typhimurium due to an altered LPS structure 
(Tamayo et al., 2005). In Pseudomonas aeruginosa, PmrAB is activated by antimicrobial 
peptides and regulates resistance to these proteins (McPhee et al., 2003). However, Arroyo 
et al. (2011) reported that the deletion of pmrAB in polymyxin B- resistant mutants of A. 
baumannii ATCC 17978 resulted in an increased susceptibility to polymyxin B, but not to 
antimicrobial peptides. It is also possible that PmrAB regulates virulence genes required for 
infection of G. mellonella in AYE, rather than the decreased virulence being a result of 
altered LPS. 
5.6. Further Work 
RNAseq would provide more information about the genes that PmrAB regulates, and 
possibly begin to address the question of why more norfloxacin accumulated in AYEΔpmrAB 
than in AYE. A comparison of the LPS and outer membrane protein profiles of AYE and 
AYEΔpmrAB could also be carried out to investigate whether the outer membrane is any 
different between the two strains. Had more time been available, the experiments carried 
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out to investigate the role of adeRS in biofilm formation and biocide susceptibility (Section 
4.3) would have been carried out for AYEΔpmrAB.  
As for AYEΔadeRS (Section 4.7), it would be interesting to investigate whether there is any 
difference in growth of AYE and AYEΔpmrAB in G. mellonella. Although there was no 
difference in growth of AYE and AYEΔpmrAB in vitro, deletion of pmrAB could reduce the 
ability of AYE to survive and cause infection in the presence of antimicrobial peptides and 
other stressors.  
5.7. Key Findings 
 pmrAB are not involved in growth in vitro 
 pmrAB are not involved in susceptibility to any of the antibiotics tested in this study 
 pmrAB are involved in the level of accumulation of some compounds, but not others 
 pmrAB are required for full virulence in a G. mellonella model of infection  
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6. Overall Discussion, Key Findings and Conclusions  
6.1. Overall Discussion 
A. baumannii are often resistant to the antibiotics commonly used to select bacteria during 
genetic manipulation experiments. A method, which used a tellurite resistance cassette to 
overcome this problem, was used to delete the genes, adeRS and pmrAB in A. baumannii 
AYE.  
AYE, AYE∆adeRS and AYE∆pmrAB were all able to accept pMo130-TelR deletion constructs by 
conjugation and recombine them into their chromosome. By contrast, none of the strains 
were able to recombine the complementation constructs. pMo130-TelR/bfmRS could not be 
introduced into AYE, suggesting that there may be regions of the chromosome, which are 
difficult to introduce new DNA into. However, since the same UP and DOWN fragments were 
used, this does not explain why the complementation construct could not recombine in the 
same region as the deletion construct used to delete the genes initially. Sequencing of the 
UP and DOWN regions in the deletion mutants suggested that the regions were sufficiently 
conserved after gene deletion for recombination to occur between the chromosome and 
complementation construct (Figure 3.13; Figure 3.27). It is not known whether the 
complementation constructs and bfmRS deletion construct were accepted by AYE during 
conjugation, since pMo130-TelR is a suicide vector and is lost if recombination does not 
occur. Therefore, the limiting factor of the method could be either the conjugation or 
recombination step. 
It was important to complement AYEΔadeRS and AYEΔpmrAB to confirm that the increased 
susceptibility of AYEΔadeRS and increased efflux in AYEΔpmrAB were a consequence of the 
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adeRS and pmrAB gene deletions respectively. However, in this research, these mutants 
could not be complemented by introducing the deleted region directly back onto the 
chromosome. This method was chosen as some of the response regulator and a downstream 
gene were deleted in each case (Figure 3.15; Figure 3.31) and it was unknown, when 
designing the complementation strategy, whether both components of the two component 
system were needed to complement, or whether only the histidine kinase was required. 
adeR transcripts were detected in both AYE and AYEΔadeRS (as shown in RNAsequencing; 
Richmond and Piddock, unpublished). However, it was hypothesised that AdeR would not be 
active in AYEΔadeRS as 126 bp of adeR (C-terminus, DNA binding domain; Figure 3.15) was 
deleted. If this is true, both adeR and adeRS would be required to complement. However, it 
was unknown whether the transcript was degraded after translation (Sabate et al., 2010), or 
whether a truncated protein remained in the cell. If both adeR and adeS were introduced on 
a plasmid, a truncated AdeR protein could compete with the normal AdeR for interaction 
with AdeRS, since the N-terminal receiver domain was unaffected. As only 12 bp of pmrA (C-
terminus, DNA binding domain, Figure 3.31) was deleted, this gene may have given rise to a 
functional protein, but again, it was not certain. Ideally, only adeS (or all of adeRS) and pmrB 
(or all of pmrAB) would have been deleted and only adeS (or adeRS) and pmrB (or pmrAB) 
complemented, respectively.  
Time did not permit investigation into whether AdeR and PmrAB were produced and 
functional. Therefore, complementation on the chromosome was considered to be the best 
strategy and this was pursued for as long as possible. However, a disadvantage of this 
method was that the genome could have been disrupted as a result of a second genetic 
manipulation. Had the complemented strains been constructed, the upstream and 
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downstream regions and the target gene would have been sequenced to ensure that the 
region was restored without any errors. If more time were available, a better strategy would 
have been to re-make the mutants, to ensure that adeRS and pmrAB were deleted without 
disrupting any flanking genes. To do this, the primers would have been designed to bind 
inside the genes to be deleted. This would have deleted an internal region of the gene(s), 
rather than the whole gene(s), but would have ensured that flanking genes were 
undisrupted. The initial strategy was to delete the whole of adeS, but it was not noticed until 
after the genes were deleted that the location of the primers meant that flanking genes 
would also be disrupted. However, since the main aim of the research was to investigate the 
role of TCSs in adaptive responses, disruption of the response regulator did not mean that 
this aim was not addressed.  
AdeRS were not essential for growth of AYE planktonic or biofilm cells in the absence of 
antimicrobials. However, in the presence of chlorhexidine and benzalkonium chloride, it 
played a role in growth and susceptibility. 
AdeRS are essential for clinical resistance to tigecycline and tobramycin, increased resistance 
to gentamicin and increased tolerance to chlorhexidine and benzalkonium chloride, 
suggesting that other efflux pumps cannot completely compensate for loss of AdeABC. 
AdeRS were also involved in a small difference in susceptibility to kanamycin and amikacin. 
The involvement of adeRS in resistance to carbapenems and polymyxins could not be 
elucidated, since AYE is susceptible to these compounds. The interpretation of the results 
obtained for AYEΔadeRS relied upon the assumption that there are no other regulatory 
mechanisms of adeABC transcription and that adeABC is down-regulated in AYEΔadeRS. 
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Biofilm formation protected both AYE and AYEΔadeRS cells against some biocides, but there 
was no difference in the protective effect of biofilm between the two strains. This may be 
because adeRS had no effect on biofilm formation and there was no difference in 
susceptibility of the biocides to which cells in biofilm were exposed. 
Data suggested efflux via ABC efflux pumps in AYEΔadeRS and AYEΔpmrAB (Figure 4.7 and 
Figure 5.4, respectively). ABC efflux pumps may compensate for down-regulation of other 
classes of efflux pump such as the RND pump, AdeABC. More work (for example analysis of 
the outer membrane protein or LPS profiles of AYEΔpmrAB) must be carried out before 
conclusions can be drawn about the role of PmrAB in antimicrobial accumulation. However, 
pmrAB may be involved in the regulation of efflux pumps. This is because the concentration 
of norfloxacin accumulated was higher for AYEΔpmrAB (73.43 ng nor/mg dry cells) than for 
AYE (53.96 ng nor/mg dry cells) in the absence of efflux inhibitors (Figure 5.4). PmrAB did not 
appear important in AYE for susceptibility to the antibiotics tested, although in some strains 
such as ATCC 19606, it may have a more important role in intrinsic polymyxin resistance 
(Beceiro et al., 2011). This suggests that any efflux pumps that may be regulated by pmrAB 
are not required for antibiotic resistance and that the role of pmrAB in antibiotic 
susceptibility varies between strains.  
Both AdeRS and PmrAB are required for wild-type levels of virulence, although they are not 
essential for growth in vitro. However, it is possible that they do play a role in growth during 
infection in G. mellonella, since this was not investigated in this study. It is also possible that 
adeRS and pmrAB regulate genes required for virulence in G. mellonella. 
Analysis of the AYE, AYEΔadeRS, AYEΔadeRS/adeRSS (Section 4.7) and AYEΔpmrAB 
transcriptomes is valuable further work, which would indicate which genes are regulated by 
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AdeRS and PmrAB and begin to answer the further questions raised by the results of this 
study. 
6.2. Overall Key Findings 
In AYE: 
 adeRS and pmrAB were deleted, but could not be complemented; bfmRS could not be 
deleted  
 In the absence of antimicrobials, neither AdeRS and PmrAB were essential for growth of 
planktonic cells and AdeRS was not required for biofilm formation 
 AdeRS played a role in antibiotic and biocide susceptibility whilst PmrAB was not 
involved in susceptibility to any of the antibiotics tested. Cells in biofilm were more 
tolerant of biocides than their planktonic counterparts 
 Efflux pumps were active in all strains. There may be increased activity of ABC efflux 
pumps in AYE∆adeRS and AYE∆pmrAB.  
 AdeRS and PmrAB are required for full virulence 
6.3. Overall Conclusions 
The TCSs AdeRS and PmrAB are important in AYE, since both are required for full virulence. 
AdeRS appears to have a more important role than PmrAB in antimicrobial susceptibility.
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7. Appendices 
Appendix 1. Buffer and Agar Constituents. 
Glycine Hydrochloride Buffer (0.1 M, pH 3.0) 
Glycine (Sigma-Aldrich, UK, 50046) (3.75 g) was dissolved in dH2O (400 ml) and the solution was 
adjusted to pH 3.0 with HCl. dH2O was added to a final volume of 500 ml. The buffer was 
sterilised by autoclaving. 
Sodium Phosphate Buffer (50mM, pH 7.0) 
Na2HPO4·2H2O (Sigma-Aldrich, UK, 71643) (2.67 g) was dissolved in dH2O (300 ml) to produce an 
alkaline solution. NaH2PO4·2H2O (Sigma-Aldrich, UK, 71505) (2.34 g) was dissolved in dH2O (300 
ml) to produce an acidic solution. The acidic solution was added to the alkaline solution until pH 
7.0 was achieved. The buffer was filter sterilised (Millipore Corporation; SCHVU05RE).  
High Magnesium Agar (MgLB)  
Tryptone, 10 g/L; yeast extract, 5g/L, NaCl, 5 g/L; 1mM MgCl2, agar, 15 g/L.
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Appendix 2. pMo130-TelR Sequence, Primers and Restriction Sites. 
gacgaaagggcctcgtgatacgcctatttttataggttaatgtcatgataataatggtttcttagacgtcaggtg
gcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctca
tgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagtatgattgaacaagatggattgcacg
caggttctccggccgcttgggtggagaggctattcggctatgactgggcacaacagacaatcggctgctctgatg
ccgccgtgttccggctgtcagcgcaggggcgcccggttctttttgtcaagaccgacctgtccggtgccctgaatg
aactccaagacgaggcagcgcggctatcgtggctggccacgacgggcgttccttgcgcagctgtgctcgacgttg
tcactgaagcgggaagggactggctgctattgggcgaagtgccggggcaggatctcctgtcatctcaccttgctc
ctgccgagaaagtatccatcatggctgatgcaatgcggcggctgcatacgcttgatccggctacctgcccattcg
accaccaagcgaaacatcgcatcgagcgagcacgtactcggatggaagccggtcttgtcgatcaggatgatctgg
acgaagagcatcaggggctcgcgccagccgaactgttcgccaggctcaaggcgcggatgcccgacggcgaggatc
tcgtcgtgacccatggcgatgcctgcttgccgaatatcatggtggaaaatggccgcttttctggattcatcgact
gtggccggctgggtgtggcggaccgctatcaggacatagcgttggctacccgtgatattgctgaagagcttggcg
gcgaatgggctgaccgcttcctcgtgctttacggtatcgccgctcccgattcgcagcgcatcgccttctatcgcc
ttcttgacgagttcttctgattaattaaactagtcacttcttgaatttgtcaaaacccgtccatataattagcac
tcgctgcacaggaggaaacgatgacgtactccaaacaagccgtttcccgtagacacaaacgtttggccctgagcg
ccgccgcgctcaccgcagccgcttgcatgtcggcgcacgcgcagagcgacggcgcaactcaagcgtttgcgaaag
aaacgaaccaaaagccatataaggaaacatacggcatttcccatattacacgccatgatatgctgcaaatccctg
aacagcaaaaaaatgaaaaatatcaagtttctgaatttgattcgtccacaattaaaaatatctcttctgcaaaag
gcctggacgtttgggacagctggccattacaaaacgctgacggcactgtcgcaaactatcacggctaccacatcg
tctttgcattagccggagatcctaaaaatgcggatgacacatcgatttacatgttctatcaaaaagtcggcgaaa
cttctattgacagctggaaaaacgctggccgcgtctttaaagacagcgacaaattcgatgcaaatgattctatcc
taaaagaccaaacacaagaatggtcaggttcagccacatttacatctgacggaaaaatccgtttattctacactg
atttctccggtaaacattacggcaaacaaacactgacaactgcacaagttaacgtatcagcatcagacagctctt
tgaacatcaacggtgtagaggattataaatcaatctttgacggtgacggaaaaacgtatcaaaatgtacagcagt
tcatcgatgaaggcaactacagctcaggcgacaaccatacgctgagagatcctcactacgtagaagataaaggcc
acaaatacttagtatttgaagcaaacactggaactgaagatggctaccaaggcgaagaatctttatttaacaaag
catactatggcaaaagcacatcattcttccgtcaagaaagtcaaaaacttctgcaaagcgataaaaaacgcacgg
ctgagttagcaaacggcgctctcggtatgattgagctaaacgatgattacacactgaaaaaagtgatgaaaccgc
tgattgcatctaacacagtaacagatgaaattgaacgcgcgaacgtctttaaaatgaacggcaaatggtacctgt
tcactgactcccgcggatcaaaaatgacgattgacggcattacgtctaacgatatttacatgcttggttatgttt
ctaattctttaactggcccatacaagccgctgaacaaaactggccttgtgttaaaaatggatcttgatcctaacg
atgtaacctttacttactcacacttcgctgtacctcaagcgaaaggaaacaatgtcgtgattacaagctatatga
caaacagaggattctacgcagacaaacaatcaacgtttgcgccgagcttcctgctgaacatcaaaggcaagaaaa
catctgttgtcaaagacagcatccttgaacaaggacaattaacagttaacaaataatagtagctttcaaataaaa
cgaaaggctcagtcgaaagactgggcctttcgttttaatctgagaattccgcaattaatgtaagttagctcactc
attaggcaccgggatctcgaccgatgcccttgagagccttcaacccagtcagctccttccggtgggcgcggggca
tgactatcgtcgccgcacttatgactgtcttctttatcatgcaactcgtaggacaggtgccggcagcgctctggg
tcattttcggcgaggaccgctttcgctggagcgcgacgatgatcggcctgtcgcttgcggtattcggaatcttgc
acgccctcgctcaagccttcgtcactggtcccgccaccaaacgtttcggcgagaagcaggccattatcgccggca
tggcggccccacgggtgcgcatgatcgtgctcctgtcgttgaggacccggctaggctggcggggttgccttactg
gttagcagaatgaatcaccgatacgcgagcgaacgtgaagcgactgctgctgcaaaacgtctgcgacctgagcaa
caacatgaatggtcttcggtttccgtgtttcgtaaagtctggaaacgcggaagtcagcgccctgcaccattatgt
tccggatctgcatcgcaggatgctgctggctaccctgtggaacacctacatctgtattaacgaagcgctggcatt
gaccctgagtgatttttctctggtcccgccgcatccataccgccagttgtttaccctcacaacgttccagtaacc
gggcatgttcatcatcagtaacccgtatcgtgagcatcctctctcgtttcatcggtatcattacccccatgaaca
gaaatcccccttacacggaggcatcagtgaccaaacaggaaaaaaccgcccttaacatggcccgctttatcagaa
gccagacattaacgcttctggagaaactcaacgagctggacgcggatgaacaggcagacatctgccgcggaggaa
cgcaaccgcagcctcatcacgccggcgcttcttggccgcgcgggattcaacccactcggccagctcgtcggtgta
 
 
242 
 
gctctttggcatcgtctctcgcctgtcccctcagttcagtaatttcctgcatttgcctgtttccagtcggtagat
attccacaaaacagcagggaagcagcgcttttccgctgcataaccctgcttcggggtcattatagcgattttttc
ggtatatccatcctttttcgcacgatatacaggattttgccaaagggttcgtgtagactttccttggtgtatcca
acggcgtcagccgggcaggataggtgaagtaggcccacccgcgagcgggtgttccttcttcactgtcccttattc
gcacctggcggtgctcaacgggaatcctgctctgcgaggctggccggctaccgccggcgtaacagatgagggcaa
gcggatggctgatgaaaccaagccaaccaggaagggcagcccacctatcaaggtgtactgccttccagacgaacg
aagagcgattgaggttaattaataactgtcagaccaagtttactcatatatactttagattgatttaaaacttca
tttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgaccaaaatcccttaacgtgagttttc
gttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgagatcctttttttctgcgcgtaatctg
ctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttcc
gaaggtaactggcttcagcagagcgcagataccaaatactgtccttctagtgtagccgtagttaggccaccactt
caagaactctgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggctgctgccagtggcgataa
gtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggttc
gtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatgagaaagcgc
cacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgaggga
gcttccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgattttt
gtgatgctcgtcaggggggcggagcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttg
ctggccttttgctcacatgttctttcctgcgttatcccctgattctgtggataaccgtattaccgcctttgagtg
agctgatatcagggccccgctagccagatcttcccgggtaccgagctcgaattggggatcttgaagttcctattc
cgaagttcctattctctagaaagtataggaacttcagagcgcttttgaagctgatgtgcttaaaaacttactcaa
tggaattagctcgagcagaaagtcaaaagcctccgaccggaggcttttgacttgagggggatcgatcccttatgg
ctctgcacccggctccatcaccaacaggtcgcgcacgcgcttcactcggttgcggatcgacactgccagcccaac
aaagccggttgccgccgccgccaggatcgcgccgatgatgccggccacaccggccatcgcccaccaggtcgccgc
cttccggttccattcctgctggtactgcttcgcaatgctggacctcggctcaccataggctgaccgctcgatggc
gtatgccgcttctccccttggcgtaaaacccagcgccgcaggcggcattgccatgctgcccgccgctttcccgac
cacgacgcgcgcaccaggcttgcggtccagaccttcggccacggcgagctgcgcaaggacataatcagccgccga
cttggctccacgcgcctcgatcagctcttgcactcgcgcgaaatccttggcctccacggccgccatgaatcgcgc
acgcggcgaaggctccgcagggccggcgtcgtgatcgccgccgagaatgcccttcaccaagttcgacgacacgaa
aatcatgctgacggctatcaccatcatgcagacggatcgcacgaacccgcagaactcacccccgaacacgagcac
ggcacccgcgaccactatgccaagaatgcccaaggtaaaaattgccggccccgccatgaagtccgtgaatgcccc
gacggccgaagtgaagggcaggccgccacccaggccgccgccctcactgcccggcacctggtcgctgaatgtcga
tgccagcacctgcggcacgtcaatgcttccgggcgtcgcgctcgggctgatcgcccatcccgttactgccccgat
cccggcaatggcaaggactgccagcgccgcgatgaggaagcgggtgccccgcttcttcatcttcgcgcctcgggc
ctccaggccgcctacctgggcgaaaacatcggtgtttgtggcattcatacggactcctgttgggccagctcgcgc
acgggctggcgggtcagcttggcttgaagatcgccacgcattgcggcgatctgcttctcggcatccttgcgcttc
tgcacgccttcctgctggatgcgaataacgtcctcgacggtcttgatgagcgtcgtctgaacctgcttgagcgtg
tccacgtcgatcaccaggcgttggttctccttcgccgtctcgacggacgtgcgatgcagcagggccgcattgcgc
ttcatcaggtcgttggtggtgtcgtcgatggccgtggccagttcgacggcgttcttctgctcgttgaggctcaag
gccagcatgaattgccgcttccacgccggcacggtgatttcgcggatggtgtggaatttatcgaccagcatctgg
ttgttggcctggatcatgcggatggtcggcaggctctgcatggccgaatgttgcaaggcgatcaggtcgccgatg
cgcttgtccaggttggcaaccatcgcatcgaggtcggccagctcctgcacgcggccagggtcgttcccgacattg
ccgcgcagaccctcggcctgctcgcgcagctcggcaaggcggaccttgccggccgcgatgtggacgccaagaagg
cggtgttcctcgcgcacggctgcgaacatttcgtcgagcgaggcattgcgctgcgcgatgccttgctgggtggtc
tgcacttcgctgaccaggtgttcgatctgctcgcgggtcgtgtcgaagcgcgccatgaagcccgtcgaacggacg
cggaagcggtcgatcagcgggccaatcaggggcaggcgggaacggttgtcggacaaagggccgacgttcagggaa
cgggccttggcgacaacctgggtcagtttctcgcctgcttcgtccaggtcgctgttgcgcacctggtccagcagg
ctatcggcgtagcgggacgtgtgctcggccacgtcgcggccgaactcggcaacggtctgcggactgccgacctcg
atccgctgcgcgaccgcatggacttccggcacgtcgctttcctgcaagcccagctcgcgcagggttgccggggtc
atgtcgaaggcgacgataggggccttggcgtcgtgcgtcgttttcagtgcgttcatagggttctcccgccgtgtt
attggttgatgccttccaggctctgcgaaaggctccgcatgagcgcctggtgagctttggccgcctcggcgacca
ttgccggattcatgttcttggtggtgatgagcgcgagggtgtgctgacgccagacgggcaccaggacggatgccg
tttcagagaagcggtccagcatgtccacggcctgcgcccgcgtgagcttcatctgagtgacgctcatttcatggg
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acgccatgagggttgccaggttggcgagcttgcgcgcgaagcgttcgcgcggcttgtcgaactcgatcacgccgg
ccttggccgcgccggcctcggggttctcgtccaggaactcgcgcccggcttgaatgtaggctctgagccggtcta
cctcggcctcatgcgtattgagcatgtcatccaaggcgcgcaacgtgtcccgcacgcgctgcgctacgccctcgg
cttcgtccagcaactggtcgagcgtcttgcgggcgacctgatacctcacctggcgttcaacctcacggccaagca
tcttctcgaaccaggtaggcttttccgcgatcttgcgggggtccgcgtcggccagcttcgccacgatctggctga
ttttgtcggccagcgcggcaactgcgccgtgctccatcagattcgacagctcgttgagggaatccgccccgtcga
tgccggccccgtactcgccaatcgtcgccggcgacgcgaagagggcgggcaaaacctcccccttcaatcgcgcca
tgttcacgctttgttcttccatggtatatctccttcttaaagttaaacaaaattattcggaacccagcatgatat
tccggaaataccaactaagtcaacggctgatatccattgctgttgacaaagggaatcaggggatcttgaagttcc
tattccgaagttcctattctctagaaagtataggaacttcagagcgcttttgaagctaattcgagctcggtaccc
gggaagcttgagctgttgacaattaatcatcggctcgtataatgtgtggaatatcacagaaggagacagaatact
atgaacaaaggtgtaatgcgaccgggccatgtgcagctgcgtgtactggacatgagcaaggccctggaacactac
gtcgagttgctgggcctgatcgagatggaccgtgacgaccagggccgtgtctatctgaaggcttggaccgaagtg
gataagttttccctggtgctacgcgaggctgacgagccgggcatggattttatgggtttcaaggttgtggatgag
gatgctctccggcaactggagcgggatctgatggcatatggctgtgccgttgagcagctacccgcaggtgaactg
aacagttgtggccggcgcgtgcgcttccaggccccctccgggcatcacttcgagttgtatgcagacaaggaatat
actggaaagtggggtttgaatgacgtcaatcccgaggcatggccgcgcgatctgaaaggtatggcggctgtgcgt
ttcgaccacgccctcatgtatggcgacgaattgccggcgacctatgacctgttcaccaaggtgctcggtttctat
ctggccgaacaggtgctggacgaaaatggcacgcgcgtcgcccagtttctcagtctgtcgaccaaggcccacgac
gtggccttcattcaccatccggaaaaaggccgcctccatcatgtgtccttccacctcgaaacctgggaagacttg
cttcgcgccgccgacctgatctccatgaccgacacatctatcgatatcggcccaacccgccacggcctcactcac
ggcaagaccatctacttcttcgacccgtccggtaaccgcaacgaagtgttctgcgggggagattacaactacccg
gaccacaaaccggtgacctggaccaccgaccagctgggcaaggcgatcttttaccacgaccgcattctcaacgaa
cgattcatgaccgtgctgacctgacctgagcggccgccctgcagcggatccctctagatgcatgcgacgggcttg
tctgctcccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagaggttttcaccgtc
atcaccgaaacgcgcga 
NotI   BamHI   SphI   NsiI 
 
 
Primer sequences  
 
pMo130-TelRFW  
ccatctacttcttcgaccc  
 
pMo130-TelRRV  
tcacagcttgtctgtaagcg  
 
 
244 
 
Appendix 3. Spreadsheet used to Calculate ng Ciprofloxacin/mg Dry Cells. 
 
Data was entered into the grey cells.  
The calculation in column F converts the mass (ng) of fluoroquinolone taken up per milliliter of culture (column E) to the mass of 
fluoroquinolone taken up per milligram of dry cells. The value obtained in column F was used to analyse differences in fluoroquinolone 
accumulation.
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